Scientifc Program

S
I
M
P
LIFY DO
S
IN
G
1
P
R
E
V
E
NT OVE
R
U
S
E

3

H
i
g
h

S
a
t
i
s
f
a
c
t
i
o
n
.
*

L
o
w

I
r
r
i
t
a
t
i
o
n
.
P
u
b
lis
h
e
d

P
.
U
.
M
.
P
.

d
a
t
a

c
o
n

r
m
s
2

Start with
satisfaction in mind
RETIN-A MICRO
®
(tretinoin gel) microsphere, 0.04% and 0.1% are indicated for topical application in the treatment of acne vulgaris.
Important Safety Information:
RETIN-A MICRO (tretinoin gel) microsphere, 0.04% and 0.1% is contraindicated in individuals with a history of sensitivity reactions to any
of its components. The skin of certain individuals may become excessively dry, red, swollen or blistered. If warranted, these individuals
should temporarily reduce the amount or frequency of application, or discontinue use temporarily or altogether. Patients should be
encouraged to minimize exposure to sunlight, including sunlamps, and to use a sunscreen with a SPF of 15 or higher and protective clothing.
The most common adverse reactions to RETIN-A MICRO 0.04% and 0.1% were limited to mild or moderate irritation of the skin. 1.3% of
patients using RETIN-A MICRO 0.04% and 6% of patients using RETIN-A MICRO 0.1% discontinued due to irritation. RETIN-A MICRO
0.04% and 0.1% showed a visible reduction in total mean lesion count in as little as 2 weeks with full benets seen after 7 weeks.
Please see brief summary of prescribing information on the next page.
*Reported at the end of the 12-week P.U.M.P. Study.


Data based on a consumer preference study designed to evaluate preference of Pump versus tube delivery. 104 male and female acne sufferers between the ages of 13 and 36
completed the study.
3
References: 1. RETIN-A MICRO 0.04%/0.1% [prescribing information]. Los Angeles, Calif: Ortho Dermatologics; May 2006. 2. Eicheneld LF, Nighland M, Rossi AB, et al; PUMP Study
Group. Phase 4 study to assess tretinoin pump for the treatment of facial acne. J Drugs Dermatol. 2008;7(12):1129-1136. 3. Data on le, Ortho Dermatologics. 4. Embil K, Nacht S.
The Microsponge
®
Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul.
1996;13(5):575-588.
RETIN-A MICRO
®
is a brand of Ortho Dermatologics division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
© Ortho Dermatologics division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2009 09DD0217 10/09 Printed in the USA
LASERS PRINTED AT
100
%
M
E
C
H
A
N
I
C
A
L
J
o
b

#
:

M
I
C

0
2
9
9

R
E
V
I
S
E
D

S
I
N
G
L
E

P
A
G
E

J
O
U
R
N
A
L

A
D

J
A
A
D
B
l
e
e
d

S
i
z
e
:

8
.
3
7
5
"
w

x

1
1
.
1
2
5
"
h



T
r
i
m

S
i
z
e
:

8
.
1
2
5
"
w

x

1
0
.
8
7
5
"
h



L
i
v
e

S
i
z
e
:

7
"
w

x

1
0
"
h
P
r
i
n
t
s
:

4
/
0
:

4
C



-
C

-
M

-
¥

-
K

P
l
r
s
t

r
o
u
n
d

m
e
c
h
a
n
l
c
a
l

b
u
l
l
t

b
y
:

S
M
H

(
P
|
C
K
L
D

U
P

P
P
O
M

M
|
C
-
0
2
5
9
)


M
a
g
e
n
t
a

r
u
l
e
s

l
n
d
l
c
a
t
e


8
L
L
L
D

-

T
P
|
M

-

L
|
v
L


÷


D
O

N
O
T

P
P
|
N
T
G16600_1a_JAAD
10/22/09
133LS
TW
A16600x01A_300ucr.tif
A16600x02A_300ucr.tif
A16600x03A_300ucr.tif
A16600x04A_300ucr.tif
C
O
N
T
R
O
L
N
4
N
O
I
I
T
TRE

FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE.
Brief Summary
Retin-A Micro
®
(tretinoin gel) microsphere, 0.1% and 0.04% is a formulation containing 0.1%
or 0.04%, by weight, tretinoin for topical treatment of acne vulgaris. This formulation uses
patented methyl methacrylate/glycol dimethacrylate crosspolymer porous microspheres
(MICROSPONGE
®
System) to enable inclusion of the active ingredient, tretinoin, in an aqueous
gel.
IMPORTANT NOTE: This information is a BRIEF SUMMARY of the complete prescribing
information provided with the product and therefore should not be used as the basis
for prescribing the product. This summary has been prepared by deleting information
from the complete prescribing information such as certain text, tables, and references.
The physician should be thoroughly familiar with the complete prescribing information
before prescribing the product.
INDICATIONS AND USAGE: Retin-A Micro (tretinoin gel) microsphere, 0.1% and 0.04%, is
indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the
use of this product in the treatment of other disorders have not been established.
CONTRAINDICATIONS: This drug is contraindicated in individuals with a history of sensitivity
reactions to any of its components. It should be discontinued if hypersensitivity to any of its
ingredients is noted.
PRECAUTIONS:
General:
• The skin of certain individuals may become excessively dry, red, swollen, or blistered. If the
degree of irritation warrants, patients should be directed to temporarily reduce the amount
or frequency of application of the medication, discontinue use temporarily, or discontinue
use all together. Efficacy at reduced frequencies of application has not been established.
If a reaction suggesting sensitivity occurs, use of the medication should be discontinued.
Excessive skin dryness may also be experienced; if so, use of an appropriate emollient
during the day may be helpful.
• Unprotected exposure to sunlight, including sunlamps, should be minimized during the use of
Retin-A Micro (tretinoin gel) microsphere, 0.1% and 0.04%, and patients with sunburn should
be advised not to use the product until fully recovered because of heightened susceptibility to
sunlight as a result of the use of tretinoin. Patients who may be required to have considerable
sun exposure due to occupation and those with inherent sensitivity to the sun should exercise
particular caution. Use of sunscreen products (SPF 15) and protective clothing over treated
areas are recommended when exposure cannot be avoided.
• Weather extremes, such as wind or cold, also may be irritating to patients under treatment
with tretinoin.
• Retin-A Micro (tretinoin gel) microsphere, 0.1% and 0.04%, should be kept away from the
eyes, the mouth, paranasal creases of the nose, and mucous membranes.
• Tretinoin has been reported to cause severe irritation on eczematous skin and should be used
with utmost caution in patients with this condition.
Information for Patients: A Patient Information Leaflet has been prepared and is included with
each package of Retin-A Micro (tretinoin gel) microsphere, 0.1% and 0.04%.
Drug Interactions: Concomitant topical medication, medicated or abrasive soaps and cleansers,
products that have a strong drying effect, products with high concentrations of alcohol, astringents,
or spices should be used with caution because of possible interaction with tretinoin. Avoid contact
with the peel of limes. Particular caution should be exercised with the concomitant use of topical
over-the-counter acne preparations containing benzoyl peroxide, sulfur, resorcinol, or salicylic acid
with Retin-A Micro (tretinoin gel) microsphere, 0.1% and 0.04%. It also is advisable to allow the
effects of such preparations to subside before use of Retin-A Micro (tretinoin gel) microsphere,
0.1% and 0.04%, is begun.
Carcinogenesis, Mutagenesis, Impairment of Fertility: In a 91-week dermal study in
which CD-1 mice were administered 0.017% and 0.035% formulations of tretinoin, cuta-
neous squamous cell carcinomas and papillomas in the treatment area were observed in
some female mice. These concentrations are near the tretinoin concentration of these clinical
formulations (0.04% and 0.1%). A dose-related incidence of liver tumors in male mice was
observed at those same doses. The maximum systemic doses associated with the administered
0.017% and 0.035% formulations are 0.5 and 1.0 mg/kg/day, respectively. These doses are
two and four times the maximum human systemic dose applied topically, when normalized
for total body surface area. The biological significance of these findings is not clear because
they occurred at doses that exceeded the dermal maximally tolerated dose (MTD) of tretinoin
and because they were within the background natural occurrence rate for these tumors in
this strain of mice. There was no evidence of carcinogenic potential when 0.025 mg/kg/day
of tretinoin was administered topically to mice (0.1 times the maximum human systemic dose,
normalized for total body surface area). For purposes of comparisons of the animal exposure
to systemic human exposure, the maximum human systemic dose applied topically is defined
as 1 gram of Retin-A Micro (tretinoin gel) microsphere, 0.1% applied daily to a 50 kg person
(0.02 mg tretinoin/kg body weight).
Dermal carcinogenicity testing has not been performed with Retin-A Micro (tretinoin gel)
microsphere, 0.04% or 0.1%.
Studies in hairless albino mice suggest that concurrent exposure to tretinoin may enhance the
tumorigenic potential of carcinogenic doses of UVB and UVA light from a solar simulator. This
effect has been confirmed in a later study in pigmented mice, and dark pigmentation did not
overcome the enhancement of photo carcinogenesis by 0.05% tretinoin. Although the significance
of these studies to humans is not clear, patients should minimize exposure to sunlight or artificial
ultraviolet irradiation sources.
The mutagenic potential of tretinoin was evaluated in the Ames assay and in the in vivo mouse
micronucleus assay, both of which were negative.
The components of the microspheres have shown potential for genetic toxicity and teratogenesis.
EGDMA, a component of the excipient acrylates copolymer, was positive for induction of structural
chromosomal aberrations in the in vitro chromosomal aberration assay in mammalian cells in
the absence of metabolic activation, and negative for genetic toxicity in the Ames assay, the
HGPRT forward mutation assay, and the mouse micronucleus assay.
In dermal Segment I fertility studies of another tretinoin formulation in rats, slight (not statisti-
cally significant) decreases in sperm count and motility were seen at 0.5 mg/kg/day (4 times
the maximum human systemic dose applied topically, and normalized for total body surface
area), and slight (not statistically significant) increases in the number and percent of nonviable
embryos in females treated with 0.25 mg/kg/day (2 times the maximum human systemic dose
applied topically and normalized for total body surface area) and above were observed. In oral
Segment I and Segment III studies in rats with tretinoin, decreased survival of neonates and
growth retardation were observed at doses in excess of 2 mg/kg/day (17 times the human
topical dose normalized for total body surface area).
Dermal fertility and perinatal development studies with Retin-A Micro (tretinoin gel) micro sphere,
0.1% or 0.04%, have not been performed in any species.
Pregnancy: Teratogenic Effects: Pregnancy Category C.
In a study of pregnant rats treated with topical application of Retin-A Micro (tretinoin gel)
microsphere, 0.1%, at doses of 0.5 to 1 mg/kg/day on gestation days 6-15 (4 to 8
times the maximum human systemic dose of tretinoin normalized for total body sur-
face area after topical administration of Retin-A Micro (tretinoin gel) microsphere, 0.1%)
some alterations were seen in vertebrae and ribs of offspring. In another study, pregnant
New Zealand white rabbits were treated with Retin-A Micro (tretinoin gel) microsphere, 0.1%, at
doses of 0.2, 0.5, and 1.0 mg/kg/day, administered topically for 24 hours a day while wearing
Elizabethan collars to prevent ingestion of the drug. There appeared to be increased incidences
of certain alterations, including domed head and hydrocephaly, typical of retinoid-induced
fetal malformations in this species, at 0.5 and 1.0 mg/kg/day. Similar malformations were
not observed at 0.2 mg/kg/day, 3 times the maximum human systemic dose of tretinoin after
topical administration of Retin-A Micro (tretinoin gel) microsphere, 0.1%, normalized for total
body surface area. In a repeat study of the highest topical dose (1.0 mg/kg/day) in pregnant
rabbits, these effects were not seen, but a few alterations that may be associated with tretinoin
exposure were seen. Other pregnant rabbits exposed topically for six hours to 0.5 or 0.1 mg/
kg/day tretinoin while restrained in stocks to prevent ingestion, did not show any teratogenic
effects at doses up to 17 times (1.0 mg/kg/day) the maximum human systemic dose after topical
administration of Retin-A Micro (tretinoin gel) microsphere, 0.1%, adjusted for total body surface
area, but fetal resorptions were increased at 0.5 mg/kg. In addition, topical tretinoin in non
Retin-A Micro (tretinoin gel) microsphere formulations was not teratogenic in rats and rabbits
when given in doses of 42 and 27 times the maximum human systemic dose after topical ad-
ministration of Retin-A Micro (tretinoin gel) microsphere, 0.1%, normalized for total body surface
area, respectively, (assuming a 50 kg adult applied a daily dose of 1.0 g of 0.1% gel topically).
At these topical doses, however, delayed ossification of several bones occurred in rabbits. In
rats, a dose-dependent increase of supernumerary ribs was observed.
Oral tretinoin has been shown to be teratogenic in rats, mice, rabbits, hamsters, and subhu-
man primates. Tretinoin was teratogenic in Wistar rats when given orally or topically in doses
greater than 1 mg/kg/day (8 times the maximum human systemic dose normalized for total
body surface area). However, variations in teratogenic doses among various strains of rats have
been reported. In the cynomolgus monkey, which metabolically is more similar to humans than
other species in its handling of tretinoin, fetal malformations were reported for doses of 10
mg/kg/day or greater, but none were observed at 5 mg/kg/day (83 times the maximum human
systemic dose normalized for total body surface area), although increased skeletal variations
were observed at all doses. Dose-related increases in embryolethality and abortion also were
reported. Similar results have also been reported in pigtail macaques.
Topical tretinoin in animal teratogenicity tests has generated equivocal results. There is evidence
for teratogenicity (shortened or kinked tail) of topical tretinoin in Wistar rats at doses greater
than 1 mg/kg/day (8 times the maximum human systemic dose normalized for total body surface
area). Anomalies (humerus: short 13%, bent 6%, os parietal incompletely ossified 14%) have
also been reported when 10 mg/kg/day was topically applied. Supernumerary ribs have been a
consistent finding in rats when dams were treated topically or orally with retinoids.
There are no adequate and well-controlled studies in pregnant women. Retin-A Micro should be
used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
With widespread use of any drug, a small number of birth defect reports associated temporally
with the administration of the drug would be expected by chance alone. Thirty human cases
of temporally associated congenital malformations have been reported during two decades of
clinical use of Retin-A. Although no definite pattern of teratogenicity and no causal association
has been established from these cases, five of the reports describe the rare birth defect category
holoprosencephaly (defects associated with incomplete midline development of the forebrain). The
significance of these spontaneous reports in terms of risk to the fetus is not known.
Non-Teratogenic Effects: Topical tretinoin has been shown to be fetotoxic in rabbits when
administered 0.5 mg/kg/day (8 times the maximum human systemic dose applied topically and
normalized for total body surface area), resulting in fetal resorptions and variations in ossifica-
tion. Oral tretinoin has been shown to be fetotoxic, resulting in skeletal variations and increased
intrauterine death in rats when administered 2.5 mg/kg/day (21 times the maximum human
systemic dose applied topically and normalized for total body surface area).
There are, however no adequate and well-controlled studies in pregnant women.
Animal Toxicity Studies: In male mice treated topically with Retin-A Micro (tretinoin gel) mi-
crosphere 0.1%, at 0.5, 2.0, or 5.0 mg/kg/day tretinoin (2, 8, or 21 times the maximum human
systemic dose after topical administration of Retin-A Micro (tretinoin gel) microsphere, 0.1%,
normalized for total body surface area) for 90 days, a reduction in testicular weight, but with
no pathological changes were observed at the two highest doses. Similarly, in female mice
there was a reduction in ovarian weights, but without any underlying pathological changes, at
5.0 mg/kg/day (21 times the maximum human dose). In this study there was a dose-related
increase in the plasma concentration of tretinoin 4 hours after the first dose. A separate toxi-
cokinetic study in mice indicates that systemic exposure is greater after topical application to
unrestrained animals than to restrained animals, suggesting that the systemic toxicity observed
is probably related to ingestion. Male and female dogs treated with Retin-A Micro (tretinoin gel)
microsphere, 0.1%, at 0.2, 0.5, or 1.0 mg/kg/day tretinoin (5, 12, or 25 times the maximum
human systemic dose after topical administration of Retin-A Micro (tretinoin gel) microsphere,
0.1%, normalized for total body surface area, respectively) for 90 days showed no evidence of
reduced testicular or ovarian weights or pathological changes.
Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many
drugs are excreted in human milk, caution should be exercised when Retin-A Micro (tretinoin
gel) microsphere, 0.1% or 0.04%, is administered to a nursing woman.
Pediatric Use: Safety and effectiveness in children below the age of 12 have not been established.
Geriatric Use: Safety and effectiveness in a geriatric population have not been established.
Clinical studies of Retin-A Micro did not include sufficient numbers of subjects aged 65 and
over to determine whether they respond differently from younger subjects.
ADVERSE REACTIONS:
The skin of certain sensitive individuals may become excessively red, edematous, blistered, or
crusted. If these effects occur, the medication should either be discontinued until the integrity
of the skin is restored, or the medication should be adjusted to a level the patient can tolerate.
However, efficacy has not been established for lower dosing frequencies.
True contact allergy to topical tretinoin is rarely encountered. Temporary hyper- or hypopig-
mentation has been reported with repeated application of tretinoin. Some individuals have been
reported to have heightened susceptibility to sunlight while under treatment with tretinoin.
OVERDOSAGE: Retin-A Micro (tretinoin gel) microsphere, 0.1% and 0.04%, is intended for topical
use only. If medication is applied excessively, no more rapid or better results will be obtained and
marked redness, peeling, or discomfort may occur. Oral ingestion of large amounts of the drug
may lead to the same side effects as those associated with excessive oral intake of Vitamin A.
Rx only.
Patent Nos.: 4,690,825; 5,145,675 & 5,955,109
Distributed by: OrthoNeutrogena
DIVISION OF ORTHO-MCNEIL PHARMACEUTICAL, INC.
Los Angeles, CA 90045
© OMP 2006 06DD0123 7/06
RETIN-A MICRO
®
is a registered trademark of Ortho-McNeil Pharmaceutical, Inc.
MICROSPONGE
®
is a registered trademark of Cardinal Health, Inc., Dublin, OH.
T
R
I
M
:

8
.
1
2
5


x

1
1

L
I
V
E
:

7


x

1
0

C
O
L
O
R
S
:

B
l
a
c
k
P
U
B
L
I
C
A
T
I
O
N
:


S
k
i
n

M
e
d
M
E
C
H
A
N
I
C
A
L
A16600_2b
10.20.2009 10:30
133 linescreen
TW
OrthNeuLogo_K.ai
RETIN-A MICRO.1&.04%Black.ai
THANK YOU
to our 2010 Sustaining Members!
e generous philanthropic support of our
Sustaining Members and friends of the Academy
helps us continue to promote excellence through our
many programs. ank you so much for your help in
Furthering Excellence in Dermatology…
Today and Tomorrow!
Visit the Pillars in Giving Recognition
Module in the Ernest N. Morial Convention Center.
SCIENTIFIC ASSEMBLY
COMMITTEE
Lawrence F. Eichenfield, M.D., FAAD,
chair
Janet A. Fairley, M.D., FAAD
Henry W. Lim, M.D., FAAD
Joan Guitart, M.D., FAAD
William D. James, M.D., FAAD,
president
Ronald L. Moy, M.D., FAAD,
president-elect
Robert D. Greenberg, M.D., FAAD,
secretary-treasurer
Suzanne Olbricht, M.D., FAAD,
assistant secretary-treasurer
Erik J. Stratman, M.D., FAAD,
chair, Council on Education
Robert S. Kirsner, M.D., Ph.D., FAAD,
deputy chair, Council on Education
Robert T. Brodell, M.D., FAAD,
chair, Annual Meeting Evaluation
Task Force
Michael E. Ming, M.D., FAAD,
chair, Needs Assessment Task Force
TARGET AUDIENCE
Te primary target audience of the American Academy of Dermatology’s Annual Meeting is
its members. Secondary audiences for the Academy’s Annual Meeting include dermatology
residents and others.
OVERALL LEARNING OBJECTIVES
Upon completion of the activity, participants should be able to:
• Recognize the results of current and evolving research.
• Update their knowledge about recent advances in the diagnosis, management, and
treatment of diseases of the skin, hair, nails, and mucous membranes.
• Review and interpret basic knowledge and skills in medical dermatology, dermatologic
surgery, pediatric dermatology, and dermatopathology.
• Improve practice management skills.
• Integrate new principles to improve their everyday practice of dermatology.
CONTINUING MEDICAL EDUCATION CREDITS
Te American Academy of Dermatology is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education for physicians.
Te American Academy of Dermatology designates this educational activity for a maximum
of 54.5 AMA PRA Category 1 Credits
TM
. Physicians should only claim credit commensurate
with the extent of their participation in the activity.
Te American Academy of Dermatology’s 69th Annual Meeting is recognized by the
American Academy of Dermatology for 54.5 AAD Recognized Category 1 CME Credits
and may be used toward the American Academy of Dermatology’s Continuing Medical
Education Award.
All Annual Meeting activities, unless otherwise specifed, are approved for direct-sponsored
AAD Category 1 CME Credit.
Credit is calculated on a 1-hour basis and will be refected on member transcripts within four
to six weeks after the meeting. For AAD meeting policies on CME, please see pages 46-47.

Register for the meeting and make hotel reservations online at www.aad.org
American Academy of Dermatology, 930 E. Woodfeld Road, Schaumburg, IL 60173
Phone: (847) 330-0230 • Fax: (847) 330-1090 • website: www.aad.org
© 2010 American Academy of Dermatology, Schaumburg, IL
No part of this publication may be reproduced without the prior written permission of the
American Academy of Dermatology.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
3
Tere is something about the city of New Orleans that is both uniquely American and, with all its cultural
diversity, an international urban melting pot. Visitors come to New Orleans throughout the year for Mardi Gras
celebrations, warm weather, world-famous cuisine, lively music, and an atmosphere of southern hospitality at its
fnest. New Orleans boasts the Café Du Monde (in business since the Civil War), the French Quarter, the Garden
District, and the contrasting business district, all thriving historic communities.
If you have not been to the city since the Academy’s last visit there, in 2005, I think you’ll be surprised how much
the city has both maintained its charm and revitalized its metropolis. Recent years have been hard on a city that
is almost paradoxically known as “the Big Easy.” But the people of New Orleans have repeatedly proved to be of
hearty, resilient stock in the face of adversity.
Like the great city of New Orleans, which perseveres thanks to the unbending spirit of its citizens, dermatology
thrives thanks to the dedication of the practitioners who have committed themselves to promoting and advancing
quality patient care. It’s that sort of spirit of dedication and determination that I believe makes our profession as
strong as it is.
New Orleans also has an impressive history of diverse dermatology presentations and lecturers. In 1999, the late,
great Walter Shelley, M.D., presented his “Self-portrait of a Dermatologist” at Chateau Sonesta Hotel in New
Orleans, as part of a dermatology society meeting in the city. In 2005, Elizabeth McBurney, M.D., gave a talk
on “Spitfre and Scandal: Huey P. Long’s Lasting Infuence on Louisiana Medicine,” at the Restaurant August
in New Orleans, and at the Academy’s 2005 Annual Meeting, Peyton E. Weary, M.D., presented “Impact of
Global Climate Change, Biodiversity and Population on Human Health.” As you look at the 2010 Annual
Meeting scientifc program and speakers, you’ll see that one thing remains consistent from year to year, and that’s a
presentation of important voices and new perspectives in dermatology. I hope you are eagerly anticipating this rich,
diverse, and medically important program as much as I am.
I hope you greet New Orleans and the 2010 Annual Meeting with that same sense of stalwart, can-do feeling, and
also with the same sense of excitement that comes from taking a solid foundation and building something great
into something even greater. Tat’s what New Orleans and dermatology are all about.
Sincerely,
William D. James, M.D., FAAD
President, American Academy of Dermatology
President’s Message
First wrinkle. First home. First visit.
P
r
e
s
c
r
i
b
e


t
h
e

N
e
w

R
E
N
O
V
A
®
P
u
m
p
Prescribe RENOVA frst—and provide the true value of control in a pump patients prefer.
1
RENOVA
®
(tretinoin cream) 0.02% is indicated as an adjunctive agent for use in the mitigation (palliation) of fne facial wrinkles in patients who use
comprehensive skin care and sunlight avoidance programs. RENOVA DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE
PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN.
Important Safety Information:
RENOVA
®
(tretinoin cream) 0.02% is contraindicated in individuals with a history of sensitivity reactions to any of its components and should be discontinued
if a reaction occurs. The safety and effcacy of using RENOVA 0.02% daily for greater than 12 months has not been established. RENOVA 0.02% is proven
effective on lightly pigmented skin, Fitzpatrick skin types I, II, and III. Do not use RENOVA 0.02% if the patient is taking drugs known to be photosensitizers,
pregnant, or nursing. RENOVA 0.02% is a dermal irritant. Almost all patients experience skin reactions, including dryness, peeling, burning/stinging, erythema,
and itching. In some patients, this may be severe. If the degree of local irritation warrants, patients should be directed to use less medication, decrease
frequency of use, discontinue use temporarily, or discontinue use altogether. Exposure to sunlight should be avoided
or minimized while using RENOVA 0.02% and use of a sunscreen with a SPF 15 or higher is recommended.
Please see a sales representative for Full Prescribing Information.
1. Data on fle, Ortho Dermatologics.
RENOVA is a trademark of Ortho Dermatologics. © 2010 Ortho Dermatologics 10DD0053 04/10 Printed in USA
Controlled-dose delivery helps ensure proper use—which may lead to optimal results and long-lasting value for your patients.
ONLY FROM
First choice.
© 2010 Ortho Dermatologics 10DD0053 04/10 Printed in USA
FOR TOPICAL USE ON THE FACE. NOT FOR
OPHTHALMIC,
ORAL, OR INTRAVAGINAL USE.
Brief Summary
RENOVA (tretinoin cream) 0.02% contains the
active ingredient tretinoin in a cream base.
IMPORTANT NOTE — This information is a
BRIEF SUMMARY of the complete prescrib-
ing information provided with the product
and therefore should not be used as the
basis for prescribing the product. This sum-
mary was prepared by deleting from the
complete prescribing information certain
text, tables, and references. The physician
should be thoroughly familiar with the com-
plete prescribing information before pre-
scribing the product.
INDICATIONS AND USAGE:
(To understand fully the indication for this prod-
uct, please read the entire INDICATIONS AND
USAGE section of the labeling.)
RENOVA (tretinoin cream) 0.02% is indicated
as an adjunctive agent (see second bullet point
below) for use in the mitigation (palliation) of
fine facial wrinkles in patients who use compre-
hensive skin care and sunlight avoidance pro-
grams. RENOVA DOES NOT ELIMINATE
WRINKLES, REPAIR SUN-DAMAGED SKIN,
REVERSE PHOTOAGING, or RESTORE
MORE YOUTHFUL or YOUNGER SKIN. In
double-blinded, vehicle-controlled clinical
studies, many patients in the vehicle group
achieved desired palliative effects on fine wrin-
kling of facial skin with the use of comprehen-
sive skin care and sunlight avoidance programs
including sunscreens, protective clothing, and
non-prescription emollient creams.
• RENOVA 0.02% has NOT DEMONSTRATED A
MITIGATING EFFECT on significant signs of
chronic sunlight exposure such as coarse or
deep wrinkling, tactile roughness, mottled
hyperpigmentation, lentigines, telangiectasia,
skin laxity, keratinocytic atypia, melanocytic
atypia, or dermal elastosis.
• RENOVA should be used under medical super-
vision as an adjunct to a comprehensive skin
care and sunlight avoidance program that
includes the use of effective sunscreens (mini-
mum SPF of 15) and protective clothing.
• Patients with visible actinic keratoses and
patients with a history of skin cancer were
excluded from clinical trials of RENOVA 0.02%.
Thus the effectiveness and safety of RENOVA
0.02% in these populations are not known at
this time.
• Neither the safety nor the effectiveness of
RENOVA for the prevention or treatment of
actinic keratoses or skin neoplasms has
been established.
• Neither the safety nor the efficacy of using
RENOVA 0.02% daily for greater than 52 weeks
has been established, and daily use beyond
52 weeks has not been systematically and
histologically investigated in adequate and well-
controlled trials. (See WARNINGS section.)
CONTRAINDICATIONS:
This drug is contraindicated in individuals with a
history of sensitivity reactions to any of its compo-
nents. It should be discontinued if hypersensitivity
to any of its ingredients is noted.
WARNINGS:
• RENOVA 0.02% is a dermal irritant, and the
results of continued irritation of the skin for
greater than 52 weeks in chronic use with
RENOVA are not known. There is evidence of
atypical changes in melanocytes and ker-
atinocytes and of increased dermal elastosis in
some patients treated with RENOVA 0.05% for
longer than 48 weeks. The significance of these
findings and their relevance for RENOVA
0.02%are unknown.
• RENOVA should not be administered if
the patient is also taking drugs known to be
photosensitizers (e.g., thiazides, tetracy-
clines, fluoroquinolones, phenothiazines, sul-
fonamides) because of the possibility of aug-
mented phototoxicity.
Exposure to sunlight (including sunlamps) should
be avoided or minimized during use of RENOVA
because of heightened sunburn susceptibility.
Patients should be warned to use sunscreens
(minimum SPF of 15) and protective clothing
when using RENOVA. Patients with sunburn
should be advised not to use RENOVA until fully
recovered. Patients who may have considerable
sun exposure, e.g., due to their occupation, and
those patients with inherent sensitivity to sunlight
should exercise caution when using RENOVA and
follow the precautions outlined in the Patient
Package Insert.
RENOVA should be kept out of the eyes,
mouth, angles of the nose, and mucous mem-
branes. Topical use may cause severe local
erythema, pruritus, burning, stinging, and peel-
ing at the site of application. If the degree of
local irritation warrants, patients should be
directed to use less medication, decrease the
frequency of application, discontinue use tem-
porarily, or discontinue use altogether and con-
sider additional appropriate therapy.
Tretinoin has been reported to cause severe irrita-
tion on eczematous skin and should be used only
with caution in patients with this condition.
Application of larger amounts of medication than
recommended has not been shown to lead to
more rapid or better results, and marked redness,
peeling, or discomfort may occur.
PRECAUTIONS:
General: RENOVA should be used only as an
adjunct to a comprehensive skin care and sunlight
avoidance program. (See INDICATIONS AND
USAGE section.)
If a drug sensitivity, chemical irritation, or a sys-
temic adverse reaction develops, use of RENOVA
should be discontinued.
Weather extremes, such as wind or cold, may
be more irritating to patients using tretinoin-
containing products.
Information for Patients: See Patient
Package Insert
Drug Interactions: Concomitant topical med-
ications, medicated or abrasive soaps, shampoos,
cleansers, cosmetics with a strong drying
effect, products with high concentrations of
alcohol, astringents, spices or lime, permanent
wave solutions, electrolysis, hair depilatories or
waxes, and products that may irritate the skin
should be used with caution in patients being
treated with RENOVA because they may
increase irritation with RENOVA.
RENOVA should not be administered if the patient
is also taking drugs known to be photosensitizers
(e.g., thiazides, tetracyclines, fluoroquinolones,
phenothiazines, sulfonamides) because of the pos-
sibility of augmented phototoxicity.
Carcinogenesis, Mutagenesis, Impairment of
Fertility: In a 91-week dermal study in which CD-1
mice were administered 0.017% and 0.035% for-
mulations of tretinoin, cutaneous squamous cell
carcinomas and papillomas in the treatment area
were observed in some female mice. These con-
centrations are near the tretinoin concentration of
this clinical formulation (0.02%). A dose-related
incidence of liver tumors in male mice was
observed at those same doses. The maximum
systemic doses associated with the 0.017% and
0.035% formulations are 0.5 and 1.0 mg/kg/day.
These doses are 10 and 20 times the maximum
human systemic dose, when adjusted for total
body surface area. The biological significance of
these findings is not clear because they occurred
at doses that exceeded the dermal maximally tol-
erated dose (MTD) of tretinoin and because they
were within the background natural occurrence
rate for these tumors in this strain of mice. There
was no evidence of carcinogenic potential when
0.025 mg/kg/day of tretinoin was administered
topically to mice (0.5 times the maximum human
systemic dose, adjusted for total body surface
area). For purposes of comparisons of the animal
exposure to systemic human exposure, the maxi-
mum human systemic dose is defined as 1 gram of
0.02% RENOVA applied daily to a 50 kg person
(0.004 mg tretinoin/kg body weight).
Studies in hairless albino mice suggest that con-
current exposure to tretinoin may enhance the
tumorigenic potential of carcinogenic doses of
UVB and UVA light from a solar simulator. This
effect has been confirmed in a later study in pig-
mented mice, and dark pigmentation did not
overcome the enhancement of photocarcino-
genesis by 0.05% tretinoin. Although the signifi-
cance of these studies to humans is not clear,
patients should minimize exposure to sunlight or
artificial ultraviolet irradiation sources.
The mutagenic potential of tretinoin was evaluated
in the Ames assay and in the in vivo mouse
micronucleus assay, both of which were negative.
In dermal Segment I fertility studies in rats, slight
(not statistically significant) decreases in sperm
count and motility were seen at 0.5 mg/kg/day (20
times the maximum human systemic dose adjust-
ed for total body surface area), and slight (not sta-
tistically significant) increases in the number and
percent of nonviable embryos in females treated
with 0.25 mg/kg/day (10 times the maximum
human systemic dose adjusted for total body sur-
face area) and above were observed. A dermal
Segment III study with RENOVA has not been per-
formed in any species. In oral Segment I and
Segment III studies in rats with tretinoin, decreased
survival of neonates and growth retardation were
observed at doses in excess of 2 mg/kg/day (83
times the human topical dose adjusted for total
body surface area).
Pregnancy:
Teratogenic effects: Pregnancy Category C.
ORAL tretinoin has been shown to be teratogenic in
rats, mice, rabbits, hamsters, and subhuman pri-
mates. It was teratogenic and fetotoxic in Wistar
rats when given orally or topically in doses greater
than 1 mg/kg/day (42 times the maximum human
systemic dose normalized for total body surface
area). However, variations in teratogenic doses
among various strains of rats have been reported.
In the cynomolgus monkey, which, metabolically, is
closer to humans for tretinoin than the other species
examined, fetal malformations were reported at
doses of 10 mg/kg/day or greater, but none were
observed at 5 mg/kg/day (417 times the maximum
human systemic dose adjusted for total body sur-
face area), although increased skeletal variations
were observed at all doses. A dose-related increase
in embryolethality and abortion was reported.
Similar results have also been reported in pigtail
macaques.
TOPICAL tretinoin in animal teratogenicity tests has
generated equivocal results. There is evidence for
teratogenicity (shortened or kinked tail) of topical
tretinoin in Wistar rats at doses greater than
1 mg/kg/day (42 times the maximum human
systemic dose adjusted for total body surface
area). Anomalies (humerus: short 13%, bent 6%,
os parietal incompletely ossified 14%) have
also been reported when 10 mg/kg/day was der-
mally applied.
There are other reports in New Zealand White rab-
bits administered doses of greater than 0.2
mg/kg/day (17 times the maximum human sys-
temic dose adjusted for total body surface area) of
an increased incidence of domed head and hydro-
cephaly, typical of retinoid-induced fetal malforma-
tions in this species.
In contrast, several well-controlled animal studies
have shown that dermally applied tretinoin may be
fetotoxic, but not overtly teratogenic, in rats
and rabbits at doses of 1.0 and 0.5 mg/kg/day,
respectively (42 times the maximum human sys-
temic dose adjusted for total body surface area in
both species).
With widespread use of any drug, a small num-
ber of birth defect reports associated tempo-
rally with the administration of the drug would
be expected by chance alone. Thirty human
cases of temporally-associated congenital
malformations have been reported during two
decades of clinical use of another formulation
of topical tretinoin (Retin-A). Although no defi-
nite pattern of teratogenicity and no causal
association has been established from these
cases, 5 of the reports describe the rare birth
defect category holoprosencephaly (defects
associated with incomplete midline develop-
ment of the forebrain). The significance of
these spontaneous reports in terms of risk to
the fetus is not known.
Non-teratogenic effects:
Dermal tretinoin has been shown to be fetotoxic in
rabbits when administered 0.5 mg/kg/day (42
times the maximum human systemic dose normal-
ized for total body surface area). Oral tretinoin has
been shown to be fetotoxic, resulting in skeletal
variations and increased intrauterine death, in rats
when administered 2.5 mg/kg/day (104 times the
maximum human systemic dose adjusted for total
body surface area).
There are, however, no adequate and well-
controlled studies in pregnant women. RENOVA
should not be used during pregnancy.
Nursing Mothers: It is not known whether this drug
is excreted in human milk. Since many drugs are
excreted in human milk, mitigation of fine facial
wrinkles with RENOVA 0.02% may be postponed
in nursing mothers until after completion of the
nursing period.
Pediatric Use: Safety and effectiveness in
patients less than 18 years of age have not
been established.
Geriatric Use: In clinical studies with RENOVA
0.02%, patients aged 65 to 71 did not demon-
strate a significant difference for improvement
in fine wrinkling when compared to patients
under the age of 65. Patients aged 65 and over
may demonstrate slightly more irritation,
although the differences were not statistically
significant in the clinical studies for RENOVA
0.02%. Safety and effectiveness of RENOVA
0.02% in individuals older than 71 years of age
have not been established.
ADVERSE REACTIONS:
(See WARNINGS and PRECAUTIONS sections.)
In double-blind, vehicle-controlled studies involv-
ing 339 patients who applied RENOVA 0.02% to
their faces, adverse reactions associated with the
use of RENOVA were limited primarily to the skin.
Almost all patients reported one or more local reac-
tions such as peeling, dry skin, burning, stinging,
erythema, and pruritus. In 32% of all study
patients, skin irritation was reported that was
severe, led to temporary discontinuation of
RENOVA 0.02%, or led to use of a mild topical
corticosteroid. About 7% of patients using
RENOVA 0.02%, compared to less than 1% of the
control patients, had sufficiently severe local
irritation to warrant short-term use of mild topical
corticosteroids to alleviate local irritation. About
4% of patients had to discontinue use of RENOVA
because of adverse reactions.
Approximately 2% of spontaneous post-marketing
adverse event reporting for RENOVA 0.05% were
for skin hypo- or hyperpigmentation. Other sponta-
neously reported adverse events for RENOVA
0.05% predominantly appear to be local reactions
similar to those seen in clinical trials.
OVERDOSAGE:
Application of larger amounts of medication than
recommended has not been shown to lead to
more rapid or better results, and marked redness,
peeling, or discomfort may occur. Oral ingestion of
the drug may lead to the same side effects as
those associated with excessive oral intake of
Vitamin A.
Rx only.
Marketed by: Ortho Dermatologics
DIVISION OF ORTHO-MCNEIL-JANSSEN
PHARMACEUTICALS, INC.
Los Angeles, CA 90045
© OMJPI 2008 Made in Canada
U.S. Patents 4,603,146 and 4,877,805
732954 201530
Scientific Program
AMERICAN ACADEMY
of DERMATOLOGY
extends a very sincere thank you
to all of our corporate partners
who have provided support for various
2010 Academy programs and activities.
Please visit our Corporate Partner
Recognition Module in the Ernest N. Morial
Convention Center and view Corporate Partner
Recognition in the Program-at-a-Glance

New Orleans welcomes the American Academy of Dermatology back for the 69th Annual Meeting. Te Academy
has planned a truly remarkable educational roster for our frst visit back to this exciting city since 2005. We are
ofering an outstanding set of courses, symposia, workshops, discussion groups, and focus sessions touching on every
aspect of our diverse specialty.
Te highlight of the meeting will be the plenary session, taking place on Sunday, February 6. Te session leads
of with the Clarence S. Livingood, M.D., Award and Lectureship, presented by Neil Prose, M.D. Dr. Prose will
present “Cultivating Curiosity,” in which he will discuss the role of curiosity in understanding our patients and
providing empathetic care. Also featured will be Tomas Kupper, M.D., presenting the Marion B. Sulzberger,
M.D., Award and Lectureship. His lecture, “Skin in the Game: New Perspective on T Cells, Immunity, and
Cancer,” will explore how our growing understanding of T cells is changing the way we think about immunity,
vaccination, cancer, and infammatory skin disease and how these insights are in turn impacting patient care.
Also featured will be W. Marston Linehan, M.D., recipient of the Lila Gruber Memorial Cancer Research Award
and Lectureship. He will explore how research into the genetic basis and clinical manifestations of kidney cancer is
leading to better treatments for these diseases in a lecture on “Familial Kidney Cancer Syndromes with Cutaneous
Manifestations.” Tis year Anton Stuetz, Ph.D., will present the Phillip Frost Leadership Lecture. His lecture,
“Lessons Learned During Research and Development of New Medicines for Treatment of Skin Diseases,” will
explore research leading to recent breakthroughs in the treatment of fungal infections, atopic dermatitis, and more.
Te plenary session will also feature guest speakers James Carville and Mary Matalin. Representing opposite sides
of the political scene, this couple will give an insider’s look at life in Washington, D.C. Academy members will also
have a chance to hear a report on the latest AAD activities from President William D. James, M.D., and a look at
what the future holds from President-elect Ronald A. Moy, M.D.
Te Annual Meeting has always featured cutting edge information in the diagnosis and treatment of skin disease,
but the latest news in research takes center stage in a new session, “Late-Breaking Research” on Saturday, February
5. Te most signifcant dermatologic research abstracts are being solicited, and the best of these will be selected for
presentation at this new session, directed by Richard L. Gallo, M.D.
“Late-Breaking Research” is just one of the many new, exciting, and innovative sessions being ofered at the 69th
Annual Meeting. I invite you to review this program book and select from the myriad topics and formats being
ofered.
Sincerely,
Lawrence M. Eichenfeld, M.D., FAAD
Chair, 2011 Annual Meeting
Chair’s Message
recommended by dermatologists
for rough, dry skin
1
When dry skin calls for a serious solution…
Recommend AmLactin
®
Visit us online at
www.amlactin.com
for samples, coupons
& more information!
For complete directions and cautions, please refer to individual product labels.
Reference: 1. Most recommended moisturizing product for rough, dry skin. Omnibus Study. Dermatology Times. May 2009.
1-800-654-2299 www.upsher-smith.com
©2010 Upsher-Smith Laboratories, Inc., Maple Grove, MN 55369
103985.02
AmLactin
®
Rejuvenating Moisturizers
Nourishing formulas— combine emollients, humectants, and alpha-hydroxy acid to
exfoliate and hydrate dry skin and dry skin associated with Keratosis Pilaris (KP)
●AmLactin
®
Moisturizing Body Lotion & Cream
Everyday hydration— 12% lactic acid provides powerful therapy leaving skin
noticeably soft and smooth
●AmLactin XL
®
Moisturizing Lotion
Targets severely dry skin— features ULTRAPLEX,
®
an extra-strength blend of three
alpha-hydroxy compounds, clinically proven to improve smoothness and hydration
Serious care for softer skin
TM
10
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
TABLE OF CONTENTS
T
A
B
L
E

O
F

C
O
N
T
E
N
T
S
AAD Art Exhibit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 292-293
AAD Meeting Policies
Independence in CME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Disclosure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Content Validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Outcomes Measurement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Disclaimer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Age Limits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Camera/Video Recording . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Cell Phones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Smoking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Alcoholic Beverages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Ofcial Language . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Scientifc Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
AAD Staf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Academy Election Information. . . . . . . . . . . . . . . . . . . . . . . . . . 32
Ancillary Groups and Reunions . . . . . . . . . . . . . . . . . . . . 347-351
Badge Information
Identifcation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
On-site Pick Up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Mailing of . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Car Rental Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Certifcate of Attendance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Chair’s Message . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Charitable Contributions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Child Care Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Committee Meetings . . . . . . . . . . . . . . . . . . . . . . . . . . . . 344-346
Continuing Medical Education Credits . . . . . . . . . . . . . . . . . . . . 3
Evaluation and CME Verifcation . . . . . . . . . . . . . . . . . . . . . . . 44
Exhibits
AAD Resource Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Electronic Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . 44, 265-294
Technical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44, 297-334
Alphabetical Directory . . . . . . . . . . . . . . . . . . . . . . . . . . . . 328
Product Category Directory . . . . . . . . . . . . . . . . . . . . 330-334
General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33-48
Honors and Awards . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 340-343
Hotel and Travel Information. . . . . . . . . . . . . . . . Brochure, 41-42
Important Dates and Times . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
In Memory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 337-338
Indices
Subject . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 353-374
Faculty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375-383
Advertising . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 384
Information Desks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Letters of Invitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Meeting Location . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Meeting Room Locations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
New Tis Year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52-53
On-Site Services and Exhibits . . . . . . . . . . . . . . . . . . . . . . . 43-46
Academy Ofces/Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43-44
Attendance Verifcation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Business Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Cyber Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
WiFi Lounges . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Press Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Information Desks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Restaurant Reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
First Aid/Nursing Mothers’ Room . . . . . . . . . . . . . . . . . . . . . . . 46
Optional Activities . . . . . . . . . . . . . . . . . . . . . . . . Brochure, 38, 46
Overall Learning Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Payment Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Personal Program Schedule . . . . . . . . . . . . . . . . . . . . . . . . . 27-28
Plenary Session
Business and Bagels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
Welcome Address . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
Clarence S. Livingood, M.D., Award and Lectureship . . . . . . . 159
President’s Address . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
Marion B. Sulzberger, M.D., Memorial Award
and Lectureship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
President-Elect’s Address . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
Lila Gruber Memorial Cancer Research Award
and Lectureship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
Eugene J. Van Scott Award for Innovative Terapy of the
Skin and Phillip Frost Leadership Lecture . . . . . . . . . . . . . . . . 162
Guest Speakers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
Presidents Message . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Program Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15-24
Registration Information . . . . . . . . . . . . . . . . . . . . . . . . . . . 34-38
Member Instructions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34-37
Non-Member Instructions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Spouse/Guest Instructions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Confrmations and Changes . . . . . . . . . . . . . . . . . . . . . . . . 35, 38
Categories, Access, and Fees . . . . . . . . . . . . . . . . . . . . . . . . 36-37
Cancellations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Optional Activities . . . . . . . . . . . . . . . . . . . . . . . Brochure, 38, 46
Corrections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Group Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
On-site Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Restaurant Reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Scientifc Assembly Committee . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Scientifc Sessions
Tursday, February 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57-58
Friday, February 4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59-104
Friday/Saturday, February 4/5 . . . . . . . . . . . . . . . . . . . . 105-106
Saturday, February 5 . . . . . . . . . . . . . . . . . . . . . . . . . . . 107-151
Sunday, February 6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152-183
Monday, February 7 . . . . . . . . . . . . . . . . . . . . . . . . . . . 185-233
Monday/Tuesday, February 7/8. . . . . . . . . . . . . . . . . . . . 234-235
Tuesday, February 8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236-264
Scooter/Wheelchair Rental . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Shuttle Bus Service . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Target Audience . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Travel Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
REGISTRATION AND HOUSING BROCHURE
Registration and Housing Form / Ofce Staf / Registered Nurses Registration Form / Hotel Reservation Information
SEPARATE ENCLOSURE
Mon May 10 14:18:48 PDT 2010 - 647843_Ax1.ps
INDICATIONS AND USAGE
ACZONE
®
Gel, 5%, is indicated for the topical treatment of acne vulgaris.
CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
Hematological Effects
Oral dapsone treatment has produced dose-related hemolysis and hemolytic anemia.
Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are more prone to
hemolysis with the use of certain drugs. G6PD deficiency is most prevalent in populations of
African, South Asian, Middle Eastern and Mediterranean ancestry.
There was no evidence of clinically relevant hemolysis or anemia in patients treated with
ACZONE
®
Gel, 5%, including patients who were G6PD deficient. Some subjects with G6PD
deficiency using ACZONE
®
Gel developed laboratory changes suggestive of mild hemolysis.
If signs and symptoms suggestive of hemolytic anemia occur, ACZONE
®
Gel, 5% should be
discontinued. ACZONE
®
Gel, 5% should not be used in patients who are taking oral dapsone
or antimalarial medications because of the potential for hemolytic reactions. Combination
of ACZONE
®
Gel, 5%, with trimethoprim/sulfamethoxazole (TMP/SMX) may increase the
likelihood of hemolysis in patients with G6PD deficiency.
Peripheral Neuropathy
Peripheral neuropathy (motor loss and muscle weakness) has been reported with oral
dapsone treatment. No events of peripheral neuropathy were observed in clinical trials with
topical ACZONE
®
Gel, 5% treatment.
Skin
Skin reactions (toxic epidermal necrolysis, erythema multiforme, morbilliform and scarla-
tiniform reactions, bullous and exfoliative dermatitis, erythema nodosum, and urticaria) have
been reported with oral dapsone treatment. These types of skin reactions were not observed
in clinical trials with topical ACZONE
®
Gel, 5% treatment.
ADVERSE REACTIONS
Clinical Studies Experience
Because clinical trials are conducted under prescribed conditions, adverse reaction rates
observed in the clinical trials of a drug cannot be directly compared to rates in the clinical
trials of another drug and may not reflect the rates observed in practice.
Serious adverse reactions reported in patients treated with ACZONE
®
Gel, 5%, during clinical
trials included but were not limited to the following:
• Nervous system/Psychiatric – Suicide attempt, tonic clonic movements.
• Gastrointestinal – Abdominal pain, severe vomiting, pancreatitis.
• Other – Severe pharyngitis
In the clinical trials, a total of 12 out of 4032 patients were reported to have depression (3
of 1660 treated with vehicle and 9 of 2372 treated with ACZONE
®
Gel, 5%). Psychosis was
reported in 2 of 2372 patients treated with ACZONE
®
Gel, 5%, and in 0 of 1660 patients
treated with vehicle.
Combined contact sensitization/irritation studies with ACZONE
®
Gel, 5%, in 253 healthy
subjects resulted in at least 3 subjects with moderate erythema. ACZONE
®
Gel, 5%, did not
induce phototoxicity or photoallergy in human dermal safety studies.
ACZONE
®
Gel, 5%, was evaluated for 12 weeks in four controlled studies for local cutaneous
events in 1819 patients. The most common events reported from these studies include
oiliness/peeling, dryness, and erythema.
One patient treated with ACZONE
®
Gel in the clinical trials had facial swelling which led to
discontinuation of medication.
In addition, 486 patients were evaluated in a 12 month safety study. The adverse event profile
in this study was consistent with that observed in the vehicle-controlled studies.
Experience with Oral Use of Dapsone
Although not observed in the clinical trials with ACZONE
®
Gel (topical dapsone) serious
adverse reactions have been reported with oral use of dapsone, including agranulocytosis,
hemolytic anemia, peripheral neuropathy (motor loss and muscle weakness), and skin
reactions (toxic epidermal necrolysis, erythema multiforme, morbilliform and scarlatiniform
reactions, bullous and exfoliative dermatitis, erythema nodosum, and urticaria).
DRUG INTERACTIONS
Trimethoprim-Sulfomethoxazole
A drug-drug interaction study evaluated the effect of the use of ACZONE
®
Gel, 5%,
in combination with double strength (160 mg/800 mg) trimethoprim-sulfamethoxazole
(TMP/SMX). During co-administration, systemic levels of TMP and SMX were essentially
unchanged. However, levels of dapsone and its metabolites increased in the presence of
TMP/SMX. Systemic exposure (AUC
0-12
) of dapsone and N-acetyl-dapsone (NAD) were
increased by about 40% and 20% respectively in presence of TMP/SMX. Notably, systemic
exposure (AUC
0-12
) of dapsone hydroxylamine (DHA) was more than doubled in the presence
of TMP/SMX. Exposure from the proposed topical dose is about 1% of that from the 100 mg
oral dose, even when co-administered with TMP/SMX.
Topical Benzoyl Peroxide
Topical application of ACZONE
®
Gel followed by benzoyl peroxide in subjects with acne
vulgaris resulted in a temporary local yellow or orange discoloration of the skin and facial hair
(reported by 7 out of 95 subjects in a clinical study) with resolution in 4 to 57 days.
Drug Interactions with Oral Dapsone
Certain concomitant medications (such as rifampin, anticonvulsants, St. John’s wort) may
increase the formation of dapsone hydroxylamine, a metabolite of dapsone associated with
hemolysis. With oral dapsone treatment, folic acid antagonists such as pyrimethamine have
been noted to possibly increase the likelihood of hematologic reactions.
USE IN SPECIFIC POPULATIONS
Pregnancy
Teratogenic Effects: Pregnancy Category C
There are no adequate and well controlled studies in pregnant women. Dapsone has been
shown to have an embryocidal effect in rats and rabbits when administered orally in doses of
75 mg/kg/day and 150 mg/kg/day (approximately 800 and 500 times the systemic exposure
observed in human females as a result of use of the maximum recommended topical dose,
based on AUC comparisons), respectively. These effects were probably secondary to
maternal toxicity. ACZONE
®
Gel, 5%, should be used during pregnancy only if the potential
benefit justifies the potential risk to the fetus.
Nursing Mothers
Although systemic absorption of dapsone following topical application of ACZONE
®
Gel,
5%, is minimal relative to oral dapsone administration, it is known that dapsone is excreted
in human milk. Because of the potential for oral dapsone to cause adverse reactions in
nursing infants, a decision should be made whether to discontinue nursing or to discontinue
ACZONE
®
Gel, 5%, taking into account the importance of the drug to the mother.
ACZONE
®
(dapsone) Gel 5%
Pediatric Use
Safety and efficacy was evaluated in 1169 children aged 12-17 years old treated with
ACZONE
®
Gel, 5%, in the clinical studies. The adverse event rate for ACZONE
®
Gel, 5%, was
similar to the vehicle control group. Safety and efficacy was not studied in pediatric patients
less than 12 years of age, therefore ACZONE
®
Gel, 5%, is not recommended for use in this
age group.
Geriatric Use
Clinical studies of ACZONE
®
Gel, 5%, did not include sufficient number of patients aged 65
and over to determine whether they respond differently from younger patients.
G6PD Deficiency
ACZONE
®
Gel, 5% and vehicle were evaluated in a randomized, double-blind, cross-over
design clinical study of 64 patients with G6PD deficiency and acne vulgaris. Subjects were
Black (88%), Asian (6%), Hispanic (2%) or of other racial origin (5%). Blood samples were
taken at Baseline, Week 2, and Week 12 during both vehicle and ACZONE
®
Gel, 5% treatment
periods. There were 56 out of 64 subjects who had a Week 2 blood draw and applied at
least 50% of treatment applications. ACZONE
®
Gel was associated with a 0.32 g/dL drop in
hemoglobin after two weeks of treatment, but hemoglobin levels generally returned to baseline
levels at Week 12.
There were no changes from baseline in haptoglobin or lactate dehydrogenase during
ACZONE
®
or vehicle treatment at either the 2-week or 12-week time point.
The proportion of subjects who experienced decreases in hemoglobin ≥1 g/dL was similar
between ACZONE
®
Gel, 5% and vehicle treatment (8 of 58 subjects had such decreases
during ACZONE
®
treatment compared to 7 of 56 subjects during vehicle treatment among
subjects with at least one on-treatment hemoglobin assessment). Subgroups based on
gender, race, or G6PD enzyme activity did not display any differences in laboratory results
from the overall study group. There was no evidence of clinically significant hemolytic anemia
in this study. Some of these subjects developed laboratory changes suggestive of mild
hemolysis.
OVERDOSAGE
ACZONE
®
Gel, 5%, is not for oral use. If oral ingestion occurs, medical advice should be
sought.
Rx ONLY
© 2008 Allergan, Inc.
Irvine, CA 92612, U.S.A.
®
marks owned by Allergan, Inc.
U.S. Patents 5,863,560; 6,060,085; and 6,620,435
647843_8x10.5_PI.pgs - Fri May 7 00:13:11 PDT 2010
For Dermatologic Use Only–Not for Ophthalmic, Oral, or Intravaginal Use
Rx only
BRIEF SUMMARY
CONSULT PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION
INDICATIONS AND USAGE
FINACEA Gel, 15%, is indicated for topical treatment of inflammatory papules and pustules of mild
to moderate rosacea. Although some reduction of erythema which was present in patients with
papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in
rosacea in the absence of papules and pustules has not been evaluated. Patients should be
instructed to avoid spicy foods, thermally hot foods and drinks, alcoholic beverages and to use
only very mild soaps or soapless cleansing lotion for facial cleansing.
CONTRAINDICATIONS
FINACEA Gel, 15%, is contraindicated in individuals with a history of hypersensitivity to propylene
glycol or any other component of the formulation.
WARNINGS
FINACEA Gel, 15%, is for dermatologic use only, and not for ophthalmic, oral or intravaginal use.
There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid
has not been well studied in patients with dark complexion, these patients should be monitored
for early signs of hypopigmentation.
PRECAUTIONS
General: Contact with the eyes should be avoided. If sensitivity or severe irritation develops with
the use of FINACEA Gel, 15%, treatment should be discontinued and appropriate therapy instituted.
In a transgenic mouse study, chronic use of FINACEA Gel led to an increased number of animals
with papillomas at the treatment site (see PRECAUTIONS: Carcinogenesis, Mutagenesis, and
Impairment of Fertility). The clinical relevance of the findings in animal studies to humans is not clear.
Information for Patients: Patients using FINACEA Gel, 15%, should receive the following
information and instructions:
• FINACEA Gel, 15%, is to be used only as directed by the physician.
• FINACEA Gel, 15%, is for external use only. It is not to be used orally, intravaginally, or for the eyes.
• Cleanse affected area(s) with a very mild soap or a soapless cleansing lotion and pat dry with a
soft towel before applying FINACEA Gel, 15%. Avoid alcoholic cleansers, tinctures and astringents,
abrasives and peeling agents.
• Avoid contact of FINACEA Gel, 15%, with the mouth, eyes and other mucous membranes. If it
does come in contact with the eyes, wash the eyes with large amounts of water and consult a
physician if eye irritation persists.
• The hands should be washed following application of FINACEA Gel, 15%.
• Cosmetics may be applied after FINACEA Gel, 15%, has dried.
• Skin irritation (e.g., pruritus, burning, or stinging) may occur during use of FINACEA Gel,
15%, usually during the first few weeks of treatment. If irritation is excessive or persists, use
of FINACEA Gel, 15%, should be discontinued, and patients should consult their physician
(See ADVERSE REACTIONS).
• Avoid any foods and beverages that might provoke erythema, flushing, and blushing (including
spicy food, alcoholic beverages, and thermally hot drinks, including hot coffee and tea).
• Patients should report abnormal changes in skin color to their physician.
• Avoid the use of occlusive dressings or wrappings.
Drug Interactions: There have been no formal studies of the interaction of FINACEA Gel, 15%,
with other drugs.
Carcinogenesis, Mutagenesis, Impairment of Fertility:
Systemic long-term animal studies have not been performed to evaluate the carcinogenic potential
of azelaic acid. In a 26-week dermal carcinogenicity study using transgenic (Tg.AC) mice, FINACEA
Gel, 15%, and the gel vehicle, when applied once or twice daily, did not increase the number of
female Tg.AC animals with papillomas at the treatment site. No statistically significant increase in
the number of animals with papillomas at the treatment site was observed in male Tg.AC animals
after once daily application. After twice daily application, FINACEA Gel, 15%, and the gel vehicle
induced a statistically significant increase in the number of male animals with papillomas at the
treatment site when compared to untreated males. This suggests that the positive effect may be
associated with the vehicle application. The clinical relevance of the findings in animals to humans
is not clear.
Azelaic acid was not mutagenic or clastogenic in a battery of in vitro (Ames assay, HGPRT in V79
cells {Chinese hamster lung cells}, and chromosomal aberration assay in human lymphocytes)
and in vivo (dominant lethal assay in mice and mouse micronucleus assay) genotoxicity tests.
Oral administration of azelaic acid at dose levels up to 2500 mg/kg/day (162 times the maximum
recommended human dose based on body surface area) did not affect fertility or reproductive
performance in male or female rats.
Pregnancy: Teratogenic Effects: Pregnancy Category B
There are no adequate and well-controlled studies of topically administered azelaic acid in pregnant
women. The experience with FINACEA Gel, 15%, when used by pregnant women is too limited to
permit assessment of the safety of its use during pregnancy.
Dermal embryofetal developmental toxicology studies have not been performed with azelaic acid,
15%, gel. Oral embryofetal developmental studies were conducted with azelaic acid in rats, rabbits,
and cynomolgus monkeys. Azelaic acid was administered during the period of organogenesis in
all three animal species. Embryotoxicity was observed in rats, rabbits, and monkeys at oral doses
of azelaic acid that generated some maternal toxicity. Embryotoxicity was observed in rats given
2500 mg/kg/day (162 times the maximum recommended human dose based on body surface
area), rabbits given 150 or 500 mg/kg/day (19 or 65 times the maximum recommended human
dose based on body surface area) and cynomolgus monkeys given 500 mg/kg/day (65 times the
maximum recommended human dose based on body surface area) azelaic acid. No teratogenic
effects were observed in the oral embryofetal developmental studies conducted in rats, rabbits
and cynomolgus monkeys.
An oral peri- and post-natal developmental study was conducted in rats. Azelaic acid was administered
from gestational day 15 through day 21 postpartum up to a dose level of 2500 mg/kg/day.
Embryotoxicity was observed in rats at an oral dose that generated some maternal toxicity (2500
mg/kg/day; 162 times the maximum recommended human dose based on body surface area). In
addition, slight disturbances in the post-natal development of fetuses was noted in rats at oral
doses that generated some maternal toxicity (500 and 2500 mg/kg/day; 32 and 162 times
the maximum recommended human dose based on body surface area). No effects on sexual
maturation of the fetuses were noted in this study.
Because animal reproduction studies are not always predictive of human response, this drug should
be used only if clearly needed during pregnancy.
Nursing Mothers: Equilibrium dialysis was used to assess human milk partitioning in vitro. At an
azelaic acid concentration of 25 µg/mL, the milk/plasma distribution coefficient was 0.7 and the
milk/buffer distribution was 1.0, indicating that passage of drug into maternal milk may occur.
Since less than 4% of a topically applied dose of azelaic acid cream, 20%, is systemically absorbed,
the uptake of azelaic acid into maternal milk is not expected to cause a significant change from
baseline azelaic acid levels in the milk. However, caution should be exercised when FINACEA Gel,
15%, is administered to a nursing mother.
Pediatric Use: Safety and effectiveness of FINACEA Gel, 15%, in pediatric patients have not been
established.
Geriatric: Clinical studies of FINACEA Gel, 15%, did not include sufficient numbers of subjects
aged 65 and over to determine whether they respond differently from younger subjects.
ADVERSE REACTIONS
Overall, treatment related adverse events, including burning, stinging/ tingling, dryness/tightness/
scaling, itching, and erythema/irritation/ redness, were 19.4% (24/124) for FINACEA Gel, 15%,
and 7.1% (9/127) for the active comparator gel at 15 weeks.
In two vehicle controlled, and one active controlled U.S. clinical studies, treatment safety was
monitored in 788 patients who used twice daily FINACEA Gel, 15%, for 12 weeks (N=333) or for
15 weeks (N=124), or the gel vehicle (N=331) for 12 weeks.
Table 3. Cutaneous Adverse Events Occurring in ≥1% of Subjects in the Rosacea Trials by
Treatment Group and Maximum Intensity*
FINACEA Gel, 15% Vehicle
N=457 (100%) N=331 (100%)
Mild Moderate Severe Mild Moderate Severe
n=99 n=61 n=27 n=46 n=30 n=5
(22%) (13%) (6%) (14%) (9%) (2%)
Burning/
stinging/
tingling 71 (16%) 42 (9%) 17 (4%) 8 (2%) 6 (2%) 2 (1%)
Pruritus 29 (6%) 18 (4%) 5 (1%) 9 (3%) 6 (2%) 0 (0%)
Scaling/dry
skin/xerosis 21 (5%) 10 (2%) 5 (1%) 31 (9%) 14 (4%) 1 (<1%)
Erythema/
irritation 6 (1%) 7 (2%) 2 (<1%) 8 (2%) 4 (1%) 2 (1%)
Contact
dermatitis 2 (<1%) 3 (1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%)
Edema 3 (1%) 2 (<1%) 0 (0%) 3 (1%) 0 (0%) 0 (0%)
Acne 3 (1%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%)
*Subjects may have >1 cutaneous adverse event; thus, the sum of the frequencies of preferred
terms may exceed the number of subjects with at least 1 cutaneous adverse event.
FINACEA Gel, 15%, and its vehicle caused irritant reactions at the application site in human dermal
safety studies. FINACEA Gel, 15%, caused significantly more irritation than its vehicle in a cumulative
irritation study. Some improvement in irritation was demonstrated over the course of the clinical
studies, but this improvement might be attributed to subject dropouts. No phototoxicity or
photoallergenicity were reported in human dermal safety studies.
In patients using azelaic acid formulations, the following additional adverse experiences have been
reported rarely: worsening of asthma, vitiligo depigmentation, small depigmented spots, hypertrichosis,
reddening (signs of keratosis pilaris), and exacerbation of recurrent herpes labialis.
Post-marketing safety-Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure
with FINACEA Gel, 15%, to the eye (see PRECAUTIONS).
Distributed under license; U.S. Patent No 6,534,070
www.myfinacea.com
©2010, Intendis, Inc. All rights reserved, July 2010
Manufactured by Intendis Manufacturing S.p.A., Segrate, Milan, Italy
Distributed by:
Morristown, NJ 07962
6706803BS
Intendis is part of the Bayer Group
Finacea
(azelaic acid) Gel,15%
®








A
d
d
i
t
i
o
n
a
l

p
a
tient b
e
n
e
f
i
t
s











M
u
l
t
i
p
l
e

m
e
c
h
a
n
is
m
s
o
f
a
c
t
i
o
n

o
f

A
z
A








C
o
n
t
i
n
u
o
u
s

i
m
p
r
o
v
e
m
e
n
t

i
n

l
e
s
io
n
s

a
n
d

e
r
y
t
h
e
m
a
2
,
3








3
6
-
w
e
e
k

m
a
i
n
t
e
n
ance
d
a
t
a
4








A
d
d
i
t
i
o
n
a
l

p
a
t
ient b
e
n
e
f
i
t
s
*










M
u
l
t
i
p
l
e

m
e
c
h
a
n
is
m
s
o
f a
c
t
i
o
n

o
f

A
z
A
1
*myfinaceaskinsavvy.com – a website for patient support and education
Finacea is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some
reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy
for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.
Finacea is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. Finacea is contraindicated in individuals with
a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/
stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing
safety—Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports
of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexion,
these patients should be monitored for early signs of hypopigmentation.
Please see brief summary of full Prescribing Information on following page.
References: 1. Draelos ZD, Kayne AL. Implications of azelaic acid’s multiple mechanisms of action: therapeutic versatility. Poster presented at: 66th Annual Meeting of the American Academy of
Dermatology; February 1-5, 2008, San Antonio, TX. 2. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results
from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48(6):836-845. FINACEA was only studied in clinical trials for 12 weeks. 3. Elewski BE, Fleischer AB,
Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:
1444-1450. 4. Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich P. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel
as maintenance monotherapy. J Drugs Dermatol. 2009;8(7):639-648.
®
©2009 Intendis, Inc. All rights reserved. 09-JA-004 October 2009
8
ja
1
Q1 Q2
Cosmos Communications 718.482.1800
12764a1 10.06.09 133
C M Y K
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
15
PROGRAM OVERVIEW
P
R
O
G
R
A
M

O
V
E
R
V
I
E
W
THURSDAY, FEBRUARY 3
Course — 8:00 a.m. to 1:00 p.m.
C001 Volunteers Abroad Course: Beginner . . . . . . . . . .57
Course — 1:00 p.m. to 5:00 p.m.
C002 Volunteers Abroad Course: Advanced . . . . . . . . . .58
FRIDAY, FEBRUARY 4
Course — 7:00 a.m. to 9:00 a.m.
C06A Basic Self-Assessment of Dermatopathology . . . . .64
Discussion Groups — 7:15 a.m. to 8:45 a.m.
D001 Pregnancy Dermatoses: Moving Towards a
Better Understanding . . . . . . . . . . . . . . . . . . . . . .64
D002 Appropriate Uses of Lasers . . . . . . . . . . . . . . . . . .64
Focus Sessions — 7:15 a.m. to 8:45 a.m.
U001 Tricks of the Blade . . . . . . . . . . . . . . . . . . . . . . . .65
U002 Management of Post-Acne Scarring . . . . . . . . . . .65
U003 Management of High-Risk Squamous
Cell Carcinoma (SCC) . . . . . . . . . . . . . . . . . . . . .65
U004 Advances in Web-Based Medical Education:
How Best to Teach Dermatology . . . . . . . . . . . . .66
U005 High-Yield “Power Hour” for Residents . . . . . . . .66
U006 International Teledermatology Overview. . . . . . . .66
U007 Ectodermal Dysplasias . . . . . . . . . . . . . . . . . . . . .66
U008 Recognition and Management of
High-Risk Skin Cancer . . . . . . . . . . . . . . . . . . . .67
U009 Phototherapy and Photochemotherapy:
Nuances and Peals for the Practicing Clinician . . .67
U010 Te Tzanck Smear Test: Reintroducing Our Good
Old Friend! . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .67
U011 Medical and Aesthetic Dermatology in
Skin of Color . . . . . . . . . . . . . . . . . . . . . . . . . . . .68
U012 Leading with Your Strengths . . . . . . . . . . . . . . . . .68
U013 Vitamin D and Dermatology . . . . . . . . . . . . . . . .68
Forums — 9:00 a.m. to 11:00 a.m.
F001 Advanced Medical Dermatology . . . . . . . . . . . . . .69
F002 Erosive Vulvar Diseases: Approach to Diagnosis,
Diferential Diagnosis, and Treatment. . . . . . . . . .69
F003 Case-Based Challenges in Pediatric Dermatology 70
F004 Geriatric Dermatology: Advanced Cases . . . . . . . .70
F005 Board Blitz . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .71
F006 Vitiligo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .71
F007 Management of Difcult Wounds. . . . . . . . . . . . .72
F008 Decreasing Iatrogenic Problems
in Your Practice. . . . . . . . . . . . . . . . . . . . . . . . . . .72
Workshop — 9:00 a.m. to 11:00 a.m.
W001 MOC Self-Assessment A. . . . . . . . . . . . . . . . . . . .72
Courses — 9:00 a.m. to 12:00 p.m.
C003 Pediatric Dermatology . . . . . . . . . . . . . . . . . . . . .73
C004 Diagnosis and Terapeutics:
Te Fundamentals. . . . . . . . . . . . . . . . . . . . . . . . .74
C005 Basic Contact Dermatitis . . . . . . . . . . . . . . . . . . .74
Symposia — 9:00 a.m. to 12:00 p.m.
S001 Disorders of Pigmentation . . . . . . . . . . . . . . . . . .75
S002 Alopecia: Workup and Treatment . . . . . . . . . . . . .75
S003 Hot Topics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .76
S004 When Bad Tings Happen to Good Doctors . . . .76
S005 Leading from Your Vision to Exceptional Service 77
S006 Approach to Pigmented Lesions . . . . . . . . . . . . . .78
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
Practice Management Session open to eligible
offce staff/registered nurses
Represents Patient Safety Session in program overviews
Patient Safety Session
Represents Audience Response System Session
Audience Response System Session
Represents activities that meet MOC-D

M
O
C
This activity has been approved by the ABD to satisfy
component 2 of MOC-D
Represents Leadership Institute in program overviews
Leadership Institute — addresses leadership
competencies specifc to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
16
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
PROGRAM OVERVIEW
P
R
O
G
R
A
M

O
V
E
R
V
I
E
W
Courses — 9:00 a.m. to 5:00 p.m.
C007 Immunology . . . . . . . . . . . . . . . . . . . . . . . . . . . . .79
C008 Derm Exam Prep Course: Refresher . . . . . . . . . . .79
Course — 9:30 a.m. to 11:30 a.m.
C06B Basic Self-Assessment of Dermatopathology . . . . .80
Forums — 12:00 p.m. to 2:00 p.m.
F009 Photobiology for Dermatologists . . . . . . . . . . . . .80
F010 Hidradenitis Suppurativa: An Update . . . . . . . . . .81
F011 Dermatopathology Made Simple . . . . . . . . . . . . .81
F012 Update on Genetic Skin Disease. . . . . . . . . . . . . .82
F013 EHR Implementation, Maintenance, and
Lessons Learned . . . . . . . . . . . . . . . . . . . . . . . . . .82
F014 Challenging Diagnostic Cases for Advanced
Practitioners: PA/NP I . . . . . . . . . . . . . . . . . . . . .83
F015 Ethical Economics in Dermatology and
Dermatologic Surgery . . . . . . . . . . . . . . . . . . . . . .83
F016 Advances in Dermatologic Surgery . . . . . . . . . . . .84
Discussion Groups — 12:15 p.m. to 1:45 p.m.
D003 Selected Topics in Medical Dermatology. . . . . . . .84
D004 Dealing with Disappointing Outcomes and
Medical Mistakes . . . . . . . . . . . . . . . . . . . . . . . . .84
Focus Sessions — 12:15 p.m. to 1:45 p.m.
U014 When Acne Really Isn’t Acne . . . . . . . . . . . . . . . .85
U015 Merkel Cell Carcinoma. . . . . . . . . . . . . . . . . . . . .85
U016 Sports Dermatology —
Skin Infections in Athletes . . . . . . . . . . . . . . . . . .85
U017 Clincial Trials for the Private Practitioner . . . . . . .86
U018 Outcomes Research in Dermatology. . . . . . . . . . .86
U019 Sun, Drugs, and Invervention: How to Prevent
Non-Melanoma Skin Cancer . . . . . . . . . . . . . . . .87
U020 Challenging Diagnostic Cases for Advanced
Practitioners: PA/NP II. . . . . . . . . . . . . . . . . . . . .87
U021 Acne in the Adult Female Patient . . . . . . . . . . . . .87
U022 Vulvar Dermatoses . . . . . . . . . . . . . . . . . . . . . . . .87
U023 Highlights from JAAD . . . . . . . . . . . . . . . . . . . . .88
U024 Leading Confdently through Powerful
Communication . . . . . . . . . . . . . . . . . . . . . . . . . .88
U025 A Personalized Planner for Rejuvenation. . . . . . . .88
U026 Teledermatology 101: Integrating Teledermatology
into Your Practice . . . . . . . . . . . . . . . . . . . . . . . . .89
Course — 12:30 p.m. to 2:30 p.m.
C06C Basic Self-Assessment of Dermatopathology . . . . .89
Courses — 2:00 p.m. to 5:00 p.m.
C009 Dermatologic Syndromes and Genetic Disorders 90
C010 Advanced Contact Dermatitis. . . . . . . . . . . . . . . .90
C011 Live Patient Demonstration: Te State of the
Art of Aesthetic Dermatology . . . . . . . . . . . . . . . .91
Symposia — 2:00 p.m. to 5:00 p.m.
S008 Consultative Dermatology for the
Hospitalized Patient . . . . . . . . . . . . . . . . . . . . . . .91
S009 Advanced Medical Dermatology . . . . . . . . . . . . . .92
S010 Surviving Healthcare Reform . . . . . . . . . . . . . . . .92
S011 Terapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . .93
S012 Aging Gracefully . . . . . . . . . . . . . . . . . . . . . . . . . .93
S013 Leading Others for Peak Performance. . . . . . . . . .94
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
Practice Management Session open to eligible
offce staff/registered nurses
Represents Patient Safety Session in program overviews
Patient Safety Session
Represents Audience Response System Session
Audience Response System Session
Represents activities that meet MOC-D

M
O
C
This activity has been approved by the ABD to satisfy
component 2 of MOC-D
Represents Leadership Institute in program overviews
Leadership Institute — addresses leadership
competencies specifc to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
PROGRAM OVERVIEW
P
R
O
G
R
A
M

O
V
E
R
V
I
E
W
Discussion Groups — 2:30 p.m. to 4:00 p.m.
D005 Dermatoethics: Contemporary Issues
in Ethics and Professionalism . . . . . . . . . . . . . . . .94
D006 Serologic Testing for Connective Tissue Diseases 94
Focus Sessions — 2:30 p.m. to 4:00 p.m.
U027 Practical Approaches to Medical and Cosmetic
Dermatology in Skin of Color . . . . . . . . . . . . . . .95
U028 Oral Ulcers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .95
U029 Skin Cancer in Patients with Non-Melanoma
Hodgkin’s Lymphoma. . . . . . . . . . . . . . . . . . . . . .96
U030 Treatment of Pediatric Psoriasis. . . . . . . . . . . . . . .96
U031 Dermatomyositis. . . . . . . . . . . . . . . . . . . . . . . . . .97
U032 Chronic Infammatory Hand and
Foot Dermatoses . . . . . . . . . . . . . . . . . . . . . . . . . .97
U033 Electrolysis: When Laser Isn’t the Answer . . . . . . .98
U034 Pediatric Hyperhidrosis and Ectodermal Dysplasia:
To Sweat or Not to Sweat? . . . . . . . . . . . . . . . . . .98
U035 Paraneoplastic Dermatoses . . . . . . . . . . . . . . . . . .98
U036 Subcutaneous Fat in Dermatology . . . . . . . . . . . .98
U037 Paraneoplastic Autoimmune Multiorgan
Syndrome (PAMS) . . . . . . . . . . . . . . . . . . . . . . . .99
Course — 3:00 p.m. to 5:00 p.m.
C06D Basic Self-Assessment of Dermatopathology . . . . .99
Forums — 3:00 p.m. to 5:00 p.m.
F017 Resident Jeopardy . . . . . . . . . . . . . . . . . . . . . . . .100
F018 Atopic Dermatitis . . . . . . . . . . . . . . . . . . . . . . . .100
F019 Journal Watching . . . . . . . . . . . . . . . . . . . . . . . .101
F020 Volunteerism and Humanitarianism. . . . . . . . . .101
F021 FDA Presents: Information for Dermatologists. . .102
F022 Coding and Ofce Management. . . . . . . . . . . . .102
F023 Psoriasis Guidelines: Implementing Tem in
Your Practice. . . . . . . . . . . . . . . . . . . . . . . . . . . .103
Workshops — 3:00 p.m. to 5:00 p.m.
W002 Dermatology Speaker Development . . . . . . . . . .104
W003 MOC Self-Assessment: Dermatopathology. . . . .104
FRIDAY/SATURDAY, FEBRUARY 4/5
Course — 9:00 a.m. to 5:00 p.m.
C012 Structure and Function of the Skin . . . . . . . . . . 105
Symposium — 9:00 a.m. to 5:00 p.m.
S007 Gross and Microscopic Dermatology . . . . . . . . .106
SATURDAY, FEBRUARY 5
Poster Discussion Sessions — 7:15 a.m. to 8:45 a.m.
PD01 Surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .112
PD02 Clinical Dermatology . . . . . . . . . . . . . . . . . . . . .112
Discussion Groups — 7:15 a.m. to 8:45 a.m.
D007 Leading from Confict to Resolution . . . . . . . . .113
D008 PUVA and Phototherapy Beyond Psoriasis . . . . .113
Focus Sessions — 7:15 a.m. to 8:45 a.m.
U038 Nanotechnology . . . . . . . . . . . . . . . . . . . . . . . . .114
U039 Good Closures Gone Bad: A Story of Blood,
Pus, and Tears . . . . . . . . . . . . . . . . . . . . . . . . . . .114
U040 Military Unique Dermatology . . . . . . . . . . . . . .114
U041 Uncommon Cutaneous Infections:
Clinical and Histologic Features . . . . . . . . . . . . .114
U042 Te Vices of Devices in Dermatology . . . . . . . . .115
U043 Dermatopathology Challenges Encountered
by the Mohs Surgeon . . . . . . . . . . . . . . . . . . . . .115
U044 Tumescent Liposuction, Lasers, and New Devices:
A State-of-the-Art Liposuction Practice. . . . . . . .115
U045 Non-cultured Epidermal Suspension in Vitiligo:
From Lab to Clinic . . . . . . . . . . . . . . . . . . . . . . .116
U046 Social Media and Dermatology: How Twitter and
Facebook Will Help You and Your Practice. . . . .116
U047 Mini - MBA for the Dermatologist. . . . . . . . . . .116
U048 Challenging Cases in Pediatric Dermatology. . . .117
Forums — 9:00 a.m. to 11:00 a.m.
F024 Evaluation and Management of Hemangiomas. .117
F025 Dramatic Oral Disease . . . . . . . . . . . . . . . . . . . .118
F026 Chronic Urticaria and Angioedema:
What’s New in Pathogenesis and Treatment . . . .118
F027 Practical Approaches to Patient Problems . . . . . .119
F028 What You Need to Know About Coding
But Were Afraid to Ask. . . . . . . . . . . . . . . . . . . .119
F029 Acne and Rosacea Update. . . . . . . . . . . . . . . . . .120
F030 Managing Online Reputation . . . . . . . . . . . . . . .120
F031 Food Allergy and Dermatology. . . . . . . . . . . . . .121
Workshop — 9:00 a.m. to 11:00 a.m.
W004 MOC Self-Assessment: Procedural
Dermatology. . . . . . . . . . . . . . . . . . . . . . . . . . . .121
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
17
18
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
PROGRAM OVERVIEW
P
R
O
G
R
A
M

O
V
E
R
V
I
E
W
Courses — 9:00 a.m. to 12:00 p.m.
C06E Basic Self-Assessment of Dermatopathology
Discussion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .122
C013 Advanced Botulinum Toxin:
Live Patient Demonstration . . . . . . . . . . . . . . . .122
C014 Coding, Documentation, and Practice
Management . . . . . . . . . . . . . . . . . . . . . . . . . . . .123
Symposia — 9:00 a.m. to 12:00 p.m.
S014 Patient Safety and Quality . . . . . . . . . . . . . . . . .124
S015 Advanced Pediatric Dermatology . . . . . . . . . . . .125
S016 Drug Actions . . . . . . . . . . . . . . . . . . . . . . . . . . .125
S017 Terapeutic Decision Making in
Cutaneous Oncology . . . . . . . . . . . . . . . . . . . . .126
S018 Late-Breaking Research. . . . . . . . . . . . . . . . . . . .126
Courses — 9:00 a.m. to 5:00 p.m.
C015 Internal Medicine . . . . . . . . . . . . . . . . . . . . . . . .127
C016 Advanced Self-Assessment of Dermatopathology 127
C017 Advanced Dermoscopy . . . . . . . . . . . . . . . . . . . .128
Forums — 12:00 p.m. to 2:00 p.m.
F032 Multidisciplinary Preventive Networking in
Occupational Contact Dermatitis . . . . . . . . . . . .129
F033 Introduction to Oral Dermatology . . . . . . . . . . .130
F034 From the Dermatology Rheumatology Clinics:
Practical Tips and Advances in Management . . .130
F035 Practical Aspects of Biologic Terapy . . . . . . . . .131
F036 Careers in Academic Dermatology . . . . . . . . . . .131
F037 Pediatric Dermatology: Systemic Evaluation of
Cutaneous Findings in Infants and Children:
What’s New and What’s True?. . . . . . . . . . . . . . .132
F038 Itch . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .132
Workshop — 12:00 p.m. to 2:00 p.m.
W005 MOC Self-Assessment:
Pediatric Dermatology . . . . . . . . . . . . . . . . . . . .133
Discussion Groups — 12:15 p.m. to 1:45 p.m.
D009 Educate Your Patients and Improve Outcomes . .133
D010 Recent Advances in Skin Biology and
Skin Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . .133
Focus Sessions — 12:15 p.m. to 1:45 p.m.
U049 Avoiding Complications and Maximizing Results
in Cutaneous Laser Surgery. . . . . . . . . . . . . . . . .134
U050 Viral Exanthem Update . . . . . . . . . . . . . . . . . . .134
U051 Terapy for Lipodermatosclerosis,
Venous Ulceration, and Atrophie Blanche. . . . . .134
U052 Diseases of Male Genitalia . . . . . . . . . . . . . . . . .134
U053 Trough the Looking Glass: Te Use of
Dermoscopy in the Management of the
Pigmented Lesion Patient . . . . . . . . . . . . . . . . . .135
U054 Building Beauty: Understanding Facial
Proportions, Phi, and the Use of Volumizing
Soft Tissue Fillers . . . . . . . . . . . . . . . . . . . . . . . .135
U055 Practical Approaches to Cosmeceuticals . . . . . . .135
U056 Recommended Screening Practices in
Medical Dermatology . . . . . . . . . . . . . . . . . . . . .136
U057 Procedural Safety in Dermatology. . . . . . . . . . . .136
U058 From Stem To Skin: Precursor Cells Tat Have
a Lot of Potential . . . . . . . . . . . . . . . . . . . . . . . .136
U059 Potpourri of CPC . . . . . . . . . . . . . . . . . . . . . . . .136
U060 Stress, the Nervous System, and Cutaneous
Immunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .137
Courses — 2:00 p.m. to 5:00 p.m.
C018 Dermatologic Drug Safety and Efcacy . . . . . . .137
C019 Hair and Nails . . . . . . . . . . . . . . . . . . . . . . . . . .138
C020 Live Patient Demonstrations: Application of
Our Aesthetic Toolbox for the Treatment of
Medical and Dermatologic Disorders . . . . . . . . .139
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
Practice Management Session open to eligible
offce staff/registered nurses
Represents Patient Safety Session in program overviews
Patient Safety Session
Represents Audience Response System Session
Audience Response System Session
Represents activities that meet MOC-D

M
O
C
This activity has been approved by the ABD to satisfy
component 2 of MOC-D
Represents Leadership Institute in program overviews
Leadership Institute — addresses leadership
competencies specifc to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
19
PROGRAM OVERVIEW
P
R
O
G
R
A
M

O
V
E
R
V
I
E
W
Symposia — 2:00 p.m. to 5:00 p.m.
S019 Rheumatologic Dermatology . . . . . . . . . . . . . . .139
S020 Birthmarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . .140
S021 Skin of Color . . . . . . . . . . . . . . . . . . . . . . . . . . .141
S022 Acne and Rosacea . . . . . . . . . . . . . . . . . . . . . . . .142
S023 Teledermatology . . . . . . . . . . . . . . . . . . . . . . . . .143
Discussion Groups — 2:30 p.m. to 4:00 p.m.
D011 Women With Hair Loss . . . . . . . . . . . . . . . . . . .144
D012 Aging Skin: Mechanism-Based Rejuvenation . . .144
Focus Sessions — 2:30 p.m. to 4:00 p.m.
U061 Calciphylaxis. . . . . . . . . . . . . . . . . . . . . . . . . . . .144
U062 Herpes Simplex and Varicella Zoster Virus . . . . .144
U063 Dermatoscopy. . . . . . . . . . . . . . . . . . . . . . . . . . .145
U064 Helping You Meet Component 4 of MOC. . . . .145
U065 Dermoscopy: It’s Time for A Quiz . . . . . . . . . . .145
U066 Compliance in Pharmaceutical Development:
What You Need to Know . . . . . . . . . . . . . . . . . .145
U067 Twists and Splits: How to Approach Hair Shaft
Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .146
U068 Electrosurgery Update. . . . . . . . . . . . . . . . . . . . .146
U069 Half-Truths, Lies, and Statistics: Understanding
Medical Statistics for the Practitioner . . . . . . . . .146
U070 Getting Started with Interpolation Flaps. . . . . . .146
U071 Warts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .147
U072 Pediatric Dermatologic Surgery in the
Outpatient Setting: Tricks of the Trade . . . . . . . .147
Forums — 3:00 p.m. to 5:00 p.m.
F039 Treating Severe Skin Disease in Children . . . . . .147
F040 Resident Transitions . . . . . . . . . . . . . . . . . . . . . .148
F041 Finessing Facial Reconstruction. . . . . . . . . . . . . .148
F042 Hair and Nail Clinicopathologic Correlations. . .149
F043 Role of Dermatologist in Management of Skin
Disease in Solid Organ Transplant Recipients . . .149
F044 Dermatology Teaching and Education Group. . .150
F045 Rosacea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .150
F046 Leading Your Team by Coaching
and Mentoring . . . . . . . . . . . . . . . . . . . . . . . . . .150
Workshops — 3:00 p.m. to 5:00 p.m.
W006 MOC Self-Assessment: Contact Dermatology . .151
SUNDAY, FEBRUARY 6
Discussion Groups — 7:00 a.m. to 8:00 a.m.
D013 Challenging Pediatric Dermatology Cases. . . . . .154
D014 Advances in Pemphigus and Pemphigoid . . . . . .154
Focus Sessions — 7:00 a.m. to 8:00 a.m.
U073 Amyloidosis: Changing Our
View in Dermatology . . . . . . . . . . . . . . . . . . . . .154
U074 Eczema Centers: World Experiences . . . . . . . . . .154
U075 Drug Safety: Do No Harm . . . . . . . . . . . . . . . .155
U076 Immunofuorescence in Dermatopathology . . . .155
U077 Hair Disease and the African American Patient .155
U078 Case-Based Approach to Lentigo Maligna. . . . . .156
U079 Dermatologic Disease in Asians . . . . . . . . . . . . .156
U080 Uncommon Neonatal Dermatosis . . . . . . . . . . .156
U081 Medical and Surgical Practice . . . . . . . . . . . . . . .156
U082 Practical and Realistic Ofce Mycology for the
Epidemiology, Diagnosis, and Treatment of
Human Mycoses . . . . . . . . . . . . . . . . . . . . . . . . .157
U083 Hair Highlights: Common and Challenging
Hair Loss Disorders . . . . . . . . . . . . . . . . . . . . . .157
U084 Climate Change, Allergy, and the Skin . . . . . . . .157
U085 Emerging Laser and Aesthetic Technology . . . . .158
P151 Plenary Session — 8:00 a.m. to 12:00 p.m.
8:00 a.m. Business and Bagels . . . . . . . . . . . . . . . . . . . . . .159
8:45 a.m. Welcome
Lawrence M. Eichenfeld, M.D. . . . . . . . . . . . . . .159
8:50 a.m. Clarence S. Livingood, M.D.,
Award and Lectureship
Neil S. Prose, M.D. . . . . . . . . . . . . . . . . . . . . . . .159
9:15 a.m. Introduction of President/President’s Address
William D. James, M.D. . . . . . . . . . . . . . . . . . . .160
9:45 a.m. Marion B. Sulzberger, M.D., Memorial Award
and Lectureship
Tomas S. Kupper, M.D. . . . . . . . . . . . . . . . . . . .160
10:15 a.m. President-Elect’s Address
Ronald L. Moy, M.D. . . . . . . . . . . . . . . . . . . . . .161
10:30 a.m. Lila Gruber Memorial Cancer Research
Award and Lectureship
W. Marston Linehan, M.D. . . . . . . . . . . . . . . . . .161
11:00 a.m. Eugene J. Van Scott Award for
Innovative Terapy of the Skin and
Phillip Frost Leadership Lecture
Anton Stuetz, Ph.D. . . . . . . . . . . . . . . . . . . . . . .162
11:30 a.m. Guest Speakers
Mary Matalin and James Carville. . . . . . . . . . . . .162

Symposium — 11:00 a.m. to 2:00 p.m.
S024 Residents and Fellows Symposium . . . . . . . . . . .163
20
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
PROGRAM OVERVIEW
P
R
O
G
R
A
M

O
V
E
R
V
I
E
W


Discussion Groups — 12:15 p.m. to 1:45 p.m.
D015 Urticaria and Angioedema . . . . . . . . . . . . . . . . .159
D016 Photodermatology . . . . . . . . . . . . . . . . . . . . . . .159
Poster Discussion Sessions — 12:15 p.m. to 1:45 p.m.
PD03 Acne . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .164
PD04 Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .164
Focus Sessions — 12:15 p.m. to 1:45 p.m.
U086 Melasma: Pathogenesis and Treatment . . . . . . . .165
U087 Fulflling Great Expectations: Caring for
New Mothers and Mothers-to-Be . . . . . . . . . . . .165
U088 Hereditary Diseases of the Epidermis . . . . . . . . .165
U089 Lasers 101. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .166
U090 Angiogenesis and Clinical Dermatology . . . . . . .166
U091 Challenging Cases in Dermatopathology . . . . . .166
U092 Opening Your Own Practice:
Blunders and Breakthroughs . . . . . . . . . . . . . . . .166
U093 Notes of a Terapeutic Iconoclast . . . . . . . . . . . .167
U094 Dermatologic Manifestations of HIV and AIDS 167
U095 Biologic Drugs for Psoriasis:
Do We Use Tem Enough?. . . . . . . . . . . . . . . . .167
U096 Medical Terapies and How Tey Work. . . . . . .167
U097 Immunostimulatory Treatment of Skin Cancer. .168
Symposia — 2:00 p.m. to 5:00 p.m.
S025 New Emerging Terapies . . . . . . . . . . . . . . . . . .168
S026 Cutaneous Oncology . . . . . . . . . . . . . . . . . . . . .169
S027 Contact and Occupational Dermatitis . . . . . . . .170
S028 Nails . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .171
S029 Lessons from Great Leaders . . . . . . . . . . . . . . . .172
S030 Electronic Health Record (EHR) Physician
Demonstration Symposium . . . . . . . . . . . . . . . .172
S031 Tropical Dermatology . . . . . . . . . . . . . . . . . . . . .173
Discussion Groups — 2:30 p.m. to 4:00 p.m.
D017 Churning Out the Learning . . . . . . . . . . . . . . . .173
D018 Practice Tips and Surgical Gems . . . . . . . . . . . . .173
Focus Sessions — 2:30 p.m. to 4:00 p.m.
U098 HIT EMRs and Documenting Clinical Care:
Pitfalls and Promises . . . . . . . . . . . . . . . . . . . . .174
U099 Lumps and Bumps in Children. . . . . . . . . . . . . .174
U100 Current Management of Skin Cancer in
Transplant Patients . . . . . . . . . . . . . . . . . . . . . . .175
U101 Pediatric Drug Eruptions . . . . . . . . . . . . . . . . . .175
U102 From Pigment to PUPP (or PEP): What to Expect
When Your Patient is Expecting . . . . . . . . . . . . .175
U103 Drug Reaction Update 2011. . . . . . . . . . . . . . . .176
U104 Cosmeceuticals: Topical Terapies for Treating
the Aging Face . . . . . . . . . . . . . . . . . . . . . . . . . .176
U105 Advances in Fat Transfer and Liposuction for
Correction of Lipodystrophy: Te USC
Experience . . . . . . . . . . . . . . . . . . . . . . . . . . . . .176
U106 What’s Tat? Syndrome Update . . . . . . . . . . . . .176
U107 Dermatology in Cinema . . . . . . . . . . . . . . . . . . .177
U108 Safety of Biologic Terapies: What’s the
Real Story? . . . . . . . . . . . . . . . . . . . . . . . . . . . . .177
Forums — 3:00 p.m. to 5:00 p.m.
F047 Managing an Efcient Practice . . . . . . . . . . . . . .177
F048 Psoriasis as a Systemic Disease. . . . . . . . . . . . . . .178
F049 Laser Pearls . . . . . . . . . . . . . . . . . . . . . . . . . . . . .178
F050 What’s New in Immunomodulation . . . . . . . . . .179
F051 Controversies in Vitamin D . . . . . . . . . . . . . . . .179
F052 Advanced Dermatopathology . . . . . . . . . . . . . . .180
F053 Autoimmune Disease Update . . . . . . . . . . . . . . .180
F054 Dermatologic Health of Women. . . . . . . . . . . . .181
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
Practice Management Session open to eligible
offce staff/registered nurses
Represents Patient Safety Session in program overviews
Patient Safety Session
Represents Audience Response System Session
Audience Response System Session
Represents activities that meet MOC-D

M
O
C
This activity has been approved by the ABD to satisfy
component 2 of MOC-D
Represents Leadership Institute in program overviews
Leadership Institute — addresses leadership
competencies specifc to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
21
PROGRAM OVERVIEW
P
R
O
G
R
A
M

O
V
E
R
V
I
E
W
Workshops — 3:00 p.m. to 5:00 p.m.
W007 Efective Communication . . . . . . . . . . . . . . . . . .181
W008 Basic Dermoscopy. . . . . . . . . . . . . . . . . . . . . . . .182
W009 MOC Self-Assessment B. . . . . . . . . . . . . . . . . . .183
MONDAY, FEBRUARY 7
Poster Discussion Sessions — 7:15 a.m. to 8:45 a.m.
PD05 Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .187
PD06 Internal Medicine . . . . . . . . . . . . . . . . . . . . . . . .187
Discussion Groups — 7:15 a.m. to 8:45 a.m.
D019 Enhancing Observational Skills. . . . . . . . . . . . . .188
D020 When Does Chronic Dermatitis Become Cutaneous
T Cell Lymphoma? . . . . . . . . . . . . . . . . . . . . . .188
Focus Sessions — 7:15 a.m. to 8:45 a.m.
U109 Pediatric Connective Tissue . . . . . . . . . . . . . . . .189
U110 Review of Dermatological Adverse Reactions . . .189
U111 Reconstruction in Dermatologic Surgery:
An Introductory and Review Session . . . . . . . . .189
U112 Histopathology of Scarring Alopecia. . . . . . . . . .190
U113 Immunology for Dermatologists . . . . . . . . . . . . .190
U114 Stem Cells in Melanoma and Nevi . . . . . . . . . . .190
U115 Medication Use: Improving Adherence
and Compliance . . . . . . . . . . . . . . . . . . . . . . . . .191
U116 Utilize websites that Enhance Your Career . . . . .191
U117 Diagnosis and Management of Unusual
Skin Tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . .192
U118 Holy Moly: Religion and the Skin . . . . . . . . . . .192
U119 New Botulinum Toxins Practice Integration . . . .192
Forums — 9:00 a.m. to 11:00 a.m.
F055 Vitiligo: Problems and Solutions. . . . . . . . . . . . .193
F056 Terapeutic Safety. . . . . . . . . . . . . . . . . . . . . . . .193
F057 Adolescent Dermatology. . . . . . . . . . . . . . . . . . .194
F058 Hair Loss in Women. . . . . . . . . . . . . . . . . . . . . .194
F059 Case-Based Discussion in Cutaneous
Lymphomas . . . . . . . . . . . . . . . . . . . . . . . . . . . .195
F060 Immunohistochemistry in Dermatology . . . . . . .195
F061 Medical Dermatology Challenge: Complex Cases
from the Collection of Dr. Samuel Moschella. . .196
F062 Ethical Dilemmas in Dermatology . . . . . . . . . . .196
Workshops — 9:00 a.m. to 11:00 a.m.
W010 MOC Self-Assessment: Cosmetic Dermatology .197
W011 Leading by Advocating for Dermatology. . . . . . .197
Courses — 9:00 a.m. to 12:00 p.m.
C021 Intermediate Cosmetic Surgery. . . . . . . . . . . . . .198
C022 Advanced Practice Management: Mini MBA . . .199
C023 Advanced Pediatric Dermatology . . . . . . . . . . . .200
Symposia — 9:00 a.m. to 12:00 p.m.
S032 Cutaneous Tumors Benign and Malignant . . . . .201
S033 Photodermatology. . . . . . . . . . . . . . . . . . . . . . . .202
S034 Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .203
S035 Controversies in Dermatologic Drug Terapy. . .204
S036 Blistering Disease . . . . . . . . . . . . . . . . . . . . . . . .205
S037 Key Surgical Principles We All Should Know . . .206
Courses — 9:00 a.m. to 5:00 p.m.
C024 Infectious Diseases . . . . . . . . . . . . . . . . . . . . . . .207
C025 Fundamentals of Dermoscopy . . . . . . . . . . . . . .208
Forums — 12:00 p.m. to 2:00 p.m.
F063 Young Physician Pearls and Pitfalls:
A Survival Guide for the First 10 Years . . . . . . . .209
F064 Te Approach to the Patient with Cutaneous
T-Cell Lymphoma. . . . . . . . . . . . . . . . . . . . . . . .209
F065 What’s New and Emerging: Terapeutics . . . . . .210
F066 Merkel Cell Carcinoma: Diagnosis,
Management, and Controversies . . . . . . . . . . . . .210
F067 Managing Hair Loss Made Easy . . . . . . . . . . . . .211
F068 Use of Physician Extenders . . . . . . . . . . . . . . . . .211
F069 Cutaneous Oncology: Multidisciplinary
Management of Common and
Uncommon Skin Cancers . . . . . . . . . . . . . . . . . .212
F070 Fungal Infections . . . . . . . . . . . . . . . . . . . . . . . .212
Workshop — 12:00 p.m. to 2:00 p.m.
W012 Dealing with Difcult People and Looking
Forward to It. . . . . . . . . . . . . . . . . . . . . . . . . . . .213
Discussion Groups — 12:15 p.m. to 1:45 p.m.
D021 Dermatology, Diagnosis, and the Visual Arts . . .213
D022 Common Dermatologic Diseases with Myriad
Treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . .213
Focus Sessions — 12:15 p.m. to 1:45 p.m.
U120 Sexually Transmitted Infections:
Te Current Standard of Diagnosis and Care . . .214
U121 Update on Graft-Versus-Host Disease . . . . . . . .214
U122 High-Risk Squamous Cell Carcinomas:
A Clinical and Pathologic Case Review. . . . . . . .214
U123 Forensics in Dermatology . . . . . . . . . . . . . . . . . .215
22
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
PROGRAM OVERVIEW
P
R
O
G
R
A
M

O
V
E
R
V
I
E
W
U124 Graft-Versus-Host Disease. . . . . . . . . . . . . . . . . .215
U125 Penile Growths . . . . . . . . . . . . . . . . . . . . . . . . . .216
U126 Healing the Pyoderma Gangrenosum Ulcer:
Lessons for the PG Clinic . . . . . . . . . . . . . . . . . .216
U127 Interactive Clinical Pathologic Challenge . . . . . .217
U128 Leg Ulcer Quiz for the Astute Dermatologist! . .217
U129 Informed Shared Decision Making in
Psoriasis Management . . . . . . . . . . . . . . . . . . . . .217
U130 Sarcoidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . .217
U131 Neurofbromatosis. . . . . . . . . . . . . . . . . . . . . . . .218
U132 Te Year in Review in Pediatric Dermatology:
How Does It Change My Practice? . . . . . . . . . .218
Courses — 2:00 p.m. to 5:00 p.m.
C026 Basic Botulinum Toxin . . . . . . . . . . . . . . . . . . . .219
C027 Sclerotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . .220
C028 Soft Tissue Augumentation. . . . . . . . . . . . . . . . .220
Symposia — 2:00 p.m. to 5:00 p.m.
S038 Surgical Pearls . . . . . . . . . . . . . . . . . . . . . . . . . . .221
S039 Terapeutic and Diagnostic Pearls . . . . . . . . . . .221
S040 Fundamentals of Cutaneous Surgery. . . . . . . . . .222
S041 Clinical Issues in Medical Dermatology . . . . . . .223
S042 International Dermatology . . . . . . . . . . . . . . . . .224
S043 Melanoma Update . . . . . . . . . . . . . . . . . . . . . . .225
Discussion Groups — 2:30 p.m. to 4:00 p.m.
D023 Cutaneous T-Cell Lymphoma . . . . . . . . . . . . . . .226
D024 PAPA Syndrome, SAPHO, and Acne:
Skin and Bones and Infammation . . . . . . . . . . .226
Focus Sessions — 2:30 p.m. to 4:00 p.m.
U133 Psychodermatology: Not Just a Delusion; ‘Bugs,’
Trichotillomania, and the Morgellons Debate. . .226
U134 Issues in Ofce Design . . . . . . . . . . . . . . . . . . . .227
U135 What’s New in Dermatopathology and Why
It’s Important to You. . . . . . . . . . . . . . . . . . . . . .227
U136 Management of Challenging Pigmented Lesions. . . 227
U137 Developing a Unifed Approach to Investigating
Autoimmune Disease . . . . . . . . . . . . . . . . . . . . .227
U138 Digital Imaging and Medical Informatics: Decision
Support for Clinicians and Teachers . . . . . . . . . .228
U139 Inherited Cancer Syndromes:
Te Role of the Dermatologist . . . . . . . . . . . . . .228
U140 Past, Present, and Pearls of Treatment of
Autoimmune Bullous Disease . . . . . . . . . . . . . . .229
U141 Skin Signs of Systemic Disease . . . . . . . . . . . . . .229
U142 Cryosurgical Update . . . . . . . . . . . . . . . . . . . . . .229
Forums — 3:00 p.m. to 5:00 p.m.
F071 Advanced Treatment for Chronic Wounds . . . . .230
F072 Medium and Deep Chemical Peeling . . . . . . . . .230
F073 Techniques for Flap Success . . . . . . . . . . . . . . . .230
F074 Te Use of the Confocal Microscope in a
Private Clinical Practice . . . . . . . . . . . . . . . . . . .231
F075 Alopecia CPC. . . . . . . . . . . . . . . . . . . . . . . . . . .231
F076 Pediatric Dermatology . . . . . . . . . . . . . . . . . . . .232
F077 Aesthetic Dermatologic Complications . . . . . . . .232
F078 Epidermolysis Bullosa: Cases and Discussion . . .233
Workshop — 3:00 p.m. to 5:00 p.m.
W013 MOC Self-Assessment Ofce-based Safety . . . . .233
MONDAY/TUESDAY, FEBRUARY 7/8
Courses — 9:00 a.m. to 5:00 p.m.
C029 Dermatology Review. . . . . . . . . . . . . . . . . . . . . .234
C030 Basic Dermatopathology. . . . . . . . . . . . . . . . . . .235
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
Practice Management Session open to eligible
offce staff/registered nurses
Represents Patient Safety Session in program overviews
Patient Safety Session
Represents Audience Response System Session
Audience Response System Session
Represents activities that meet MOC-D

M
O
C
This activity has been approved by the ABD to satisfy
component 2 of MOC-D
Represents Leadership Institute in program overviews
Leadership Institute — addresses leadership
competencies specifc to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
23
PROGRAM OVERVIEW
P
R
O
G
R
A
M

O
V
E
R
V
I
E
W
TUESDAY, FEBRUARY 8
Discussion Groups — 7:15 a.m. to 8:45 a.m.
D025 Integration of Photodynamic Terapy into
Your Practice. . . . . . . . . . . . . . . . . . . . . . . . . . . .238
D026 A Practical Approach to Photosensitivity. . . . . . .238
Focus Sessions — 7:15 a.m. to 8:45 a.m.
U143 Pediatric Surgery. . . . . . . . . . . . . . . . . . . . . . . . .238
U144 Serial Screening for Melanoma: Measures
Tat Have Consistently Achieved Early
Detection and Cure . . . . . . . . . . . . . . . . . . . . . .238
U145 Advances in Psoriasis. . . . . . . . . . . . . . . . . . . . . .239
U146 Management of Cutaneous Toxicity in the Era
of Targeted Chemotherapy . . . . . . . . . . . . . . . . .239
U147 Dermatological Signs of Child Abuse . . . . . . . . .239
U148 Lessons Learned from Challenging Pediatric Cases:
Targeted Novel Molecular Terapies . . . . . . . . .239
U149 Overgrowth Syndromes . . . . . . . . . . . . . . . . . . .240
U150 Skin Cancer Viruses: Bench to Bedside. . . . . . . .240
U151 Approach to Non-scarring Hair Loss in Women. . . 240
U152 Cutaneous Mucinosis . . . . . . . . . . . . . . . . . . . . .241
U153 Facing Facial Dermatoses . . . . . . . . . . . . . . . . . .241
Forums — 9:00 a.m. to 11:00 a.m.
F079 Update on Alopecia Areata . . . . . . . . . . . . . . . . .241
F080 Fractional Laser and Light-Based Technologies . . .242
F081 Geriatric Dermatology . . . . . . . . . . . . . . . . . . . .242
F082 Managing Ofce Politics: Private Practice,
Academics, and Everything in Between. . . . . . . .243
F083 Psoriasis Terapy in the Age of Biologics . . . . . .243
F084 Medical Applications of Topical
Photodynamic Terapy. . . . . . . . . . . . . . . . . . . .243
F085 Autoimmune Blistering Disorders. . . . . . . . . . . .244
Workshop — 9:00 a.m. to 11:00 a.m.
W014 Dermoscopy Cases . . . . . . . . . . . . . . . . . . . . . . .244
Courses — 9:00 a.m. to 12:00 p.m.
C031 Advanced Cosmetic Surgery and Aesthetics . . . .245
C032 Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .246
Symposia — 9:00 a.m. to 12:00 p.m.
S044 Terapeutic Hotline . . . . . . . . . . . . . . . . . . . . . .247
S045 Disorders of Mucous Membranes . . . . . . . . . . . .247
S046 Pediatric Dermatology . . . . . . . . . . . . . . . . . . . .248
S047 Managing Melanoma in the Modern
Millennium. . . . . . . . . . . . . . . . . . . . . . . . . . . . .249
S048 Cutaneous Lymphomas. . . . . . . . . . . . . . . . . . . .249
S049 Cosmetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .250
S050 Organizational Approaches to AIDS/STDs
From a Global Perspective. . . . . . . . . . . . . . . . . .250
Forums — 12:00 p.m. to 2:00 p.m.
F086 BCC Update and Options of Treatment . . . . . . .251
F087 Nail Disorders in Children . . . . . . . . . . . . . . . . .251
F088 Clinical Trials . . . . . . . . . . . . . . . . . . . . . . . . . . .252
F089 Advances in Photomedicine . . . . . . . . . . . . . . . .252
F090 Autoimmune Mucocutaneous Blistering
Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .253
F091 Supportive Onco-dermatology:
Dermatologic Reactions in Oncology . . . . . . . . .253
F092 Diagnosing and Monitoring Hair
and Scalp Disease . . . . . . . . . . . . . . . . . . . . . . . .254
Discussion Group — 12:15 p.m. to 1:45 p.m.
D027 Diferential Diagnosis of Leprosy in
a Non-Endemic Country . . . . . . . . . . . . . . . . . .254
Focus Sessions — 12:15 p.m. to 1:45 p.m.
U154 Caring for the Hospitalized Patient: Interesting
Cases from the Inpatient Consultative Service . .255
U155 What’s New in Skin Cancer Prevention . . . . . . .255
U156 Finding the Needle in the Haystack:
A Guide to More Efective Patch Testing . . . . . .255
U157 Rosacea Update. . . . . . . . . . . . . . . . . . . . . . . . . .255
U158 Acne: Etiopathogenesis and Treatment 2011. . . .256
U159 An Approach to Cultural
Diversity in Dermatology . . . . . . . . . . . . . . . . . .256
U160 Pigmented Lesions in Pediatric Dermatology . . .257
U161 Actinic Keratoses Update . . . . . . . . . . . . . . . . . .257
U162 Full Facial Approach with Botulinum Toxin
and Hyaluronic Acid: Cases From a
European Practice . . . . . . . . . . . . . . . . . . . . . . . .257
24
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
PROGRAM OVERVIEW
P
R
O
G
R
A
M

O
V
E
R
V
I
E
W
U163 Garden Variety Derm: Identifying and Managing
Exposures to Hazardous Plants and Arthropods in
the Garden . . . . . . . . . . . . . . . . . . . . . . . . . . . . .258
U164 Hypercoagulability, Purpura, and the Skin . . . . .258
U165 Te Management of TEN/SJS:
Te US Army Burn Unit Experience . . . . . . . . .258
Courses— 2:00 p.m. to 5:00 p.m.
C033 Advanced Surgery . . . . . . . . . . . . . . . . . . . . . . . .259
C034 Skin Resurfacing and Rejuvenation. . . . . . . . . . .259
Symposia — 2:00 p.m. to 5:00 p.m.
S051 Evidence-Based Medicine . . . . . . . . . . . . . . . . . .260
S052 Surgical Complications . . . . . . . . . . . . . . . . . . . .261
Focus Sessions — 2:30 p.m. to 4:00 p.m.
U166 Great Cases in Teledermatology . . . . . . . . . . . . .261
U167 Establishing a Mohs Practice:
Pearls for New Surgeons . . . . . . . . . . . . . . . . . . .261
U168 Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .261
U169 Cryosurgery Present and Future . . . . . . . . . . . . .261
U170 Pitfalls in Dermatopathology: When Tings Are
Not What Tey Seem to Be . . . . . . . . . . . . . . . .262
U171 Frontiers of Dermatopathology: Utility,
Methodology, and Interpretation of Current
(and Future) Molecular Testing. . . . . . . . . . . . . .262
U172 Transplant Research in Dermatology . . . . . . . . .262
Forums — 3:00 p.m. to 5:00 p.m.
F093 Psychocutaneous Medicine . . . . . . . . . . . . . . . . .263
F094 Melasma: Advances in the Treatment of a
Terapeutically Challenging Disease . . . . . . . . . .263
F095 Challenges in the Diagnosis and Management of
Lentigo Maligna Melanoma . . . . . . . . . . . . . . . .264
F096 Phototherapy . . . . . . . . . . . . . . . . . . . . . . . . . . .264
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
Practice Management Session open to eligible
offce staff/registered nurses
Represents Patient Safety Session in program overviews
Patient Safety Session
Represents Audience Response System Session
Audience Response System Session
Represents activities that meet MOC-D

M
O
C
This activity has been approved by the ABD to satisfy
component 2 of MOC-D
Represents Leadership Institute in program overviews
Leadership Institute — addresses leadership
competencies specifc to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
When comedonal acne is your primary concern…
PRESCRIBE DIFFERIN
®
GEL, 0.3%
www.differin.com
POWERFUL EFFICACY

From baseline to week 12, lesion reduction
(total, noninflammatory, and inflammatory)
was similar to tazarotene gel, 0.1%
1*
Important Safety Information
Of the patients who experienced cutaneous irritation (erythema, scaling, dryness, and/or
stinging/burning) during the clinical trial, the majority of cases were mild to moderate in
severity, occurred early in treatment, and decreased thereafter. Adverse events that occurred
in greater than 1% of the subjects included dry skin (14.0%), skin discomfort (5.8%), pruritus
(1.9%), desquamation (1.6%), and sunburn (1.2%). Pregnancy Category C.
Concomitant use of potentially irritating products or overexposure to sunlight or sunlamps,
extreme wind or cold, may increase the potential for irritation. Use of sunscreen and
protective clothing over treated areas are recommended when exposure cannot be avoided.
Please see brief summary of Prescribing Information on adjacent page.
* A phase 3b, 12-week, noninferiority, multicenter, investigator-blinded, controlled clinical study of patients 12 to 35 years of age with acne vulgaris (N=172). At the end of 12 weeks,
neither product was found to be inferior. 160 patients participated in the satisfaction survey.

A single-center, randomized, investigator/evaluator-blinded, bilateral (split-face) comparison of healthy subjects ≥18 years of age (N=30). Subjects received Differin
®
Gel, 0.3%
on one half of the face and tretinoin gel microsphere, 0.04% on the other half for 22 days.
HIGH PATIENT SATISFACTION

86% of patients on adapalene gel, 0.3%
were satisfied or very satisfied vs 69%
on tazarotene gel, 0.1%
1*

Local tolerability scores comparable
to tretinoin gel microsphere, 0.04%
2†
Primarily comedonal acne:
EXAMPLE A
EXAMPLE B
S:6.75”
S
:
9
.
5

T:8.5”
T
:
1
1

B:9.25”
B
:
1
2
.
2
5

45989ETL_Asize_v1 1 3/10/10 4:56:05 PM
DIFFERIN
®
(adapalene) Gel, 0.3% Rx only
BRIEF SUMMARY
For topical use only. Not for ophthalmic, oral or intravaginal use.
INDICATIONS AND USAGE: DIFFERIN
®
Gel, 0.3% is indicated for the topical treatment of acne vulgaris in patients
12 years of age and older.
CONTRAINDICATIONS: DIFFERIN
®
Gel, 0.3% should not be administered to individuals who are hypersensitive to
adapalene or any of the components in the gel vehicle.
PRECAUTIONS:
General: Certain cutaneous signs and symptoms of treatment such as erythema, scaling, dryness, and
stinging/burning may be experienced with use of DIFFERIN
®
Gel, 0.3%. These are most likely to occur during the
first four weeks of treatment, are mostly mild to moderate in intensity, and usually lessen with continued use of the
medication. Depending upon the severity of these side effects, patients should be instructed to either use a mois-
turizer, reduce the frequency of application of DIFFERIN
®
Gel, 0.3% or discontinue use.
If a reaction suggesting sensitivity or chemical irritation occurs, use of the medication should be discontinued.
Exposure to sunlight, including sunlamps, should be minimized during use of adapalene. Patients who normally
experience high levels of sun exposure, and those with inherent sensitivity to sun, should be warned to exercise cau-
tion. Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot
be avoided. Weather extremes, such as wind or cold, also may be irritating to patients under treatment with
adapalene.
Avoid contact with the eyes, lips, angles of the nose, and mucous membranes. The product should not be applied
to cuts, abrasions, eczematous or sunburned skin. As with other retinoids, use of “waxing” as a depilatory method
should be avoided on skin treated with adapalene.
Information for Patients: Patients using DIFFERIN
®
Gel, 0.3%, should receive the following information and instruc-
tions:
1. This medication is to be used only as directed by the physician.
2. It is for external use only.
3. Avoid contact with the eyes, lips, angles of the nose, and mucous membranes.
4. Cleanse affected area with a mild or soapless cleanser before applying this medication.
5. Moisturizers may be used if necessary; however, products containing alpha hydroxy or glycolic acids should
be avoided.
6. Exposure of the eye to this medication may result in reactions such as swelling, conjunctivitis, and eye
irritation.
7. This medication should not be applied to cuts, abrasions, eczematous, or sunburned skin.
8. Wax epilation should not be performed on treated skin due to the potential for skin erosions.
9. During the early weeks of therapy, an apparent exacerbation of acne may occur. This may be due to the
action of the medication on previously unseen lesions and should not be considered a reason to discontinue
therapy.
Drug Interactions: As DIFFERIN
®
Gel, 0.3% has the potential to induce local irritation in some patients, concomi-
tant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cos-
metics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices, or
lime) should be approached with caution. Particular caution should be exercised in using preparations containing
sulfur, resorcinol, or salicylic acid in combination with DIFFERIN
®
Gel, 0.3%. If these preparations have been used,
it is advisable not to start therapy with DIFFERIN
®
Gel, 0.3%, until the effects of such preparations have subsided.
Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenicity studies with adapalene have been con-
ducted in mice at topical doses of 0.4, 1.3, and 4.0 mg/kg/day, and in rats at oral doses of 0.15, 0.5, and 1.5
mg/kg/day. These doses are up to 3 times (mice) and 2 times (rats) in terms of mg/m²/day the potential exposure
at the maximum recommended human dose (MRHD), assumed to be 2.5 grams DIFFERIN
®
Gel, 0.3%. In the oral
study, increased incidence of benign and malignant pheochromocytomas in the adrenal medullas of male rats was
observed.
No photocarcinogenicity studies were conducted. Animal studies have shown an increased risk of skin neoplasms
with the use of pharmacologically similar drugs (e.g., retinoids) when exposed to UV irradiation in the laboratory or
to sunlight. Although the significance of these studies to human use is not clear, patients should be advised to avoid
or minimize exposure to either sunlight or artificial UV irradiation sources.
Adapalene did not exhibit mutagenic or genotoxic effects in vitro (Ames test, Chinese hamster ovary cell assay,
mouse lymphoma TK assay) and in vivo (mouse micronucleus test).
Reproductive function and fertility studies were conducted in rats administered oral doses of adapalene in amounts
up to 20 mg/kg/day (up to 26 times the MRHD based on mg/m² comparisons). No effects of adapalene were found
on the reproductive performance or fertility of the F0 males or females. There were also no detectable effects on the
growth, development and subsequent reproductive function of the F1 offspring.
Pregnancy: Teratogenic effects. Pregnancy Category C. Retinoids may cause fetal harm, when administered to
pregnant women. Adapalene has been shown to be teratogenic in rats and rabbits when administered orally (see Animal
Data below). There are no adequate and well-controlled studies in pregnant women. DIFFERIN
®
Gel, 0.3% should be
used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The safety and efficacy of
DIFFERIN
®
Gel, 0.3% in pregnancy has not been established.
1. Human Data
In clinical trials involving DIFFERIN
®
Gel, 0.3% in the treatment of acne vulgaris, women of child-bearing potential
initiated treatment only after having had a negative pregnancy test and used effective birth control measures during
therapy. However, 6 women treated with DIFFERIN
®
Gel, 0.3% became pregnant. One patient elected to terminate
the pregnancy, two patients delivered healthy babies by normal delivery, two patients delivered prematurely and the
babies remained in intensive care until reaching a healthy state and one patient was lost to follow-up.
2. Animal Data
• No teratogenic effects were seen in rats at oral doses of 0.15 to 5.0 mg/kg/day adapalene representing up
to 6 times the maximum recommended human dose (MRHD) based on mg/m² comparisons. Adapalene has
been shown to be teratogenic in rats and rabbits when administered orally at doses 25 mg/kg representing
32 and 65 times, respectively, the MRHD based on mg/m² comparisons. Findings included cleft palate,
microphthalmia, encephalocele and skeletal abnormalities in the rat and umbilical hernia, exophthalmos and
kidney and skeletal abnormalities in the rabbit.
• Cutaneous teratology studies in rats and rabbits at doses of 0.6, 2.0, and 6.0 mg/kg/day exhibited no feto-
toxicity and only minimal increases in supernumerary ribs in both species and delayed ossification in rabbits.
Systemic exposure (AUC0-24h) to adapalene 0.3% gel at topical doses of 6.0 mg/kg/day in rats and rabbits
represented 5.7 and 28.7 times, respectively, the exposure in acne patients treated with adapalene 0.3% gel
applied to the face, chest and back (2 grams applied to 1000 cm
2
of acne involved skin).
Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted
in human milk, caution should be exercised when DIFFERIN
®
Gel, 0.3% is administered to a nursing woman.
Pediatric Use: Safety and effectiveness in pediatric patients below the age of 12 have not been established.
Geriatric Use: Clinical studies of DIFFERIN
®
Gel, 0.3% did not include subjects 65 years of age and older to deter-
mine whether they respond differently than younger subjects. Safety and effectiveness in geriatric patients age 65
and above have not been established.
ADVERSE REACTIONS: In the multi-center, controlled clinical trial, signs and symptoms of local cutaneous irritation
were monitored in 258 acne patients who used DIFFERIN
®
Gel, 0.3% once daily for 12 weeks. Of the patients who
experienced cutaneous irritation (erythema, scaling, dryness, and/or burning/stinging), the majority of cases were
mild to moderate in severity, occurred early in treatment and decreased thereafter. The incidence of local cutaneous
irritation with DIFFERIN
®
Gel, 0.3% from the controlled clinical study is provided in the following table:
Table 2: Physician assessed local cutaneous irritation with DIFFERIN
®
Gel
* Total number of subjects with local cutaneous data for at least one post-Baseline evaluation.
Table 3: Patient reported local cutaneous adverse events with DIFFERIN
®
Gel
* Selected adverse events defined by investigator as Possibly, Probably or Definitely Related
Related adverse events from the controlled clinical trial that occurred in greater than 1% of patients who used
DIFFERIN
®
Gel, 0.3% once daily included: dry skin (14.0%), skin discomfort (5.8%), pruritus (1.9%), desquamation
(1.6%), and sunburn (1.2%). The following selected adverse events occurred in less than 1% of patients: acne flare,
contact dermatitis, eyelid edema, conjunctivitis, erythema, pruritus, skin discoloration, rash, and eczema.
In a one-year, open-label safety study of 551 patients with acne who received DIFFERIN
®
Gel, 0.3%, the pattern of
adverse events was similar to the 12-week controlled study.
OVERDOSAGE: DIFFERIN
®
Gel, 0.3% is intended for topical use only. If the medication is applied excessively, no
more rapid or better results will be obtained and marked redness, scaling, or skin discomfort may occur. Chronic
ingestion of the drug may lead to the same side effects as those associated with excessive oral intake of vitamin A.
Incidence of Local Cutaneous Irritation with DIFFERIN
®
Gel, 0.3% from Controlled Clinical Study
(N=253*)
Maximum Severity Scores Higher Than Baseline
Mild Moderate Severe
Erythema 66 (26.1%) 33 (13.0%) 1 (0.4%)
Scaling 110 (43.5%) 47 (18.6%) 3 (1.2%)
Dryness 113 (44.7%) 43 (17.0%) 2 (0.8%)
Burning/Stinging 72 (28.5%) 36 (14.2%) 9 (3.6%)
DIFFERIN
®
(adapalene) Gel, 0.3%
N=258
Vehicle Gel
N=134
Related* Adverse Events 57 (22.1%) 6 (4.5%)
Dry Skin 36 (14%) 2 (1.5%)
Skin Discomfort 15 (5.8%) 0 (0.0%)
Desquamation 4 (1.6%) 0 (0.0%)
Reference: 1. Thiboutot D, Pariser DM, Egan N, et al; Adapalene Study Group. Adapalene gel 0.3% for the
treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad
Dermatol. 2006;54:242-250.
Marketed by:
GALDERMA LABORATORIES, L.P.
Fort Worth, Texas 76177 USA
Manufactured by:
DPT Laboratories, Ltd.
San Antonio, Texas 78215 USA
GALDERMA is a registered trademark.
Revised: June 2007 325089-0607
Differin and Galderma are registered trademarks.
©2007 Galderma Laboratories, L.P.
Galderma Laboratories, L.P.
14501 N. Freeway
Fort Worth, TX 76177
DIF-888 Printed in USA 11/07
References: 1. Thiboutot D, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel
compared to tazarotene 0.1% gel in the treatment of acne vulgaris. J Drugs Dermatol. 2008;7
(6)(suppl):S3-S10. 2. Data on file. Galderma Laboratories, L.P. A 3-week, single-center, randomized,
investigator/evaluator-blinded, bilateral (split-face) comparison, clinical study of adults 18 years of age
and older with healthy skin (N=30).
Galderma is a registered trademark.
©2010 Galderma Laboratories, L.P.
Galderma Laboratories, L.P.
14501 N. Freeway
Fort Worth, TX 76177
DIFF-088 03/10 www.differin.com
Marketed by:
GALDERMA LABORATORIES, L.P.
Fort Worth, Texas 76177 USA
Manufactured by:
DPT Laboratories, Ltd.
San Antonio, Texas 78215 USA
GALDERMA is a registered trademark.
Revised: June 2007 325089-0607
S:6.75”
S
:
9
.
5

T:8.5”
T
:
1
1

B:9.25”
B
:
1
2
.
2
5

45989ETL_Asize_v1 2 3/10/10 4:56:27 PM
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
27
PERSONAL PROGRAM SCHEDULE
P
E
R
S
O
N
A
L

P
R
O
G
R
A
M

S
C
H
E
D
U
L
E
THURSDAY, FEBRUARY 3
8:00 a.m. to 12:00 p.m.
12:00 p.m. to 5:00 p.m.
FRIDAY, FEBRUARY 4
7:00 a.m. to 9:00 a.m.
7:15 a.m. to 8:45 a.m.
9:00 a.m. to 11:00 a.m.
9:00 a.m. to 12:00 p.m.
9:00 a.m. to 5:00 p.m.
9:30 a.m. to 11:30 a.m.
12:00 p.m. to 2:00 p.m.
12:15 p.m. to 1:45 p.m.
12:30 p.m. to 2:30 p.m.
2:00 p.m. to 5:00 p.m.
2:30 p.m. to 4:00 p.m.
3:00 p.m. to 5:00 p.m.
FRIDAY/SATURDAY, FEBRUARY 4/5
9:00 a.m. to 5:00 p.m.
SATURDAY, FEBRUARY 5
7:15 a.m. to 8:45 a.m.
9:00 a.m. to 11:00 a.m.
9:00 a.m. to 12:00 p.m.
9:00 a.m. to 5:00 p.m.
12:00 p.m. to 2:00 p.m.
12:15 p.m. to 1:45 p.m.
2:00 p.m. to 5:00 p.m.
2:30 p.m. to 4:00 p.m.
3:00 p.m. to 5:00 p.m.
You may use this personal program schedule to plan your daily/weekly schedule while on site at the meeting.
Fill in appropriate time slots as necessary with your schedule.
continued
28
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
PERSONAL PROGRAM SCHEDULE
P
E
R
S
O
N
A
L

P
R
O
G
R
A
M

S
C
H
E
D
U
L
E
SUNDAY, FEBRUARY 6
7:00 a.m. to 8:00 a.m.
8:00 a.m. to 12:00 p.m.
11:00 a.m. to 2:00 p.m.
12:15 p.m. to 1:45 p.m.
2:00 p.m. to 5:00 p.m.
2:30 p.m. to 4:00 p.m.
3:00 p.m. to 5:00 p.m.
MONDAY, FEBRUARY 7
7:15 a.m. to 8:45 a.m.
9:00 a.m. to 11:00 a.m.
9:00 a.m. to 12:00 p.m.
9:00 a.m. to 5:00 p.m.
12:00 p.m. to 2:00 p.m.
12:15 p.m. to 1:45 p.m.
2:00 p.m. to 5:00 p.m.
2:30 p.m. to 4:00 p.m.
3:00 p.m. to 5:00 p.m.
MONDAY/TUESDAY, FEBRUARY 7/8
9:00 a.m. to 5:00 p.m.
TUESDAY, FEBRUARY 8
7:15 a.m. to 8:45 a.m.
9:00 a.m. to 11:00 a.m.
9:00 a.m. to 12:00 p.m.
9:00 a.m. to 5:00 p.m.
12:00 p.m. to 2:00 p.m.
12:15 p.m. to 1:45 p.m.
2:00 p.m. to 5:00 p.m.
2:30 p.m. to 4:00 p.m.
3:00 p.m. to 5:00 p.m.
You may use this personal program schedule to plan your daily/weekly schedule while on site at the meeting.
Fill in appropriate time slots as necessary with your schedule.
The National Eczema Association (NEA) Seal of Acceptance is
awarded to products that have been created or intended for
use by persons with eczema or severe sensitive skin conditions
and have satisfied the NEA Seal of Acceptance Criteria. NEA
has awarded the Seal of Acceptance to these products with a
4 out of 5 rating. Read the label to determine if these products
contain ingredients that may be unsuitable for your skin. Visit
nationaleczema.org for more information.
Now replenish skin
at the structural level
NEW Cetaphil
®
RESTORADERM
®
Skin Restoring Moisturizer
and Body Wash formulated for atopic dermatitis
Patented technology helps restore hydration
in atopic skin
1,2
:
Ceramides help replenish the skin’s natural lipids
Filaggrin technology helps restore moisture to help rebuild the
damaged skin barrier

Clinically proven to help soothe itch and reduce redness,
dryness and irritation
2

Highly tolerable; preservative and fragrance free
2
www.cetaphil.com
References: 1. Sugarman JL. The epidermal barrier in atopic dermatitis. Semin
Cutan Med Surg. 2008;27:108-114. 2. Data on fle. Galderma Laboratories.
Galderma, Cetaphil and RESTORADERM are registered trademarks.
© 2010 Galderma Laboratories, L.P.
Galderma Laboratories, L.P., 14501 N. Freeway, Fort Worth, TX 76177
CETA-186 Printed in USA 08/10
Scientific Program
AMERICAN ACADEMY
of DERMATOLOGY
extends a very sincere thank you to
our Corporate Partners
for their very generous support of the
2011 Annual Meeting.
Your support is greatly appreciated!
Please visit our Corporate Partner
Recognition Module in the Ernest N. Morial
Convention Center and view Corporate Partner
Recognition in the Program-at-a-Glance
Bio-Oil
®
is a skincare oil that helps improve the appearance of scars, stretch marks
and uneven skin tone. It is a combination of natural oils and vitamins, together
with the breakthrough ingredient PurCellin Oil

. It was developed in 1987 and is
today the number one selling scar and stretch mark product in 12 countries. It is
available at drugstores at the recommended price of $11.99. For comprehensive
product information, and details of clinical trials, please visit bio-oil.com.
Bio-Oil
®
is a product of Union Swiss, successfully treating skin since 1954.
bus_m_pack_e_fp.indd 1 8/23/10 2:43:23 PM
Ballot books will mail by Friday, February 4, 2011 and will be available on site at the
Ernest N. Morial Convention Center information desks.
Go to www.aad.org/election
Remember to access the AAD website from your personal computer
whether you are in your hotel room, a designated Wi-Fi Lounge, or the Cyber Center
at the Ernest N. Morial Convention Center.
Comments from members who voted online . . .
“Easy to vote online, no postage or pen needed.”
“Online voting – I don’t think it could be any easier!"
“The e-mail with direct link and password made the process very easy!”
“I liked being able to click on the name of the candidates on the ballot to refresh my
memory about their qualifications, background, and views.”
“Being able to click on the proposed bylaw changes to read the description
was very helpful.”
2011 American Academy of Dermatology Election for
Officers, Directors and Nominating Committee Member Representatives, and
Proposed Bylaw Amendments
Watch for your Secure Access Code, which will be sent in mid-January 2011 via e-mail or mail.

Academy Election
Opens February 5
YOUR VOTE IS IMPORTANT
View electronic ballot book beginning
January 28, 2011
Listen to candidates and review background materials
Read proposed bylaw amendments
Conveniently VOTE ONLINE
DRAFTFCB HealthCare
File Name: S1304_Journal_Ad.indd
Location: PrePress Server
Client: Centecor
Product: Stelara
Job #: 2CNT_USTE_S1304
Live Area: 7.125" x 10"
Small Trim: 8.375" x 10.875"
Large Trim:
Bleed: 8.625" x 11.125"
Colors: 4C

PMS XXX PMS XXX PMS XXX
CAD Router
Art Director: Nils (x2405)
Production: jim Palazzolo (x2446)
Traffc Person: Kristine Clark (x2394)
Mac Operator: Paul (x 3051)
Date: 08.16.10
Time: 3:00 pm
Round: 2 after DQC
SIGN-OFF Date Time OK Correx Query
Studio Manager
Traffc
Visual QC
Editor
Copywriter
Copy Supervisor
Art Director
Art Supervisor
Acct. Executive
Acct. Executive
Production
COMMENTS
8/10/10 • DQC and corrections • LA
8/11/10 • Logo moved up to safety • LP
8/16/10 • Resize and set up for PDF/x1a
(2nd round after DQC) • PL
What’s the next number
in this sequence?
(Turn for the answer)
1, 4, 9,
2
5, 49, 1
2
1, 169,
2
8
9

S:7.125”
S
:
1
0

T:8.375”
T
:
1
0
.
8
7
5

B:8.625”
B
:
1
1
.
1
2
5

S1304_Journal_Ad.indd 1 8/16/10 4:16:40 PM
DRAFTFCB HealthCare
File Name: S1304_Journal_Ad.indd
Location: PrePress Server
Client: Centecor
Product: Stelara
Job #: 2CNT_USTE_S1304
Live Area: 7.125" x 10"
Small Trim: 8.375" x 10.875"
Large Trim:
Bleed: 8.625" x 11.125"
Colors: 4C

PMS XXX PMS XXX PMS XXX
CAD Router
Art Director: Nils (x2405)
Production: jim Palazzolo (x2446)
Traffc Person: Kristine Clark (x2394)
Mac Operator: Paul (x 3051)
Date: 08.16.10
Time: 3:00 pm
Round: 2 after DQC
SIGN-OFF Date Time OK Correx Query
Studio Manager
Traffc
Visual QC
Editor
Copywriter
Copy Supervisor
Art Director
Art Supervisor
Acct. Executive
Acct. Executive
Production
COMMENTS
8/10/10 • DQC and corrections • LA
8/11/10 • Logo moved up to safety • LP
8/16/10 • Resize and set up for PDF/x1a
(2nd round after DQC) • PL
© Centocor Ortho Biotech Inc. 2010 8/10 25ST10036
Find out more about 361 at Booth 1440.
S:7.125”
S
:
1
0

T:8.375”
T
:
1
0
.
8
7
5

B:8.625”
B
:
1
1
.
1
2
5

S1304_Journal_Ad.indd 2 8/16/10 4:16:41 PM
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
33
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
GENERAL INFORMATION
IMPORTANT DATES AND TIMES TO REMEMBER
(Please refer to the specifc section of the General Information pages for additional details regarding these dates and times)
Optional Activities Cancellation Deadline .................................................. Wednesday, January 5, 2011, at 12:00 p.m. (CT)
Early Registration Fees End ......................................................................... Wednesday, January 5, 2011, at 12:00 p.m. (CT)
Late Fees Begin ........................................................................................... Wednesday, January 5, 2011, at 12:01 p.m. (CT)
Badge Mailing for Registrations Received by January 5, 2011, at 12:00 p.m. (CT) ............................... January 10 –21, 2011
Housing Cancellation Deadline ....................................................................Tursday, January 13, 2011, at 12:00 p.m. (CT)
Deadline for Program Books and Brochures to Be Mailed .................................................................Friday, January 14, 2011
Deadline to Request a Letter of Invitation ................................................ Wednesday, January 19, 2011, at 12:00 p.m. (CT)
Deadline to Request an Access ID# ........................................................... Wednesday, January 19, 2011, at 12:00 p.m. (CT)
Registrants Must Call the Hotels Directly for Changes ............................................ Monday, January 19, 2011 (and beyond)
Registration Cancellation Deadline ........................................................... Wednesday, January 26, 2011, at 12:00 p.m. (CT)
On-Site Registration Begins ..........................................................................Tursday, February 3, 2011, at 12:00 p.m. (CT)
Dermatology in Action Service Initiative ................................................ Tursday, February 3, 2011, at 1:00-4:00 p.m. (CT)
Ofcial Start of the Meeting .................................................................................Friday, February 4, 2011 at 7:15 a.m. (CT)
(Specialty Courses on Volunteerism will take place Tursday, February 3 beginning at 8:00 a.m. and 12:00 p.m.)
Technical Exhibits Open ................................................................................ Saturday, February 5, 2011, at 10:00 a.m. (CT)
Technical Exhibits Close .................................................................................. Monday, February 7, 2011, at 5:00 p.m. (CT)
Spouse/Guest Access to Exhibit Hall ...................................................................................Monday, February 7, 2011 (Only)
Ofcial Close of the Meeting ...........................................................................Tuesday, February 8, 2011, at 5:00 p.m. (CT)
34
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
GENERAL INFORMATION
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
MEETING LOcATION
Te 69th Annual Meeting of the American Academy of
Dermatology will take place February 4-8, 2011 in
New Orleans, La. Registration and educational sessions will
be located at:
New Orleans Ernest N. Morial Convention Center
900 Convention Center Blvd.
New Orleans, LA 70130
www.mccno.com
REGISTRATION INFORMATION
Early registration
Early registration and housing for the 69th Annual Meeting
begins at 12:00 p.m. (CT), Wednesday, October 27, 2010,
according to the following schedule:
IMPORTANT NOTE: Registration and housing forms faxed
in prior to the opening of early registration will be held and
processed based on the date and time received and the schedule
listed below.
Physician, life, honorary members,
and applicants for membership ..........................October 27
Graduate members, residents,
research fellows, and medical students .............. November 3
Adjunct and corporate individual members,
physician assistants and nurse practitioners, ofce
staf, registered nurses, and non-members ...... November 10
Early registration and housing for members and approved
non-members closes at 12:00 p.m. (CT) on January 5,
2011. After this date and time late registration will apply.
January 26 at 12:00 p.m. (CT) through February 3, 2011
at 12:00 p.m. (CT) all registration systems will be closed.
On-site registration will begin at 12:00 p.m. (CT) on
February 3, 2011.
NON-MEMBER REGISTRATION
Non-members must submit an online request form for
registration approval and access ID number. See the chart
on page 36 for a list of non-member registration categories.
Non-member requests and required documentation will
only be accepted via the online submission site at the
following:
1. Visit www.aad.org
2. Click on Annual Meeting, under the Scientifc
Meetings
3. Click on the Attendee tab
4. Click on Non-Member under the Registration section
Once approved, the registration and housing brochure along
with the optional activities brochure will be sent via US mail.
Due to processing and delivery time, these materials can
no longer be sent out after January 14, 2011.
Access ID numbers will be sent to the e-mail supplied
online. Te deadline for submission and approval is
January 19, 2011, at 12:00 p.m. (CT).
Allow 10 to 12 days for approval, processing, and receipt
of materials, including access ID number.
Note: In an efort to make the meeting more
environmentally friendly, program books will no longer
be mailed out to non-member registrants. Te complete
program book can be viewed online and program books
will be available on site for reference.
Questions:
E-mail: registration@aad.org
Toll-free phone: (866) 503-SKIN (7546)
or (847) 240-1280
SPOUSE / GUEST REGISTRATION
Spouse/guest registration includes spouses, family members
(children 16 years or older), and guests accompanying
registrants. A “guest” is defned as a signifcant other, friend, or
a child 16 years or older. Spouse/guest registration is available
for one person per physician registrant. A co-worker or an
associate within the industry does not qualify for the guest
registration category. Photo ID and proof of age (driver’s license,
student ID, birth certifcate) will be required.
Registrants in this category may attend non-restricted
symposia, the plenary session, electronic poster and
technical exhibits. Spouse/guest registrants will be
admitted into the Technical Exhibit Hall on Monday,
February 7 only. Tis category will not be issued a
certifcate of attendance.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
35
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
GENERAL INFORMATION
REGISTRATION
TyPE
REGISTRATION
INSTRUcTIONS
PAyMENT
METhOD
PROcESSING
TIME
ONLINE REGISTRATION to register and book housing online for the 69th annual meeting, go to:
www.aad.org/meetings/annual/index.html
click on attendee registration and housing. you will need to input the Id number
printed above your name on the back of the registration and housing brochure.
credit card only
(Visa, Mastercard,
or American Express)
Instant
FAX REGISTRATION to register by fax, complete all registration and housing forms and fax to:
(800) 521-6017 (U.S. and Canada)
(847) 996-5401 (International)
due to fax volume, confrmation of fax receipt will not be provided.
Registration and housing forms faxed in prior to the opening of early registration
will be held and processed based on the date and time received and the schedule
listed on the previous page.
credit card only
(Visa, Mastercard,
or American Express)
three to fve
business days
from receipt
US MAIL send payment, registration, and housing forms to:
aad housing and registration
568 atrium drive
Vernon hills, IL 60061-1731
registrants should retain a copy of both sides of the form for their records before
mailing. only materials delivered to the above address will be accepted.
credit card
(Visa, Mastercard,
or American Express)
or
check payable to
AAD Housing and
Registration
Five to seven
business days
from receipt
cUSTOMER SERVIcE
For additional assistance in completing your registration call the aad registration office at (847) 996-5876 or (800) 974-3084 or call the aad
meetings and conventions department at (847) 330-0230.
ADA / SPEcIAL ASSISTANcE
academy staff will be available to help individuals with any special needs (i.e., physical). Please complete the appropriate section online or on the
registration form and a staff member will contact you.
TIcKETED SESSIONS
registrants should identify sessions for which they are requesting tickets when they complete general registration (see chart page ?? for
information on session categories, including ticket requirements and tuition fees). enrollment in ticketed sessions is on a frst-come, frst-
served basis. alternate choices should be identifed. enrollment in multiple sessions during the same time slot is not permitted.
TOUR/OPTIONAL AcTIVITy TIcKETS
Physicians who have registered for the meeting and wish to purchase tour/optional activity tickets may do so online or using the spouse/guest
registration form. the physician must enter his or her own name on the form. tickets will automatically be printed along with the physician’s
registration badge. If a spouse or guest is registered, tour tickets will print along with the spouse or guest’s badge.
Early registration instructions
Early registration and housing for the 69th Annual Meeting may be completed online, by fax, or by mail. Registration,
including enrollment in specifc sessions, is on a frst-come, frst-served basis. Registration forms are enclosed with this
mailing. All forms are non-transferable.
cONFIRMATIONS AND chANGES
Confrmation letters will be sent to all individuals who register prior to the start of on-site registration. If an e-mail address is
provided, confrmation will be sent via e-mail. If no e-mail address is provided, the confrmation will be sent via fax. If neither
an e-mail address nor fax number is supplied, confrmation will be sent via US mail. Once you have received a confrmation
letter, you may review and print registration information online. To do so, take the following steps:
1. Visit www.aad.org
2. Click on Annual Meeting under Scientifc Sessions
3. Click on Attendee Registration and Housing
4. Click on Already Registered. Enter your registration confrmation number and last name, and then click Find Me
Once in your personal record, you may print a copy of your receipt, pay a balance due, or make changes to your registration
and housing. An updated confrmation will be sent after changes are processed.
Ticketed event changes/cancellations for individuals who register by Wednesday, January 5, 2011 at 12:00 p.m. (CT) and who
will be receiving their materials by mail will only be accepted until Wednesday, January 5, 2011 at 12:00 p.m. (CT). After this
date and time ticket cancellations and changes will need to be made at the Tickets Only Counters located in the Full Service
On-Site Registration area located in Hall G of the Convention Center. For housing changes/cancellations refer to the Hotel
and Travel Information section of the program book (page 41).
36
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
GENERAL INFORMATION
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
REGISTRATION cATEGORIES, AccESS, AND FEES
Te chart below details fees and session access for all categories eligible to register for the 69th Annual Meeting. For further
information on membership eligibility, please refer to http://www.aad.org/members/join/index.html or e-mail mrc@aad.org.
Member categories
REGISTRATION FEES SESSION AccESS
REGISTRATION cATEGORy EARLy,
Wednesday,
October 27 -
Wednesday,
January 5 at
12:00 p.m. (cT)
LATE,
Wednesday,
January 5 at
12:01 p.m. (cT) -
Tuesday, February 8
OPEN TIcKETED RESTRIcTED
Physician member $445 $510 y y y
Adjunct member** $445 $510 y y n
corporate individual member**
(approved through membership process)
$445 $510 y y y
Life member $145 $160 y y y
honorary member no fee no fee y y y
Graduate member, resident, research fellow** $130 $145 y y y – dermatologist,
n – non-dermatologist
Applicant for membership + $130 $145 y y y – dermatologist,
n – non-dermatologist
NOTE: Day Pass — On-site only $510. Medical personnel only. One Day Pass per meeting. Can only be purchased on day of use.
Non-member categories
(see p. 34 for information on submitting a non-member registration materials request)
REGISTRATION FEES SESSION AccESS
REGISTRATION cATEGORy EARLy,
Wednesday,
October 27 -
Wednesday,
January 5 at
12:00 p.m. (cT)
LATE,
Wednesday,
January 5 at
12:01 p.m. (cT) -
Tuesday, February 8
OPEN TIcKETED RESTRIcTED
Medical student* ** no fee no fee y y n
Non-dermatology resident** $130 $145 y y y
Non-member physician +
(treating patients in a offce setting)
$1,500 $1,800 y y y – dermatologist,
n – non-dermatologist
Physician assistant/nurse practitioner* ** $445 $510 y y n
Resident/Research Fellow**
(outside US. or canadian program)
$130 $145 y y y – dermatologist,
n – non-dermatologist
Offce staff/registered nurse* $225 $250 y Practice
management
sessions only
n
Non-member, non-physician (non-member
corporate individuals, Industry Representatives,
or Scientist/Researcher working in the feld of
Dermatology)* **++
$1,500 $1,800 y y n
NOTE: Day Pass — On-site only $510. Medical personnel only. One Day Pass per meeting. Can only be purchased on day of use.
* this category is not eligible to register a spouse/guest along with their registration.
** this category is not eligible to register offce staff/rn along with their registration.
+ only dermatologists in this category may register offce staff/rn along with their registration
++ this category of registration will not be issued an expocard with their registration.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
37
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
GENERAL INFORMATION
TUITION FEE
SESSION
TyPE
SESSION
DEScRIPTION
TIcKET
REQUIRED
Members
and PAs/NPs
Non-members and
offce staff/RNs
Medical students
and residents
courses** Intensive sessions offering in-depth coverage of
a single subject.
half-day courses y $40 $120 $30
One-day courses y $60 $180 $40
Two-day courses y $100 $300 $60
Self-assessment
courses**
Basic, advanced, and comprehensive sessions;
attendees review slides from skin biopsy
specimens in a format that allows self-assessment.
y $90 $300 $50
Derm Exam Prep course:
Refresher**
this course is targeted at the Board certifed
dermatologist preparing for the american
Board of dermatology (aBd) maintenance of
certifcation in dermatology (moc-d) exam.
residents preparing for their Board exam may
also beneft, but this course is not designed as
a Prep for initial board certifcation.
y $300 n/a $150
Review of Dermatology
course**
a course that provides in-depth coverage of
multiple areas of medical dermatology; the
course is not inclusive but covers areas of new
information and advancement in the past fve
years.
y $200 $500 $100
Live Patient
Demonstration**
Interactive session presenting live
demonstrations of botulinum toxin and soft
tissue fller injection; open to dermatologists
and corporate individual members only.
y $100 $390 $60
Restricted symposia* sessions comprised of individual presentations
focused on a specifc subject; open to
dermatologists and corporate individual
members only.
y no fee no fee no fee
Non-restricted symposia sessions comprised of an individual
presentation focused on a specifc subject.
n no fee no fee no fee
Workshops** sessions emphasizing media training, clinical
care, and technical skills.
y $35 $90 $25
Forums* sessions exploring a single subject. y no fee no fee no fee
Focus Sessions* sessions with an emphasis on discussion and
participant interaction.
y no fee no fee no fee
Discussion groups** sessions limited to 50 participants; emphasis
is on active discussion and interaction between
director and audience.
y $25 $90 $25
Poster discussion
sessions*
sessions limited to 50 participants with
interaction encouraged; emphasis is on
important issues raised in the selected posters.
y no fee no fee no fee
MOc – Self Assessment
Workshop**
a session with interactive question-and-answer
format utilizing an audience response system.
Feedback provided to participants to identify
areas of weakness that may require further self-
directed study.
y $35 $90 $25
SESSION cATEGORIES AND FEES
Te chart below details the sessions being ofered at the 69th Annual Meeting, as well as session fees where applicable.
Registrants should sign up for specifc sessions requiring tickets when completing general registration.
See p.38 for details on distribution of tickets and other meeting materials.
* Tickets for sessions with no fee will hold a seat for 15 minutes after the ofcial start time, after which seats will be available on a frst-come, frst-served basis for eligible categories.
** Attendees of sessions with a fee must have a ticket for admittance.
38
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
GENERAL INFORMATION
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
cancellations
GENERAL REGISTRATION
Registrants who wish to cancel all of their general
registration should send a letter of cancellation via one of
the following methods:
E-mail: aad@experient-inc.com
Fax: (800) 521-6017 or (847) 996-5401
Te following policies apply to cancellations:
Deadline: 12:00 p.m. (CT), Wednesday,
January 26, 2011; no refund will be
given for cancellations received after this
date. No exceptions will be made.
Fee: $75 (fee will be deducted from refund
amount); $25 (fee will be deducted for
all spouse/guest cancellations)
Processing: Cancellations received by 12:00 p.m.
(CT), January 26, 2011 will be
processed and refunds issued prior to the
meeting.
No-shows: No-shows are considered to have missed
the Wednesday, January 26, 2011
deadline and are not eligible for
a refund.
On site: No refunds will be issued for on-site
registration.
Name change: Registration is non-transferable. If you
cannot attend the meeting, you must
submit a cancellation; you may not
change the name on your registration.
For hotel reservation cancellation, please see Hotel and
Travel Information section on page 41.
SESSION TIcKETS
Session tickets must be returned prior to the start time of
the session for a refund to be issued. To return session
tickets prior to the meeting, refer to the Confrmations
and Changes section located on page 35. Session tickets
may be returned at the Tickets Only Counters located in
the Full-Service On-Site Registration area located in Hall
G of the Convention Center. Tickets cannot be returned
or exchanged after the start of the session. Refunds will
not be issued for late arrival or for non-attendance.
OPTIONAL AcTIVITIES
Te deadline for cancellation of optional activities is
Wednesday, January 5, 2011 at 12:00 p.m. (CT). Tickets
purchased during late registration are non-refundable.
Cancellations must be submitted in writing via e-mail to
aad@experient-inc.com or fax to: (847) 996-5401 or
(800) 521-6017. Refunds will not be issued for weather
conditions unless the tour operator cancels the activity.
MEETING MATERIALS
Badges, tickets, vouchers
EARLy REGISTRANTS [By JANUARy 5, 2011 AT 12:00 P.M. (cT)]
All individuals, who complete registration by Wednesday,
January 5, 2011 at 12:00 p.m. (CT), will receive their
badges, tickets, and attendance verifcation/meeting bag
voucher by mail. Registration packets will be sent via
U.S. mail to U.S. registrants and via special courier service
to Canadian and international registrants between
January 10 - January 21, 2011. Materials will be mailed
to the address listed on the recipient’s registration records,
which will also be listed on recipient’s ExpoCard.
REGISTRANTS WhO REGISTER AFTER WEDNESDAy, JANUARy 5,
2011 AT 12:00 P.M. (cT)
All individuals who register after 12:00 p.m. (CT) on
January 5, 2011 will need to pick up badges, tickets, and
vouchers on site. See p. 43 for locations.
cORREcTIONS
Upon receipt, please review materials for accuracy. If a
discrepancy or error is found, send an e-mail to
registration@aad.org by 12:00 p.m. (CT), Wednesday,
January 26, 2011 with the following information:
• Full name
• Registration confrmation number
• Error or discrepancy found
Te AAD will make every attempt to make corrections
received by the deadline prior to the start of the meeting.
Corrected tickets must be picked up at the Full Service
On-Site Registration area located in Hall G. (see page 43
for locations and times.) Corrections received after the
deadline must be made on site at the Full Service On-Site
Registration area.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
39
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
GENERAL INFORMATION
Changes/Cancellations: Early registrants
Ticketed event changes/cancellations for individuals who
register by Wednesday, January 5, 2011 at 12:00 p.m.
(CT) (and will be receiving their materials by mail) will
only be accepted until Wednesday, January 5, 2011 at
12:00 p.m. (CT). After this date and time ticket
cancellations and changes will need to be made at the
Tickets Only counters located in the Full-Service
On- Site Registration area located in Hall G of the
Convention Center. For housing changes/cancellations
refer to the Hotel and Travel Information section of the
program book on page 41.
Attendance verifcation, meeting bags,
handout DVDs, other materials
Tose who registered during early registration and
received their meeting packet may redeem their
attendance verifcation/meeting bag voucher and pick up
handout DVDs and other materials on site at the
Attendance Verifcation/Meeting Bag Pick-up Counter.
Tis voucher must be redeemed in order to claim CME
credit. (See page 44 for counter times and location.)
Medical personnel materials pick-up
Medical personnel who register by Wednesday, January
26, 2011 at 12:00 p.m. (CT) and have not received their
meeting packet in advance and have no changes to make
to their registration, may print their badges, tickets, and
other materials at the Self-Service Materials Pick-up
Stations located in Hall D Lobby. (See p. 43 for hours of
operation.) You will need to scan your registration bar-
code contained in your registration confrmation letter,
or input your registration confrmation number to print
your materials.
A photo ID is required to pick up materials. Each
individual is permitted to pick up ONLY his or her own
registration materials. See p. 43 for locations and times
Note: Session tickets cannot be purchased or
returned at the Self-Service Materials Pick-up
Stations. To make corrections or changes to your
registration you will need to go to the Full Service
On-site Registration area, located in Hall G
(see p. 43 for locations and times).
Te self-service Materials Pick Up Stations are
available for medical personnel only.
Badge identifcation
Registration categories will be indicated by badge color
as described below. Specifc categories will appear in bold
at the bottom of each badge.
Letters of invitation
If you require a letter of invitation, please submit a
written request via e-mail to registration@aad.org once
you have completed your registration. Letters will be sent
after registration verifcation is complete. Due to security
concerns, letters will only be issued to registrants who
have completed their registration by January 19, 2011 at
12:00 p.m. (CT). Allow 3-5 business days for processing.
BADGE TyPE
BLUE
Medical
personnel
Physician members, life members, honorary
members, applicants for membership, graduate
members, residents, research fellows, physician
assistants/nurse practitioners, non-dermatology
residents, medical students,
non-member physicians
yELLOW
Allied health
personnel
adjunct members, corporate individual members,
offce staff/registered nurses, and non-member
non-physicians
GREEN
spouse/guest (note: no badge will be issued to
children under 16 years)
RED
exhibitors
BEIGE
Press
ORANGE
aad staff
40
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
GENERAL INFORMATION
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
Group registration
Group registration must be completed in advance of the
meeting. On-site group registration will not be available.
Group pick-up is only available for approved groups
who have completed the advance group registration
process with the AAD prior to the meeting. New group
registration and pick-up is not permitted on site.
On-site registration of corporate or medical groups by
group organizers is not permitted. Refer to the Annual
Meeting section of the AAD website, www.aad.org, for
deadline and additional information on group
registration.
Evaluation and cME Verifcation
CME Credit is awarded based on actual participation in
the learning activities. An overall evaluation form and
CME credit claim form will be provided in the registration
bag distributed on-site at registration. Learners should
complete the session evaluation forms and drop them into
the boxes labeled “CME Evaluations” throughout the
duration of the meeting.
Prior to departure, learners should complete the
CME credit claim form and drop it into the “CME
Evaluations” boxes for processing. Credit is calculated
on a 1-hour basis and will be refected on member
transcripts within four to six weeks after the meeting.
certifcate of Attendance for Nonphysicians
International registrants as well as physicians assistants/
nurse practitioners, ofce staf/registered nurses, medical
students, corporate individual members, and adjunct
members may print out a Certifcate of Attendance on
site. To do so, please take your ExpoCard to the
registration area located in Hall D Lobby of the
Convention Center. Certifcate of Attendance Stations
will be available beginning Saturday, February 5th.
charitable contribution
You can make a tax-deductible contribution to the
programs below as you register for the Annual Meeting
or in the AAD Resource Center located in the Technical
Exhibit Hall.
AAD Camp Discovery Endowment
Help expand summer camp opportunities for children
with chronic skin conditions! Kids come out of their
shells at AAD Camp Discovery where they meet others
with similar conditions and learn they are not alone. Four
week-long sessions serve nearly 250 children each year.
A ffth week of camp will be added in 2011. Additional
funds are needed to support this new camp as well as
future expansion.
AAD Shade Structure Program
Be part of the Academy’s eforts to reduce the incidence
of and mortality from skin cancer over the next three
decades! Te protective shade structures erected through
this program protect hundreds of thousands of people
each day from harmful UV rays.
Tank you for
Furthering Excellence in Dermatology…Today and Tomorrow.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
41
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
GENERAL INFORMATION
hOTEL AND TRAVEL INFORMATION
hotel accommodations and reservations
Guest rooms are being held for 69th Annual Meeting
registrants at several major hotels in New Orleans at
AAD discounted meeting rates for those booking
through the AAD Housing Ofce. Tese rates are lower
than available hotel rack rates. See the registration and
housing brochure for information on hotel reservations.
Individuals who book reservations directly with the hotel
are not guaranteed the AAD discount.
Reservations may be made online, by fax, or by mail
through the AAD Housing Ofce in conjunction with
registration for the meeting and according to the
registration schedule on page 34. Hotel reservations for
those not registered for the meeting cannot be
accommodated.
Be prepared to fnalize your travel plans immediately as
hotel rooms go quickly. Availability cannot be guaranteed
for reservation requests received after the housing
deadline of January 13, 2011 at 12:00 p.m. (CT).
Payment information
Registration and housing fees may be paid by check
payable to AAD Registration and Housing or credit card
(Visa, Mastercard, or American Express).
hotel reservation cancellation
Deadline: January 13, 2011 at 12:00 p.m. (CT)
Send a letter of cancellation to:
• E-mail: aad@experient-inc.com or
• Fax: (800) 521-6017 or (847) 996-5401
A full refund of your deposit will be issued.
After January 13, 2011 at 12:00 p.m. (CT)
Requests for changes or cancellations will NOT be
processed by the AAD Housing Ofce after 12:00 p.m.
(CT), January 13, 2011. Refund of deposits will NOT
be issued for cancellations received after 12:00 p.m.
(CT), January 13, 2011 regardless of method of
cancellation.
Between January 14, 2011 and January 19, 2011
Te Academy will be transferring reservation information
to hotels, and hotels will be processing reservations into
their system.
Refund of deposits will NOT be issued for cancellations
received after 12:00 p.m. (CT), January 13, 2011
regardless of method of cancellation.
Starting January 19, 2011
Contact the hotel directly to cancel or change a
reservation. Phone numbers for the main host hotels will
be posted on the AAD website, www.aad.org, beginning
January 13, 2011.
Refund of deposits will NOT be issued for cancellations
received after 12:00 p.m. (CT), January 13, 2011
regardless of method of cancellation.
No late check-in
Failure to check in on the scheduled date of arrival will
result in the loss of deposit and cancellation of the room.
42
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
GENERAL INFORMATION
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
Travel information
AIR TRAVEL
Te following discounts and services have been negotiated
for registrants traveling to the AAD 69th Annual Meeting
through the Academy’s ofcial travel agency, Association
Travel Concepts (ATC), on United Airlines and American
Airlines:
• Up to 15 percent of applicable classes of service for
United Airlines tickets purchased more than 30 days
prior to the meeting. Restrictions apply.
• 5 percent of applicable classes of service for American
Airlines tickets purchased prior to the meeting.
• Personalized services.
• Low fare options.
• Advanced seat assignment and special meal requests.
• Frequent fyer program updates.
Te above discounts apply for fights between
February 1 - 11, 2011 to or from Louis Armstrong
New Orleans International Airport.
Additional services are available through Association Travel
Concepts when booking online, including airport parking,
event tickets, dining reservations, mobile device alerts,
personal profle, 24/7 online access, powerful search options,
hold trips, and low-fare search options.
Association Travel Concepts
Registrants may book online, by phone or e-mail with the
AAD’s ofcial travel agency, Association Travel Concepts
Online: www.atcmeetings.com/aad
Use the “search for discounted fights”
search box to begin your search
E-mail: reservations@atcmeetings.com
Phone: (800) 458-9383
Hours: Monday – Friday,
7:30 a.m. to 6:00 p.m. (CT)
Booking fees: online: $10
e-mail: $35
phone: $35
(Fees apply to ticketed reservations)
United and American Airlines
You may also book through your own agency or contact the
airlines directly. Refer to the ID numbers indicated below to
receive applicable discounts.
United Airlines: (800) 521-4041
ID: 510CK
American Airlines: (800) 433-1790
ID: 2321BN
cAR RENTAL
Discounts on vehicle rentals with Avis and Hertz are
available to meeting registrants.
Avis
Contact Avis directly and provide the Avis World Wide
discount number A723900 when making your reservation.
Reservations may be made on the Web or by phone.
Website: www.avis.com
Phone: (800) 831-8000 (U.S.)
(800) 879-2847 (Canada)
(Tose outside U.S. and Canada should contact their
local Avis ofce.)
Hertz
Contact Hertz directly and provide the discount code
0010533 when making your reservation or submit a coupon
or promotional coupon number. Reservations may be made
on the Web or by phone.
Website: www.hertz.com
Phone: (800) 654-2210 (U.S.)
(800) 263-0600 (Canada)
(Tose outside U.S. and Canada should contact their
local Hertz ofce.)
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
43
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
GENERAL INFORMATION
ON-SITE SERVIcES AND EXhIBITS
Academy offces/exhibits
All locations are in the New Orleans Ernest N. Morial Convention Center (CC) or Hilton New Orleans Riverside Hotel
(HR) unless otherwise indicated.
AAD Resource Center..................................................................................................................................Booth 3623 (CC)
Board of Directors’ Ofce .............................................................................................................................. Room 347 (CC)
Business Center ................................................................................................................................................. Lobby F (CC)
Convention Ofce .......................................................................................................................... Room 353/354/355 (CC)
Development Ofce ....................................................................................................................................... Room 237(CC)
Cyber Center ............................................................................................................................... Hall E and Lobby G (CC)
Certifcate of Attendance Counter ........................................................................................................... Hall G Foyer (CC)
First Aid/Nursing Mothers’ Room ............................................................................................... Lobby E and Lobby H (CC)
Information Desks ..................................................................................................................... Lobby D and Lobby G (CC)
Poster Exhibits/Poster Presentations ..................................................................................................................... Hall E (CC)
Registration
Full-Service Registration (Attendee) .................................................................................................................Hall G (CC)
Self-Service Materials Pick-up Stations (Medical Personnel only) .........................................................Hall D Lobby (CC)
Registration (Exhibitor) .................................................................................................................................... Hall E (CC)
Optional Activities ............................................................................................................................................ Lobby F (CC)
Press Ofce .................................................................................................................................................... Room 286 (CC)
Press Conferenc Room ................................................................................................................................... Room 287 (CC)
Speaker Ready Room ..............................................................................................................................Room 344/345 (CC)
Technical Exhibits ..........................................................................................................................................Halls D-H (CC)
Wi-Fi .......................................................................................................................................................... Public Areas (CC)
Restaurant Reservations .................................................................................................................................... Lobby D (CC)
Registration services
FULL SERVIcE ON-SITE REGISTRATION cOUNTERS: hALL G (cc)
Full-Service On-site Registration will open on Tursday,
February 3 at 12:00 p.m. for those who have not registered
prior to this date and time. Previously purchased tickets can
be returned here, and tickets for available sessions may also
be selected here. A photo ID is required to obtain any
registration materials. Each individual is permitted to pick
up ONLY his or her own registration materials, with the
exception of the spouse/guest badge.
Early registrants who simply wish to return, exchange, or
purchase tickets, should proceed directly to a counter marked
Tickets Only within the Full-Service On-Site Registration
area. Medical personnel who registered early and have no
changes should proceed to the Self-Service Materials Pick-up
Stations in Hall D Lobby (CC).
Full-Service On-Site Registration will be open during the
following times:
Tursday, February 3 ........................ 12:00 p.m. – 6:00 p.m.
Friday, February 4 ........................... 7:00 a.m. – 5:00 p.m.
Saturday, February 5 .......................... 7:00 a.m. – 5:00 p.m.
Sunday, February 6 ........................... 6:45 a.m. – 5:00 p.m.
Monday, February 7 ........................... 7:00 a.m. – 5:00 p.m.
Tuesday, February 8 ........................... 7:00 a.m. – 5:00 p.m.
44
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
GENERAL INFORMATION
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
SELF-SERVIcE MATERIALS PIcK-UP STATIONS (MEDIcAL
PERSONNEL ONLy): hALL D LOBBy (cc)
Medical personnel who register prior to January 26, 2011 at
12:00 p.m. (CT) and have not received their meeting
packet and have no changes to make may print their
badges, tickets, and other materials at the Self-Service
Materials Pick-up Stations located in Hall D Foyer. At these
self-service stations you will need to scan your bar-code
contained in your registration confrmation letter, or input
your registration confrmation number to print your
materials. A photo ID is required in order to pick up your
materials. Each individual is permitted to pick up ONLY
his or her own registration materials.
Stations will be available during the following hours:
Tursday, February 3 ......................12:00 p.m. – 6:00 p.m.
Friday, February 4 ......................... 7:00 a.m. – 5:00 p.m.
Saturday, February 5 ........................ 7:00 a.m. – 5:00 p.m.
Note: session tickets cannot be purchased or
returned at the Self-Service Materials Pick-up Stations.
To make corrections or changes to your registration
you will need to go to the Full-Service On-Site
Registration area in Hall G of the Convention Center.
(see p. 43 for locations and times).
ATTENDANcE VERIFIcATION/MEETING BAG PIcK-UP cOUNTER:
hALL G LOBBy (cc)
All registrants should redeem their attendance verifcation/
meeting bag voucher and pick up their handout CD-ROM,
and any updated meeting materials at the Attendance
Verifcation/Meeting Bag Pick-up Counter beginning at
8:30 a.m. on Tursday, February 3, 2011.
Exhibits
TEchNIcAL EXhIBITS: hALLS D-h (cc)
Te Technical Exhibit Hall will be open during the
following hours:
Saturday, February 5 ....................... 10:00 a.m. – 5:00 p.m.
Sunday, February 6 ........................ 10:00 a.m. – 5:00 p.m.
Monday, February 7 ........................ 10:00 a.m. – 5:00 p.m.
Admittance into the Technical Exhibit Hall is limited to
Medical and Allied Health Personnel only on Saturday
and Sunday. Only those attendees with blue or yellow
badges will be given access to the Technical Exhibit Hall
on those days. In addition to Medical and Allied Health
Personnel, Individuals with spouse/guest green badges will
be admitted on Monday, February 7 only.
Infants and children under age 16 will not be admitted to
the Technical Exhibit Hall. Tis policy has been created for
the safety of the children of Academy members and guests.
Your compliance is appreciated.
AAD RESOURcE cENTER: BOOTh 3623 (cc)
Te AAD Resource Center contains information on
Academy membership, products, or services. Staf will be
available during regular exhibit hours to answer questions.
ELEcTRONIc POSTER EXhIBITS/POSTER PRESENTATIONS:
hALL E (cc)
Electronic Poster Exhibits viewing stations will be open
during the following hours:
Friday, February 4 ........................... 7:00 a.m. – 5:00 p.m.
Saturday, February 5 .......................... 7:00 a.m. – 5:00 p.m.
Sunday, February 6 ........................... 7:00 a.m. – 5:00 p.m.
Monday, February 7 ........................... 7:00 a.m. – 5:00 p.m.
Tuesday, February 8 ......................... 7:00 a.m. – 12:00 p.m.
Poster authors will conduct brief presentations of their
electronic posters at the Poster Presentation Centers in
Hall E during the meeting. A full schedule of
presentations will be available on the Annual Meeting
website at www.aad.org in November and posted on
site at the meeting.
Limited copies of the Poster Abstract Supplement will
be available on a complimentary basis to registered
medical personnel only at the Poster Abstract Counter
located in Hall E at the New Orleans Ernest N. Morial
Convention Center.
Other services
SPEAKER READy ROOM: ROOM 344/345 (cc)
Te Speaker Ready Room will be open during the following
hours:
Tursday, February 3 ....................... 12:00 p.m. – 6:00 p.m.
Friday, February 4 .......................... 6:30 a.m. – 5:30 p.m.
Saturday, February 5 ......................... 6:30 a.m. – 5:30 p.m.
Sunday, February 6 .......................... 6:30 a.m. – 5:30 p.m.
Monday, February 7 .......................... 6:30 a.m. – 5:30 p.m.
Tuesday, February 8 .......................... 6:30 a.m. – 5:00 p.m.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
45
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
GENERAL INFORMATION
BUSINESS SERVIcE cENTER: LOBBy F (cc)
Te Business Service Center is available to all meeting
registrants. Available services include photocopying,
transparencies, fax transmissions and receipts, and FedEx
and US mail drop-of. Payment is required at time of
service; major credit cards are accepted. Te Center will be
open during the following hours:
Tursday, February 3 ..........................2:00 p.m. – 6:00 p.m.
Friday, February 4 ........................... 8:00 a.m. – 5:00 p.m.
Saturday, February 5 .......................... 8:00 a.m. – 5:00 p.m.
Sunday, February 6 ........................... 8:00 a.m. – 5:00 p.m.
Monday, February 7 ........................... 8:00 a.m. – 5:00 p.m.
Tuesday, February 8 ........................... 8:00 a.m. – 5:00 p.m.
cyBER cENTER: hALL E AND LOBBy G (cc)
Registrants may check e-mails at the Cyber Center, which
will be open during the following hours:
Tursday, February 3 .......................... 8:00 a.m. – 6:00 p.m.
Friday, February 4 ........................... 7:00 a.m. – 5:00 p.m.
Saturday, February 5 .......................... 7:00 a.m. – 5:00 p.m.
Sunday, February 6 ........................... 7:00 a.m. – 5:00 p.m.
Monday, February 7 ........................... 7:00 a.m. – 5:00 p.m.
Tuesday, February 8 ........................... 7:00 a.m. – 5:00 p.m.
WI-FI (PUBLIc AccESS) (cc):
Wi-Fi will be accessible in public lobbies during meeting
days.
PRESS REGISTRATION/INFORMATION: ROOM 286 (cc)
Journalists who are working for and representing recognized
news organizations are encouraged to register to attend the
meeting as Press. Press may register to attend the Annual
Meeting in advance or at the On-Site Press Registration
Desk. To register, journalists must provide a business card
and samples of their work. All freelancers must present a
letter of assignment.
Te Press Ofce will be stafed by Academy media relations
staf and ofer workstations for registered journalists. Press
conferences will be held in Room 287 (CC).
Tursday, February 3 .......................... 2:00 p.m. – 5:00 p.m.
Friday, February 4 .............................. 8:00 a.m. – 5:00 p.m.
Saturday, February 5 .......................... 8:00 a.m. – 5:00 p.m.
Sunday, February 6............................. 8:00 a.m. – 5:00 p.m.
Monday, February 7 ........................... 8:00 a.m. – 5:00 p.m.
ScOOTER/WhEELchAIR RENTAL
Twenty-four hour mobility service is available by contacting
ScootAround, Inc.
Toll-free phone ............................................. (888) 441-7575
E-mail .............................................. info@scootaround.com
Fax ............................................................. (204) 478-1172
Mobility service during Annual Meeting ofcial meeting
hours is available.
Should your needs require mobility service strictly during
ofcial meeting hours, you may reserve a scooter through
the Academy, free of charge. To do so, check the “ADA
Mobile” box under the Personal Information page of your
online registration. You will be required to pick up
and drop of your scooter in the AAD Convention Ofce
Room 353 each meeting day.
AUDIO REcORDINGS
Pre-Order your Annual Meeting Audio Recordings for a discounted rate of $299!
Each session recording provides a convenient way for you to experience the Annual Meeting and expand your
knowledge of the latest advancements in the specialty of dermatology.
Enjoy the exclusive content that this year’s meeting ofers:
• Hundreds of speakers • Audio DVD-ROM with access to online version
• Slides synchronized with audio of select talks • Load talks directly to MP3 player, iTunes playlist and iPod
• Both MAC and PC Compatible
46
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
GENERAL INFORMATION
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
INFORMATION DESKS: LOBBy D AND LOBBy G (cc)
Tursday, February 3 ........................ 12:00 p.m. – 6:00 p.m.
Friday, February 4 .............................. 7:00 a.m. – 5:00 p.m.
Saturday, February 5 .......................... 7:00 a.m. – 5:00 p.m.
Sunday, February 6............................. 7:00 a.m. – 5:00 p.m.
Monday, February 7 ........................... 7:00 a.m. – 5:00 p.m.
Tuesday, February 8 ........................... 7:00 a.m. – 5:00 p.m.
OPTIONAL AcTIVITIES
New Orleans is flled with numerous cultural and fun-flled
venues. Come explore New Orleans by signing up for tours
arranged exclusively for registered attendees and their
spouses/guests of the Annual Meeting. Numerous tours in
and around New Orleans are featured in the Optional
Activities Brochure or at www.aad.org. Buses for the tours
will depart from the New Orleans Ernest N. Morial
Convention Center (Hall F lobby).
RESTAURANT RESERVATIONS: LOBBy D (cc)
Tursday, February 3 ........................12:00 p.m. – 6:00 p.m.
Friday, February 4 ......................... 10:00 a.m. – 6:00 p.m.
Saturday, February 5 ........................ 10:00 a.m. – 6:00 p.m.
Sunday, February 6 ......................... 10:00 a.m. – 6:00 p.m.
Monday, February 7 ......................... 10:00 a.m. – 5:00 p.m.
To make reservations in advance go to www.opentable.com
or go to www.neworleanscvb.com to see restaurant options.
chILD cARE SERVIcES
Contact the concierge desk at your hotel to arrange for child
care services. Arrangements should be made as early as
possible prior to your anticipated arrival. Te Academy has
no control over and assumes no responsibility for the care
provided through the hotels. Tis information is provided
solely as a service to help registrants identify possible
resources for child care services.
FIRST AID/NURSING MOThERS’ ROOM: LOBBy E AND LOBBy h (cc)
Te New Orleans Ernest N. Morial Convention Center is
equipped with frst aid rooms with space available for
nursing mothers.
MEETING ROOM LOcATIONS
Please be aware that the room locations in this program book
may change prior to the meeting. Refer to the Program Book
Update under the Annual Meeting section of the AAD website
at www.aad.org. When on site, the Program-at-A-Glance will
have updated room changes. Te Program-at-A-Glance will be
distributed to all registrants in their meeting bags.
ShUTTLE BUS SERVIcE
Shuttle bus service is available for meeting attendees who have
booked reservations through the Academy’s Hotel Reservation
System. Service runs between the convention center and
designated convention hotels. Te shuttle bus does not serve
hotels within a three-block radius of the convention center.
Please refer to the Registration/Housing Brochure or the
Registration/Housing website for specifc shuttle bus stops.
Tose who require special needs transportation should
request rooms at the Hilton New Orleans Riverside. Tis
route will be equipped with lift vehicles.
AAD meeting policies
INDEPENDENcE IN cME
Te mission of the Academy’s continuing medical education
program is to improve patient care and health care outcomes
by maintaining, developing and enhancing medical
knowledge, patient care, interpersonal and communication
skills, and professionalism. As a provider accredited by the
Accreditation Council for Continuing Medical Education
(ACCME) and in support of this mission, the Academy is
dedicated to providing continuing medical education that is
independent, fair, balanced, objective and free of commercial
bias. Te Academy employs several strategies to ensure these
standards will be met. Te Planning Committee members
submit and consider their own disclosure information and
recuse themselves from planning educational activities should
they have conficts related to the subject area presented.
When developing an educational program, the Planning
Committee reviews applications and disclosure of confict
of interest forms, along with physician competence gaps
and evaluative data from past activities in order to develop
programming.
Potential participants are sent detailed guidelines that
provide direction on necessary components to ensure
independence in continuing medical education activities and
to resolve confict, as itemized below.
Disclosure of Relevant Financial Relationships
Te Board of Directors requires that all participants in the
Annual and Summer Meetings comply with all applicable
laws and regulations governing disclosure. Session directors
and speakers are required to provide the Academy with a
comprehensive disclosure of fnancial relationships with a
commercial interest producing health care goods or services
consumed by or used on patients. Individuals who refuse to
disclose relevant fnancial relationships are disqualifed from
participation in the educational program(s).
Disclosure statements must include all fnancial relationships
occurring within 12 months of the educational activity.
If no fnancial relationships exist, the individual is required
to indicate such on the disclosure form. A comprehensive
disclosure of fnancial relationships is published in the
Program-at-A-Glance and is available online on the
Academy’s website at www.aad.org.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
47
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
GENERAL INFORMATION
In addition, directors/speakers are expected to make a verbal
disclosure of relevant fnancial relationships or indicate no
conficts exist at the beginning of their presentation.
A digital slide with a disclosure template will be provided
to the speaker for inclusion in the presentation prior to the
meeting. Failure to disclose will result in a denial of the
opportunity to participate in the CME activity.
It is the responsibility of the session director to ensure
balance with regards to disclosure of potential conficts of
interest. In addition, all speakers are required to complete
the speaker attestation form indicating compliance with
these policies.
Content Validation
Academy-sponsored educational activities are designed to
promote improvements or quality in health care and not promote
a specifc proprietary business interest or a commercial interest.
Presentations and related materials must be based on scientifc
methods generally accepted by the medical community.
Presentations should be evidence-based and discuss the
validity of the evidence upon which they base opinion(s). (See
Sackett et al, BMJ 1996;312:71-2.) Tis ensures the audience
that the recommendations are supported by the evidence
and contributes to management of any potential conficts of
interest. Further, if the presentation includes discussion of “of-
label” or investigational use of a commercial product, this also
must be disclosed to the participants.
Continuing Medical Education (CME) must give a balanced
view of therapeutic options. Use of generic names will
contribute to this impartiality. If CME educational material
or content includes trade names, trade names from several
companies should be used where available, as opposed to using
trade names from just a single company. Educational materials
such as slides, abstracts, and handouts cannot contain any
advertising or product-group messages.
Outcomes Measurement
Several methods of evaluation are utilized in assessing the
educational program. Session directors, speakers, attendees, and
formal observers are all given the opportunity to evaluate the
educational content and speaker performance. Included in this
process are measures to rate the success of the Academy’s policies
regarding independence in continuing medical education
activities with particular focus on the absence of commercial bias.
In addition, the Academy may review speaker presentations
stored on the meeting servers to collect aggregate data regarding
disclosure. Tese data are only used to determine efectiveness
of the Academy’s policies and procedures regarding disclosure.
Should it be determined that a member of the Academy’s
educational program violated the Academy’s “Policy to
Ensure Independence in Continuing Medical Education,”
the individual may not be asked to participate in future
educational programs.
DIScLAIMER
Te views expressed and the techniques presented by the
speakers at the AAD-sponsored educational meetings are not
necessarily shared or endorsed by the Academy. Te Academy
requires speakers to disclose all relevant personal/professional
relationships and any unapproved or “of-label” uses of
medical devices or pharmaceutical agents that they discuss,
describe, or demonstrate during their presentations.
Registrants must use their independent judgment in applying
the information discussed in Academy educational sessions in
the treatment of their patients. Handout materials are
prepared and submitted for distribution by the presenters,
who are solely responsible for their content.
AGE LIMITS
Infants and children under the age of 16 are not allowed
into educational sessions or the Technical Exhibit Hall. Tis
policy is due to the nature of some presentations and to
ensure the safety of registrants’ children. Your support and
compliance are appreciated.
cAMERA /VIDEO REcORDING
Use of cameras, camera phones, and video cameras is
prohibited in all educational sessions. Violations of this
policy will result in removal from the session and
confscation of equipment. Directors and room monitors
will be closely monitoring adherence to this policy.
cELL PhONES
Cell phone usage during educational sessions is disruptive
and is therefore prohibited. Attendees are asked to turn of
cell phones or place them on vibrate prior to entering a
session room. Violations of this policy will result in removal
from the session room. Session directors and room monitors
will be closely monitoring adherence to this policy.
SMOKING
All AAD educational programs in meeting rooms and
seated functions occurring during the meeting are
smoke free. Please also comply with the smoking policy
of each individual facility.
ALcOhOLIc BEVERAGES
Te Academy’s ofcial policy regarding the minimum
age for alcohol consumption is the age applicable to
the jurisdiction of the event venue.
OFFIcIAL LANGUAGE
Te ofcial language of the Annual Meeting is English.
TIcKETED SESSION ADMITTANcE/WALK-INS
Sessions that have a ticket, but no fee, will hold a seat for
15 minutes after the ofcial start time, after which seats will
be available on a frst-come, frst-served basis for eligible
categories. Attendees attending sessions with a fee must have
a ticket for admittance.
g
48
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
GENERAL INFORMATION
G
E
N
E
R
A
L

I
N
F
O
R
M
A
T
I
O
N
Education Department
Te Education Department develops and administers the
education program for the Annual Meeting. For further
information, please contact the following staf members by
phone or e-mail at the following: (847) 330-0230 or
mrc@aad.org.
Debbie Gist, MPH, FACME ................ Director, Education
Jennifer Tompson, MS ...... Senior Manager, Live Meetings
Chris Presta ................ Senior Manager, Enduring Materials
Jennifer Wahl .................... Program Development Specialist
Joanna King .................................................CME Specialist
creative and Publishing Department
Te Creative and Publishing Department edits and produces
the Annual Meeting Program Book.
Lara Lowery ..................... Director, Creative and Publishing
Ed Wantuch ................................................Design Manager
Nicole Torling ................................................Lead Designer
Joe Miller ..................................................Graphic Designer
Katie Domanowski .................... Senior Manager, Publishing
Nate Jenkins ......................................... Production Manager
Carrie DeGuide .................................. Advertising Specialist
Jon Dudek .......................................... Production Specialist
AAD STAFF
Meetings and conventions Department
Te Meetings and Conventions Department administers
the Annual Meeting. For further information, please
contact the following staf members by phone or e-mail at
the following: (847) 330-0230, fax (847) 330-1090 or
mrc@aad.org.
Timothy Moses, CMP .........Director, Meetings and Conventions
Debra Barrett ..............................Senior Manager, Meetings
Robin Downey ....................... Senior Manager, Registration
Sara Peterson, CEM ..................... Senior Manager, Exhibits
Amanda Sage, CMP ....................Senior Manager, Meetings
Tamara Pundsack ........................ Senior Meetings Specialist
Joni Taylor ................................................Exhibit Specialist
Susan Jackson ................................ Administrative Specialist
Krysten Zarembski ............................ Meetings Coordinator
Marisol Sukhu .............................. Registration Coordinator
Power made personal
©2010 Merz Pharmaceuticals All rights reserved. 5/10
Naftin
®
(naftifine HCl 1%) Cream and Gel are indicated for the topical treatment of tinea pedis,
tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes,
Epidermophyton floccosum and Trichophyton tonsurans (Gel only).
Naftin
®
Cream and Gel are contraindicated in individuals who have shown hypersensitivity
to any of their components and are for topical use only.
During clinical trials with Naftin
®
Cream and Gel, the following side effects were most commonly
reported: burning/stinging, dryness, erythema, itching, local irritation, skin tenderness and rash.
Please see brief summary on the following page.
For the fungicidal power you trust, turn to Naftin
®
(naftifine HCl 1%).
Designed to suit a range of patients and preferences, Naftin
®
delivers
power against tinea pedis, cruris and corporis. Choose Naftin
®
Gel,
Naftin
®
Cream, or the innovative Naftin
®
Cream Pump and give your
patients the customized care they deserve.
For your patients with tinea pedis, tinea cruris, and tinea corporis
AAD 8/10.indd 1 6/24/10 1:35 PM
Manufactured for Merz Pharmaceuticals, Greensboro, NC 27410

© 2010 Merz Pharmaceuticals Rev 3/10
BRIEF SUMMARY
Rx ONLY
INDICATIONS AND USAGE: Naftin
®
Cream, 1% is
indicated for the topical treatment of tinea pedis, tinea
cruris, and tinea corporis caused by the organisms
Trichophyton rubrum, Trichophyton mentagrophytes, and
Epidermophyton foccosum. Naftin
®
Gel, 1% is indicated
for the topical treatment of tinea pedis, tinea cruris, and
tinea corporis caused by the organisms Trichophyton
rubrum, Trichophyton mentagrophytes, Trichophyton
tonsurans*, Epidermophyton foccosum*. *Effcacy for this
organism in this organ system was studied in fewer than
10 infections.

CONTRAINDICATIONS: Naftin
®
Cream and Gel, 1%
are contraindicated in individuals who have shown
hypersensitivity to any of their components.
WARNINGS: Naftin
®
Cream and Gel, 1% are for topical
use only and not for ophthalmic use.
PRECAUTIONS: General: Naftin
®
Cream and Gel,
1%, are for external use only. If irritation or sensitivity
develops with the use of Naftin
®
Cream or Gel, 1%,
treatment should be discontinued and appropriate
therapy instituted. Diagnosis of the disease should be
confrmed either by direct microscopic examination of
a mounting of infected tissue in a solution of potassium
hydroxide or by culture on an appropriate medium.
Information for patients: The patient should be told to:
1. Avoid the use of occlusive dressings or wrappings
unless otherwise directed by the physician.
2. Keep Naftin
®
Cream and Gel, 1% away from the
eyes, nose, mouth and other mucous membranes.
Carcinogenesis, mutagenesis, impairment of fertility:
Long-term studies to evaluate the carcinogenic
potential of Naftin
®
Cream and Gel, 1% have not been
performed. In vitro and animal studies have not
demonstrated any mutagenic effect or effect on fertility.

Pregnancy: Teratogenic Effects: Pregnancy
Category B: Reproduction studies have been performed
in rats and rabbits (via oral administration) at doses
150 times or more than the topical human dose and have
revealed no evidence of impaired fertility or harm to the
fetus due to naftifne. There are, however, no adequate
and well-controlled studies in pregnant women. Because
animal reproduction studies are not always predictive
of human response, this drug should be used during
pregnancy only if clearly needed.
Nursing mothers: It is not known whether this drug is
excreted in human milk. Because many drugs are excreted
in human milk, caution should be exercised when Naftin
®

Cream or Gel,1% are administered to a nursing woman.
Pediatric use: Safety and effectiveness in pediatric
patients have not been established.

ADVERSE REACTIONS: During clinical trials with
Naftin
®
Cream, 1%, the incidence of adverse reactions
was as follows: burning/stinging (6%), dryness (3%)
erythema (2%), itching (2%), local irritation (2%).
During clinical trials with Naftin
®
Gel, 1%, the incidence
of adverse reactions was as follows: burning/stinging
(5.0%), itching (1.0%), erythema (0.5%), rash (0.5%),
skin tenderness (0.5%).
See more patients in the same amount
of time without increasing staff.

Varitronics, the leader in Non-
Verbal Interoffice Communica-
tions for over four decades,
offers the most feature-rich
systems on the market today.
Our custom designed Call
Systems will streamline the
way you work so that you can
decrease your patient’s waiting
time while increasing your staff‘s
efficiency.
Call, email, or visit our web site today to
see how easy it is to benefit from the
efficiency of Varitronics’ Call System.
800.345.1244 • email:varimed@varitronics.com
www.varitronics.com
Increase patient flow and overall
practice efficiency.
Increase profits.
Varitronics can show you how!
Va
Ve
tio
off
sy
Ou
Call Systems
are available
for both new
and existing
construction.
Leading the way in Interoffice Communications
Wal l panel
and pager
CS 2000
Wi r el ess Syst em
See more patients in the same amount
of time without increasing staff.

Varitronics, the leader in Non-
Verbal Interoffice Communica-
tions for over four decades,
offers the most feature-rich
systems on the market today.
Our custom designed Call
Systems will streamline the
way you work so that you can
decrease your patient’s waiting
time while increasing your staff‘s
efficiency.
Call, email, or visit our web site today to
see how easy it is to benefit from the
efficiency of Varitronics’ Call System.
800.345.1244 • email:varimed@varitronics.com
www.varitronics.com
Increase patient flow and overall
practice efficiency.
Increase profits.
Varitronics can show you how!
Va
Ve
tio
off
sy
Ou
Call Systems
are available
for both new
and existing
construction.
Leading the way in Interoffice Communications
Wal l panel
and pager
CS 2000
Wi r el ess Syst em
attract new clients
i mprove conversi ons
www.canfieldsci.com
|
phone +1.973.276.0336
(USA) 1.800.815.4330
I M A G I N G E X C E L L E N C E F R O M
CANFIELDScientific, Inc. is the
global leader in photographic imaging systems,
services and products for scientific research
and health care applications.
Driven by a quality-focused mission to provide
best-in-class imaging solutions and services,
Canfield has achieved an industry-wide reputation
for excellence and innovation through out its
product lines, industry services and customer support.
VECTRA, Face Sculptor, Body Sculptor, Breast Sculptor, VISIA, Reveal Imager, Mirror,
DermaGraphix, PhotoFile, MatchPose, IntelliStudio, OMNIA, TwinFlash, EpiFlash,
and IntelliFlash are registered trademarks of Canfield Scientific, Inc.
3D solutionṡ
facial
imaging &̇
analysis
imaging
̇
software
photographẏ
research
systems &̇
services
®
3D capture system
& sculptor 3D simulation software
the next dimension of medical imaging accuracy
®
COMPLEXION ANALYSIS imager
®
transforming skin care practices worldwide
®
medical imaging software
the core of advanced medical imaging solutions
to fit your practice today—and in the future
IntelliStudio® OMNIA® TwinFlash® EpiFlash® IntelliFlash®
innovative medical photography systems, accessories,
and custom designed studios
VECTRA-CR and custom designed
systems for clinical research
Clinical researchers around the world rely on Canfield for
the high quality medical imaging their studies demand.
1007-03 AD-AAD-2011ProgramBook 8/11/10 11:35 AM Page 1
52
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
W
h
A
T

S

N
E
W
WhAT’S NEW
NEW ThIS yEAR!
REGISTRATION
Meeting Materials Mailing
Meeting materials, including badges, tickets, and
attendance verifcation/meeting bag voucher, will
now be mailed to ALL registrants including
International registrants who register by January 5,
2011 at 12:00 p.m. (CT).
In order for US, Canadian, and International
registrants to receive their materials by mail,
registration must be completed by Wednesday,
January 5, 2011 at 12:00 p.m. (CT), the close of early
registration. Registration packets containing these
items will be sent via US mail to US registrants and via
special courier service to Canadian and International
registrants between January 10 – January 21, 2011.
Materials will be mailed to the address listed on your
registration records, which will also be listed on your
ExpoCard.
Due to the mailing of meeting materials, pre-meeting
changes/cancellations for ticketed events must be
completed by January 5 at 12:00 p.m. (CT). After this
date and time ticket cancellations and changes must be
made at the Tickets Only Counters located in the Full-
Service On-Site Registration Area located in Hall G of
the Convention Center at the meeting. For housing
changes/cancellations refer to the hotel and travel
information section of the program book.
REGISTRANTS WhO REGISTER AFTER
WEDNESDAy, JANUARy 5, 2011 AT 12:00 P.M. (cT)
All registrants who register after 12:00 p.m. (CT) on
January 5, 2011 will need to pick up badges, tickets,
and vouchers on site. See p. 43 for locations.


Medical Personnel Materials Pick-up
MATERIALS PIcK-UP STATIONS (MEDIcAL PERSONNEL ONLy):
hALL D LOBBy, cONVENTION cENTER
Medical personnel who register by Wednesday,
January 26, 2011 at 12:00 p.m. (CT) and who have not
received their meeting packet in advance and have no
changes to make to their registration, may print their
badges, tickets, and other materials at the Self-Service
Materials Pick-up Stations located in Hall D Lobby of the
Convention Center. You will need to scan your
registration bar-code contained in your registration
confrmation letter, or input your registration
confrmation number to print your materials. A photo ID
is required to pick up your materials. Each individual is
permitted to pick up ONLY his or her own registration
materials. Self-Service Stations will be available during the
following hours:
Tursday, February 3 ...............12:00 p.m. – 6:00 p.m.
Friday, February 4 ..................... 7:00 a.m. – 5:00 p.m.
Saturday, February 5 ................. 7:00 a.m. – 5:00 p.m.
Note: Session tickets cannot be purchased or
returned at the Self-Service Materials Pick-up Stations.
To make corrections or changes to your registration you
will need to go to the Full-Service On-Site Registration
area in Hall G of the Convention Center.
(see p. 43 for locations and times).
Te Self-Service Materials Pick-up Stations are
open to Medical Personnel only.
Ticket Only counters
Registrants who wish to only purchase or return tickets
may do so at these specially-designated counters in the
Full-Service On-Site Registration area in Hall G of the
Convention Center. Tese counters are only for ticket
returns/purchases, not the processing of full on-site
registration. Tose who wish to complete registration
on site should proceed to a full service counter in the
on-site registration area.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
53
W
h
A
T

S

N
E
W
WhAT’S NEW
ScIENTIFIc SESSIONS
SyMPOSIA
S018 Late-Breaking Research Session
A two-hour session dedicated to Late-Breaking Research
will be presented on Saturday, February 5, 2011. All
members of the Academy are invited to submit abstract
presentations for review and selection for this Late-
Breaking Research session. Te Late-Breaking Research
session provides an opportunity for a 9-minute oral
presentation. Abstract descriptions are limited to
150 words. Te deadline for applications is January 7,
2011, at 5:00 p.m. (CT). Please see page 126 for more
information.
FOcUS SESSIONS
To provide a more diverse program, Focus Sessions
will now be ofered three times a day. Tey will take
place daily 7:15 a.m. to 8:45 a.m.
(Sunday 7:00 a.m. to 8:00 a.m.);
12:15 p.m. to 1:45 p.m.; and
2:30 p.m. to 4:00 p.m.
DIScUSSION GROUPS
To provide a more diverse program Discussion Groups
will now be ofered three times a day. Tey will take
place daily 7:15 a.m. to 8:45 a.m.
(Sunday 7:00 a.m. to 8:00 a.m.);
12:15 p.m. to 1:45 p.m.; and
2:30 p.m. to 4:00 p.m.
Attendance will be limited to 50 registrants.
AAD POLIcy
SESSION LATE ADMITTANcE/WALK-IN POLIcy
As a reminder, due to the high demand of educational
sessions, those sessions that have a ticket, but no fee,
will hold a seat for 15 minutes after the ofcial start
time, after which seats will be available on a frst-come,
frst-served basis for eligible categories. Tose attending
sessions with a fee must have a ticket for admittance.
chARITABLE cONTRIBUTION
You can make a tax-deductible contribution to the AAD
Camp Discovery Endowment and/or the Shade
Structure Program as you register for the Annual
Meeting or in the AAD Resource Center located in the
Technical Exhibit Hall. See page 40 for details.
DERMATOLOGy IN AcTION
SERVIcE INITIATIVE
Members can make a lasting impression as part of their
meeting experience by volunteering to the Academy’s new
Dermatology in Action program, where the AAD gives
back to the community hosting its scientifc meetings.
In New Orleans, volunteers will be needed to help paint,
clean up and refurbish a local school. If you are unable
to volunteer time, consider donating some of your
medical supplies. Tese will be collected at the meeting
and donated to a local clinic. Financial support is also
vital to the program and will be used to support future
and current volunteer activities. To learn more and
sign up to be a part of Dermatology in Action go to
www.aad.org/members/leadership, and watch for more
information in upcoming editions of Annual Meeting
News and Dermatology World.
LEADERShIP INSTITUTE EXPANDS IN 2011
Te Academy’s Leadership Institute has proven to be a
popular, efective way to assist in preparing dermatologists
to serve successfully in organized medicine and support
the specialty through efective advocacy and policy
development. In New Orleans in 2011, the AAD has
added exciting Leadership Institute sessions and activities
to the Annual Meeting program, including special
presentations during the plenary session, opportunities to
recognize your favorite mentors, and the ability to
communicate leadership messages on a new electronic
message board, throughout the meeting.
Look for the Leadership Institute icon in the
program book and check out the latest AAD
leadership buzz at www.aad.org/leadership.
PRODUcT ThEATERS
Tese unique sessions, being held Saturday through
Monday in Hall F at the Convention Center, will
present new research fndings on products, provide
product details, ofer demonstrations, and highlight new
products to meeting attendees. Science supporting the
product will be provided by experts in the feld, and will
be presented in a relaxed, low-pressure environment.
Product theaters are free to meeting attendees, but be
prepared to arrive early. Seating will be available on a frst-
come, frst-served basis. Tese sessions are solely
promotional, and are not eligible for continuing medical
education credit.
©2010 Abbott Laboratories Abbott Park, IL 60064 64V-415702 August 2010 Printed in U.S.A.
See what’s REVEALed at Abbott booth 2721.
Orleans for AAD!
©2010 Abbott Laboratories Abbott Park, IL 60064 64V-415702 August 2010 Printed in U.S.A.
See what’s REVEALed at Abbott booth 2721.
Orleans for AAD!
Ortho Dermatologics
commends all
and
members
for their exceptional commitment to the future of dermatology.
Their contributions will help develop the next generation of
teachers and researchers, and enable advancements in patient care.
Please visit the Dermatology Foundation booth #2740 in the technical exhibit area.
Dermatology
Foundation
Shaping the Future of Dermatology
www.dermatologyfoundation.org
®
Available in 100-g tubes
1
0
THE ONLY VITAMIN D
3
OINTMENT AVAILABLE FOR MILD TO MODERATE PLAQUE PSORIASIS
@ss`bgdrsnxntqqdfhldm
Customize your regimen with a unique chemical entity different
from other psoriasis treatments
º Contains a natura||y occurring, active form of Vitamin D
3
º Proven safe and effective in a 52-week study
2,3
The most frequent adverse events (≥3%) reported
in clinical trials were lab test abnormality, urine
abnormality, psoriasis, hypercalciuria, pruritus and skin
discomfort. Vectical
®
should be used with caution in
patients with known or suspected disturbances in
calcium homeostasis, who are taking calcium or
Vitamin D supplements or who are on diuretics. If
aberrations in parameters of calcium metabolism
occur, discontinue use until these normalize. Caution
patients to avoid excessive exposure to natural or
artificial sunlight after applying the ointment. Avoid
contact with eyes, lips and face. Limit use to
200 grams per week.
Please see next page for brief summary of
Prescribing Information.
VECTICAL
TM
(calcitriol) OINTMENT, 3 mcg/g
For topical use only.
Not for oral, ophthalmic, or intravaginal use.
Not to be applied to the eyes, lips, or facial skin.
BRIEF SUMMARY
INDICATIONS AND USAGE:
VECTICAL Ointment is a vitamin D analog indicated for the topical treatment of
mild to moderate plaque psoriasis in adults 18 years and older.
CONTRAINDICATIONS
None
WARNINGS AND PRECAUTIONS
Effects on Calcium Metabolism
In controlled clinical trials with VECTICAL Ointment, among subjects having
laboratory monitoring, hypercalcemia was observed in 24% (18/74) of subjects
exposed to active drug and in 16% (13/79) of subjects exposed to vehicle.
However, the increases in calcium and albumin-adjusted calcium levels were less
than 10% above the upper limit of normal.
If aberrations in parameters of calcium metabolism occur, treatment should be
discontinued until these parameters have normalized. The effects of VECTICAL
Ointment on calcium metabolism following treatment durations greater than 52
weeks have not been evaluated. Increased absorption may occur with occlusive use.
Ultraviolet Light Exposure
Animal data suggest that the vehicle of VECTICAL Ointment may enhance the
ability of ultraviolet radiation (UVR) to induce skin tumors.
Subjects who apply VECTICAL Ointment to exposed skin should avoid excessive
exposure of the treated areas to either natural or artificial sunlight, including
tanning booths and sun lamps. Physicians may wish to limit or avoid use of
phototherapy in patients who use VECTICAL Ointment.
Unevaluated Uses
The safety and effectiveness of VECTICAL Ointment in patients with known or
suspected disorders of calcium metabolism have not been evaluated. The safety
and effectiveness of VECTICAL Ointment in patients with erythrodermic,
exfoliative, or pustular psoriasis have not been evaluated.
ADVERSE REACTIONS
Because clinical studies are conducted under widely varying conditions, adverse
reaction rates observed in the clinical studies of a drug cannot be directly
compared to rates in the clinical studies of another drug and may not reflect the
rates observed in practice.
Clinical Studies Experience
VECTICAL Ointment was studied in two vehicle-controlled studies (419 subjects), and
in one open label study (324 subjects). The table below describes exposure to
VECTICAL Ointment in 743 subjects, including 239 exposed for 6 months and 116
exposed for one year.
Four hundred and nineteen subjects were treated with VECTICAL Ointment twice
daily for 8 weeks. The population included subjects ages 13 to 87, males (284) and
females (135), Caucasians (372) and non-Caucasians (47); with mild (105) to
moderate (313) chronic plaque psoriasis.
Selected Adverse Events Occurring in at least 1% of Subjects in the
Two Pooled Vehicle-Controlled Studies
VECTICAL Ointment Vehicle Ointment
(n=419) (n=420)
Discomfort skin 3% 2%
Pruritus 1% 1%
Among subjects having laboratory monitoring, hypercalcemia was observed in 24%
(18/74) of subjects exposed to active drug and in 16% (13/79) of subjects exposed
to vehicle, however the elevations were less than 10% above the upper limit of normal.
The open label study enrolled 324 subjects with psoriasis who were then treated
for up to 52 weeks. Adverse events reported at a rate of greater than or equal to
3% of subjects treated with VECTICAL Ointment were lab test abnormality (8%),
urine abnormality (4%), psoriasis (4%), hypercalciuria (3%), and pruritus (3%).
Kidney stones were reported in 3 subjects and confirmed in two.
Postmarketing Experience
The following adverse reactions have been identified during worldwide post-
approval use of VECTICAL Ointment: acute blistering dermatitis, erythema,
pruritus, skin burning sensation, and skin discomfort. Because these reactions
are reported voluntarily from a population of uncertain size, it is not always
possible to reliably estimate their frequency or establish a causal relationship to
drug exposure.
DRUG INTERACTIONS
VECTICAL Ointment should be used with caution in patients receiving medications
known to increase the serum calcium level, such as thiazide diuretics. Caution
should also be exercised in patients receiving calcium supplements or high doses
of vitamin D.
USE IN SPECIFIC POPULATIONS
Pregnancy
Teratogenic Effects: Pregnancy Category C.
VECTICAL Ointment contains calcitriol which has been shown to be fetotoxic.
There are no adequate and well-controlled studies for VECTICAL Ointment in
pregnant women. VECTICAL Ointment should be used during pregnancy only if the
potential benefit to the patient justifies the potential risk to the fetus.
Teratogenicity studies with calcitriol were performed in which rats were treated orally
at dosages up to 0.9 mcg/kg/day (5.4 mcg/m
2
/day) and in which rabbits received
topical application of calcitriol ointment (3 ppm) to 6.4% of the body surface area.
No effects on reproductive or fetal parameters were observed in rats. In rabbits,
topically applied calcitriol induced a significantly elevated mean post-implantation
loss and an increased incidence of minor skeletal abnormalities due to retarded
ossification of the pubic bones. A slightly increased incidence of skeletal variation
(extra 13
th
rib, reduced ossification of epiphyses) was also observed. These effects
may have been secondary to maternal toxicity. Based on the recommended human
dose and instructions for use, it is not possible to calculate human dose equivalents
for animal exposures in these studies.
Nursing Mothers
It is not known whether calcitriol is excreted in human milk. Because many drugs
are excreted in human milk, caution should be exercised when VECTICAL Ointment
is administered to a nursing woman.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
Geriatric Use
Clinical studies of VECTICAL Ointment did not include sufficient numbers of
subjects aged 65 and over to determine whether they respond differently from
younger subjects. Other reported experience has not identified differences in
responses between the elderly and younger patients.
OVERDOSAGE
Topically applied calcitriol can be absorbed in sufficient amounts to produce
systemic effects.
NONCLINICAL TOXICOLOGY
Carcinogenesis, Mutagenesis, Impairment of Fertility
When calcitriol was applied topically to mice for up to 24 months, no significant
changes in tumor incidence were observed. Concentrations of calcitriol in ointment
base of 0 (vehicle control), 0.3, 0.6 and 1.0 ppm were evaluated.
A two-year carcinogenicity study was conducted in which calcitriol was orally
administered to rats at dosages of approximately 0.005, 0.03, and 0.1 mcg/kg/day
(0.03, 0.18, and 0.6 mcg/m
2
/day, respectively). The incidence of benign
pheochromocytomas was significantly increased in female rats. No other
significant differences in tumor incidence data were observed.
In a study in which albino hairless mice were exposed to both ultra-violet radiation
(UVR) and topically applied calcitriol ointment, a reduction in the time required for
UVR to induce the formation of skin tumors was observed in all groups that
received the ointment base, including the vehicle-treated control group, relative to
animals that received no ointment but which were exposed to UVR. The time
required for UVR to induce the formation of skin tumors did not differ between
animals that received plain vehicle and those that received vehicle that contained
calcitriol. Concentrations of calcitriol in ointment base of 0 (vehicle control), 0.3,
0.6 and 1.0 ppm were evaluated. These data suggest that the vehicle of VECTICAL
Ointment may enhance the ability of UVR to induce skin tumors.
Calcitriol did not elicit genotoxic effects in the mouse lymphoma TK locus assay.
Studies in which male and female rats received oral doses of calcitriol of up to
0.6 mcg/kg/day (3.6 mcg/m
2
/day) indicated no impairment of fertility or general
reproductive performance.
Based upon the recommended human dose and instructions for use, it is not possible
to calculate human dose equivalents for animal exposure in these studies.
PATIENT COUNSELING INFORMATION
This information is intended to aid in the safe and effective use of this medication.
It is not a disclosure of all possible adverse or intended effects. Patients using
VECTICAL Ointment should receive the following information:
Instructions for Use
This medication is to be used as directed by the physician. It is for external use
only. This medication is to be applied only to areas of the skin affected by psoriasis,
as directed. It should be gently rubbed into the skin so that no medication remains
visible.
Adverse Reactions
Patients should report any signs of adverse reactions to their physician.
Marketed by:
GALDERMA LABORATORIES, L.P.
Fort Worth, Texas 76177 USA
Manufactured by:
Galderma Production Canada Inc. GALDERMA is a registered trademark.
Baie d’Urfé, QC, H9X 3S4 Canada P51460-0
Made in Canada. Revised: January 2009
©2009 Galderma Laboratories, L.P.
GALDERMA and Vectical are registered trademarks.
Galderma Laboratories, L.P.
14501 N. Freeway, Fort Worth, TX 76177
VEC-337C Printed in USA 12/09
References: 1. Vectical
®
Prescribing Information. Fort Worth, TX: Galderma Laboratories, L.P.; 2009.
2. Data on file. Galderma Laboratories. 3. Lebwohl M, Ortonne JP, Andres P, Briantais P. Calcitriol ointment 3 µg/g is
safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. Cutis. 2009;83:205-212.
®
GALDERMA and Vectical are registered trademarks.
December 2009
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
57
SCIENTIFIC SESSIONS
T
H
U
R
S
D
A
Y
,

F
E
B
R
U
A
R
Y

3
For description of session categories and fees see page 37
REFERENCES
1. NortonSA.Tedermatologist’sBaedeker.Preparation
formedicalassistancemissions.Dermatol Clin.1999
Jan;17(1):187-208,ix-x.
SCHEDUlE
8:00a.m. WelcomeandIntroduction / Dr. Kovarik
8:05a.m. OverviewofHealthcareinDevelopingCountries
/ Dr. Nordlund
8:40a.m. VolunteeringAbroadandFindingtheProgramfor
You / Dr. Rehmus
8:55a.m. CommunityDermatologyinMexico
/ Dr. Chavez López/Dr. Estrada-Castanon
9:15a.m. WorkingwithaLimitedFormulary / Dr.VanBeek
9:45a.m. WorkingwithLocalDermatologistsinResource
LimitedSettings / Dr.Craft
10:00a.m. Break / Faculty
10:15a.m. IssuesofPersonalPreparedness / Dr. Norton
/Dr. Schaefer
11:00a.m. InternationalVolunteerismasaResident / Dr. Introcaso
11:15a.m. TeDermatologist’sRoleinDisasterRelief
/ Dr. Kantor
11:30a.m. PediatricDermatologyintheInternationalSetting
/ Dr. Prose
11:45a.m. CulturalCompetenceandLanguageBarriers
/ Ms. Kelly
12:00p.m. LunchwithTable-TopDiscussions / Faculty
6:00p.m. InformalNetworkingDinner (additionalfeesapply)
/ Faculty
C001 Volunteers Abroad Course: Beginner
Room:395/396
DIRECTOR Carrie L. Kovarik, M.D.
SpEAkERS
MariableGuadalupe NancyKelly,M.H.S
ChavezLópez,M.D. JamesJ.Nordlund,M.D.
NoahA.Craft,M.D.,Ph.D.ScottA.Norton,M.D.,M.P.H.
RobertoA.Estrada- NeilProse,M.D.
Castanon,M.D. WingfeldEllisRehmus,M.D.,M.P.H.
CamilleIntrocaso,M.D. StephanieSchaefer,M.D.
JonathanKantor,M.D. MartaJaneVanBeek,M.D.
lEARNINg OBjECTIVES
Followingthiscourse,theattendeewillbeableto:
1. Recognizethedermatologist’sroleininternationaloutreach.
2. Identifystepsnecessarytoparticipateinclinicalcareand
educationabroad.
3. Examinebasicconceptsinthediagnosisandtreatmentof
diseasesoftenseenindevelopingcountries,andlearntowork
withalimitedpharmacy.
DESCRIpTION
Tiscoursewilldetailtheneedsandrolesininternationaloutreach
andeducation.Tedermatologist’sroleintheseefortsand
opportunitiesforparticipationwillbereviewed.Anoverviewof
medicalhumanitarianassistanceandtipsforplanningandpreparing
forparticipationinaclinicalorteachingprogramabroadwillbe
providedinthisbeginner-levelcourse,aswellasareviewofcommonly
encounteredconditionsanddiseasesinthefeld.Strategiesforworking
withalimitedpharmacywillalsobediscussed.
4.75 Category 1 CME Credits
AAD learner Rights and Responsibilities
AsanAADmeetingparticipantyouhavetherighttoexpect:
• Contentthatpromotesimprovementsinqualityhealthcare • Contentthatisvalid,reliableandaccurate
• Contributionsbasedonthebestscientificevidenceavailable • Balancedpresentations,freeofcommercialbias
• Disclosureofrelationshipswithindustry • Disclosureofoff-labelusage
Eachspeakerhasattestedtoprovidetheabove.Pleaseevaluateeacheducationalactivityyouattendforitseffectivenessinmeetingthe
identifiedneedandaccomplishingtheaboveLearnerRightsandResponsibilities.
Inaddition,eachAADmeetingparticipantisresponsibleforprovidingrelevantdisclosureduringQuestionsandAnswerssessions.
COURSE
8:00a.m.to1:00p.m.
Tuition fee and ticket required for admission.
OVERVIEw
THURSDAY, FEBRUARY 3
Course — 8:00 a.m. to 1:00 p.m.
C001 VolunteersAbroadCourse:Beginner . . . . . . . . . .57
Course — 12:00 p.m. to 5:00 p.m.
C002 VolunteersAbroadCourse:Advanced . . . . . . . . . .58
58
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
T
H
U
R
S
D
A
Y
,

F
E
B
R
U
A
R
Y

3
For description of session categories and fees see page 37
COURSE
12:00p.m.to5:00p.m.
Tuition fee and ticket required for admission.
C002 Volunteers Abroad Course: Advanced
Room:395/396

DIRECTOR Carrie L. Kovarik, M.D.
SpEAkERS
DanielBerg,M.D. ScottA.Norton,M.D.,M.P.H.
CaseyCarlos,M.D. AishaSethi,M.D.
TobyA.Maurer,M.D. AndreaL.Zaenglein,M.D.
KarenMcKoy,M.D.,M.P.H.
lEARNINg OBjECTIVES
Followingthiscourse,theattendeewillbeableto:
1. Recognizethedermatologist’sroleininternationalclinicalcare
andeducation.
2. Discussthediagnosisandtreatmentofdiseasesseenmore
commonlyindevelopingcountriesanddisasterareas.
3. Identifystepsneededtohandlelogisticalissuesinproviding
clinicalcareandeducationabroad,includingcreatinglocal
partnerships,capacitybuilding,anddesigningsustainable
programs.
DESCRIpTION
Teadvanced-levelcoursewillincludesomeofthetopicsfrom
thebeginner-levelcourseinmoredetail,andwillalsoinclude
newtopicsformoreexperiencedvolunteers.Troughoutboth
courses,theeducationalsessionswillalternatewithtravel
vignettesgivenbydermatologistswhohaveworkedinavarietyof
countriesandassistedinmedicalcare.Inaddition,theglobaluse
ofteledermatologywillbediscussed,followedbyaninteractive
sessionwithinternationalteledermatologycases.
3.75 Category 1 CME Credits
SCHEDUlE
12:00p.m. LunchwithTable-TopDiscussions / Faculty
1:00p.m. TropicalDermatologyReview / Dr. Kovarik
1:20p.m. AlbinoPrograminMalawi / Dr. Sethi
1:35p.m. DermatologyAbroad:Inter-UrbantoRemoteVillages
/ Dr. Maurer
1:50p.m. LessonsLearnedinTanzania / Dr. Zaenglein
2:05p.m. PopulationBasedDermatology / Dr. Norton
2:50p.m. Break / Faculty
3:05p.m. DermatologicSurgeryAbroad / Dr. Berg
3:20p.m. HIVandtheGlobalImpact / Dr. Kovarik
3:45p.m. TeachingDermatologyinResourceLimitedSettings
/ Dr. Carlos
4:00p.m. InternationalTeledermatology:Potentialand
Limitations / Dr. McKoy
4:20p.m. InteractiveCasesinTeledermatology / Dr. Kovarik
5:00p.m. SessionWrap-up / Dr. Kovarik
6:00p.m. InformalNetworkingDinner(additionalfeesapply)
/ Faculty
Volunteer your time
Help us refurbish a local school on ursday,
February 3rd from 1:00 p.m. – 4:00 p.m.
For more information or to
sign up, visit www.aad.org/
members/leadership
$
Donate supplies
From medical to office supplies, a local
clinic will benefit from your donation.
Provide fnancial support
Your donation provides support for current
. and future activities volunteer
Be a part of in New Orleans!
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
59
SCIENTIFIC SESSIONS
FRIDAY, FEBRUARY 4
Course — 7:00 a.m. to 9:00 a.m.
C06A BasicSelf-AssessmentofDermatopathology
(includesdiscussionC06E–seepage122) . . . . . .64
Discussion groups — 7:15 a.m. to 8:45 a.m.
D001 PregnancyDermatoses:MovingTowardsa
BetterUnderstanding. . . . . . . . . . . . . . . . . . . . . .64
D002 AppropriateUsesofLasers . . . . . . . . . . . . . . . . . .64
Focus Sessions — 7:15 a.m. to 8:45 a.m.
U001 TricksoftheBlade ........................65
U002 ManagementofPost-AcneScarring ...........65
U003 ManagementofHigh-RiskSquamous
CellCarcinoma(SCC).....................65
U004 Advances inWeb-BasedMedicalEducation:
HowBesttoTeachDermatology .............66
U005 High-Yield“PowerHour”forResidents........66
U006 InternationalTeledermatologyOverview. . . . . . . .66
U007 EctodermalDysplasias .....................66
U008 RecognitionandManagementof
High-RiskSkinCancer ....................67
U009 PhototherapyandPhotochemotherapy:
NuancesandPealsforthePracticingClinician . . .67
U010 TeTzanckSmearTest:ReintroducingOurGood
OldFriend! . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .67
U011 MedicalandAestheticDermatologyin
SkinofColor ............................68
U012 LeadingwithYourStrengths . . . . . . . . . . . . . . . . .68
U013 VitaminDandDermatology................68
Forums — 9:00 a.m. to 11:00 a.m.
F001 AdvancedMedicalDermatology . . . . . . . . . . . . . .69
F002 ErosiveVulvarDiseases:ApproachtoDiagnosis
DiferentialDiagnosis,andTreatment. . . . . . . . . .69
F003 Case-BasedChallengesinPediatricDermatology. .70
F004 GeriatricDermatology:AdvancedCases . . . . . . . .70
F005 BoardBlitz. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .71
F006 Vitiligo.................................71
F007 ManagementofDifcultWounds. . . . . . . . . . . . .72
F008 DecreasingIatrogenicProblems
inYourPractice. . . . . . . . . . . . . . . . . . . . . . . . . . .72
workshop — 9:00 a.m. to 11:00 a.m.
W001 MOCSelf-AssessmentA. . . . . . . . . . . . . . . . . . . .72
OVERVIEw
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
practice Management Session open to eligible
offce staff/registered nurses
Represents Patient Safety Session in program overviews
patient Safety Session
Represents Audience Response System Session
Audience Response System Session
Represents activities that meet MOC-D

M
O
C
This activity has been approved by the ABD to satisfy
component 2 of MOC-D
Represents Leadership Institute in program overviews
leadership Institute — addresses leadership
competencies specifc to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
60
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
OVERVIEw
Courses — 9:00 a.m. to 12:00 p.m.
C003 PediatricDermatology .....................73
C004 DiagnosisandTerapeutics:
TeFundamentals. . . . . . . . . . . . . . . . . . . . . . . . .74
C005 BasicContactDermatitis ...................74
Symposia — 9:00 a.m. to 12:00 p.m.
S001 DisordersofPigmentation . . . . . . . . . . . . . . . . . .75
S002 Alopecia:WorkupandTreatment.............75
S003 HotTopics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .76
S004 WhenBadTingsHappentoGoodDoctors....76
S005 LeadingfromYourVisiontoExceptionalService 77
S006 ApproachtoPigmentedLesions. . . . . . . . . . . . . .78
Courses — 9:00 a.m. to 5:00 p.m.
C007 Immunology . . . . . . . . . . . . . . . . . . . . . . . . . . . . .79
C008 DermExamPrepCourse:Refresher...........79
Course — 9:30 a.m. to 11:30 a.m.
C06B BasicSelf-AssessmentofDermatopathology
(includesdiscussionC06E–seepage122) . . . . . .80
Forums — 12:00 p.m. to 2:00 p.m.
F009 PhotobiologyforDermatologists .............80
F010 HidradenitisSuppurativa:AnUpdate . . . . . . . . . .81
F011 DermatopathologyMadeSimple .............81
F012 UpdateonGeneticSkinDisease. . . . . . . . . . . . . .82
F013 EHRImplementation,Maintenance,and
LessonsLearned . . . . . . . . . . . . . . . . . . . . . . . . . .82
F014 ChallengingDiagnosticCasesforAdvanced
Practitioners:PA/NPI .....................83
F015EthicalEconomicsinDermatologyand
DermatologicSurgery . . . . . . . . . . . . . . . . . . . . . .83
F016 AdvancesinDermatologicSurgery . . . . . . . . . . . .84
Advisory Board
Activities
Advisory Board
Reference Committee Hearing
(All AAD Members are Welcome)
Friday, February 4
2:00 p.m. – 4:00 p.m.
Room 350 (CC)
Advisory Board
Reference Committee Executive Session
(Reference Committee Members Only)
Friday, February 4
4:00 p.m. – 5:00 p.m.
Room 349 (CC)
Advisory Board General Meeting
(All AAD Members are Welcome)
Sunday, February 6
2:30 p.m. – 5:30 p.m.
Room 383/384/385 (CC)
Advisory Board Executive Committee
(Executive Committee Members Only)
Monday, February 7
8:00 a.m. – 9:00 a.m.
Room 349 (CC)
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
61
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
Discussion groups — 12:15 p.m. to 1:45 p.m.
D003 SelectedTopicsinMedicalDermatology. . . . . . . .84
D004 DealingwithDisappointingOutcomesand
MedicalMistakes .........................84
Focus Sessions — 12:15 p.m. to 1:45 p.m.
U014 WhenAcneReallyIsn’tAcne ................85
U015 MerkelCellCarcinoma. . . . . . . . . . . . . . . . . . . . .85
U016 SportsDermatology—
SkinInfectionsinAthletes . . . . . . . . . . . . . . . . . .85
U017 ClincialTrialsforthePrivatePractitioner.......86
U018 OutcomesResearchinDermatology. . . . . . . . . . .86
U019 Sun,DrugsandInvervention:HowtoPrevent
Non-MelanomaSkinCancer ................87
U020 ChallengingDiagnosticCasesforAdvanced
Practitioners:PA/NPII. . . . . . . . . . . . . . . . . . . . .87
U021 AcneintheAdultFemale...................87
U022 VulvarDermatoses ........................87
U023 HighlightsfromJAAD.....................88
U024 LeadingConfdentlythroughPowerful
Communication. . . . . . . . . . . . . . . . . . . . . . . . . .88
U025 APersonalizedPlannerforRejuvenation. . . . . . . .88
U026 Teledermatology101:IntegratingTeledermatology
intoYourPractice.........................89
Course — 12:30 p.m. to 2:30 p.m.
C06C BasicSelf-AssessmentofDermatopathology . . . . .89
(includesdiscussionC06E–seepage122)
Courses — 2:00 p.m. to 5:00 p.m.
C009 DermatologicSyndromesandGeneticDisorders 90
C010 AdvancedContactDermatitis. . . . . . . . . . . . . . . .90
C011 TeStateoftheArtofAestheticDermatology:
LivePatientDemonstration.................91
Symposia — 2:00 p.m. to 5:00 p.m.
S008 ConsultativeDermatologyforthe
HospitalizedPatient .......................91
S009 AdvancedMedicalDermatology . . . . . . . . . . . . . .92
S010 SurvivingHealthcareReform .. .. .. .. .. .. .. ..92
S011 Terapeutics. .. .. .. .. .. .. .. .. .. .. .. .. .. ..93
S012 AgingGracefully . . . . . . . . . . . . . . . . . . . . . . . . . .93
S013 LeadingOthersforPeakPerformance. . . . . . . . . .94
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
practice Management Session open to eligible
offce staff/registered nurses
Represents Patient Safety Session in program overviews
patient Safety Session
Represents Audience Response System Session
Audience Response System Session
Represents activities that meet MOC-D

M
O
C
This activity has been approved by the ABD to satisfy
component 2 of MOC-D
Represents Leadership Institute in program overviews
leadership Institute — addresses leadership
competencies specifc to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
62
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
Discussion groups — 2:30 p.m. to 4:00 p.m.
D005 Dermatoethics:ContemporaryIssues
inEthicsandProfessionalism................94
D006 SerologicTestingforConnectiveTissueDiseases 94
Focus Sessions — 2:30 p.m. to 4:00 p.m.
U027 PracticalApproachestoMedicalandCosmetic
DermatologyinSkinofColor ...............95
U028 OralUlcers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .95
U029 SkinCancerinPatientswithNon-Melanoma
Hodgkin’sLymphoma. . . . . . . . . . . . . . . . . . . . . .96
U030 TreatmentofPediatricPsoriasis. . . . . . . . . . . . . . .96
U031 Dermatomyositis. . . . . . . . . . . . . . . . . . . . . . . . . .97
U032 ChronicInfammatoryHandand
FootDermatoses . . . . . . . . . . . . . . . . . . . . . . . . . .97
U033 Electrolysis:WhenLaserIsn’ttheAnswer . . . . . . .98
U034 PediatricHyperhidrosisandEctodermalDysplasia:
ToSweatorNottoSweat? . . . . . . . . . . . . . . . . . .98
U035 ParaneoplasticDermatoses . . . . . . . . . . . . . . . . . .98
U036 SubcutaneousFatinDermatology ............98
U037 ParaneoplasticAutoimmuneMultiorgan
Syndrome(PAMS)........................99
Course — 3:00 p.m. to 5:00 p.m.
C06D BasicSelf-AssessmentofDermatopathology . . . . .99
(includesdiscussionC06E–seepage122)
Forums — 3:00 p.m. to 5:00 p.m.
F017 ResidentJeopardy . . . . . . . . . . . . . . . . . . . . . . . .100
F018 AtopicDermatitis . . . . . . . . . . . . . . . . . . . . . . . .100
F019 JournalWatching . .. .. .. .. .. .. .. .. .. .. .. .101
F020 VolunteerismandHumanitarianism . . . . . . . . . .101
F021 FDAPresents:InformationforDermatologists. .102
F022 CodingandOfceManagement. . . . . . . . . . . . .102
F023 PsoriasisGuidelines:ImplementingTemin
YourPractice. . . . . . . . . . . . . . . . . . . . . . . . . . . .103
workshops — 3:00 p.m. to 5:00 p.m.
W002 DermatologySpeakerDevelopment. .. .. .. .. .104
W003 MOCSelf-Assessment:Dermatopathology. . . . .104

Visit the Academy Resource Center Booth 3623 to place your order.
Learn the latest techniques for facial rejuvenation, injecting collagen, hyaluronic
acid, calcium hydroxyapatite, poly-L-lactic acid, and polymethylmethacrylate.
• Observe live aesthetic demonstrations by expert faculty
• Evaluate the aging face
• Understand the value of facial musculature and treatment of the upper and
lower face
The Art of Aesthetic Dermatology was developed for the practicing
dermatologist and has been approved for AMA PRA Category 1 Credits
TM
.
THE ART OF AESTHETIC DERMATOLOGY
SPECIAL OFFER: , now available at the new low price of $150!
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
63
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
Residents’ Reception
5:00pm-6:30pm
Napoleon Ballroom
DAN/SkinPAC Reception
5:00pm-7:00pm
Jefferson
Career Fair
5:00pm-7:00pm
Grand Salon ABC
Welcome Reception for Young Physicians and New Members
5:00pm-6:30pm
Versailles Ballroom
International Member Reception
5:00pm-6:30pm
Grand Salon D
Volunteer Fair
5:00pm-7:00pm
Court Assembly
Leaders in Giving Recognition Reception
(by invitation only)
5:00pm-7:00pm
Rosedown
Reception Row Events
Friday, February 4, 2011 • Hilton New Orleans Riverside
64
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
COURSE
7:00a.m.to9:00a.m.
Tuition fee and ticket required for admission.
DISCUSSION gROUp
7:15a.m.to8:45a.m.
Tuition fee and ticket required for admission.
C06A Basic Self-Assessment of
Dermatopathology
Room:275/276/277
DIRECTOR Clay J. Cockerell, M.D.
SpEAkERS AntoanellaBardan,M.D.
lEARNINg OBjECTIVES
Followingthiscourse,theattendeewillbeableto:
1. Interpretandidentifydermatologichistologicaldiagnosesmore
efectivelyandaccurately.
2. Classifyandrecognizecommonhistopathologicskinconditions
andformulatediferentialdiagnoses.
DESCRIpTION
Attendeeswillview60slidesfromskinbiopsyspecimensinaformat
thatwillallowself-assessment.Caseswillspanthefullspectrumof
dermatopathology.Eachspecimenwillbediscussedbyafaculty
memberwithemphasisplacedonestablishingthecorrectdiagnosis
andconsiderationofthediferentialdiagnosis.Tesesessionsare
directedtodermatologyresidentsandpracticingdermatologists.
Toallowforalargerparticipationthisyear,thiscoursewillbe
oferedwithduplicatecontentat7:00a.m.,9:30a.m.,12:30p.m.,
and3:00p.m.Attendeesneedonlyselectoneofthesesessions.
TissessionincludesthediscussionC06E–seepage122.
2.00 Category 1 CME Credits
D001 pregnancy Dermatoses: Moving Towards
a Better Understanding
Room:240
DIRECTOR Samantha A. Vaughan-Jones, M.D.
lEARNINg OBjECTIVES
Followingthisdiscussiongroup,theattendeewillbeableto:
1. Recognizeanddiferentiatethecommonandspecifc
pregnancydermatoses.
2. Identifysafeandefectivetreatmentsformotherandfetus.
3. Discusstheefectofpregnancyonotherskindiseases.
DESCRIpTION
Tissessionwilloutlinethecommonphysiologicalchangesin
pregnancy,includingimmunechangesthatpredisposepregnant
womentoskindisease.Teterminologyofthespecifcpregnancy
dermatoseshistoricallycausedmuchconfusion,andasimplifed
classifcationandalgorithmwillbedescribed.Participantswill
learnhowtorecognize,diferentiate,andmanagethevarious
pruriticskindisorders.Polymorphiceruption,atopiceruption,
pemphigoidgestationis,andobstetriccholestasiswillallbe
describedindetailwithpreviousresearchfndings.Teefects
ofpregnancyoncommonskindiseaseswillalsobehighlighted.
Patienteducationandtreatmentsthataresafeandefectivein
pregnancywillbesummarized.
1.50 Category 1 CME Credits
D002 Appropriate Uses of lasers
Room:241
DIRECTOR Ronald G. Wheeland, M.D.
lEARNINg OBjECTIVES
Followingthisdiscussiongroup,theattendeewillbeableto:
1. Comparetheadvantagesanddisadvantagesoflasersintreating
patients.
2. Describetheappropriateuseoflasersindiferentclinical
conditions.
3. Determinehowlasersinteractwithtissuetoobtainthebest
clinicalresults.
DESCRIpTION
Tissessionwillconsistofadiscussionofthemostcommonlasers
availableandhowtheyareusedappropriatelytotreatdiferent
skinconditions.Teadvantagesanddisadvantagesofthesedevices
inmanagingavarietyofskinconditionswillalsobedetailed.After
thisintroduction,therewillbeampletimefortheattendeestoask
questionsaboutproblemstheyhaveencounteredintreatingtheir
ownpatientsortoseekadviceonhowtoimprovetheirresults.
Tishighlyinteractiveportionofthesessionshouldpermitan
exchangeofideasbetweentheattendeesandthecoursedirector.
1.50 Category 1 CME Credits
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
65
SCIENTIFIC SESSIONS
U003 Management of High-Risk Squamous Cell
Carcinoma (SCC)
Room:242
DIRECTOR Chrysalyne Delling Schmults, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. IdentifySCCsthatareatincreasedriskformetastasis,aswell
asmedicalconditionsthatelevatepatientsmetastaticrisk.
2. Discussthelatestliteratureregardingprognosis,staging,and
treatmentoptionsforhigh-risktumors.
3. Determineanappropriatestaging,treatment,andfollow-up
strategyforpatientswithhigh-riskSCC.
DESCRIpTION
AlthoughmostSCCsarecurablewithcurrenttherapies,a
smallsubsetoftumorsfailtreatmentandmetastasize.Tus,
dermatologistsmustbefamiliarwiththeavailabledataregarding
identifcationandtreatmentofSCCswithanelevatedriskof
metastasis.Tissessionwillreviewtumor-specifcfactors,such
asdegreeofperineuralinvasionanddepthofinvasion,that
increaseriskofmetastasis.Hostfactorsassociatedwithworse
outcomes,suchasunderlyingimmunosuppression,willalsobe
addressed.Dataonstagingoptions,suchasradiologicimaging
andsentinelnodebiopsy,willbediscussed.Treatmentoptions,
includingMohssurgery,multidisciplinarysurgery,andadjuvant
radiotherapy,willbediscussedusingcaseexamples.Tesession
willbegearedtowarddermatologistsanddermatologicsurgeons.
1.50 Category 1 CME Credits
FOCUS SESSION
7:15a.m.to8:45a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U001 Tricks of the Blade
Room:267/268
DIRECTOR Cyndi Jill Yag-Howard, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Developsurgicaltipsandtricksthatwillbesatisfyingtoyou
andyourpatientsandimprovesurgicaloutcome.
2. Demonstratecreativesurgicalandperioperativewoundcare
techniquesthatwillenhancesurgicalcosmesis.
3. Expressconfdenceinyourownpracticeasyouventureoutside
thepagesofasurgicaltextbook.
DESCRIpTION
Tissessionisintendedforalldermatologicsurgeons,whether
newtopracticeorestablished,whoareinterestedinpicking
uptipstoimprovesurgicaloutcomes.Includedwillbethe
presentationoftheSITandtheSILstitchtoimprovecosmesis,as
wellastheSQgrabbingstitchandtheinvertedSQcrossmattress
stitchforeaseofclosure.Presenterwillreviewwoundcarebeyond
standardpetrolatumandbandageandwillalsoaddressclosures,
withemphasisonspecifcclosuresthatworkexceptionallywellin
certainanatomiclocations.Teaudiencewillbeinvitedtoshare
experiencesasthepresenterreviewscasesanddiscussestechniques
thatonelearnsoveryearsofpractice.
1.50 Category 1 CME Credits
U002 Management of post-Acne Scarring
Room:263
DIRECTOR Gregory J. Goodman, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Assessandcategorizethepatientwithpost-acnescarring.
2. Adequatelyprepareandeducatethepatientaboutalternative
availabletreatments.
3. Designandindividualizethemanagementofthepatientwith
post-acnescarring.
DESCRIpTION
Acnescarringmaypresentwithdiferentshapesandsizes,and
varygreatlyinseverity.Classifcationaccordingtothescartype
andseverityinbothatrophicandhypertrophicscarringisusefulin
planningtherapyasvariousscarmorphologiesandseverityrequire
diferentapproaches.Manynewandoldtherapiesareavailableand
areoftenbestcombined.Some--likepunchtechniques,subcision,
skinrollingandoccasionallybotulinumtoxinanddermaland
deeperfllers--arepossibleinallclinics;others,suchasvascular,
pigmented,ablative,nonablative,andfractionatedresurfacing
lasers,willrequiresignifcantclinicalinterestandexpenditure.
1.50 Category 1 CME Credits
SCIENTIFIC SESSIONS
66
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
FOCUS SESSION
7:15a.m.to8:45a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U004 Advances in web-Based Medical
Education: How Best to Teach
Dermatology
Room:274
DIRECTOR Jacqueline C. Dolev, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. RecognizetheefcacyofWeb-basedcurriculaindermatology.
2. Identifykeyconceptsinefectivelearningofvisualcuesand
patternrecognition.
3. Summarizecurrentstudiesevaluatinglearningretentionusing
theWeb.
DESCRIpTION
Tissessionisgearedtobotheducatorsandpracticing
dermatologists;whetheryouareteachingmedicalstudents,
residents,ornon-specialistproviders,orjusthaveaninterestin
thetheoreticalbasisofvisuallearning.Tesessionwillemphasize
emergingtrendsinteachingvisualdiagnosticskillsandsummarize
currentstudiesutilizingonlinecurriculaforknowledgeretention.
Tekeyelementsnecessarytoteachdermatologyastheyrelateto
learningtheory,patternrecognition,andvisuallearningwillbe
discussed.
1.50 Category 1 CME Credits
U005 High-Yield “power Hour” for Residents
Room:270
DIRECTOR Harley A. Haynes, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Examinepearlsandmeasurecompetencyinhigh-yieldtopics.
2. Discusskeytopicsindermatology,includingdrugsused
indermatology,proceduraldermatology,allergiccontact
dermatitis,andbasementmembranedisorders.
3. Demonstratecomprehensionthroughmultiplechoice
questions.
DESCRIpTION
Tisforumisdesignedfordermatologyresidentswhoseekto
achieveacomfortlevelwithfourhigh-yieldtopicsencountered
duringtraining.Image-basedlearningwillfocuson:1)
mechanismsofactionandsideefectsofsystemicdermatologic
therapies,2)basicconceptsoflaserandsurgicaldermatology,3)
allergensassociatedwithcontactdermatitis,and4)inheritedand
immunobullousdisordersoftheepidermalbasementmembrane.
Multiplechoicequestionswillhighlighttake-homepearls.Tese
sessionsarepopularamongresidentsatourinstitution.
1.50 Category 1 CME Credits
U006 International Teledermatology Overview
Room:264
DIRECTOR Karen McKoy, M.D., M.P.H.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Examinethechallengesofprovidingteledermatology
consultationtothoseindevelopingcountries.
2. Prepareforparticipationinthearenaofinternational
teledermatology.
3. Recognizethevarioustypesofinternationalteledermatology
andreasonsforcurrentpractices.
DESCRIpTION
TeInternationalSocietyofTeledermatologywasrecentlyformed
withthegoalofestablishingworldwideaccesstoteledermatology
services,particularlyforreachingunderservedorremotepatient
populations.Tethirdmeetingin2010hadattendeesfrom
acrosstheworld.Tissessionwilldiscussnotonlythetypesof
teledermatologyactivitypracticedinvariouscountries(fromthe
UnitedStatestoAustralia,governmentfundedornot),butalso
theuseofteledermatologyasacharitabletooltoeducateandto
aidthoseinunderservedandimpoverishedregions.Aninvitation
willbeissuedandmethodsdiscussedtoparticipateinthisgrowing
internationalcollaboration.
1.50 Category 1 CME Credits
U007 Ectodermal Dysplasias
Room:269
DIRECTOR Alanna Flath Bree, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Identifythepathogenesisandclassifcationofthemajor
ectodermaldysplasias(EDs).
2. IdentifyandaccuratelydiagnosethemajorEDs.
3. EvaluateandmanagepatientswiththemajorEDs.
DESCRIpTION
Tissessionwillreviewthepathogenesis,classifcation,andclinical
featuresofthemajorectodermaldysplasias(EDs),including
hypohidroticectodermaldysplasia,hidroticectodermaldysplasia,
ectodactyly-ectodermaldysplasia-clefting(EEC)syndrome,and
ankyloblepharon-ectodermaldefects-clefting(AEC)syndrome.
Participantswilllearnhowtoaccuratelyevaluateanddiagnose
theseconditionsinafectedpatients.Appropriatemanagement
strategieswillalsobediscussed.
1.50 Category 1 CME Credits
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
67
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
SCIENTIFIC SESSIONS
U009 phototherapy and photochemotherapy:
Nuances and peals for the practicing
Clinician
Room:298/299
DIRECTOR Charles R. Taylor, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Managepatientsonultraviolettherapyinaccordancewiththeir
specifcstateanddistributionofskindisease.
2. Recognizetheimportanceofagivendiagnosistothe
managementofapatientonultraviolettherapy.
3. Choosethebestultravioletprotocolforthetreatmentofa
givenpatient.
DESCRIpTION
Tissessionisintendedforthepractitionerofultravioletlight
therapytoenhancemanagementskills,takingintoconsiderationa
patient’sdiagnosis,condition,medications,skintype,distribution
ofdisease,andoccupation,allthewayemphasizingsafety.Some
individualprotocolswillbereviewed.Mostattentionwillbespent
onnarrowbandUVBphototherapy,butsomementionofother
modalities,suchasPUVAandUVA-1therapy,willoccur.
1.50 Category 1 CME Credits
U010 The Tzanck Smear Test: Reintroducing
our good Old Friend!
Room:283
DIRECTOR Deniz Seckin, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. PrepareTzancksmearsfordiagnosisofskindiseases.
2. Identifythecharacteristiccytologicfeaturesofcertainskin
diseases.
3. ChoosetheTzancksmeartestinsteadofunnecessary,harmful,
invasiveorcostlydiagnosticprocedures.
DESCRIpTION
Cytologyisasimple,rapid,andinexpensivediagnosticmethod
whichinvestigatesthecharacteristicsofindividualcells.Tzanck
smearscanaidinthediagnosisofvariousskindiseases,including
bacterial,viralandfungalinfections,leishmaniasis,pemphigus,
spongioticdermatitis,Darier’sdisease,Hailey-Haileydisease,
granulomatousdisorders,andtumorallesions.Tissessionwill
teachthepreparationofaTzancksmearandhelptheattendees
tointerpretthecharacteristiccytologicfndingsofcertainskin
diseasesindailypractice.Finally,analgorithmicapproachwillbe
givenandparticipantswillbeencouragedtodiscussthevarious
caseexamplesthatcouldbediagnosedbyaTzancksmear.
1.50 Category 1 CME Credits
FOCUS SESSION
7:15a.m.to8:45a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U008 Recognition and Management of
High-Risk Skin Cancer
Room:284
DIRECTOR Clark C. Otley, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Discussfeaturessuggestingpotentiallyaggressivebehaviorofa
skincancer.
2. Outlinetherapeuticconsiderationswhenconfrontedbyahigh-
riskskincancer.
3. Identifyindicationsforadjuvantmodalitiestoreducetherisk
ofrecurrenceofhigh-riskskincancers.
DESCRIpTION
Dermatologistspracticingatthehighestlevelareabletorecognize
featuresofhigh-riskskincancersbeforerecurrenceormetastasis,
thusoferingoptimaltreatmenttopatients.Inthissession,we
willreviewthelatestdataonhigh-riskskincancersanddiscuss
howtoprospectivelyrecognizethem.Moreimportantly,we
willconsidervariousstrategiestoimproveoutcomesforpatients
withhigh-riskskincancers,includingwhentoemployadjuvant
therapies.Learnhowtopracticecutting-edgecutaneousoncology
throughthiscasebasedsession.
1.50 Category 1 CME Credits
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
68
|
amerIcan academy oF dermatoLogy • 68th annuaL meetIng
FOCUS SESSION
7:15a.m.to8:45a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U011 Medical and Aesthetic Dermatology in
Skin of Color
Room:285
DIRECTOR Valerie D. Callender, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Recognizethephysiologicalandmorphologicaldiferencesin
skinofcolor.
2.Assessdiagnosesandtreatmentsforcommonethnicskinand
hairdisorders.
3.Reviewindicationsandprotocolsforcosmeticproceduresin
dark-skinnedracialethnicities.
DESCRIpTION
Dark-skinnedracialethnicgroupsconstitutethemajority
oftheglobalpopulations.Tisfocussessionwillreview
thepathogenesisandtreatmentofcommonskinandhair
disordersindarkerskintypes,includingacne,rosacea,post-
infammatoryhyperpigmentation,melasma,seborrheicdermatitis,
pseudofolliculitisbarbae,keloids,andalopecia.Inaddition,
indicationsandprotocolsforcosmeticproceduressuitablefor
darkerskintypeswillbediscussed,includingchemicalpeels,laser
hairremoval,injectablefllers,andhairtransplantation.
1.50 Category 1 CME Credits
U012 leading with Your Strengths
Room:293/294
DIRECTOR Elizabeth Shannon Martin, M.D.
SpEAkER
SandraEllison,CenterforCreativeLeadership
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Identifyhis/herownleadershipstrengthsandweaknesses.
2. Demonstrateefectiveofcommunicationwithothers.
3. Implementcoreleadershipcompetenciesintodailypractice.
DESCRIpTION
Nomatterthesetting,dermatologistsarefacedwithleadership
opportunitieseveryday.Whethertheyinvolvestafmanagement,
practicepromotion/expansion,involvementinorganizedmedicine,
oradvancinganacademiccareer,strongleadershipskillsallowa
physiciantomeetthesechallengeswithaplomb.Tisinteractive
sessionwillallowparticipantstoperformapersonalityself-assessment
andfocusonhowinformationlearnedallowsthedermatologistto
capitalizeonhis/herstrengthsandimproveonhis/herweaknesses.
Howtoimprovecommunicationswithothersusingpersonality
assessmentwillalsobediscussed.Tissessionaddressesthe
LeadershipInstituteCoreCompetenciesofIncreasingSelf-Awareness
andCommunicatingEfectively.
1.50 Category 1 CME Credits
U013 Vitamin D and Dermatology
Room:235/236
DIRECTOR Tissa R. Hata, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. OutlinevitaminDmetabolismandrelevantsourcesofvitaminD.
2. DescribehowvitaminDrelatestotheinnateimmunesystemin
dermatologicdiseases.
3. AssessthevalidityofthecontroversiesregardingvitaminDand
sunlight.
DESCRIpTION
VitaminD’sroleinbonehealthhasbeenwellestablished.Recently,
however,studieshaveidentifedadditionalrolesforvitaminDinthe
immunesystem,cardiovascularsystem,andincancerprevention,
causingsometoadvocateunprotectedsunexposureasameansto
increasevitaminDlevels.TisspeakerwillreviewthevitaminD
literatureasrelevanttothedermatologist,withrespecttothesafety
anddoseofdiferentsourcesofvitaminD,andtheefectofvitamin
Dontheinnateimmunesysteminatopicdermatitis,psoriasis,and
infections.
1.50 Category 1 CME Credits
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
69
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
SCIENTIFIC SESSIONS
F002 Erosive Vulvar Diseases: Approach to
Diagnosis, Differential Diagnosis, and
Treatment
Room:252/253/254
DIRECTOR Bethanee Jean Schlosser, M.D., Ph.D.
SpEAkER
GinatW.Mirowski,D.M.D.,M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Identifyprimaryskindiseasesaswellassystemicdisorders
whichcausevulvovaginalerosionsandulcers.
2. Discussthediferentialdiagnosisoferosivevulvovaginallesions
andtheapproachtoobtainingadiagnosis.
3. Describetherapeuticoptionsforthemanagementoferosive
vulvovaginaldisorders.
DESCRIpTION
Tissessionwillfocusonprimarycutaneousdiseasesandsystemic
disordersthatcommonlypresentwitherosivelesionsofthe
vulvaand/orvagina.Emphasiswillbeplacedondeveloping
analgorithmicapproachtotheevaluationanddiagnosis
ofvulvovaginalerosions,includingsalientclinicalfeatures,
non-genitalcutaneousfndings,andtheutilityofbiopsyfor
routinehistopathologyaswellasdirectimmunofuorescence.
Managementoptionsfortheseimportantdisorderswillalsobe
discussed.Temostup-to-dateguidelinesforthemonitoringof
patientswitherosivevulvardiseasewillbeprovided.
2.00 Category 1 CME Credits
SCHEDUlE
9:00a.m. Introduction / Dr. Schlosser
9:05a.m. ApproachtotheVulvarExamination / Dr. Schlosser
9:25a.m. VulvarErosions:Case-BasedApproachtoDiagnosis
andTreatment / Dr. Mirowski
9:50a.m. QuestionsandAnswers / Faculty
10:00a.m. VulvarErosionsandUlcers:Case-BasedApproachto
DiagnosisandTreatment / Dr. Schlosser
10:50a.m. QuestionsandAnswers / Faculty
FORUM
9:00a.m.to11:00a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F001 Advanced Medical Dermatology
Room:295/296
DIRECTOR Lindy Peta Fox, M.D.
SpEAkERS
SusanBurgin,M.D. MishaRosenbach,M.D.
AmitGarg,M.D. KanadeShinkai,M.D.,Ph.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Describethecutaneousmanifestationsofautoinfammatory
diseases.
2. Recognizeemergingissuesintheevaluationandmanagement
ofrheumatologicdiseaseanddrugeruptionsastheyinvolve
theskin.
3. Recognizeemergingtrendsininternalmedicineand
consultativedermatologythatinfuencethedailypracticeof
medicaldermatology.
DESCRIpTION
Inthissession,attendeeswilllearntorecognizewhatisatthe
forefrontofmedicaldermatology,especiallywheredermatology
interfaceswithinternalmedicine.Tisforumisintendedfor
practicingdermatologistsandresidents,especiallythosewithan
interestinmedicaldermatologyandwhoenjoycaringforpatients
withcomplexmedicaldermatologicconditions.Teforumwill
emphasizehottopicsnotyetintextbooks,emergingtrends,new
diagnostictools,andtherapeuticupdates.
2.00 Category 1 CME Credits
SCHEDUlE
9:00a.m. CutaneousManifestationsofAuto-Infammatory
Diseases / Dr. Shinkai
9:20a.m. QuestionsandAnswers / Dr. Shinkai
9:25a.m. RecognizingPsoriaticArthritis / Dr. Garg
9:45a.m. QuestionsandAnswers / Dr. Garg
9:50a.m. DermatologyintheInternalMedicineLiterature
/ Dr. Rosenbach
10:10a.m. QuestionsandAnswers / Dr. Rosenbach
10:15a.m. HotTopicsinDrugEruptions / Dr. Burgin
10:35a.m. QuestionsandAnswers / Dr. Burgin
10:40a.m. InpatientDermatology: CasesTatHaveTaughtMe
Dermatology / Dr. Fox
70
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
FORUM
9:00a.m.to11:00a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F003 Case-Based Challenges in pediatric
Dermatology
Room:281/282
DIRECTOR James R. Treat, M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Developskillsinmanagingcommonandrarecomplex
pediatricdermatologicpatients.
2. Recognizeanddiagnosechallengingpediatricdermatologic
patients.
3. Selectbesttreatmentplansforpediatricpatients.
DESCRIpTION
Inacase-basedfashion,wewillreviewdiagnosticandtreatment
strategiesforchallengingcommonandrarepediatricdermatologic
patients.Categoriesreviewedwillincludeneonataldermatology,
vascularlesionsandhemangiomas,infammatorydermatosis,
infectiousdiseases,drugreactions,proceduralchallenges,newand
emergingpediatricskinconditionsandtherapeutics.
2.00 Category 1 CME Credits
F004 geriatric Dermatology: Advanced Cases
Room:291/292
DIRECTOR Joely Anne Kaufman, M.D.
SpEAkERS
RobinA.C.Graham-Brown,M.D. RobertA.Norman,D.O.
MalcolmW.Greaves,M.D.,Ph.D. AntonellaTosti,M.D.
AlysaR.Herman,M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Reviewthephysiologicchangesingeriatricskin.
2. Summarizethelateststrategiesfordiagnosisandtreatmentof
pruritus.
3. Discussthediferenttherapiesforcommongeriatricconditions
representedincasepresentations.
DESCRIpTION
Tissessionwillcoverthemostcommongeriatricconditions
encounteredintheoutpatientsetting,includingpruritus,drug
eruptions,cutaneousmalignancies,andhairandnaildiseases.
Focuswillbeonnovelandnewtherapiesforgeriatricdisorders.
Casepresentationswillbeusedforopendiscussionofinteresting
diagnosesortherapies.
2.00 Category 1 CME Credits
SCHEDUlE
9:00a.m. Introduction / Dr. Kaufman
9:15a.m. NewTerapiesforOldDiseases / Dr. Graham-Brown
9:35a.m. HairandNailDisordersintheElderly / Dr. Tosti
9:50a.m. SpecialConsiderationsforGeriatricSurgicalPatients
/ Dr. Herman
10:15a.m. Pruritus:NewIdeasandNovelTerapies / Faculty
10:30a.m. CasePresentationandDiscussion / Dr. Norman
10:50a.m. CasePresentationsandDiscussion / Dr. Kaufman
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
71
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
SCIENTIFIC SESSIONS
F006 Vitiligo
Room:388/389/390
DIRECTOR James J. Nordlund, M.D.
SpEAkER RebatM.Halder,M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Recognizethetypesofvitiligo,theirclinicalcourse,thelatest
informationaboutpathogenesis,andpeculiaritiesabout
depigmentedskin.
2. Identifyallformsoftreatmentofvitiligo,theiradvantagesand
disadvantages,indicationsforuse,andoutcomes.
DESCRIpTION
Onsetandcourseandclinicalmanifesetationsofvitiligowillbe
presented.In-depthreviewoftheknowncausesintrinsicand
extrinsictomelanocyteswillbepresented.Segmentalvitiligowill
bediferentiatedfromdermatomalaberrationsandcompared
withnevusdepigmentosus.Tealterationintheinfammatory
systemindepigmentedskinwillbereviewed.Teresistanceof
depigmentedskin-to-skincancerwillbediscussed.Tegenetic
basisforvitiligowillbepresented.Inthesecondhour,allforms
oftherapywillbereviewedandtheimportanceofthemelanocyte
reservoiremphasized.Teusesoftopicalmedications,ultraviolet
light,surgicaltransplantation,tattooing,anddepigmentationwill
bediscussedindetail.
2.00 Category 1 CME Credits
SCHEDUlE
9:00a.m. Vitiligo:Manifestation,Causes,andTreatment
/ Dr. Nordlund
10:45a.m. QuestionsandAnswers / Dr. Nordlund
FORUM
9:00a.m.to11:00a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F005 Boards Blitz
Room:255/256/257
DIRECTOR Jennifer Lucas, M.D.
SpEAkERS
AdamJ.Friedman,M.D.
MichelleB.Tarbox,M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Recognizeand/ordiagnosecommonlytestedimagesrelated
tomedicaldermatology,pediatricdermatology,surgical
dermatology,andclinicalpathologiccorrelates.
2. Identifystrengthsandweaknessesinone’sknowledgebase
forthedigitalimagesectionoftheAmericanBoardof
Dermatologycertifcationexam,recertifcationexam,ormock
boardsandmakeimprovementsasnecessary.
DESCRIpTION
StudyingfortheAmericanBoardofDermatology(ABD)
certifcationorrecertifcationexamcanbeoverwhelming!
Tisinteractivesessionwillprovidekeypointsandtipsfor
identifyingandmakingdiagnosesforthedigitalimageportion
ofthecertifcationorrecertifcationexam.Attendeeswillhave
theopportunitytoviewnumerousdigitalimagesinrapid-fre
progressionpreparingthemforthedigitalimageportionofthe
exam.High-yieldstudymaterialwillalsobecoveredastheimages
arereviewed.Tissessionwillbeneftanydermatologistpreparing
fortheABDcertifcation,recertifcation,ormockboardexams.
2.00 Category 1 CME Credits
SCHEDUlE
9:00a.m. Medical/PediatricDermatology / Dr. Friedman
9:40a.m. ClinicalPathologicCorrelations / Dr. Babb-Tarbox
10:20a.m. Procedural/SurgicalDermatology / Dr. Lucas
72
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
FORUM
9:00a.m.to11:00a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
wORkSHOp
9:00a.m.to11:00a.m.
Tuition fee and ticket required for admission.
F007 Management of Diffcult wounds
Room:392
DIRECTOR Oliver Fred Miller III, M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Distinguishamongtheulcersseenonthefeetandlegs.
2. Evaluateandtreatvenouslegulcers.
3. Treatulcerationswithvariousmethodsofdebridement.
DESCRIpTION
Discussionwillprovideanoverviewoflegandfootulcer
classifcationanddiferentialdiagnosisfollowedbyafocused
discussionofetiology,evaluation,treatment,andaftercareof
venouslegulcersanddiabeticneuropathicfootulcers.Adetailed
discussionofefectivedebridementwillbeincluded.Practical
aspectsoftherapywillbedirectedtothepracticingphysician
interestedinwoundcare.
2.00 Category 1 CME Credits
F008 Decreasing Iatrogenic problems
in Your practice
Room:265/266
DIRECTOR Eliot N. Mostow, M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Identifyexamplesofiatrogenicproblemsinamedical
dermatologyclinic.
2. Examinethebestpracticedata,whereavailable,toprevent
iatrogenicproblems.
3. Developasystemorsystemswithinthepracticetoreduce
iatrogenicproblemsandimprovepatientoutcomes.
DESCRIpTION
Iatrogenicproblemsindermatologicpracticewillbediscussed
andcompared,whenpossible,tobestpracticedataandsystematic
reviewsto:identifyareasofconcern;identifyopportunities
topreventtheseerrorsandimprovepatientoutcomesinan
efcientandcost-efectivemanner.Audienceparticipationwillbe
encouraged.
2.00 Category 1 CME Credits
w001 MOC Self-Assessment A
M
O
C
Room:288/289/290
DIRECTOR Steven B. Deliduka, M.D.
lEARNINg OBjECTIVES
Followingthisworkshop,theattendeewillbeableto:
1. Identifythestrengthsandweaknessesinone’sdermatology
knowledgeandmakeimprovementsasneeded.
2. Demonstratecommitmenttolifelonglearningandself-
assessmentviacompletionofaforumof25questionsand
answers.
DESCRIpTION
Tissessionisstructuredinaquestion-and-answerformat
usinganautomatedresponsesystem.Itwillcovertopicsin
generaldermatology,pediatricdermatology,dermatopathology,
dermatologicsurgery,andcosmeticdermatology.Teparticipant
willhaveimmediatefeedbackforeachsessionandwillbe
abletoidentifyanyareasofweaknessthatrequirefurtherself-
directedstudy.Duetothetimedframeworkofthissession,itis
imperativethatparticipantsarriveontimeforthisworkshop.
2.00 Category 1 CME Credits
* Self-assessment questions utilized in this session are
the same as those used for Workshop W005 MOC:
Self-Assessment ofered at Annual Meeting 2010.
Physicians should not claim CME/MOC credit for
attending this session if they attended Workshop W005
at Annual Meeting 2010.
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
73
SCIENTIFIC SESSIONS SCIENTIFIC SESSIONS
SCHEDUlE
9:00a.m. Introduction/Dr. Dohil
9:05a.m. MakeA“Rash”-IonalDecision:ExathemsIn
Children/Dr. Mancini
9:25a.m. “Rheum”WithAView:SkinSignsofSystemic
Disease/Dr. Eichenfeld
9:35a.m. QuestionsandAnswers/Faculty
9:40a.m. LumpsandBumpsInKids:WhenTeyNeedToGo!
/Dr. Connelly
9:50a.m. PediatricDermatologyJeopardy:SyndromesYou
ShouldKnow!/Dr. Treat
10:05a.m. AtopicDermatitis:TriedandTestedTreatment
/Dr. Tom
10:25a.m. QuestionsandAnswers/Faculty
10:30a.m. VascularBirthmarks:ManagementPearls
/Dr. Friedlander
10:45a.m. Nevi:HowTeyHappen,HowtoView,
WhattoDo?/Dr. Marghoob
11:00a.m. QuestionsandAnswers/Faculty
11:05a.m. Bugs,andthedrugsthatTreatTem/Dr. Yan
11:20a.m. SkinInfectionsandInfestations:Preventionand
Treatment/Dr. Levy
11:35a.m. PediatricDermatology:NewsFlashfromthe
Literature/Dr. Sidbury
11:40a.m. QuestionsandAnswers/Faculty
COURSE
9:00a.m.to12:00p.m.
Tuition fee and ticket required for admission.
C003 pediatric Dermatology
Room:238/239
DIRECTOR Magdalene A. Dohil, M.D.
SpEAkERS
ElizabethAlvarezConnelly,M.D. AshfaqA.Marghoob,M.D.
AndrewEichenfeld,M.D. RobertSidbury,M.D.
SheilaFallonFriedlander, M.D. WynnisL.Tom,M.D.
MoiseL.Levy,M.D. JamesR.Treat,M.D.
AnthonyJ.Mancini,M.D. AlbertC.Yan,M.D.
lEARNINg OBjECTIVES
Followingthiscourse,theattendeewillbeableto:
1. Diagnosecommonanduncommonpediatricdermatologic
conditionsmoreefectively.
2. Recognizeadvancesinpediatricdermatologythroughliterature
updates.
3. Treatavarietyofcutaneousconditionsinchildrenmore
comfortably.
DESCRIpTION
Tissessionwillprovidepracticalandclinicallyusefulinformation
onthediagnosisandmanagementofmanycommonskin
conditionsinnewborns,infants,children,andteens.Tefocus
willbeoncutaneousproblemsthatareconfusingordifcultfor
thosewhodonotseemanychildrenintheirpractices.Itisgeared
towardthegeneraldermatologistordermatologyresident.
3.00 Category 1 CME Credits
REFERENCES
1. EichenfeldLF,FriedenIJ,EsterlyNB.Textbook of Neonatal
Dermatology 2001.
2. PallerAS,ManciniAJ.HurwitzClinical Pediatric Dermatology,
3rdedition.2006.
74
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
COURSE
9:00a.m.to12:00p.m.
Tuition fee and ticket required for admission.
C004 Diagnosis and Therapeutics:
The Fundamentals
Room:383/384/385
DIRECTOR Peter A. Lio, M.D.
SpEAkERS
AprilW.Armstrong,M.D.
SusanBurgin,M.D.
RuthAnnVleugels,M.D.
lEARNINg OBjECTIVES
Followingthiscourse,theattendeewillbeableto:
1. Developanapproachtothediferentialdiagnosisofabroad
rangeofinfammatoryandneoplasticdermatosesbyemploying
color,reactionpatterns,andelementsoftheWheelof
Diagnosis.
2. Discussthehistoryofvehiclesandtherapyindermatologyand
formulateanapproachtoselectingtreatment.
3. Recognizeclinicallyimportantadversedruginteractionsto
improvetherapeuticsuccessandavoiduntowardconsequences.
DESCRIpTION
Tiscourseprovidesacomprehensiveapproachtodiferential
diagnosesandtherapeuticsindermatology.Tetargetisnewer
practitionersandseniordermatologistswhoteachresidentsand
studentsabouttheseconcepts.Tecoursepresentsaproblem-
solvingmethodtoassistinthecreationofdiferentialdiagnoses.
Diagnosticalgorithmsareintroduced,andparticipantswill
practiceformulatingdiferentialdiagnosesusingthesetools.Te
coursealsopresentsaframeworkforthinkingabouttherapy.
Startingwithanoverviewofvehiclesanddrugdelivery,this
sectioncontainshistoricalinsightsandpracticalapproachesto
implementation.Finally,therewillbeareviewofimportant
therapeuticinteractions,somesynergisticandothersdetrimental.
3.00 Category 1 CME Credits
SCHEDUlE
9:00a.m. TeWheelofDiagnosis1 / Dr. Burgin
9:45a.m. TeWheelofDiagnosis2 / Dr. Vleugels
10:30a.m. Terapeutics:ArtandScience / Dr. Lio
11:15a.m. ImportantTerapeuticInteractionsEvery
DermatologistShouldKnow / Dr. Armstrong
C005 Basic Contact Dermatitis
Room:386/387
DIRECTOR Sharon E. Jacob, M.D.
SpEAkERS
BryanErikAnderson,M.D. SusanT.Nedorost,M.D.
DavidEricCohen,M.D. PamelaL.Scheinman,M.D.
VincentAnthonyDeLeo,M.D. JamesSelwynTaylor,M.D.
AlisonEhrlich,M.D. ErinM.Warshaw,M.D.
ChristenM.Mowad,M.D. MatthewZirwas,M.D.
lEARNINg OBjECTIVES
Followingthiscourse,theattendeewillbeableto:
1. Developadiferentialdiagnosisofcontactdermatitisand
relatedentities.
2. Identifyappropriateallergensforpatchtestingandallergen
sourcesinimplementingallergenavoidanceregimens.
3. Evaluatepatientsforphotocontactdermatitis.
DESCRIpTION
Tissessionwillstartwithbasicinformationoncontact
dermatitis,exploringthediferentialandapproachtopatch
testing.Common,aswellasnewandemerging,allergenswillbe
discussed.Inaddition,specifccategoriesofcontactdermatitis
willbepresented:handdermatitis,contactdermatitistometals,
antibioticsandcosmetics,occupationalcontactdermatitis,and
photocontactdermatitis.Instructionalcaseswillbepresentedto
encourageattendeestoaskquestions.
3.00 Category 1 CME Credits
SCHEDUlE
9:00a.m. DefningtheDiferentialDiagnosis / Dr. Zirwas
9:20a.m. BasicsofPatchTesting / Dr. Nedorost
9:35a.m. PatientCounselingandEducation / Dr. Scheinman
9:50a.m. MetalsAllergy / Dr. Taylor
10:05a.m. HandDermatitis / Dr. Warshaw
10:25a.m. Preservative-AssociatedContactDermatitis / Dr. Cohen
10:40a.m. CosmeticandPlant-AssociatedContactDermatitis
/ Dr. Ehrlich
10:55a.m. PhotocontactDermatitisandPhotoPatchTesting
/ Dr. DeLeo
11:10a.m. Antibiotic-AssociatedContactDermatitis / Dr. Mowad
11:25a.m. SportsGear-AssociatedContactDermatitis
/ Dr. Anderson
11:40a.m. CaseReview:QuestionandAnswerSession
/ Dr. Jacob
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
75
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
SCIENTIFIC SESSIONS
S002 Alopecia: workup and Treatment
Room:278/279/280
DIRECTOR Wilma Fowler Bergfeld, M.D.
SpEAkERS
GeorgeCotsarelis,M.D. MelissaPiliang,M.D.
EliseOlsen,M.D. KenWashenik,M.D.,Ph.D.
lEARNINg OBjECTIVES
Followingthissymposium,theattendeewillbeableto:
1. Diagnosisthecommonalopecicdisordersandhavean
evaluation,treatment,andfollow-upalgorithm.
2. Identifycurrentscreeningdiagnosticlaboratorytestsand
procedures.
3. Summarizerecentscientifcadvancesinthediagosisand
treatmentofalopecicdisorders.
DESCRIpTION
Dermatologistsarethemostknowledgeablephysicianstoevaluate
andmanagepatientswithalopecicdisorders.Tissymposiumwill
refreshandupdatetheattendeesdiagnosticandtreatmentoptions.
3.00 Category 1 CME Credits
REFERENCES
1. OlsenEA.ed.Disorders of Hair Growth: Diagnosis and
Treatment.NewYork:McGraw-Hill;2003.
2. McMichaelAJ,HordinskyM,eds.Hair and Scalp Disease:
Medical, Surgical, and Cosmetic Treatments.InformaHealthcare
2008.
3. SomaniN,Bergfeld WF.CicatricialAlopecia:Classifcation
andHistopathology.Dermatol Ter.2008Jul;21(4):221-237.
4.Blume-PeytaviU,ed.Hair Growth and Disorders.Berlin:
Springer;2008.
SCHEDUlE
9:00a.m. Introduction/CommonAlopecicDisorders,
EvaluationandTreatmentOptions / Dr. Bergfeld
9:30a.m. UpdateonScarringAlopecicDisorders / Dr. Piliang
10:00a.m. StemCellsinAlopecia / Dr. Cotsarelis
10:30a.m. HairLossinAfricanAmericanWomen / Dr. Olsen
11:00a.m. EmergingTerapiesintheTreatmentofHairLoss
/ Dr. Washenik
11:30a.m. PanelDiscussion/QuestionsandAnswers / Faculty
SYMpOSIUM
9:00a.m.to12:00p.m.
Open admission, no tuition or ticket.
S001 Disorders of pigmentation
Room:AuditoriumC
DIRECTOR Harvey Lui, M.D.
SpEAkERS
JeanL.Bolognia,M.D. RebatM.Halder,M.D.
Ilona J.Frieden,M.D. AmitG.Pandya,M.D.
PearlE.Grimes,M.D.
lEARNINg OBjECTIVES
Followingthissymposium,theattendeewillbeableto:
1. Classifyandrecognizeimportantandcommonpigmentary
disordersinadultsandchildren.
2. Describethelatestapproachestomanagingpatientswith
pigmentarydisorders.
DESCRIpTION
Teonlyorganofthebodythatmanifestsdisordersofpigmentation
toanysignifcantextentistheskin.Pigmentdiseaseiscommonly
seenindermatologicpractice,andhasamajordirectimpacton
normalskinfunctionandoverallqualityoflife.Tespectrumand
variouspresentationsofpatientswithabnormalskinpigmentation
arebroadandincludehyperpigmentation,hypopigmentation,and
depigmentation.Systematicapproachestoclassifyingandtreating
pigmentaryconditionsbasedonage,pattern,clinicalevidence,and
experiencewillbethefocusofthissymposium.Ampletimewillbe
scheduledforaudienceparticipation.
3.00 Category 1 CME Credits
REFERENCES
1. Halder,RM,NandekarMA,NealKW.Pigmentarydisorders
inpigmentedskins.In:HalderRM.Dermatology and
Dermatological Terapy of Pigmented Skins.1sted.NewYork:
TaylorandFrancis;2006:91-114.
2. NordlundJJ,BoisseyRE,HearingVJ,KingRA,Oetting
W,OrtonneJ. Te Pigmentary System: Physiology and
Pathophysiology,2nded.NewYork:BlackwellPublishing
Limited,2006.
SCHEDUlE
9:00a.m. AnApproachToPigmentaryDisorders/Dr. Bolognia
9:20a.m. QuestionsAndAnswers/Dr. Bolognia
9:25a.m. Lines,Segments,andMosaics:AnUpdateon
PatternedPediatricPigmentaryAnomalies/Dr.
Frieden
9:45a.m. QuestionAndAnswer/ Dr. Frieden
9:50a.m. Melasma:ACriticalUpdate/ Dr. Pandya
10:10a.m. PostinfammatoryHyperpigmentation/ Dr. Grimes
10:30a.m. LasersforPigmentaryDisorders/ Dr. Lui
10:50a.m. QuestionsandAnswers/Faculty
11:05a.m. CommonYetChallengingHypopigmentation
Disorders/ Dr. Nordlund
11:25a.m. Vitiligo:AnythingNew?/ Dr. Halder
11:50a.m. QuestionsandAnswers/Faculty
76
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
SYMpOSIUM
9:00a.m.to12:00p.m.
Open admission, no tuition or ticket.
S003 Hot Topics
Room:AuditoriumA
DIRECTOR Kenneth J. Tomecki, M.D.
lEARNINg OBjECTIVES
Followingthissymposium,theattendeewillbeableto:
1. Recognizeavarietyof‘hottopics,’asidentifedbyregistrants at
theAnnualMeeting.
2. Discussthe‘hottopics’ofmedicalandsurgicaldermatology,
includingitemsofsocialandeconomicimport.
DESCRIpTION
Te‘hottopics’symposiumwilladdressandhighlightavariety
oftopicsestablishedbyregistrantconsensusattheAnnual
Meeting.Tosetopics,derivedfromregistants’topthreechoices,
willrefectthemedical/surgicalandsocial/economicconcerns
ofthemembership.Tesomewhatunstructured sessionwill
beapotpouriofcontemporaryissuesthatcurrentlyafectand
impactthespecialty.Expertspeakerswilltacklethetopicsinan
interactivemanner,hopefullystimulatingdebateandminimizing
controversy.Presentationswillbestateoftheart,andattendees
willderiveasenseofwhat’simportanttodermatologistsin2011.
3.00 Category 1 CME Credits
S004 when Bad Things Happen
To good Doctors
Room:LaNouvelleOrleansBallroom
DIRECTOR Mary E. Maloney, M.D.
SpEAkERS
Ilona J.Frieden,M.D. MartaJaneVanBeek,M.D.
SuzanneOlbricht,M.D. SummerR.Youker,M.D.
MichaelD.Tarp,M.D.
lEARNINg OBjECTIVES
Followingthissymposium,theattendeewillbeableto:
1. Recognizesituationsthatqualifyasriskforthephysicianor
practice.
2. Identifyskillsthatwillresolvethesituationwiththeleaststress
andbestoutcome.
3. Delineateriskmanagementstrategies(procedures,skills,and/or
behaviors)toreducerecurrenceofthesesituations.
DESCRIpTION
Manysituationsariseinmedicinethattaxourabilities.
Whilewearewelltrainedin medicine,wedonothavetraining
inthemanagementofangryorthreateningpatients,chargesof
harassment,diversityissues,howtohandlemisseddiagnosis,
andalitanyofotherchallengingproblems.Tissymposium
willaddressthesetypesofissues.Eachpresentationwillbegin
withacasestudy,andthefacultyforthatscenariowilldiscuss
thecase,withparticularattentiontotheuseofleadershipskills
inthemanagementofthesituationandtheemploymentofrisk
managementstrategies.
3.00 Category 1 CME Credits
SCHEDUlE
9:00a.m.Introduction/Dr. Maloney
9:05a.m. RecurrentCancerMissed:HowtoManage
atallLevels/Dr. Maloney
9:25a.m.QuestionsAndAnswers/Faculty
9:35a.m.TePoorOutcomeandHowToManageIt
/Dr. VanBeek
9:55a.m.QuestionsandAnswers/Discussion/Faculty
10:05a.m.“WasTisTeSpot?”WrongSiteSurgery
/ Dr. Youker
10:25a.m.QuestionsandAnswers/Discussion/Faculty
10:35a.m. AdverseOutcomesinPediatricDermatology:
LessonsLearned/Dr. Frieden
10:55a.m.QuestionsAndAnswers/Discussion/Faculty
11:00a.m.TeNewConceptsofHarassmentintheWorkPlace/
Dr. Tarp
11:20a.m. QuestionsandAnswers/Discussion/Faculty
11:30a.m. Anger,FrustrationandtheUnbalancedLifeof
APhysician/Dr. Olbricht
11:50a.m. QuestionsandAnswers
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
77
SCIENTIFIC SESSIONS SCIENTIFIC SESSIONS
SYMpOSIUM
9:00a.m.to12:00p.m.
Open admission, no tuition or ticket.
S005 leading from Your Vision
to Exceptional Service
Room:293/294
DIRECTOR Victor J. Marks, M.D.
SpEAkER SandraEllison,CenterforCreativeLeadership
lEARNINg OBjECTIVES
Followingthissymposium,theattendeewillbeableto:
1. Design,convey,andteachaninspiringvisionfortheirpractice.
2. Examinethepowerofsettingbehaviorstandardsforthe
formationofadesiredpracticeculture.
3. Describetheimportanceofmeasuringserviceperception.
DESCRIpTION
Developingandteachinganinspiringvisionisthecentralaspect
ofcreatingthepracticeyoudesire.Everypracticehasaculture,
defnedas“thewaywedothingsaroundhere.”Culturecomes
fromthebehaviorsofthosewhomakeuptheworkgroupor
practice.Wewilldiscusstheimportanceofvision-settingand
willhelpyoudeveloponethatftsyouridealfuturepractice.As
importantly,wewillshowyouhowtosetandreinforcebehavior
standardsforyourselfandyouremployeesthatwillleadtothe
kindofcultureyouwantinyourofce.
3.00 Category 1 CME Credits
The Teaching
Tool You’ve Been
Waiting For!
Educate audiences of
all ages about the
importance of
sun-safety and skin
cancer detection and
prevention with the
new See SPOT (Skin
Cancer Presentation
Outlining The Facts) CD.
See SPOT CD features:
• Four PowerPoint™ presentations
targeted to: Children, grades K-2;
Children, grades 3-5; Pre-teens and
Teenagers; and Adults
• Corresponding script with each presentation
• Pre- and post-presentation audience
evaluations
• Printable children’s coloring pages
featuring Sammy the Skin Cell
The See SPOT CD is perfect for school
presentations and screening events!
Visit the Academy Resource Center
Booth 3623 to place your order!
78
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
SYMpOSIUM
9:00a.m.to12:00p.m.
Open admission, no tuition or ticket.
S006 Approach to pigmented lesions
Room:243/244/245
DIRECTOR Ashfaq A. Marghoob, M.D.
SpEAkERS
ClaraN.Curiel-Lewandrowski,M.D. AllanC.Halpern,M.D.
JamesM.Grichnik,M.D.,Ph.D. ScottMenzies,MBBS,Ph.D.
Jean-JacquesGrob,M.D. AlonScope,M.D.
lEARNINg OBjECTIVES
Followingthissymposium,theattendeewillbeableto:
1. RecognizethelimitationsoftheABCDEruletodetect
melanoma.
2. Describetheaddedbeneftofnewertechnologiestoassistin
melanomadiagnosis.
3. Determinethemostappropriatebiopsytechniqueforsuspect
pigmentedlesions.
DESCRIpTION
Managementofpigmentedlesionsdependsontheirstaticand
dynamicmorphology.However,relianceonstaticmorphology(i.e.,
ABCD)resultsinsensitivityandspecifcityformelanomathatis
farfromperfect.Furthermore,relianceondynamicmorphology
oflesions(i.e.,change)isnotreliablesincenevichangeand
melanomasmaynotrevealchangesformanymonths.Tus,
additionaltechniquestoimproveourdiagnosticaccuracywould
bewelcomed.Tesetechniquesincludetheuglyducklingsign,
cognitiverecognition,dermoscopyandconfocal.Onceadecisionto
biopsyhasbeenrenderedthephysicianwillneedtodecideonthe
mostappropriatebiopsymethod(shave,punch,excision).
3.00 Category 1 CME Credits
REFERENCES
1. Scopeetal.Teuglyducklingsign:agreementbetween
observers.Arch Dermatol.2008;144:58-64.
2. Argenzianoetal.Slow-growingmelanoma:adermoscopy
follow-upstudy.Br J Dermatol.2009;162:267-273.
3. Marghoobetal.Dermatologists,generalpractioners,andthe
bestmethodtobiopsysuspectmelanocyticneoplasms. Arch
Dermatol.2010;146:325-328.
SCHEDUlE
9:00a.m. ClinicalABCD,UglyDuckling,andCognitive
Approach:HowGoodAreTeyatIdentifying
Melanoma? / Dr. Grob
9:20a.m. TeSignifcanceofNewandChangingLesions
/ Dr. Grichnik
9:40a.m. AdvancesinImagingtoDetectNewandChanging
Lesions / Dr. Curiel-Lewandrowski
10:00a.m. AreAllStableLesionsBenign? / Dr. Marghoob
10:25a.m. DoesDermoscopyandConfocalAddUtilityin
ClinicalDiagnosis? / Dr. Menzies
10:50a.m. FutureTechnologiestoAssistintheinVivo
DiagnosisofMelanoma / Dr. Halpern
11:10a.m. Shave,PunchAndExcisionalBiopsy:TeProsAnd
Cons / Dr. Scope
11:30a.m. QuestionsandAnswers / Faculty
Before you take
the MOC-D Exam, take the
Derm Exam Prep
Course: Refresher
• Benchmarkyourclinicalknowledge
againsttheABD’sMOC-Drecertifcation
examstudyguide
• Coverthegeneraldermatologysection
oftheMOC-Drecertifcationexamwith
expertfaculty
• EarnCMEasyoupreparefortheABD
MOC-Dexam
Derm Exam Prep Course: Refresher
February 4, 2011
Ernest N. Morial Convention Center,
New Orleans, LA
Does not include ABD Exam offered
on Wednesday, February 9, 2011
Visit
www.aad.org/meetings/annual
to register!
Don’t Pass
this uP!
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
79
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
SCIENTIFIC SESSIONS
C008 Derm Exam prep Course: Refresher
Room:260/261/262
DIRECTOR M. Yadira Hurley, M.D.
SpEAkERS
ChristieTraveluteAmmirati,M.D.SamanthaHill,M.D.
MilanJ.Anadkat,M.D. SummerR.Youker,M.D.
NicoleM.Burkemper,M.D. ClaudiaVidal,M.D.
MichaelP.Hefernan,M.D.
lEARNINg OBjECTIVES
Followingthiscourse,theattendeewillbeableto:
1. Assessabilitytodiagnosethe150conditionsidentifedby
theAmericanBoardofDermatology(ABD)asrequiredfor
theGeneralDermatologymoduleoftheMaintenanceof
CertifcationinDermatology(MOC-D)exam.
2. Identifyareasneedingadditionalstudyinpreparationforthe
GeneralDermatologymoduleoftheMOC-Dexam.
3. RecognizetheformatusedontheMOC-Dexam.
DESCRIpTION
Tiscourseistargetedtodermatologistspreparingforthe
AmericanBoardofDermatology(ABD)Maintenanceof
CertifcationinDermatology(MOC-D)exam.Residents
preparingfortheirBoardexammayalsobeneftfromthiscourse,
however,thiscourseisnotdesignedforinitialBoardcertifcation.
Tecoursewillreviewthe150diagnoseslistedascoveredinthe
GeneralDermatologymoduleoftheMOC-Dexaminaformat
similartotheoneusedontheexam.
Note: Tis course reviews only diagnoses from the General
Dermatology module of the exam and does NOT include questions
from the subspecialty modules.
6.00 Category 1 CME Credits
SCHEDUlE
9:00a.m. GeneralContentReview:ClinicalImages / Faculty
12:00p.m. Break / Faculty
2:00p.m. GeneralContentReview:ClinicalImages / Faculty
COURSE
9:00a.m.to5:00p.m.
Tuition fee and ticket required for admission.
C007 Immunology
Room:391
DIRECTOR Jefrey B. Travers, M.D., Ph.D.
SpEAkERS
AndrewBlauvelt,M.D. LloydS.Miller,M.D.,Ph.D.
KevinD.Cooper,M.D. RobertSwerlick,M.D.
MichaelGirardi,M.D.
lEARNINg OBjECTIVES
Followingthiscourse,theattendeewillbeableto:
1. Summarizenewdevelopmentsincutaneousimmunology.
2. Discussinfammatoryskindiseasessuchasatopicdermatitis
andpsoriasis.
3. Explaintheroleoftheimmunesystemintumorimmunology.
DESCRIpTION
Tissessionisdesignedtoupdatetheaudienceonnew
developmentsingeneralimmunologywithanemphasisonskin
immunity,especiallythosethatareofmostinteresttoclinical
practitioners.Tesessionwillfocusonpracticalaspectsof
infammatoryskindiseasessuchasatopicdermatitisandpsoriasis
andtumorimmunologywithemphasisonunderstandingthe
pathogenesisandtreatmentconsiderations.
6.00 Category 1 CME Credits
SCHEDUlE
9:00a.m. Cytokines:TeLanguageofInfammation / Dr. Travers
10:00a.m. AdaptiveImmunity / Dr. Cooper
11:00a.m. ImmunologyofCancer / Dr. Girardi
2:00p.m. InnateImmunity / Dr. Miller
2:50p.m. ImmuneTolerance / Dr. Swerlick
3:35p.m. ImmunologyofPsoriasis / Dr. Blauvelt
4:20p.m. ImmunologyofAtopicDermatitis / Dr. Travers
80
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
COURSE
9:30a.m.to11:30a.m.
Tuition fee and ticket required for admission.
FORUM
12:00p.m.to2:00p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
C06B Basic Self-Assessment of
Dermatopathology
Room:275/276/277
DIRECTOR Clay J. Cockerell, M.D.
SpEAkERS
AntoanellaBardan,M.D.
lEARNINg OBjECTIVES
Followingthiscourse,theattendeewillbeableto:
1. Interpretandidentifydermatologichistologicaldiagnosesmore
efectivelyandaccurately.
2. Classifyandrecognizecommonhistopathologicskinconditions
andformulatediferentialdiagnoses.
DESCRIpTION
Attendeeswillview60slidesfromskinbiopsyspecimensinaformat
thatwillallowself-assessment.Caseswillspanthefullspectrumof
dermatopathology.Eachspecimenwillbediscussedbyafaculty
memberwithemphasisplacedonestablishingthecorrectdiagnosis
andconsiderationofthediferentialdiagnosis.Tesesessionsare
directedtodermatologyresidentsandpracticingdermatologists.
Toallowforalargerparticipationthisyear,thiscoursewillbe
oferedwithduplicatecontentat7:00a.m.,9:30a.m.,12:30p.m.,
and3:00p.m.Attendeesneedonlyselectoneofthesesessions.
TissessionincludesthediscussionC06E–seepage122.
2.00 Category 1 CME Credits
F009 photobiology for Dermatologists
Room:392
DIRECTOR Gillian M. Murphy, M.D.
SpEAkERS
MarjanGarmyn,Prof. GiovanniLeone,M.D.
JohnLyndonMcLeodHawk,M.D. HenryW.Lim,M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Summarizetheprinciplesofphotobiologywhichleadtoacute
andchronicefectsofultravioletradiation.
2. Managephotodermatosesandphototherapymoreefectively.
3. Discusswithpatientstheoptimalphotoprotection.
DESCRIpTION
Photoprotectionisabasicpartofthewaragainstskincancer.It
comprisesavoidanceofultravioletradiation(UVR)byseeking
shade,wearingappropriateclothingincludinghats,andtheuseof
topicalsunscreenstoprotectexposedsites.Systemicphotoprotective
agentsoferminorprotectionbycomparison.Patientswith
photodermatosesmayachievephotoprotectionbydesensitization
techniques.Hazardsassociatedwiththesestrategieswill beoutlined.
ReductionofexposuretoUVRwouldbeexpectedtoreduceskin
cancerratesandreducephotodermatoses.Absoluteprotectionfrom
UVRrequiresconsiderationastowhetherdietaryintakeofvitamin
Disadequate.Tissessionwillreviewthesematters.
2.00 Category 1 CME Credits
SCHEDUlE
12:00p.m. IntroductiontoPhotobiologyforDermatologists
/ Dr. Murphy
12:05p.m. BasicPrinciplesOfPhotobiologyforDermatologists
/ Dr. Lim
12:25p.m. WhatDermatologistsShouldKnowAbout
Photodermatoses / Dr. Hawk
12:45p.m. WhatDermatologistsShouldKnowAbout
Phototherapy / Dr. Leone
1:05p.m. WhatDermatologistsShouldKnowAbout
Photoageing / Prof. Garmyn
1:25p.m. WhatDermatologistsShouldKnowAbout
Photoprotection / Dr. Murphy
1:45p.m. PanelDiscussion / Dr. Murphy
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
81
SCIENTIFIC SESSIONS SCIENTIFIC SESSIONS
F011 Dermatopathology Made Simple
Room:388/389/390
DIRECTOR Christine Ko, M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Developanaptitudefordistinguishinglow-powerslideclues.
2. Formulateadiferentialfromtheinitialviewofaspecimen.
3. Predictandrecognizeevidenceathigherpowerthatnarrows
thediferential.
DESCRIpTION
Tissessionisaimedatresidentsintraining.Aquickoverviewof
over150diferententitiesindermatopathologyisreviewed,using
thelow-powerimpressionofaslideasthestartingpoint.From
theinitialimpression,cluesathigherpowerthatcanleadtothe
correctdiagnosisareemphasized.
2.00 Category 1 CME Credits
FORUM
12:00p.m.to2:00p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F010 Hidradenitis Suppurativa: An Update
Room:252/253/254
DIRECTOR Robert A. Lee, M.D., Ph.D.
SpEAkERS
GregorB.E.Jemec,M.D.
EmilyTierney,M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Diagnosehidradenitissuppurativa,diferentiateitfromclinical
simulator,andcategorizeitbasedonseverity.
2. Summarizecurrentmedicalandsurgicaltherapeuticoptions.
3. Formulateandprescribeatreatmentplanbasedonthecurrent
medicalliterature.
DESCRIpTION
Hidradenitissuppurativaisachronic,recurrent,scarring
infammatorydermatosis.Itisacommondiseasethatisassociated
withconsiderablemorbidityandoftenposessignifcantchallenges
forthepractitioner.Itsclinicalpresentationandcorresponding
histopathologywillbereviewed.Standardandnewertherapeutic
options,includinghormonetherapy,immunomodulators,surgical
andlaserprocedures,willbediscussed.Afterthispresentation,the
audiencewillbeabletodiagnoseandaccuratelystagethedisease,
describeitsnaturalhistory,andsummarizecurrenttherapies.
Teywillbeabletoapplythisinformationtodeveloparational
treatmentalgorithmforthisoftendifcult-to-treatdisease.
2.00 Category 1 CME Credits
SCHEDUlE
12:00p.m. PresentChallengesandFutureDirections / Dr. Lee
12:35p.m. RecentAdvancesinMedicalTerapy / Dr. Jemec
1:10p.m. RecentAdvancesinSurgicalTerapy / Dr. Tierney
1:45p.m. QuestionsandAnswers / Faculty
82
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
FORUM
12:00p.m.to2:00p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F012 Update on genetic Skin Disease
Room:255/256/257
DIRECTOR Julie V. Schafer, M.D.
SpEAkERS
Ilona J.Frieden,M.D. GabrieleRichard,M.D.
AmyS.Paller,M.D. EliSprecher,M.D.,Ph.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Utilizeclinicalobservationsandmoleculartechnologyto
diagnoseinheritedskindisorders.
2. Categorizegenodermatosesaccordingtotheirmolecularbases
andrecognizerelationshipswithcomplextraits.
3. Evaluate,counsel,andtreatpatientsandfamiliesafectedby
geneticskindisease.
DESCRIpTION
Inrecentyears,therehasbeentremendousprogressinelucidating
thegeneticbasesofinheritedskindisorders.Integrationof
clinicalandmoleculardatahassimplifedcategorizationand
minimizedredundantterminology.Tissessionwillreviewnew
developmentsingenodermatosesbygroupingdiseasesaccording
totheirmolecularbases,therebyclarifyingpathomechanisms
andrelationshipsbetweenconditions.Insightsintomosaicskin
diseasesandinheriteddisordersfeaturingabnormalcornifcation,
vasculature,andhairwillbediscussed,highlightingtheirrelevance
tocutaneousphysiologyandmorecommonmultifactorial/
acquiredskinconditions.Progresstowardefectivemanagement
ofgenodermatoseswillalsobeexamined,includingtherapeutic
advancesbasedonmoleculardiscoveries.
2.00 Category 1 CME Credits
SCHEDUlE
12:00p.m. MolecularInsightsintoGeneticSkinDisease
/ Dr. Schafer
12:20p.m. What’sNewinIchthyoses / Dr. Richard
12:40p.m. TeGeneticsofVascularAnomalies:Syndromesand
Beyond / Dr. Frieden
1:00p.m. QuestionsandAnswers / Faculty
1:10p.m. DisentanglingtheRootsofInheritedHairDisorders
/ Dr. Sprecher
1:30p.m. HowGeneDiscoveriesHaveLedtoTerapeutic
Advances / Dr. Paller
1:50p.m. QuestionsandAnswers / Faculty
F013 EHR Implementation, Maintenance, and
lessons learned
Room:291/292
DIRECTOR Maithily A. Nandedkar, M.D.
SpEAkERS
CourtneyR.Herbert,M.D.,M.P.H.
BrettD.Krasner,M.D.
DanielShay,JD
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Identifyanddiscusslegalissuesrelatedtotheadoptionof
electronichealthrecords(EHR).
2. AnalyzetwosuccessfuldermatologyEHRadoptioncase
studies.
DESCRIpTION
Viaexaminationoftwodermatologypracticesascasestudiesthat
havesuccessfullyadopteddiferentEHRs,thissessionwillprovide
acomprehensiveoverviewofEHRs,helpattendeesestablishing
efectivecriteriaforconductingvendorselectionandexplain
someoftheregulatoryaspectsofEHRs.Tecasestudiesshould
alsohelpattendeesassesshowtosuccessfullyplanandprepare
forEHRadoption.Tesessionwillexplorelegalissuesrelated
toHIPAAcompliancewithanEHR,itspotentialimpacton
malpractice,theprobablelegalpitfallstoavoidwhennegotiating
andpurchasingsoftware,includingcontractualtermsgoverning
EHRvendorlicensingagreements.Bringyourquestions!
2.00 Category 1 CME Credits
SCHEDUlE
12:00p.m. IntroductionandOverviewofEHR / Dr. Nandedkar
12:10p.m. EHRimplementation,LessonsLearnedfromDaily
Use / Dr. Krasner
1:10p.m. QuestionsansAnswers / Faculty
1:25p.m. LegalpitfallstoavoidwithEHR / Dr. Shay
1:40p.m. EHRimplementation,LessonsLearnedfromDaily
Use / Dr. Herbert
1:45p.m. QuestionsandAnswers / Faculty
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
83
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
SCIENTIFIC SESSIONS
F015 Ethical Economics in Dermatology and
Dermatologic Surgery

Room:288/289/290
DIRECTOR Alexander Miller, M.D.
SpEAkERS
KentStuartAftergut,M.D. ClifordWarrenLober,M.D.,J.D.
KennethE.Bloom,M.D. StevenP.Rosenberg,M.D.
CarlA.Johnson,M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Evaluateandcontrastvariousethicaldilemmasfacedin
dermatologicpractice.
2. Assesshowtheirindividualpracticepatternsrelatetoaccepted
ethicalstandards.
DESCRIpTION
Tissession,directedtoalldermatologists,willinvolvethe
audienceinaninteractiveformatutilizingaudienceresponse
keypads.Followingadiscussionofthefundamentalsofmedical
ethics,apanelofdermatologistswillpresentaseriesofpractice
situationsthatmaygenerateethicaldilemmas.Tesewillbeposed
totheaudienceforpolledresponses.Tepanel,togetherwiththe
audience,willexploretheethicalramifcationsofthevignettesand
ofthetalliedaudienceresponses.
2.00 Category 1 CME Credits
SCHEDUlE
12:00p.m. FundamentalsofMedicalEthics / Dr. Lober
12:20p.m. PresentationofPracticeVignettesandEthical
Dilemmas / Dr. Aftergut
12:40p.m. PresentationofPracticeVignettesandEthical
Dilemmas / Dr. Bloom
1:00p.m. PresentationofPracticeVignettesandEthical
Dilemmas / Dr. Johnson
1:20p.m. PresentationofPracticeVignettesandEthical
Dilemmas / Dr. Rosenberg
1:40p.m. PresentationofPracticeVignettesandEthical
Dilemmas / Dr. Miller
FORUM
12:00p.m.to2:00p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F014 Challenging Diagnostic Cases for
Advanced practitioners: pA/Np I
Room:281/282
DIRECTOR Arturo P. Saavedra-Lauzon, M.D., Ph.D.
SpEAkERS
JenniferY.Lin,M.D. RuthAnnVleugels,M.D.
PeterA.Lio,M.D. Fei-ShiuannClarissaYang,M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Identifyanddiferentiateinfammatorydermatosesthatpresent
totheadvancedpractitionerinbothadultsandchildren.
2. Identifyandevaluatenewpigmentedlesions.
DESCRIpTION
Inthissession,wewillusecasepresentationstohighlight
importanttherapeuticanddiagnosticcriteriathatcommonly
presenttotheadvancedpractitioner.Topicswillinclude:
infammatorydermatoses,pediatricdermatology,collagenvascular
disease,commoninfections,andpigmentedlesions.Attheend
ofthepresentation,thoseattendingthesessionwillbeableto
reviewanswerstocommonquestionsregardingpresentationand
managementofavarietyofdermatologiccomplaintsthatmay
presenttotheadvancedpractitioner.
2.00 Category 1 CME Credits
SCHEDUlE
12:00p.m. CommonInfammatoryDermatosesandMasquerades
/ Dr. Yang
12:20p.m. IsTisPresentationConsistentwithCollagen
VascularDisease? / Dr. Vleugels
12:40p.m. EvaluationofPigmentedLesions / Dr. Lin
1:00p.m. ApproachestothePediatricPatient / Dr. Lio
1:30p.m. UnderstandingBugsandSkinInfections:IsTis
TrulyanInfection? / Dr. Saavedra-Lauzon
84
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
FORUM
12:00p.m.to2:00p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
DISCUSSION gROUp
12:15p.m.to1:45p.m.
Tuition fee and ticket required for admission.
F016 Advances in Dermatologic Surgery
Room:295/296
DIRECTOR Hubert T. Greenway Jr., M.D.
SpEAkERS
DavidE.Kent,M.D. E.VictorRossJr.,M.D.
DanielleK.Moul,M.D. SeaverSoon,M.D.
DiamondisPapadopoulos,M.D. DanielEthanZelac,M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Determineappropriatelasertechnologyforbothcutaneous
conditionsandvaricoseveins.
2. Discussselectedsurgicalupdatesinreconstruction.
3. Discusscurrentknowledge/treatmentforMerkelcell
carcinoma.
DESCRIpTION
Tiscoursewillfocusonselectedareasofdermatologicsurgery
withimportantupdatesfor2011.Includedwillbelasersforboth
cutaneousmedicalandcosmeticconditions.Hairtransplatation
updateswillbepresented.Tumorfocuswillbeonupdateforboth
knowledgeandtreatmentofMerkelcellcarcinoma.Advanced
reconstructivefocuswillincludemuscleapplicationtechniques
aswellastheuseofdelayedforeheadfaps.Advancesinthe
treatmentofvaricoseveinswithendovenouslaserablationofer
excitingnewresults.
2.00 Category 1 CME Credits
SCHEDUlE
12:00p.m. Introduction/Dr. Greenway
12:05p.m. AdvancesinCutaneousLasers/Dr. Ross
12:25p.m. AdvancesinHairTransplantation/Dr. Zelac
12:35p.m. MerkelCellCarcinoma:AdvancesinTreatmentand
Surgery/Dr. Soon
12:50p.m. AdvancesInMusclePlicationAdjunctToFacial
ReconstructionDefects/Dr. Papadopoulos
1:10p.m. AdvancesinDelayedForeheadFlapsinFacial
Reconstruction/Dr. Kent
1:25p.m. AdvancesinVaricoseVeins:EndovenousLaser
AblationandUltrasoundGuidedSclerotherapy
/Dr. Moul
1:45p.m. QuestionsandAnswers/Faculty
D003 Selected Topics in Medical Dermatology
Room:240
DIRECTOR Joseph L. Jorizzo, M.D.
lEARNINg OBjECTIVES
Followingthisdiscussiongroup,theattendeewillbeableto:
1. Evaluateandeducatepatientsonmedicaldermatologydiseases
efectively.
2. Diagnoseandtreatdermatologicaspectsofrheumatologic
diseasesefectively.
3. Improveuseoftherapeuticladdersinmedicaldermatology.
DESCRIpTION
Anoverviewoftheapproachtothepatientwithcomplex
medical dermatologyproblemswillbepresented,followedbya
discussionofspecifcdiseases.Skinandjointproblems,systemic
lupuserythematosus,dermatomyositis,aphthosis,pyoderma
gangrenosum,vasculitis,andothermedicaldermatologyreferral
diagnoseswillbereviewed.
1.50 Category 1 CME Credits
D004 Dealing with Disappointing Outcomes and
Medical Mistakes
Room:241
DIRECTOR Neil Prose, M.D.
lEARNINg OBjECTIVES
Followingthisdiscussiongroup,theattendeewillbeableto:
1. Developanunderstandingofthemedicolegalaspectsof
medicalmistakes.
2. Performnewskillsforspeakingwithpatientswhoarefacing
disappointment.
DESCRIpTION
Disappointingclinicaloutcomesandmedicalmistakesare
inevitable.Anumberofstudiesshowthatpatientsarelesslikelyto
pursuelitigationifthephysicianistruthfulandconveysempathy
andconcern.Inthisexperientialworkshop,participantswill
havetheoppportunitytopracticeskillsthatwillenablethem
tocommunicatewithpatientswhenthingshavenotturnedout
ashoped.Telegalandethicalargumentsfortruthfulnessand
transparencywillbepresented.
1.50 Category 1 CME Credits
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
85
SCIENTIFIC SESSIONS SCIENTIFIC SESSIONS
U016 Sports Dermatology —
Skin Infections in Athletes
Room:285
DIRECTOR Brian Burke Adams, M.D., M.P.H.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Recognizecutaneousinfectionsrelatedtosportsparticipation.
2. Managetherapyanddisqualifcation,withanemphasison
evidence-basedmedicine,forindividualswithsports-related
infections.
3. Discusspreventionstrategiesfordecreasinginfectious
epidemicsinsportsteams.
DESCRIpTION
Infectionsareinherenttoathleticactivity,particularlysports
withskin-to-skincontact.Nodiferencesexistbetweenthe
causalorganismsinathletesandnon-athletes;however,the
clinicalpresentationmayvary.Byincorporatingknowledgeof
thesportingactivities,thedermatologistcanbestidentifythe
diagnosis,treatment,andpreventionstrategy.Epidemicsof
tineacorporis,herpes,andmethicillin-resistantStaphylococcus
aureus (MRSA)haveoccurredatthehighschool,collegiate,
andprofessionallevelthroughouttheworld.Sports-related
skininfectionscausedbyfungi,bacteria,viruses,andparasitic
infectionswillbeillustratedanddiscussed.SpecifcNCAA
guidelinesregardingskininfectionsandreturn-to-playissueswill
alsobediscussed.
1.50 Category 1 CME Credits
FOCUS SESSION
12:15p.m.to1:45p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U014 when Acne Really Isn’t Acne
Room:267/268
DIRECTOR Joshua Zeichner, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Identifyadiferentialdiagnosisforacnevulgaris.
2. Determinetreatmentsforpatientswithacne-likeconditions.
DESCRIpTION
Dermatologistscommonlytreatacnepatients,butsometimes
acneisnotreallyacne.Terearemanyskinconditionsthathave
aclinicalpresentationsimilartoacnevulgaris,butaredistinct
diseases.Itisimportanttorecognizethatalternativediagnoses
exist,especiallyifpatientsarenotrespondingtotraditionalacne
therapies.Tesepatientsmayhaveadiferentdiseasealtogether
andrespondtoalternativetreatments.
1.50 Category 1 CME Credits
U015 Merkel Cell Carcinoma
Room:265/266
DIRECTOR Linda Chung-Chin Wang, M.D., J.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. DiscusstheepidemiologyandproposedpathogenesisofMerkel
cellcarcinoma(MCC).
2. Orderappropriatesurgicalandradiologicevaluationsfor
accuratestaging.
3. Formulateamultidisciplinarytreatmentplanforthis
uncommonskincancer.
DESCRIpTION
MCCisanaggressivecutaneousneuroendocrinecarcinoma.
DespitetherisingincidenceofMCC,therarityofthedisease
hasresultedintheabsenceofprospectiverandomizedtrialson
optimalmanagement.Assurvivalappearstobedependenton
diseasestageatdiagnosis,promptaccuratediagnosis,staging
andinitiationoftreatmentarecritical.Tissessionwillofer
practicaltipsonmedicalandsurgicalevaluationofMCC.
TreatmentrecommendationsbasedonDF/BWCCexperience
willbeoutlined.Lastly,thissessionwilldescribeadvances
inmanagement,includingevaluationwithpositronemission
tomographyanduseofsurfacemoldcomputer-optimizedhigh-
dose-ratebrachytherapy.
1.50 Category 1 CME Credits
86
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
FOCUS SESSION
12:15p.m.to1:45p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U017 Clincial Trials for the private practitioner
Room:235/236
DIRECTOR Stefan C. Weiss, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Identifytheimpactseasonalityhasonclinicaltrialdesignand
outcome.
2. Summarizethecriticalaspectsofclinicaltrialdesign.
3. Diferentiatethekeyaspectsofregulatorystrategyutilizedto
bringanewtopicaldrugtomarket.
DESCRIpTION
Teroleofseasonalitywillbediscussed,specifcallyrelating
toclinicaltrialdesign,poweringofclinicalstudies,andthe
importanceofrecognizingtheefectofseasonalityonmanagement
ofcommondermatologicdiseases.Tissessionwillhighlightthe
criticalstepsrequiredtodesignandimplementasuccessfulclinical
trial.Tediferentphasesofaclinicaltrialwillbeexplainedwith
afocusonhowtheprivatepractitioner,asaclinicalinvestigator,
canplayaroleinthatprocess.Teparticipantwilllearnaboutthe
variousnuancesofthetwoprimaryregulatorypathways(505b1
and505b2)appliedbytheindustrytobringanewdermatologic
drugtomarket.
1.50 Category 1 CME Credits
U018 Outcomes Research in Dermatology
Room:263
DIRECTOR Suephy C. Chen, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Discusstheimportanceofthediferentqualityoflifemeasures
forcutaneousdiseases.
2. Reviewthevalueandimportanceofcost,cost-efectiveness,
andcost-beneftanalyses.
3. Assessthediferencebetweenefcacyandefectiveness.
DESCRIpTION
Terearethreemainoutcomemeasuresofwhichdermatologists
shouldbeaware:economic,qualityoflife,andclinical.Tis
focussessionservesasanoverviewofconceptsineachofthese
topics.Wealsowillreviewexamplesandreal-lifeapplications.For
economicoutcomes,wewillreviewtheadvantagesandlimitations
indiferentcost,cost-efectiveness,andcost-beneftanalyses.
Forquality-of-lifeoutcomes,wewillreviewgenericanddisease-
specifchealthstatemeasures,aswellasutilitymeasures.Wewill
alsodiscussthediferentclinicaloutcomemeasures,includingthe
diferencesbetweenefcacyandefectiveness.
1.50 Category 1 CME Credits
Search with Ease!
With a database of goods and services that are continually purchased by dermatologists, the AAD Buyer’s
Guide allows members to quickly find what they need without the clutter of general purpose search engines.
Start searching today at www.aaddermatologybuyersguide.com
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
87
SCIENTIFIC SESSIONS SCIENTIFIC SESSIONS
U021 Acne in the Adult Female
Room:242
DIRECTOR Kanade Shinkai, M.D., Ph.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Selectthebesttreatment(s)fortheadultfemalepatient
withacne.
2. Orderappropriatediagnosticevaluationoftheadultfemale
patientwithacneinthesettingofpossibleendocrinedisease.
3. Recognizetheclinicalmanifestationsofpolycysticovary
syndrome(PCOS)anditssystemiccomplications.
DESCRIpTION
Acnevulgarisisacommonreasonwhyadultwomenpresent
todermatologistsandisoftenchallengingtotreat.Itmayalso
raisesuspicionofunderlyingendocrinedisease.Managementof
acneinanadultfemalepatientmayrequiredistincttherapeutic
considerations,includinghormonaltherapy.Inthissession,a
practicalapproachtotheadultfemalepatientwithacnewillbe
reviewedtoenhanceattendees’abilitytotreatadultwomenwith
acnevulgarisandtocorrectlyidentifypatientswithacneinthe
settingofpolycysticovarysyndrome(PCOS).Tissessionis
relevanttoanydermatologyproviderwhoseesfemalepatients
withacne.
1.50 Category 1 CME Credits
U022 Vulvar Dermatoses
Room:270
DIRECTOR Mary Melinda Feldman, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Examinethebasichistologicpatternsofvulvarinfammation.
2. Recognizetheclinicalfeaturesofcommonvulvardermatoses.
3. Discusstreatmentoptionsforinfammatorydiseasesofthe
vulva.
DESCRIpTION
Vulvardermatosescanbeadiagnosticandtherapeuticchallenge
aswellasasourceofdiscomfortordistressforpatients.Although
vulvardiseaseisnotalwaysemphasizedduringdermatology
training,thedermatologistisuniquelyqualifedtomanagethese
conditions.Tegoalofthissessionistodiscussthehistologic
patternsofvulvarinfammationandtoreviewtheassociated
clinicalfeatures.Anunderstandingofdiseasemechanism
facilitatesaccuratediagnosisanddirectstherapeuticdecision
making.Becausetreatmentoptionsarelimitedandsometimes
frustrating,therewillbeaninteractivediscussionregarding
managementstrategies.
1.50 Category 1 CME Credits
FOCUS SESSION
12:15p.m.to1:45p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U019 Sun, Drugs, and Invervention: How to
prevent Non-Melanoma Skin Cancer
Room:283
DIRECTOR Gunther F.L. Hofbauer, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Recognizecurrentoptionsforprimary,secondary,andtertiary
preventionofnon-melanomaskincancers(NMSC).
2. Compareimpactofdiferentpreventivemodalities.
3. ChooseappropriatestepstopreventNMSCinpatientsatrisk.
DESCRIpTION
Non-melanomaskincancer(NMSC)willbediscussedintermsof
primaryprevention(reductionofsundamagetotheskinbybehavior,
clothing,sunscreen;systemicphotoprotectiveagents,e.g.,alpha-
MSHanalogue);secondaryprevention(earlyrecognition,education,
treatmentoffeldcancerizationby5-FU,imiquimod,photodynamic
therapy,topicalandsystemicretinoids);andtertiaryprevention
(antiproliferativeagents,e.g.,5-FU,retinoids).Treatmentswillbe
exploredfortheirrespectiveefcaciesandappliedinpracticalcase
examplesforthegeneralpopulationandpatientsatelevatedriskfor
NMSC.Tissessiontargetsgeneralmedicaldermatologists.
1.50 Category 1 CME Credits
U020 Challenging Diagnostic Cases for
Advanced practitioners: pA/Np II
Room:274
DIRECTOR TBD
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Recognizeand/ordiagnosiscommonlytestedimagesrelated
tomedicaldermatology,pediatricdermatology,surgical
dermatology,andclinicalpathologiccorrelates.
2.Identifystrengthsandweaknessesinone’sknowledgebasefor
thedigitalimagesectionoftheAmericanBoardofDermatology
certifcationexam,recertifcationexam,ormockboardsand
makeimprovementsasneeded.
DESCRIpTION
StudyingfortheAmericanBoardofDermatologycertifcationor
recertifcationexamcanbeoverwhelming!Tisinteractivesession
willprovidekeypointsandtipsforidentifyingandmakingdiagnoses
forthedigitalimageportionofthecertifcationorrecertifcation
exam.Attendeeswillhavetheopportunitytoviewnumerousdigital
imagesinrapid-freprogressionpreparingthemforthedigitalimage
portionoftheexam.High-yieldstudymaterialwillalsobecoveredas
theimagesarereviewed.Tissessionwillbeneftanydermatologist
preparingfortheABDcertifcation,recertifcation,ormock
boardexams.
1.50 Category 1 CME Credits
88
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
FOCUS SESSION
12:15p.m.to1:45p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U023 Highlights from JAAD
Room:269
DIRECTOR Bruce Harris Tiers, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Examinetherecentliteratureindermatology.
2. Identifynewdiagnosticapproachestoskindisease.
3. Discussefectsandsideefectsof newtherapies.
DESCRIpTION
Tespeaker,whoisEditoroftheJournal of the American Academy
of Dermatology,willpresentanoverviewofrecentkeyarticles
publishedinthatJournal.Emphasiswillbeplacedonnewdata
thatafecttheclinicalpracticeofdermatology.
1.50 Category 1 CME Credits
U024 leading Confdently through powerful
Communication
Room:293/294
DIRECTOR Marta J. VanBeek, M.D.
SpEAkER
MarsheilaDeVan,CommunicationConsultant
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Preparecompellingandpowerfulkeymessages.
2. Communicatekeymessagesclearly,concisely,andefectively.
3. Demonstratestrategiesforstayingfocusedonkeymessagesin
challengingsituations.
DESCRIpTION
TeAcademyhasidentifedefectivecommunicationasa
corecompetencyforleadershipindermatology.Learninghow
tosuccessfullycraftandconveykeymessageswillhelpyou
communicateefectivelyinanysituation.Attendeeswillhave
theopportunitytopracticewhattheyhavelearned.Tissession
isdesignedtochallengeparticipantstofocusoncreatingand
deliveringclearandconcisemessages.Tesessionwillbeprimarily
presentedbyacommunicationsconsultant.
1.50 Category 1 CME Credits
U025 A personalized planner for Rejuvenation
Room:264
DIRECTOR Sandy Sharon Tsao, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Identifytheuniqueclinicalfndingsforeachphotoaged
patient.
2. Recognizetherisksandbeneftsassociatedwithvariouslaser
andcosmeticprocedures.
3. Developatreatmentplantomeetthepatient’sspecifc
rejuvenationneeds.
DESCRIpTION
Terearenumerousexistingandemergingmodalitiesavailable
fortheimprovementofphotoaging.Withsomanyoptions,how
doyoudevelopatailoredtreatmentapproach?Wewillreview
individualfeaturesincludingdyspigmentation,wrinklesand
skinlaxity,whichcanbeappropriatelytargetedandtreatments
combinedtoachieveaglobalimprovement.Teadvantagesand
disadvantagesofprocedures,includinglasers,peels,botulinum
toxinsandfllers,willbediscussed.Troughacase-based
approach,participantswilldevelopapersonalizedplan.Atthe
endofthesession,theaudiencewillbeequippedtocustomizea
treatmentplantomeeteachpatient’sspecifcneeds.
1.50 Category 1 CME Credits
•Over30,000productsatdiscountedprices
•Customprintingofbusinesscards,stationery,
forms,andmore
•FREEnextdaydeliverywithminimumorderof$30
•Hassle-freereturns
•Effcienttrackingofallpracticelocationssupply
ordersthroughoneinvoice
•“AnoutstandingCustomerServiceExperience.”
–certifedJ.D.PowerandAssociates
Visit the Academy Resource Center
Booth 3623 to sign up and start saving!
Take the hassle out of
ordering offce supplies,
furniture, technology,
and print materials
with Staples Advantage
®
!
Staples, that was EASY!
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
89
SCIENTIFIC SESSIONS SCIENTIFIC SESSIONS
C06C Basic Self-Assessment of
Dermatopathology
Room:275/276/277
DIRECTOR Clay J. Cockerell, M.D.
SpEAkERS AntoanellaBardan,M.D.
lEARNINg OBjECTIVES
Followingthiscourse,theattendeewillbeableto:
1. Interpretandidentifydermatologichistologicaldiagnosesmore
efectivelyandaccurately.
2. Classifyandrecognizecommonhistopathologicskinconditions
andformulatediferentialdiagnoses.
DESCRIpTION
Attendeeswillview60slidesfromskinbiopsyspecimensinaformat
thatwillallowself-assessment.Caseswillspanthefullspectrumof
dermatopathology.Eachspecimenwillbediscussedbyafaculty
memberwithemphasisplacedonestablishingthecorrectdiagnosis
andconsiderationofthediferentialdiagnosis.Tesesessionsare
directedtodermatologyresidentsandpracticingdermatologists.To
allowforalargerparticipationthisyear,thiscoursewillbeofered
withduplicatecontentat7:00a.m.,9:30a.m.,12:30p.m.,and
3:00p.m.Attendeesneedonlyselectoneofthesesessions.Tis
sessionincludesthediscussionC06E–seepage122.
2.00 Category 1 CME Credits
FOCUS SESSION
12:15p.m.to1:45p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U026 Teledermatology 101: Integrating
Teledermatology into Your practice
Room:284
DIRECTOR April W. Armstrong, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Identifysustainablepracticesofteledermatology,including
store-and-forwardandlive-interactiveteledermatologypractice
models.
2. Recognizeoperationalneedsofincorporatingteledermatology
intocurrentpractice,includingstafng,imaging,and
communicatingwithpatientsandreferringproviders.
DESCRIpTION
Teledermatologycanbeincorporatedintoacademicandprivate
practicesettingstoimprovepatientaccesstodermatologists.
Agrowingnumberofdermatologistsareprovidingspecialty
carethroughtelemedicine.Tissessionwillenhanceyour
understandingofsustainablemodelsofteledermatology
practice,anditwillhelpyoudevelopstrategiesofincorporating
teledermatologyintoyourpractice.Tepractical
detailsofwhatisnecessarytosetupateledermatologyoperation
willbediscussed.
1.50 Category 1 CME Credits
COURSE
12:30p.m.to2:30p.m.
Tuition fee and ticket required for admission.
90
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
COURSE
2:00p.m.to5:00p.m.
Tuition fee and ticket required for admission.
C009 Dermatologic Syndromes and genetic
Disorders
Room:383/384/385
DIRECTOR Susan Joy Bayliss, M.D.
SpEAkER DavidBerk,M.D.
lEARNINg OBjECTIVES
Followingthiscourse,theattendeewillbeableto:
1. Identifyanddiagnosecommondermatologicsyndromes.
2. Recognizethemajorcriteriaforotherraresyndromes.
DESCRIpTION
Physicianswhowanttobecomefamiliarwithcommonandnot-
so-commondermatologicsyndromeswillgetanupdateoncriteria
andgeneticcauses.Aquestion-answerformatwillbeusedtohelp
uslearn!
3.00 Category 1 CME Credits
REFERENCES
1. SBMallory.An Illustrated Dictionary of Dermatologic
Syndromes.TaylorandFrancis;2006.
2. SBMallory,ABree,PChern.Illustrated Manual of Pediatric
Dermatology.TaylorandFrancis;2005.
C010 Advanced Contact Dermatitis
Room:238/239
DIRECTOR Vincent Anthony DeLeo, M.D.
SpEAkERS
AnthonyA.Gaspari,M.D. FrancesJ.Storrs,M.D.
MelanieD.Pratt,M.D. JamesSelwynTaylor,M.D.
DenisSasseville,M.D. KathrynA.Zug,M.D.
lEARNINg OBjECTIVES
Followingthiscourse,theattendeewillbeableto:
1. Distinguishclinicalrelevanceoffragrance-positivepatchtests.
2. Determinetheinfuenceofprostheticmetalsondermatitis.
3. Identifynewcosmeticallergens.
DESCRIpTION
Tissessionwillbecomposedofspeakerswhopracticetertiary
referralpatchtesting.Tespeakerswilltouchonsubjectsthatdeal
withtheunusualbutimportantcasesofallergiccontactdermatitis.
Topicstobecoveredincludeanupdateonthebasicscienceaspects
ofallergytotopicalchemicalsintheskin;thetrueincidenceof
clinicallyrelevantfragranceallergy;occupationalcontactdermatitis;
newcosmeticallergens;allergytoorthopedicappliances;allergens
infabricsandfurniture;andcontactallergyinpersonsofcolor.
3.00 Category 1 CME Credits
SCHEDUlE
2:00p.m. Introduction/Dr. DeLeo
2:10p.m. BasicScienceAspects:NewStuf/Dr. Gaspari
2:30p.m. QuestionsandAnswers/Faculty
2:35p.m. Preservatives:CommonAndNotSo/Dr. Zug
2:55p.m. QuestionsandAnswers/Faculty
3:00p.m. Implants/Dr. Taylor
3:20p.m. QuestionsandAnswers/Faculty
3:25p.m. OccupationalDermatitis-Update/Dr. Sasseville
3:45p.m. QuestionsandAnswers/Faculty
3:50p.m. ClothesAndFurniture?!/Dr. Pratt
4:10p.m. QuestionsandAnswers/Faculty
4:15p.m. FragranceAllergy:BahHumbug!/Dr. Storrs
4:35p.m. QuestionsandAnswers/Faculty
4:40p.m. ContactDermatitisInSkinOfColor/ Dr. DeLeo
4:55p.m. QuestionsandAnswers/Faculty
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
91
SCIENTIFIC SESSIONS SCIENTIFIC SESSIONS
S008 Consultative Dermatology for the
Hospitalized patient
Room:278/279/280
DIRECTOR Daniela Kroshinsky, M.D.
lEARNINg OBjECTIVES
Followingthissymposium,theattendeewillbeableto:
1. Identifycommonandcomplexcutaneousconditionsimpacting
thehospitalizedpatient.
2. Recognizeemergingcutaneousdiseases.
3. Manageskindiseaseintheinpatientsetting.
DESCRIpTION
Tedermatologistisanimportantmemberoftheteamcaringfor
hospitalizedpatients.Commonproblemsandtheiruncommon
manifestationswillbediscussed.Interestingandrareexamplesof
seriousskinconditionswillbepresented.Valuablediagnosticand
therapeuticinterventionswillbereviewed.Tissessionisgeared
towarddermatologistscaringforinpatientsaswellasphysicians
treatingcomplexpatientspresentingtotheofce.
3.00 Category 1 CME Credits
COURSE
2:00p.m.to5:00p.m.
Tuition fee and ticket required for admission.
C011 The State of the Art of Aesthetic
Dermatology: live patient Demonstration
Room:AuditoriumB
DIRECTOR Tomas E. Rohrer, M.D.
SpEAkERS
KimberlyJ.Butterwick,M.D. MaryP.Lupo,M.D.
AlastairCarruthers,M.D. SethL.Matarasso,M.D.
WilliamP.ColemanIII,M.D. GaryD.Monheit,M.D.
PatriciaFarris,M.D. NowellJ.Solish,M.D.
RebeccaL.Fitzgerald,M.D. SusanH.Weinkle,M.D.
lEARNINg OBjECTIVES
Followingthiscourse,theattendeewillbeableto:
1. Assesstheagingfaceandchoosethemostappropriateinjection
techniques.
2. Identifysofttissuefllersappropriateforavarietyofconditions.
3. Recognizetheimportanceoffacialmusculatureandhowto
optimizetreatmentwithbotulinumtoxins.
DESCRIpTION
Tisliveinteractivesessionwillfeatureexpertsfromaround
thecountrydemonstratingtheirsofttissuefllerandbotulinum
toxintreatmenttechniquesandtips.Attendeeswillobserveina
liveinteractivemannerhowthevariousfacultymembersassess,
interactwith,andtreatavarietyofpatients.Eachareaoftheface
willbeaddressedbytwofacultymembersandaudienceinteraction
isencouraged.Terewillbediscussionanddemonstrationof
optimaltechniquesusingbotulinumtoxinandawidevarietyof
softtissuefllers.
3.00 Category 1 CME Credits
REFERENCES
1. Kaminer,M,DoverJ,ArndtK,edsAtlas of Cosmetic Surgery.
Philadelphia:Elsevier;2008.
2. CarruthersA,CarruthersJ.Botulinum Toxin in Procedures in
Cosmetic Dermatology Series.Philadelphia:Elsevier;2008.
3. CarruthersA,CarruthersJ.Soft TIssue Augmentation In
Cosmetic Dermatology Series. Philadelphia:Elsevier;2005.
SCHEDUlE
2:00p.m. Introduction/Tom Rohrer
2:05p.m. UpperFaceRejuvenation:ForeheadandGlabella
/Dr. Ferris / Dr. Lupo
2:30p.m. Eyes/TearTrough/Dr. Fitzgerald / Dr. Carruthers
2:55p.m. QuestionsandAnswers/Faculty
3:00p.m.FillingtheTemple/Dr. Weinkle / Dr. Lupo
3:20p.m. VolumizingtheMidFace/Dr. Fitzgerald / Dr. Solish
3:50p.m. QuestionsandAnswers/Faculty
3:55p.m. LipEnhancement/Dr. Weinkle / Dr. Matarasso
4:15p.m. LowerFaceRejuvenation/ Dr. Lupo / Dr. Monheit
4:40p.m. NeckandHandRejuvenation
/Dr. Coleman / Dr. Butterwick
4:55p.m. QuestionsandAnswers/Faculty
SYMpOSIUM
2:00p.m.to5:00p.m.
Open admission, no tuition or ticket.
92
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
SYMpOSIUM
2:00p.m.to5:00p.m.
Open admission, no tuition or ticket.
S009 Advanced Medical Dermatology
Room:243/244/245
DIRECTOR Francisco Kerdel, M.D.
SpEAkERS
CraigL.Leonardi,M.D. BruceElliotStrober,M.D.,Ph.D.
CarlosRicottiJr.,M.D. AntonellaTosti,M.D.
PaoloRomanelli,M.D. MartinN.Zaiac,M.D.
lEARNINg OBjECTIVES
Followingthissymposium,theattendeewillbeableto:
1. Discusstheroleofbiologicsinpsoriasisandpsoriaticnail
disease.
2. Identifytheessentialsoftreatmentintoxicepidermal
necrolysis.
3. Detectantibodiesagainstbiologicagentsandtheirclinical
signifcance.
DESCRIpTION
Tesessionwillcoverseveralpertinantissuesinmedical
dermatology.Telectureswillincludethefutureofbiologicsin
psoriasisaswellastheuseofbiologicsinpsoriaticnaildisease.
Terewillalsobealectureonnewdiseaseswithimportant
dermatologicalimplications.Terewillalsobealectureonthe
medicalmanagementoftoxicepidermalnecrolysis.Alecturewill
bededicatedtochangesinhairandsystemicdisease.Tefnal
topicwillbethatofantibodiesagainstbiologics:theirprevalence
andclinicalsignifcance.
3.00 Category 1 CME Credits
REFERENCES
1. LecluseLLAetal.Extentandclinicalconsequencesofantibody
formationagainstadalimumabinpatientwithplaquepsoriasis.
Arch.Dermatol2010;146:26.
2. deBerkerD.ManagementofPsoriaticNailDisease.SemCut
MedSurg2009;28:39.
3. PrinsCetal.Treatmentoftoxicepidermalnecrolysiswith
highdoseintravenousimmunoglobulins.Arch.Dermatol
2003;139:26.
SCHEDUlE
2:00p.m. Introduction / Dr. Kerdel
2:05p.m. RoleofBiologicsinPsoriaticNailDisease / Dr. Zaiac
2:30p.m. What’sontheHorizonfortheTreatmentofPsoriasis
WithBiologics / Dr. Leonardi
3:00p.m. UpdateonNewDiseaseswithImportant
DermatologicalImplications / Dr. Romanelli
3:30p.m. UpdateontheMedicalManagementofToxic
EpidermalNecrolysis / Dr. Ricotti
4:00p.m. HairasaSignofSystemicDisease / Dr. Tosti
4:30p.m. Anti-BiologicAntibodies:TeirPrevalenceand
Signifcance / Dr. Strober
S010 Surviving Healthcare Reform
Room:LaNouvelleNewOrleansBallroom
DIRECTOR Jack S. Resneck Jr., M.D.
lEARNINg OBjECTIVES
Followingthissymposium,theattendeewillbeableto:
1. Summarizehealthsystemreformimpactsondermatologists
andourpatients.
2. Prepareforandassessupcomingrequirementsofhealthsystem
reformlawandpilotpaymentreforms.
DESCRIpTION
Howwillhealthsystemreformafectyouandyourpractice,
andhowcanyouprepareforimpendingchanges?Tesession
willcovercurrentelementsofthehealthsystemreformlaw
andthoseslatedforfutureimplementation,focusingonthose
provisionsmostrelevanttodermatology.Likelytopicsinclude
paymentreforms,insurancemarketreforms,qualitymeasures,
andpublicreporting.Speakerswillalsoprovideinformation
aboutthediferentmodelsofcaredeliveryandpaymentthatare
beingtestedandevaluated(e.g.,accountablecareorganizations,
patient-centeredmedicalhomes,bundledpayments,etc.)andthe
potentialimplicationsfordermatologiccare.
3.00 Category 1 CME Credits
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
93
SCIENTIFIC SESSIONS SCIENTIFIC SESSIONS
S012 Aging gracefully
Room:AuditoriumC
DIRECTOR Zoe Diana Draelos, M.D.
SpEAkERS
PatriciaFarris,M.D. DavidH.McDaniel,M.D.
HenryW.Lim,M.D. DanaLynnSachs,M.D.
lEARNINg OBjECTIVES
Followingthissymposium,theattendeewillbeableto:
1. Summarizeareasofinterventionintheskinagingprocess.
2. Describethevarioustechnologiestoforestallortreat
manifestationsofskinaging.
3. Discusswithpatientstheprosandconsofageprevention
strategies.
DESCRIpTION
Understandingtheagingprocessandappropriateintervention
methodsiskeytoaginggracefully.Tissessionwillexamineaging
conceptsandthefutureofantiagingtechnologywhilediscussing
bothtopicalandoralcosmeceuticals.Itwillexaminetheability
ofnewsunscreenstopreventagingandaddressskincareissues
inallskintypes.Asurveyofthenewconsumer-purchased,
antiagingdevicemarketwillalsobepresented.Attendanceatthis
symposiumisimportantforthosewhowishtokeepcurrenton
antiagingtechnologyanddesireathought-provokingwindowinto
thefutureofcosmeticdermatology.
3.00 Category 1 CME Credits
REFERENCES
1. DraelosZD.Cosmeceuticals.Philadelphia:Elsevier;2008.
2. DraelosZD.Cosmetic Dermatology: Products and Procedures.
Hoboken,NJ:Wiley-Blackwell;2010.
SCHEDUlE
2:00p.m. Introduction:TeoriesofAgingwithGrace
/ Dr. Draelos
2:20p.m. QuestionsandAnswers / Dr. Draelos
2:30p.m. PreventativeAgingGracefullywithNovelSunscreen
Technology / Dr. Lim
2:50p.m. QuestionsandAnswers / Dr. Lim
3:00p.m. Te“InsideOut”NutraceuticalApproachtoAging
Gracefully / Dr. McDaniel
3:20p.m. QuestionsandAnswers / Dr. McDaniel
3:30p.m. StructuralandCellularMediatorsinAgingGracefully
/ Dr. Sachs
3:50p.m. QuestionsandAnswers / Dr. Sachs
4:00p.m. TopicalCosmeceuticalsforAgingGracefully
/ Dr. Farris
4:20p.m. QuestionsandAnswers / Dr. Farris
4:30p.m. Summary:FutureConceptsofAgingGracefully
/ Dr. Draelos
4:50p.m. QuestionsandAnswers / Dr. Draelos
SYMpOSIUM
2:00p.m.to5:00p.m.
Open admission, no tuition or ticket.
S011 Therapeutics
Room:AuditoriumA
DIRECTOR Mark Lebwohl, M.D.
SpEAkERS
JefreyPhillipCallen,M.D. DarrellS.Rigel,M.D.
BariB.Cunningham,M.D. TeodoreRosen,M.D.
BoniE.Elewski,M.D. LindaF.Stein,M.D.
SuzanneOlbricht,M.D. BruceHarrisTiers,M.D.
lEARNINg OBjECTIVES
Followingthissymposium,theattendeewillbeableto:
1. Identifythemostup-to-datetherapiesintopical,systemic,
surgical,andpediatricdermatology.
2. Prescribethetherapiesavailablefortheirpatients.
DESCRIpTION
Tissessionwillemphasizenewdevelopmentsindermatologic
therapy.Advancesintopicaltreatments,systemictreatments,
surgicaltherapiesandprocedures,andpediatrictreatmentswillbe
presented.
3.00 Category 1 CME Credits
REFERENCES
1. LebwohlM,HeymannWR,Berth-JonesJ,Coulson,I,eds.
Treatment of Skin Disease.3rded.,London:MosbyElsevier;
2010.
SCHEDUlE
2:00p.m. What’sNewintheTreatmentofConnectiveTissue
Diseases? / Dr. Callen
2:16p.m. TerapyofNailDisorders / Dr. Elewski
2:32p.m. SurgicalTerapeutics:What’sNew? / Dr. Olbricht
2:48p.m. QuestionsandAnswers / Faculty
3:03p.m. What’sNewinTopicalDermatologicTerapy?
/ Dr. Stein
3:19p.m. AlternativeTerapies / Dr. Tiers
3:35p.m. What’sNewintheTreatmentofInfectiousDiseases?
/ Dr. Rosen
3:51p.m. QuestionsandAnswers / Faculty
4:01p.m. MalignantMelanomaandPhotoprotection:
NewDevelopments / Dr. Rigel
4:17p.m. AdvancesinPediatricTerapies / Dr. Cunningham
4:33p.m. What’sNewinMedicalDermatology? / Dr. Lebwohl
4:49p.m. QuestionsandAnswers / Faculty
94
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
SYMpOSIUM
2:00p.m.to5:00p.m.
Open admission, no tuition or ticket.
DISCUSSION gROUp
2:30p.m.to4:00p.m.
Tuition fee and ticket required for admission.
S013 leading Others for peak performance
Room:293/294
DIRECTOR Bryan Erik Anderson, M.D.
SpEAkERS
SandraEllison, VictorJ.Marks,M.D.
CenterforCreativeLeadership JefreyJ.Miller,M.D.
JoslynS.Kirby,M.D. OliverFredMillerIII,M.D.
lEARNINg OBjECTIVES
Followingthissymposium,theattendeewillbeableto:
1. Describetheimperativeandimplementtheskillofinspiring
commitment.
2. Recognizetheimportanceofselectingwell,accepting
idiosyncrasies,anddevelopingemployeepotential.
3. Demonstrateefectivemethodstoprovidefeedbackto
constructivelyoferothersopportunitiesforimprovement
andgrowth.
DESCRIpTION
Tissessionisdesignedforthosewishingtoenhancetheir
leadershipcompetencyinleadingotherstopeakperformance.
Inspiringcommitment;selecting,developingandaccepting
people;copingwithchange;efectivecommunicationandleading
employeesaresomeofthetopicstobediscussed.Expertswill
presentmethodsformotivating;“sizingup”andhiringtalent;
providingefectivefeedback;settinggoals;bringingoutthe
best;delegatingefectively;oferingchallengingopportunities
andprovidingopportunitiesforgrowth;broadeningemployee
opportunities;actingfairly;andachievingexcellence.
Developmentoffaculty,residentsandemployeeswillbe
addressed.
3.00 Category 1 CME Credits
SCHEDUlE
2:00p.m. YouWinwithPeople / Dr. Anderson
2:30p.m. MotivatingPeople / Dr. Miller
3:00p.m. DevelopingStaf / Dr. Miller
3:30p.m. EfectiveCommunication / Dr. Marks
4:00p.m. EfectiveFeedback / Ms. Ellison
4:30p.m. SettingGoals / Dr. Kirby
D005 Dermatoethics: Contemporary Issues in
Ethics and professionalism
Room:240
DIRECTOR Lionel Gordon Bercovitch, M.D.
lEARNINg OBjECTIVES
Followingthisdiscussiongroup,theattendeewillbeableto:
1. Applyprinciplesofbioethicsandprofessionalismtoissuesin
clinicalpractice.
2. Comparetheethicaldiferencesinthepracticeofaprofession
andabusiness.
3. Analyzereal-lifeissuesrelatingtoconfictsofinterestandthe
physician’sfduciaryresponsibility.
DESCRIpTION
Dermatologistsandresidentsfaceethicalandprofessionalissues
throughouttheirworkdayyetreceivelittleformaltrainingin
thesedisciplines.Tissessioninethicsandprofessionalism
willpresentthreetimelycase-basedtopicsofimportanceto
dermatologists.Specifcareasthatmightbecoveredinclude
cosmeticdermatology,pediatricdermatology,dermatologist-
industryrelationships,regulatoryissues,professionalism,and
physicianhealth.Eachtopicwillincludereal-lifecasescenarios
andabriefdidacticpresentationontherelevantbioethicaltopics,
followedbylivelyinteractivediscussionwiththeaudience.
Participantsareencouragedtobringtheirowncasesforan“Ask
theDermatoethicist”interactivesession.
1.50 Category 1 CME Credits
D006 Serologic Testing for Connective Tissue
Diseases
Room:241
DIRECTOR Diya F. Mutasim, M.D.
lEARNINg OBjECTIVES
Followingthisdiscussiongroup,theattendeewillbeableto:
1. Orderappropriatetestsforevaluatingpatientswith
connectivetissuediseases.
2. Identifythelimitationsofthesetests.
3. Interprettestresultsinconjunctionwithclinicaldata.
DESCRIpTION
Tesessionwillfocusontheindicationsandinterpretationof
teststhathelpinthediagnosisofconnectivetissuediseases.
TesewillincludeANA,antibodiestoU1RNP,SM,SSA,SSB,
nDNA,andantiphospholipidantibodies.Tissessionisdirected
topracticingdermatologistsandresidents.
1.50 Category 1 CME Credits
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
95
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
SCIENTIFIC SESSIONS
U028 Oral Ulcers
Room:274
DIRECTOR Lynne H. Morrison, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Identifydiferentcausesofacute,recurrent,andchronicoral
ulcers.
2. Diferentiateclinicalfeaturesofdiseasespresentingwithoral
ulcers.
3. Evaluateandprescribeappropriatetherapyinpatientswithoral
ulcers.
DESCRIpTION
Tissessionwillpresentanoverviewofthediagnosis,
evaluation,andmanagmentofpatientspresentingwithoral
ulcers.Causesofacute,recurrent,andchronicoralulcerswill
bereviewed,whichshouldhelpdevelopapracticalapproachto
thesepatients.Conditionsthatwillbecoveredincluderecurrent
aphthousstomatitis,autoimmunebullousdiseasessuchas
pemphigusvulgaris,paraneoplasticpemphigus,mucousmembrane
pemphigoid,andulcerativelichenplanus.Tesessionisdirected
atdermatologistsinpracticeaswellasresidents.Attendeesare
encouragedtobringquestionsandcasesfordiscussion.
1.50 Category 1 CME Credits
FOCUS SESSION
2:30p.m.to4:00p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U027 practical Approaches to Medical and
Cosmetic Dermatology in Skin of Color
Room:283
DIRECTOR Andrew F. Alexis, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Identifyracial/ethnicvariationsintheepidemiology,clinical
presentation,andqualityoflifeimpactofdermatologic
disorders.
2. Recognizeleadingmedicalandaestheticdermatologicconcerns
innon-Caucasianpopulations.
3. Utilizesafeandefectivetreatmentapproachesforcommon
dermatologicconcernsinethnicskin.
DESCRIpTION
Ethnicskinorskinofcolorreferstothebroadrangeofskintypes
andcomplexionsthatcharacterizeindividualsofAfrican,Asian,
Latino,andNativeAmericandescent.Diferencesinstructure,
function,andculturalpracticesinindividualswithethnicskin
contributetovariationsintheprevalenceandclinicalpresentation
ofnumerousskinconditions.Tissessionwillserveasapractical
overviewofleadingmedicalandaestheticdermatologicconcerns
innon-Caucasianpopulations.Emphasiswillbeonsafeand
efectivetreatmentapproachesfordyschromias,follicular
disorders,alopecias,andskinagingconcernsinpatientsofcolor.
1.50 Category 1 CME Credits
96
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
FOCUS SESSION
2:30p.m.to4:00p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U029 Skin Cancer in patients with Non-
Melanoma Hodgkin’s lymphoma
Room:267/268
DIRECTOR Jerry D. Brewer, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Discusstherelativeriskofskincancerinpatientswithchronic
lymphocyticleukemiaandnon-Hodgkin’slymphoma.
2. Recognizethetypesofskincancerassociatedwithanincreased
riskofrecurrence,metastasis,anddeathinthesepatients.
3. Formulateanefectivetreatmentplanforskincancerin
patientswithnon-Hodgkin’slymphomathataddressesthe
higherrisksofrecurrence,metastasis,anddeath.
DESCRIpTION
Non-Hodgkin’slymphomaisthemostcommonhematologic
malignancyinmankind.Skincanceristhemostcommon
epithelialmalignancyintheworld.Tecombinationofinherent
immunologicdisease-relatedimmunosuppressionandiatrogenic
treatment-associatedimmunosuppressioninpatientswithchronic
lymphocyticleukemia(CLL)predisposesthemtoanincreased
incidenceofnon-melanomaandmelanomaskincanceraswell
asahigherincidenceofadverseoutcomes.Tepathogenic
mechanismsofincreasedskincancerinpatientswithCLLwill
bereviewed,aswellastheepidemiologicevidencesupporting
anincreasedincidence.Adverseoutcomesassociatedwithskin
cancerinpatientswithCLL,includinghighratesofrecurrence,
metastasis,andmortalitywillbereviewed.Tecomplexitiesof
histopathologicinterpretationofsurgicalmarginswillbediscussed
aswellasoptimalmanagementandpreventionstrategies.
1.50 Category 1 CME Credits
U030 Treatment of pediatric psoriasis
Room:269
DIRECTOR Kelly M. Cordoro, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Describetheepidemiology,triggeringfactors,potential
comorbidities,anduniqueclinicalpresentationsofpediatric
psoriasis.
2. Chooseappropriatelyamongtheavailablesystemic,biologic,
andlight-basedtreatmentsformoderatetoseverepediatric
psoriasis.
3. Formulateatherapeuticplanfordiferentclinicalpresentations
ofmoderatetoseverepediatricpsoriasis.
DESCRIpTION
Temanagementofpediatricpsoriasispresentsauniqueset
ofchallengesandrequiresanupdatedunderstandingofthe
epidemiology,triggeringfactors,potentialcomorbidities,unique
clinicalpresentations,andcommonlyusedtherapiesinthisage
group.Tissessionisdesignedtoarmtheclinicianwiththebasic
principlesandadvancedpracticesnecessarytotreatmoderateto
severepsoriasisinchildren.Systemic,biologic,andlight-based
treatmentoptionsaloneandinnovelcombinationsarediscussed
andtheappropriateclinicalsettingfortheiruseispresentedin
acase-basedformat.Tesessionisdirectedtowardspracticing
cliniciansandresidents.
1.50 Category 1 CME Credits
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
97
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
SCIENTIFIC SESSIONS
U032 Chronic Infammatory Hand and Foot
Dermatoses
Room:264
DIRECTOR Robert Bissonnette, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Identifyanddiagnosecommoninfammatoryhandandfoot
infammatorydermatosesincludingpsoriasis,atopicdermatitis,
contactdermatitisandpalmo-plantarpustulosis.
2. Reviewanddiscussevidence-basedefcacyoftopicaltherapy,
phototherapy,oralsystemic,andbiologictherapyforhandand
footinfammatorydermatoses.
3. Selectthebesttreatmentoptionforpatientswithinfammatory
handandfootdermatoses.
DESCRIpTION
Commoninfammatorydermatoses,suchaspsoriasis,atopic
dermatitisandcontactdermatitis,ofteninvolvehandsand
feet.Unfortunatelythemorphologyofsomeofthesediseases
issometimesdiferentonpalmsandsoles,makingthediagnosis
morechallenging.Treatmentoftheseinfammatorydiseases
isalsomoredifcultwhenpalmsorsolesareinvolvedasthe
thicknessoftheepidermiscanlimittheefcacyoftopicaltherapy
andphototherapy.Tissessionwillreviewthediferentclinical
presentationsofcommonhandandfeetdermatosesandfocuson
theirmanagement.Recentdataontheefcacyofphototherapy,
oralagents,andbiologicalagentswillbediscussed.
1.50 Category 1 CME Credits
FOCUS SESSION
2:30p.m.to4:00p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U031 Dermatomyositis
Room:284
DIRECTOR Jason C. Sluzevich, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Recognizemorphologicfeaturesofclassicandatypical
presentations.
2. Orderappropriatesymptom-directedandage-basedlaboratory
studies.
3. Prepareanefectivetreatmentplancognizantofcommon
outcomes.
DESCRIpTION
Tissessionwillprovideapracticalapproachtothediagnosis
andmanagementofpatientswithdermatomyositis.Acase-based
formatwillbeusedtoillustratekeydiagnosticpointswithan
emphasisonuniqueclinicalpresentations.Teroleandlimitations
ofhistology,immunofuorescence,laboratorytesting,andimaging
studieswillbeoutlined.Aconceptualframeworkfortreatment
willbepresented,alongwithaselectreviewoftheevidence
supportingvarioustreatmentmodalities.
1.50 Category 1 CME Credits
98
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
FOCUS SESSION
2:30p.m.to4:00p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U033 Electrolysis: when laser Isn’t the Answer
Room:285
DIRECTOR Lesly Salgado Davidson, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Identifypatientswhowouldbeneftfromelectrolysis.
2. Distinguishcandidatesforelectrolysisfromcandidatesforlaser.
3. Comparevariousmethodsofhairremoval.
DESCRIpTION
Tissessionisintendedfordermatologistsandphysician
extenders.Tefocuswillbeonelectrolysis:itshistory,its
evolution,anditscurrentindications.Wewilldeterminethe
profleofpatientsmorelikelytobeneftfromelectrolysisthan
laser.Circumstanceswherelasertherapyisunlikelytoachieve
efectivehairremovalwillbeidentifed.Wewillassesssomeother
non-permanentmethodsofhairremoval.Criteriaforchoosinga
qualifedelectrologistwillbedescribed.
1.50 Category 1 CME Credits
U034 pediatric Hyperhidrosis and Ectodermal
Dysplasia: To Sweat or Not to Sweat?
Room:235/236
DIRECTOR Jane S. Bellet, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Assessapediatricpatientwithhyperhidrosisandselect
appropriatetreatment.
2. Distinguishbetweenthediferentformsofectodermaldysplasia
andidentifycluesthatcanhelpwiththediagnosis.
DESCRIpTION
Tediagnosisofprimaryfocalhyperhidrosisinchildrenand
adolescentswillbereviewed,aswellasanin-depthdiscussionof
treatmentoptionsforaxillary,palmar,andplantarhyperhidrosis.
Teoppositesideofthecoinwillbeaddressedwithareviewof
themainformsofectodermaldysplasia,howtomakeadiagnosis
andwhattreatments,ifany,maybeefcacious.Sweat,whether
toomuchortoolittle,canbealargeproblemandthiswillbe
discussed.
1.50 Category 1 CME Credits
U035 paraneoplastic Dermatoses
Room:270
DIRECTOR Seemal Desai, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Identifyanddistinguishearlyformsandvariousclinical
presentationsofparaneoplasticdermatoses.
2. Utilizerecentdatafromtheliteraturetoenablecliniciansto
diferentiateprimaryunderlyingmalignanciesandtheirmost
commontypeofskinpresentation.
3. Developtreatmentandworkupplansforpatientspresenting
withskinconditionssuspiciousforunderlyingmalignancy.
DESCRIpTION
Paraneoplasticdermatosesincludevariouspapulosquamous,
bullous,rheumatologic,pruritic,andhairandnaildisorders
whichmanifestsecondarytounderlyingmalignancy.Numerous
clinicalandpathologicimagesencompassingvariousdiagnoses
includingparaneoplasticpemphigus,acrokeratosisparaneoplastica,
paraneoplasticdermatomyositis,acquiredichthyosis,scleromyxedema,
Sweet’ssyndrome,pyodermagangrenosum,hypertrichosislanuginosa
acquisita,andreactiveerythemaswillbeshownanddiscussed.Te
useofpatientcasesandaudienceparticipationwillfacilitatesession
attendees’abilitytobetterformulateworkupandtreatmentplans,as
wellasdevelopskillsonhowtobettercommunicatewithotherhealth
careproviders.Tiscourseisdesignedforbothcliniciansinpractice
andthoseintraining.
1.50 Category 1 CME Credits
U036 Subcutaneous Fat in Dermatology
Room:242
DIRECTOR Mathew M. Avram, M.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Describethephysiologyofsubcutaneousfatanditsefecton
systemichealth.
2. Describetheemergingtechnologiesinnoninvasive
fatremoval.
3. Criticallyassessemergingtechnologiesinnoninvasive
fatremoval.
DESCRIpTION
Tissessionwillprovideanoverviewofsubcutaneousfatin
dermatologywithregardtoanatomy,physiology,andnoninvasive
fatremoval.Itwillbeginbyexaminingsubcutaneousfatintermsof
itsanatomy,physiology,androleinsystemichealth.Itwillgoonto
criticallyassesstheemergingfeldofnoninvasivefatremoval.
1.50 Category 1 CME Credits
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
99
SCIENTIFIC SESSIONS SCIENTIFIC SESSIONS
C06D Basic Self-Assessment of
Dermatopathology
Room:275/276/277
DIRECTOR Clay J. Cockerell, M.D.
SpEAkERS AntoanellaBardan,M.D.
lEARNINg OBjECTIVES
Followingthiscourse,theattendeewillbeableto:
1. Interpretandidentifydermatologichistologicaldiagnosesmore
efectivelyandaccurately.
2. Classifyandrecognizecommonhistopathologicskinconditions
andformulatediferentialdiagnoses.
DESCRIpTION
Attendeeswillview60slidesfromskinbiopsyspecimensinaformat
thatwillallowself-assessment.Caseswillspanthefullspectrumof
dermatopathology.Eachspecimenwillbediscussedbyafaculty
memberwithemphasisplacedonestablishingthecorrectdiagnosis
andconsiderationofthediferentialdiagnosis.Tesesessionsare
directedtodermatologyresidentsandpracticingdermatologists.
Toallowforalargerparticipationthisyear,thiscoursewillbe
oferedwithduplicatecontentat7:00a.m.,9:30a.m.,12:30p.m.,
and3:00p.m.Attendeesneedonlyselectoneofthesesessions.
TissessionincludesthediscussionC06E–seepage122.
2.00 Category 1 CME Credits
FOCUS SESSION
2:30p.m.to4:00p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U037 paraneoplastic Autoimmune Multiorgan
Syndrome (pAMS)
Room:263
DIRECTOR Sergei A. Grando, M.D., Ph.D.
lEARNINg OBjECTIVES
Followingthisfocussession,theattendeewillbeableto:
1. Identifyclinicalvariantsoftheparaneoplasticautoimmune
multiorgansyndrome(PAMS).
2. RecognizethepathophysiologyofPAMS.
3. ManagepatientswithPAMS.
DESCRIpTION
Teparaneoplasticdiseaseofepithelialadhesionknown
asparaneoplasticpemphigusrepresentsaclinicaland
immunopathologicalvariantofanovelheterogeneous
autoimmunesyndrome,termedparaneoplasticautoimmune
multiorgansyndrome(PAMS),inwhichpatients,inadditionto
typicalskinlesions,developsmallairwayocclusionanddeposition
ofautoantibodiesindiferentorgans.Insomeinstancesanti-
desmogleinantibodiesareidentifed,butthesedonotcorrelate
wellwiththeclinicalphenotype.Tepathophysiologyof
PAMSinvolvescellularautoimmunityresponses.Tepeculiar
immunopathologyofPAMSanditspoorprognosisrequirea
thoroughworkuptoallowdiferentiationfromcommonformsof
autoimmunepemphigus.
1.50 Category 1 CME Credits
COURSE
3:00p.m.to5:00p.m.
Tuition fee and ticket required for admission.
100
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
FORUM
3:00p.m.to5:00p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F017 Resident jeopardy
Room:386/387
DIRECTOR Amit Garg, M.D.
SpEAkERS
EmmyM.Graber,M.D.
PranauB.Sheth,M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Assesscorecompetenciesacrossnumerousdomainsin
dermatology.
2. Identifyanygapsinmedicalknowledge.
3. Measureselfagainstcolleaguesatsimilarcareerlevelsfrom
variousinstitutionsacrossthecountryandinternationally.
DESCRIpTION
Joinyourcolleaguesforself-assessmentthroughafamiliar
engaginggameshowformat.Queriesandimage-basedinquiries
encompassingthebreadthofdermatologyareposedtocontestants
inafriendlycompetitionarrangement.Audiencemembersare
invitedtoplayalong.
WillEmoryrepeataschampions,orwillthe2011AADResident
Jeopardytrophybeawardedtoanotherdeservinginstitution?
Registeredparticipantswhowishtorepresenttheirtraining
programascontestantsinteamsoftworesidentsshouldsendan
emailindicatingtheirinteresttoagarg@bu.edu.
2.00 Category 1 CME Credits
F018 Atopic Dermatitis
Room:291/292
DIRECTOR Eric Lawrence Simpson, M.D.
SpEAkERS
JamesBaker,M.D.
PeterA.Lio,M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Examineemergingclinicalandbasicscienceinsightsintothe
pathogenesisofatopicdermatitis.
2. Utilizetopicalandsystemictherapeuticsandpatient
educationmoreefectivelyforcontrollingfaresandforrelapse
prevention.
3. Demonstratehowtoapproachtheissueofallergy,IgEtesting,
andexclusiondietsinatopicdermatitismanagement.
DESCRIpTION
Tisforumwillprovideanupdateonthelatestresearchinatopic
dermatitisincludingdiseaseepidemiology,pathophysiology,
therapyandprevention,andtopicalandsystemictreatments.We
willspecifcallyaddressalternativemedicine,probiotics,biologics,
andnewmethodsforcontrollingstaphylococcusinfections.A
practicalapproachtoefectivepatienteducationwillbedetailed.
Anallergistwillprovideanevidence-basedandpracticaldiscussion
oftheroleofallergyineczemamanagement.
2.00 Category 1 CME Credits
SCHEDUlE
3:00p.m. IntroductionandPathogenesisUpdate / Dr. Simpson
3:10p.m. QuestionsandAnswers / Faculty
3:15p.m. TopicalTerapy,AlternativeMedicine,and
Education / Dr. Lio
3:45p.m. QuestionsandAnswers / Faculty
3:55p.m. EczemafromanAllergist’sPerspective / Dr. Baker
4:25p.m. QuestionsandAnswers / Faculty
4:35p.m. SystemicTreatmentLadderandFutureResearch
Directions / Dr. Simpson
4:50p.m. QuestionsandAnswers / Faculty
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
101
SCIENTIFIC SESSIONS SCIENTIFIC SESSIONS
F020 Volunteerism and Humanitarianism
Room:252/253/254
DIRECTOR Amit G. Pandya, M.D.
SpEAkERS
DouglasW.Johnson,M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Listthevariousvolunteeropportunitiesavailableinour
specialty.
2. Selectavolunteeractivitythatmatchestheskillsetofthe
attendee.
3. Describetheactivitiesrequiredforvolunteeringinvariousroles
withinourspecialty.
DESCRIpTION
Despiteadvancesinhealthcare,manyindividualssuferbecauseof
lackofaccesstodermatologiccare.Tesafetynetforindividuals
worldwideisjustnotsufcienttoholdthemanyindividualswho
fallthrough.Dermatologistshaveauniqueopportunitytohelpby
caringforthesepatientsaswellasteachingothershowtogivethis
care.Givingbacktodermatologyforallisthereasonwhymany
volunteerinourspecialty.Tissessionwillhighlightdermatology
volunteeropportunitiesininnercityclinics,drug-addiction
centers,bordercities,internationallocations,teledermatology,
academicinstitutions,andvariousorganizations.
2.00 Category 1 CME Credits
SCHEDUlE
3:00p.m. VolunteerismatHomeandAbroad / Dr. Pandya
3:45p.m. LocalandInternationalVolunteerExperiencesand
Teledermatology / Dr. Johnson
4:30p.m. QuestionsandAnswers / Faculty
FORUM
3:00p.m.to5:00p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F019 journal watching
Room:255/256/257
DIRECTOR Lowell A. Goldsmith, M.D.
SpEAkERS
JefreyPhillipCallen,M.D. GeorgeJ.Hruza,M.D.
MaryWuChang,M.D. M.AngelicaSelim,M.D.
CraigA.Elmets,M.D. HensinTsao,M.D.,Ph.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Evaluatecriticallythemostrecentliteratureindermatologic
andnon-dermatologicjournals.
2. Recognizethediferencebetweenfatalandnon-fatalfawsin
peer-reviewedarticles.
3. Formulateefcientstrategiesfortrackingtheever-enlarging
literature.
DESCRIpTION
Teknowledgeandskillsneededtothriveintheinformation
explosionwillbediscussedbymembersoftheJournalWatch
Dermatologyeditorialboard.Tisgroupfollowsover50
journalsannuallyandreportsweeklyonlineandmonthlyin
print.Tediscussionsemphasizerecentlypublishedarticles.
Memberswilldiscussthearticlesintheirspecialinterest:Dr.
Callen,autoimmunediseasesandpharmacology;Dr.Chang,
pediatricdermatology;Dr.Dahl,immunodermatology;Dr.
Elmets,photodermatology;Dr.Goldsmith,genetics;Dr.Selim,
dermatopathology;Dr.Tsao,pigmentationandmelanoma.
2.00 Category 1 CME Credits
SCHEDUlE
3:00p.m. GeneWatching:MyGeneoftheYear / Dr. Goldsmith
3:05p.m. DermatologySurgery:MyTopCuts / Dr. Hruza
3:25p.m. Melanoma:LiftingtheDarkCloud / Dr. Tsao
3:45p.m. DermatopathologyPearls / Dr. Selim
4:00p.m. VitaminDandPhotobiology / Dr. Elmets
4:20p.m. DrugsandCollagenVascularDiseases / Dr. Callen
4:40p.m. PediatricNuggetsfromJournalWatching / Dr. Chang
102
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
FORUM
3:00p.m.to5:00p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F021 FDA presents: Information
for Dermatologists
Room:392
DIRECTOR Susan J. Walker, M.D.
SpEAkERS
DeniseCook,M.D. JillA.Lindstrom,M.D.
JaneE.Liedtke,M.D. PeterD.Rumm,M.D.,M.P.H.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Identifyandprovideinformation,obtainedfromyourclinical
practice,thatwillimpactdrugsafetyandadvancepublic
health.
2. Optimallyutilizetheinformationindruglabelingtomake
informedclinicaldecisions.
3. Describetheregulatoryprocessfordrugsusedindermatology.
DESCRIpTION
Tisforum,designedforthepracticingdermatologist,willdiscuss
themanywaysinwhichdermatologistscanparticipateinthe
ongoingsafetydialoguefordrugsusedinourspecialty.FDA
dermatologistswilldiscussdrugsafety,withspecialemphasison
riskmanagementprogramsandthechallengesofevaluatingrisk
withincompleteinformation.Recentchangesintheformatand
contentofthephysician’spackageinsertwillbepresented.At
theconclusionofthisforum,participantswillbetterunderstand
theprocessbywhichdrugsbecomeavailabletothepracticing
community.
2.00 Category 1 CME Credits
SCHEDUlE
3:00p.m. Overview:FDA/Dr. Walker
3:15p.m. DrugSafetyandtheFDAReviewProcess
/ Dr. Lindstrom
3:45p.m. Medwatch:What,Why,HowtoReport/Dr. Liedtka
4:05p.m. HaveYouNoticed:LabelsAreChanging!/ Dr. Cook
4:25p.m. UpdateonDevicesforDermatology/Dr. Rumm
4:45p.m. QuestionsandAnswers/Faculty
F022 Coding and Offce Management
Room:295/296
DIRECTOR Murad Alam, M.D.
SpEAkERS
AshishBhatia,M.D. ClifordWarrenLober,M.D.,J.D.
KennethE.Bloom,M.D. AlexanderMiller,M.D.
WilliamPatrickDavey,M.D. LucileE.White,M.D.
DirkMichaelElston,M.D. JamesA.Zalla,M.D.
CarlMartinLeichter,M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Describerecentchangesincoding,andpendingchangesthat
maysoonbeimplemented.
2. Discussselectedtopicsinofcemanagement,includingthe
electronichealthrecord,personnelmanagement,andpatient
satisfaction.
DESCRIpTION
Tepurposeofthissessionistoprovideanupdateregarding
currentandimpendingcodingchanges,includingthosepertaining
toevaluationandmanagementcodes,aswellasprocedurecodes.
Additionally,elementsofofcemanagementwillbeaddressed,
includingadoptionofanelectronichealthrecord,personnel
management,anddeliveryoftheidealpatientexperience.
2.00 Category 1 CME Credits
SCHEDUlE
3:00p.m. Introduction/GrowingAPracticeInTeNewDecade
/Alam
3:12p.m. PQRIAndQualityInitiatives/ Dr. Elston
3:24p.m. NegotiatingWithManagedCareOrganizations
/ Dr. Davey
3:36p.m. TipsOnPersonnelManagementAndLowCost
Marketing/Dr. White
3:48p.m. InformedConsent/ConsiderationsInPediatric
Patients/Dr. Bloom
4:00p.m. TipsOnCodingAndPracticeManagement
/Dr. Zalla
4:12p.m. ImplementingAnEMRAndScribing/Dr. Bhatia
4:24p.m. WinningAMedicareModifer25Audit
/Dr. Leichter
4:36p.m. ClosureDocumentation/Dr. Miller
4:48p.m. RAC/MedicolegalIssues/Dr. Lober
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
103
SCIENTIFIC SESSIONS SCIENTIFIC SESSIONS SCIENTIFIC SESSIONS
FORUM
3:00p.m.to5:00p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F023 psoriasis guidelines: Implementing Them
in Your practice
Room:388/389/390
DIRECTOR Alan Menter, M.D.
SpEAkERS
StevenR.Feldman,M.D.,Ph.D.
CraigL.Leonardi,M.D.
HenryW.Lim,M.D.
lEARNINg OBjECTIVES
Followingthisforum,theattendeewillbeableto:
1. Describeanoverallapproachtothemanagementofpatients
withpsoriasisandpsoriaticarthritiswithanemphasis
ondecision-makingcriteriathatenabletheclinicianto
individualizetherapybasedupondiseasetype,extent,
responsetoprevioustreatments,quality-of-lifeissues,and
co-morbidities.
2. Describeclinicalcasestudiesanddiscussevidence-based
treatmentofcasesbasedontherecentlypublishedAAD
psoriasisevidence-basedguidelines,whichincludebest
practices.
3. Identifygapsinclinicalknowledgepatientcare.
DESCRIpTION
Tesessionwillbehelpfulinexpandingthephysicianknowledge
baseandimprovingclinicalconfdenceandefectiveness
intreatingpsoriasispatientswithawiderangeofclinical
presentationsincludingpsoriaticarthritis.Tesessionwill
consistoffourpresentationswithtimeavailableaftereachtalk
forinteractionwiththeattendees.Itwillbestructuredina
question-and-answerformatwhencasestudiesarediscussed.To
prepareparticipants,allattendeeswillbesentthefullsetofAAD
guidelinesandimplementationproductsinadvancesotheyhave
sufcienttimetostudybeforethesession.Ashortsurveywill
beconductedbeforeandafterthesession,andfollow-upsurvey
willfollow6monthslatertogaugeandevaluateifguidelinesand
presentationswereeasytotranslateintodailyclinicalpractice.
Studieshaveshownthathigh-qualityguidelinescanmake
importantcontributionstoimprovingmedicalcare.
2.00 Category 1 CME Credits
SCHEDUlE
3:00p.m. IntroductionandOverviewwithSurvey / Dr. Menter
3:10p.m. TopicalTerapyforPsoriasiswithCaseStudy
/ Dr. Feldman
3:35p.m. PhototherapyforPsoriasiswithCaseStudy / Dr. Lim
4:00p.m. SystemicTerapywithCaseStudy / Dr. Menter
4:25p.m. BiologicTerapywithCaseStudy / Dr. Leonardi
4:50p.m. PanelDiscussionwithSurvey / Faculty
LOOKING FOR A NEW
OPPORTUNITY?
Whether you’re looking for a clinical or academic/
research position or interested in purchasing an
established practice, the American Academy
of Dermatology’s Career Development Fair will
provide you the opportunity to meet potential
employers and network with other professionals
just like you!
In addition, experts will be on hand to answer
questions on starting or expanding an existing
practice, coding and reimbursement, and
practice management.
Employers can register online at www.aad.org/careerfair
or by contacting the Member Resource Center at
866-503-SKIN (7546).
Hilton New Orleans Riverside
Two Poydras Street
New Orleans, Louisiana 70130
Friday, February 4, 2011
5:00pm – 7:00pm
Free for
Job Seekers!
104
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
,

F
E
B
R
U
A
R
Y

4
For description of session categories and fees see page 37
w003 MOC Self-Assessment: Dermatopathology
M
O
C
Room:288/289/290
DIRECTOR Molly A. Hinshaw, M.D.
SpEAkERS
NnekaI.Comfere,M.D. LoriD.Prok,M.D.
WhitneyA.High,M.D. BrianL.Swick,M.D.
lEARNINg OBjECTIVES
Followingthisworkshop,theattendeewillbeableto:
1. Determinecommonanduncommondermatologic
histopathologicdiagnoses.
2. Recognizetheimportanceoftheclinical-pathologiccorrelation
inhistopathology.
3. Identifyareasforimprovementinknowledgeofhistopathologic
diagnosisusingself-assessment.
DESCRIpTION
Inthissession,attendeeswillbepresentedwithawiderange
ofhistopathologicspecimensfordiagnosisandself-assessment.
Clinicalinformationmayalsobeprovidedtoaiddiagnosis.For
eachcasepresented,anonymousanswerswillberecordedviaself-
responsecomputerizedsystem,followedimmediatelybydiscussion
ofthecase.
2.00 Category 1 CME Credits
SCHEDUlE
3:00p.m. Cases1-5 / Dr. High
3:20p.m. Cases6-10 / Dr. Comfere
3:40p.m. Cases11-15 / Dr. Prok
4:00p.m. Cases16-20 / Dr. Swick
4:20p.m. Cases21-25 / Dr. Hinshaw
* Self-assessment questions utilized in this session are the
same as those used for Forum F024 and Workshop
W001 MOC: Self-Assessment ofered at Annual
Meeting 2009 and 2010. Physicians should not
claim CME/MOC credit for attending this session if
they attended Forum F024 and Workshop W001 at
Annual Meeting 2009 and 2010.
w002 Dermatology Speaker Development
Room:265/266
DIRECTOR Hilary E. Baldwin, M.D.
SpEAkERS
StevenKennethShama,M.D., M.P.H.
lEARNINg OBjECTIVES
Followingthisworkshop,theattendeewillbeableto:
1. Developtechniquesformaximizingtheefectivenessofyour
presentations.
2. DesignefectivePowerPointslidestosupportyourmessages
andmaintainaudienceinterest.
3. Choosememorableimagesandmessages.
DESCRIpTION
Weareallteachersforourpatients,students,andpeers.We
allwanttoleavememorableimagesandmessageswithour
audience.Yetonly10percentofwhatwesayisretainedbythe
endoftheweek.Whatcanwedotoassurethatthe10percent
thatisrememberedisthe10percentthatwewant?Wewill
discussefectivestrategiesandtechniquesthatwillmakeyoua
comfortable,confdent,andmemorablespeaker.
2.00 Category 1 CME Credits
SCHEDUlE
3:00p.m. DevelopingMemorableMessages/Dr. Shama
3:30p.m. PreparingEfectivePowerPointSlides/Dr. Baldwin
4:00p.m. PresentationsArePerformance:HowtoPrepare
/Dr. Baldwin
4:30p.m. HandlingtheQuestionsandAnswers/ Dr. Baldwin
4:45p.m. QuestionsandAnswers/Faculty
wORkSHOp
3:00p.m.to5:00p.m.
Tuition fee and ticket required for admission.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
105
SCIENTIFIC SESSIONS
F
R
I
D
A
Y
/
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

4
/
5
For description of session categories and fees see page 37
SCHEDUlE
FRIDAY, FEBRUARY 4, 2011
9:00a.m. Introduction / Dr. Hornyak
9:05a.m. SkinEmbryologyandMorphogenesis / Dr. Radhika
9:30a.m. KeratinocyteBiologyandPathology / Dr. DiGiovanna
10:00a.m. Break / Dr. Hornyak
10:15a.m. EpidermalCell-CellandCell-MatrixAdhesion
/ Dr. Kowalczyk
11:00a.m. Pemphigus:Anti-DesmosomalAutoimmuneDiseases
/ Dr. Stanley
11:30a.m. AutoimmuneandInheritedDiseasesoftheEpidermal
BasementMembrane / Dr. Yancey
2:00p.m. DiseaseofthePilosebaceousUnit / Dr. Tiboutot
2:30p.m. CutaneousPhotobiology / Dr. Oh
3:00p.m. DNARepairAbnormalitiesandSkinCancer
/ Dr. Kraemer
3:30p.m. Break / Dr. Hornyak
3:45p.m. ExtracellularMatrixinAcquiredandInheritedSkin
Diseases / Dr. Uitto
4:15p.m. WoundHealing / Dr. Clark
4:45p.m. QuestionsandAnswers / Dr. Hornyak
SATURDAY, FEBRUARY 5, 2011
9:00a.m. Introduction / Dr. Hornyak
9:05a.m. AdnexalStructuresinSkin / Dr. Seykora
9:45a.m. DiseasesofHair / Dr. Cotsarelis
10:15a.m. Break / Dr. Hornyak
10:30a.m. MelanocytesandDisordersofPigmentation
/ Dr. Hornyak
11:00a.m. OncogenesandTumorSuppressorGenes
/ Dr. Darling
11:30a.m. PathogenesisofBCC,SCC,andMelanoma / Dr. Tsao
2:00p.m. InnateImmunity / Dr. Miller
2:30p.m. TeCutaneousMicrobiome / Dr. Kong
2:50p.m. SkinasanImmuneOrgan / Dr. Udey
3:20p.m. Break / Dr. Hornyak
3:35p.m. CurrentConceptsinPsoriasis / Dr. Krueger
4:15p.m. RegulatoryTcells:TeGood,theBad,andthe
Inefective / Dr. Clark
4:45p.m. QuestionsandAnswers / Dr. Hornyak
C012 Structure and Function of the Skin
Room:271/272/273
DIRECTOR Tomas J. Hornyak, M.D., Ph.D.
SpEAkERS
RichardAugustClark,M.D. DennisH.Oh,M.D.,Ph.D..
RachaelClark,M.D.,Ph.D. AtitRadhika,Ph.D.,M.D.
GeorgeCotsarelis,M.D. JohnT.Seykora,M.D.
TomasN.Darling,M.D.,Ph.D. JohnRogerStanley,M.D.
JohnJ.DiGiovanna,M.D. DianeM.Tiboutot,M.D.
HeidiH.Kong,M.D. HensinTsao,M.D.,Ph.D.
AndrewP.Kowalczyk,Ph.D. MarkC.Udey,M.D.,Ph.D.
KennethHowardKraemer,M.D. JouniJ.Uitto,M.D.,Ph.D.
JamesG.Krueger,M.D.,Ph.D. KimB.Yancey,M.D.
LloydS.Miller,M.D.,Ph.D.
lEARNINg OBjECTIVES
Followingthiscourse,theattendeewillbeableto:
1. Defnebasicstructuresinepidermisanddermis,andlisttheir
functions.
2. Summarizethepathophysiologyofrepresentativedermatologic
diseases.
3. Describetherationaleofselectedtherapeuticagents.
DESCRIpTION
Lectureswilldiscussthenormalstructureandfunctionofcells
andtissueswithinskin,aswellashowtheseelementsareimpaired
inrepresentativediseases.Specifcelementsoftheskinthatwillbe
discussedincludekeratinocytes,melanocytes,Langerhanscells,the
epidermalbasementmembrane,fbroblasts,connectivetissue,and
adnexalstructuresincludinghair,pilosebaceousunits,andsweat
glands.Abnormalfunctionsoftheseelementswillberelatedto
pathologicalconditions,includinginfammation,autoimmunity,
blistering,cancer,photosensitivity,dyspigmentation,
infection,andgenodermatoses.Itwillbeshownhowincreased
understandingofskinbiologyisbeingtranslatedintonew
therapiesandimprovedcareforpatients.
11.00 Category 1 CME Credits
OVERVIEw
FRIDAY/SATURDAY, FEBRUARY 4, 5
Course — 9:00 a.m. to 5:00 p.m.
C012 StructureandFunctionoftheSkin. . . . . . . . . . .105
Symposium — 9:00 a.m. to 5:00 p.m.
S007 GrossandMicroscopicDermatology . . . . . . . . .106
COURSE
9:00a.m.to5:00p.m.
Tuition fee and ticket required for admission.
106
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
F
R
I
D
A
Y
/
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

4
/
5
SYMpOSIUM
9:00a.m.to5:00p.m.
Open admission, no tuition or ticket.
S007 gross and Microscopic Dermatology
Room:343
DIRECTOR Karen Warschaw, M.D.
SpEAkERS
MarkA.Cappel,M.D. TammieC.Ferringer,M.D.
MichaelP.Conroy,M.D. LawrenceE.Gibson,M.D.
lEARNINg OBjECTIVES
Followingthissymposium,theattendeewillbeableto:
1. Reviewandinterpretawidevarietyofbriefpaperswithclinical
andpathologicalcorrelations.
2. Compareanddiscussawidevarietyofdermatologicentities.
DESCRIpTION
Approximately240papersof4minutes’durationwillbe
presentedduringthissession.Presentationswillbeseparatedinto
severalbroadcategories.Tissessionisdirectedtoallacademy
membersandnon-membersincludingmedicalstudents,residents,
andfellows.
12.00 Category 1 CME Credits
REFERENCES
1. WeedonD.Skin Pathology.3rded.ChurchillLivingstone;2010.
Psoriasis Guidelines:
Implementing them
in Your Practice
Friday, February 4
3:00 p.m. – 5:00 p.m.
Speakers:
• AlanMenter,M.D.–Forum Director
• StevenR.Feldman,M.D.,Ph.D.
• HenryW.Lim,M.D.
• CraigL.Leonardi,M.D.
Tis Forum will provide an ideal
opportunity to learn best practices in
the complex management of psoriasis
and psoriatic arthritis. Experts in the
feld will review the latest clinical
guidelines with four question-and-
answerpresentations.
Attendeesreceiveafullsetofrecently
published AAD Guidelines together
withimplementationproducts,which
willassistinusingtheevidence-based
AAD psoriasis guidelines in your
practice.FREEofcharge!
Visit www.aad.org/
meetings/annual toregister.
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
107
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
Forums — 9:00 a.m. to 11:00 a.m.
F024 EvaluationandManagementofHemangiomas. .117
F025 DramaticOralDisease....................118
F026 ChronicUrticariaandAngioedema:
What’sNewinPathogenesisandTreatment....118
F027 PracticalApproachestoPatientProblems......119
F028 WhatYouNeedtoKnowAboutCoding
ButWereAfraidtoAsk. . . . . . . . . . . . . . . . . . . .119
F029 AcneandRosaceaUpdate. . . . . . . . . . . . . . . . . .120
F030 ManagingOnlineReputation . . . . . . . . . . . . . . .120
F031 FoodAllergyandDermatology. . . . . . . . . . . . . .121
workshop — 9:00 a.m. to 11:00 a.m.
W004 MOCSelf-Assessment:Procedural
Dermatology. . . . . . . . . . . . . . . . . . . . . . . . . . . .121
Courses — 9:00 a.m. to 12:00 p.m.
C06E BasicSelf-AssessmentofDermatopathology
Discussion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .122
C013 AdvancedBotulinumToxin:
LivePatientDemonstration................122
C014 Coding,Documentation,andPractice
Management . . . . . . . . . . . . . . . . . . . . . . . . . . . .123
SATURDAY, FEBRUARY 5
poster Discussion Sessions— 7:15 a.m. to 8:45 a.m.
PD01 Surgery................................112
PD02 ClinicalDermatology. . . . . . . . . . . . . . . . . . . . .112
Discussion groups — 7:15 a.m. to 8:45 a.m.
D007 LeadingfromConficttoResolution . . . . . . . . .113
D008 PUVAandPhototherapyBeyondPsoriasis . . . . .113
Focus Sessions — 7:15 a.m. to 8:45 a.m.
U038 Nanotechnology. . . . . . . . . . . . . . . . . . . . . . . . .114
U039 GoodClosuresGoneBad:AStoryofBlood,
Pus,andTears . . . . . . . . . . . . . . . . . . . . . . . . . . .114
U040 MilitaryUniqueDermatology ..............114
U041 UncommonCutaneousInfections:
ClinicalandHistologicFeatures.............114
U042 TeVicesofDevicesinDermatology . . . . . . . . .115
U043 DermatopathologyChallengesEncountered
bytheMohsSurgeon . . . . . . . . . . . . . . . . . . . . .115
U044 TumescentLiposuction,Lasers,andNewDevices:
AState-of-the-ArtLiposuctionPractice. . . . . . . .115
U045 Non-culturedEpidermalSuspensioninVitiligo:
FromLabtoClinic . . . . . . . . . . . . . . . . . . . . . . .116
U046 SocialMediaandDermatology:HowTwitterand
FacebookWillHelpYouandYourPractice. . . . .116
U047 Mini-MBAfortheDermatologist. . . . . . . . . . .116
U048 ChallengingCasesinPediatricDermatology. . . .117
OVERVIEw
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
practice Management Session open to eligible
offce staff/registered nurses
Represents Patient Safety Session in program overviews
patient Safety Session
Represents Audience Response System Session
Audience Response System Session
Represents activities that meet MOC-D

M
O
C
This activity has been approved by the ABD to satisfy
component 2 of MOC-D
Represents Leadership Institute in program overviews
leadership Institute — addresses leadership
competencies specifc to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
For description of session categories and fees see page 37
108
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
Symposia — 9:00 a.m. to 12:00 p.m.
S014 Patient Safety and Quality 124
S015 Advanced Pediatric Dermatology 125
S016 Drug Actions 125
S017 Terapeutic Decision Making in
Cutaneous Oncology 126
S018 Late-Bre ak in g Re s e a rc h 126
Courses — 9:00 a.m. to 5:00 p.m.
C015 In te rn al Me dic in e 127
C016 Advanced Self-Assessment of Dermatopathology 127
C017 Advan c e dDe rmo s c o p y 128
Forums — 12:00 p.m. to 2:00 p.m.
F032 Multidisciplinary Preventive Networking in
Occupational Contact Dermatitis 129
F033 Introduction to Oral Dermatology 130
F034 From the Dermatology Rheumatology Clinics:
Practical Tips and Advances in Management 130
F035 Practical Aspects of Biologic Terapy 131
F036 Careers in Academic Dermatology 131
F037 Pediatric Dermatology: Systemic Evaluation of
Cutaneous Findings in Infants and Children:
What’s New an dWh at’s Tru e ? 132
F038 Itc h 132
Workshop — 12:00 p.m. to 2:00 p.m.
W005 MOC Self-Assessment:
Pediatric Dermatology 133
Discussion Groups — 12:15 p.m. to 1:45 p.m.
D009 Educate Your Patients and Improve Outcomes 133
D010 Recent Advances in Skin Biology and
Skin Disease 133
Focus Sessions — 12:15 p.m. to 1:45 p.m.
U049 Avoiding Complications and Maximizing Results
in Cutaneous Laser Surgery 134
U050 Viral Exanthem Update 134
U051 Terapy for Lipodermatosclerosis,
Venous Ulceration, and Atrophie Blanche 134
U052 Diseases of Male Genitalia 134
U053 Trough the Looking Glass: Te Use of
Dermoscopy in the Management of the
Pigmented Lesion Patient 135
U054 Building Beauty: Understanding Facial
Proportions, Phi, and the Use of Volumizing
Soft Tissue Fillers 135
U055 Practical Approaches to Cosmeceuticals 135
U056 Recommended Screening Practices in
Me dical De rmato l o gy 136
U057 Procedural Safety in Dermatology 136
U058 From Stem to Skin: Precursor Cells Tat Have
a Lot of Potential 136
U059 Po tpourri o fCPC 136
U060 Stress, the Nervous System, and Cutaneous
Immunity 137
Courses — 2:00 p.m. to 5:00 p.m.
C018 Dermatologic Drug Safety and Efcacy 137
C019 Hair and Nails 138
C020 Live Patient Demonstrations: Application of
Our Aesthetic Toolbox for the Treatment of
Medical and Dermatologic Disorders 139
Symposia — 2:00 p.m. to 5:00 p.m.
S019 Rheumatologic Dermatology 139
S020 Birthmarks 140
S021 Skin of Color 141
S022 Ac n e an dRo s a c e a 142
S023 Teledermatology 143
Discussion Groups — 2:30 p.m. to 4:00 p.m.
D011 Women With Hair Loss 144
D012 Aging Skin: Mechanism-Based Rejuvenation 144
OVERVIEW
SCIENTIFIC SESSIONS
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
Practice Management Session open to eligible
offce staff/registered nurses
Represents Patient Safety Session in program overviews
Patient Safety Session
Represents Audience Response System Session
Audience Response System Session
Represents activities that meet MOC-D

M
O
C
This activity has been approved by the ABD to satisfy
component 2 of MOC-D
Represents Leadership Institute in program overviews
Leadership Institute — addresses leadership
competencies specifc to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
109
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
OVERVIEW
Focus Sessions — 2:30 p.m. to 4:00 p.m.
U061 Calciphylaxis 144
U062 Herpes Simplex and Varicella Zoster Virus 144
U063 De rmato s c o p y 145
U064 Helping You Meet Component 4 of MOC 145
U065 Dermoscopy: It’s Time for A Quiz 145
U066 Compliance in Pharmaceutical Development:
What Yo u Ne e dto Kn ow 145
U067 Twists and Splits: How to Approach Hair Shaft
Disorders 146
U068 El e c t ros u r ge ry Update 146
U069 Half-Truths, Lies, and Statistics: Understanding
Medical Statistics for the Practitioner 146
U070 Getting Started with Interpolation Flaps 146
U071 Warts 147
U072 Pediatric Dermatologic Surgery in the
Outpatient Setting: Tricks of the Trade 147
Forums — 3:00 p.m. to 5:00 p.m.
F039 Treating Severe Skin Disease in Children 147
F040 Resident Transitions 148
F041 Finessing Facial Reconstruction 148
F042 Hair and Nail Clinicopathologic Correlations 149
F043 Role of Dermatologist in Management of Skin
Disease in Solid Organ Transplant Recipients 149
F044 Dermatology Teaching and Education Group 150
F045 Ro s a c e a 150
F046 Leading Your Team by Coaching
and Mentoring 150
Workshop — 3:00 p.m. to 5:00 p.m.
W006 MOC Self-Assessment: Contact Dermatology 151
SCIENTIFIC SESSIONS
Gain access to the most highly qualifed
candidates in the feld of dermatology with
AADCareerCompass.org.
EMPLOYERS CAN:
• Post clinical and
academic/research
positions as well
as practices for sale
• Hire for all recruitment
needs, including: dermatologists,
nurses, and other healthcare professionals
• Receive e-mail notifcations of job seekers
matching open positions
• Obtain discounted membership pricing for
each ad posted
SEARCH.
RECRUIT.
HIRE.
To place job opportunities or
practice for sale online,
visit www.aadcareercompass.org
or contact HealtheCareers Network
toll-free at (888) 884-8242.
Visit the Academy Resource
Center Booth 3623 for
more information.
COMPETITIVE
PRICING
STARTING AT
JUST $350!
MOCmdVol.4
TheAcademy’spremierself-assessment
programhasanewaddition!Thisproductcan
beusedforexaminationpreparation,earning
CME,andfulfllingComponent2ofMaintenance
ofCertifcation.Purchasetheself-assessment
libraryandsave$100.
AADDermsOnline.org
Needawebsiteorhaveonethatneedsrevamping?
AADDermsOnline.orgofferspremiumdesignsand
onlinesearchsolutionstoeducatecurrentpatientsand
attractnewones.Besuretoinquireaboutdiscounted
ratesformembers.
Buyer’sGuide
Searchforproductsand
servicesalittleeasier
withthiscomprehensive
supplierlistingdesignedspecifcallyforthefeldof
dermatology.Updateddailyforbettersearchresults,
visitaaddermatologybuyersguide.comtostartsearching.
QualityReporting
System
UsethenewQRSsystemtoreportyourquality
measures.Availablemodulesinclude:2011PQRI
MelanomaReportingandE-Prescribing.Don’tleaveyour
1%CMSbonusbehind!DemothesystemattheResourceCenter.
DialoguesinDermatology
Newonlineformatoffersfeatures
liketheabilitytodownloadMP3s
toyouriPod,printabletranscripts,
andlinkstoadditionalverifed
referencesforfurtherstudy.
Subscribetodayandsave$40!
Thisactivityisavailablefor
AMA PRA Category 1 Credit
TM
.
PracticeManagementEssentialSeries
CheckouttheAAD’slatestmanuals,
2011 Coding and Documentation
Manualandthenew,Dermatology
Employment: A Guide to Personnel
Policies and Procedures.Show
special-pricingavailableat
theResourceCenter!
SeeSPOTCD
Educatepatientsandthe
publiconsun-safetyand
skincancerdetectionand
preventionwiththeAAD’s
newestteachingtool.
Includesfourdynamic
PowerPoint

presentations,
eachtargetedtoadifferent
agegroup.
Dermoscopy:AGuideforthePhysician
LearnmoreabouttheDermoscopytechnique
withthisextensivetwo-discset.Viewover
8,000slidesand400casesforidentifying
anddiagnosinglesionsoftheskin.
Thisactivityisavailablefor
AMA PRA Category 1 Credit
TM
.
Visit the
Academy Resource Center Booth 3623 to see What’s NEW from the Academy!
FREE
Sample
Pack!
Clinical Performance
Assessment Tool (CPAT)
Designed to help you evaluate
your practice with the goal of
improved patient care, it also
satisfes Component 4 of MOC and earns CME credit. Available
modules include: 2011 CPAT Melanoma with PQRI Reporting,
Acne, Atopic Dermatitis, Melanoma, and Offce Safety Biopsy.
DermClips
Save time and stay up-to-date with
DermClips, the Academy’s literature review
newsletter, featuring evidence-based
summaries of clinical content. Six issues
per year in print and NEW online format.
This activity is available for AMA PRA
Category 1 Credit
TM
.
AAD Advantage
Save, save, save! With AAD
Advantage, the Academy’s
member buying program through Henry Schein. Receive Discounts on medical
and surgical supplies as well as generic and brand-name pharmaceuticals.
AAD Insurance
The Academy has nine custom-
designed insurance programs
to help protect your future and the future of your family.
Apparel
Includes a line of white lab coats for men
and women, and scrubs in variety of new
colors with option to personalize. Come
to the Resource Center to purchase and
receive 5% off all AAD Apparel!
Visit the
Academy Resource Center Booth 3623 to see What’s NEW from the Academy!
Staples Advantage
®
Receive special discounts on offce
supplies, furniture, technology, and
print material. Choose from over 30,000
products and experience free next day
delivery with a minimum order of $30. Sign up at the Resource Center!
AADCareerCompass.org
The resources you need to
fnd the right employee or
employer. Employers can post practices for sale and clinical or aca-
demic positions. Job seekers can search for positions on the new
online job board and post their résumés/CVs for FREE!
Body Mole Map
Teach patients the importance
of monitoring their moles with
the ABCDEs of Melanoma.
Handout illustrates how to do a
self-examination of the skin and
includes a chart for tracking suspicious moles.
Skin Self-Exam Shower Card
A two-sided, laminated shower card that
shows the steps of how to conduct a full
body self-examination of the skin. Also
explains the ABCDEs of Melanoma.
Patient Education Pamphlets
A variety of topics including: common
dermatologic conditions, cosmetic
surgery, general dermatology, sun
protection, skin reactions, and viral
diseases. Pick up a FREE sample
pack at the Resource Center!
For description of session categories and fees see page 37
112
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
POSTER DISCUSSIONS
7:15 am to 8:45 am
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
PD01 Surgery
Room: 283
NoCMECredits
MODERATOR
Keyvan Nouri, MD
P100
Te use of Mohs micrographic surgery for the treatment of
nonmelanoma skin cancers in the Medicare population
P101
Association between Mohs surgery wait times and surgical defect
size in patients with squamous cell or basal cell carcinoma of the
skin
P102
Safety during dermatologic procedures and surgeries: A survey of
physician injuries and prevention strategies
P103
Skin assessment by high-frequency ultrasound is a useful and
reliable method to quantify photoaging in skin
P104
Melanocyte-keratinocyte transplantation in the treatment of
vitiligo: Te experience of an academic medical center in the
United States
P105
Association of facial skin aging and vitamin D levels in healthy
middle-aged white women
P106
Cryosurgery followed by imiquimod 375% to treat actinic
keratosis
P107
A novel high-power bipolar RF technology for noninvasive body
contouring
PD02 Clinical Dermatology
Room: 284
NoCMECredits
MODERATOR
Jan Izakovic, MD
P200
Survey of bacterial diversity on infant skin over the frst year of life
P201
Baby sun protection products: A competitive assessment of eye
mildness, SPF:PFA ratio, stability, and antimicrobial robustness
P202
A large study of 826 patients confrms the safety and efectiveness
of doxycycline monohydrate 40-mg capsules for the treatment of
papulopustular rosacea
P203
Lymphoma among patients with atopic dermatitis treated with
topical corticosteroids and/or topical calcineurin inhibitors
P204
A six-year retrospective review of drug reaction with eosinophilia
and systemic symptoms (DRESS)
P205
A survey of mortality in patients admitted to intensive care with
skin disorders
P206
Cutaneous epithelial to mesenchymal transition is mediated by
TGF-β and TNF-α synergism: implications for scleroderma
P207
Simvastatin inhibits transforming growth factor-β1, induced
collagen type I, CTGF, and α-SMA expression in keloid
fbroblasts
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
113
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
DISCUSSION GROUP
7:15 am to 8:45 am
Tuition fee and ticket required for admission.
D007 Leading from Confict to Resolution
Room: 240
DIRECTOR ChristinePoblete-Lopez,M.D.
SPEAkERS
Mary E Maloney, MD
Paul Seymour, Center for Creative Leadership
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 Identify one’s confict resolution style and the importance of
optimizing this style to efectively manage confict
2 Recognize the role of crucial conversations
3 Apply a straightforward and efective method for confict
resolution
DESCRIPTION
Confict occurs when two or more people difer in their views
on a topic or an issue In the workplace, and life in general,
there are numerous situations when confict arises Handled
inappropriately, confict can result in strained relationships and
poor cooperation among team members, potentially threatening
the entire mission of the group Tis discussion group will give
participants an opportunity to discuss various areas of confict
in the workplace and to identify one’s confict resolution style
Te presenters will review principles of confict management and
efective strategies to resolve confict including the importance
of crucial conversations Co-presented with a faculty member
from the Center for Creative Leadership, participants will learn
straightforward and efective methods for confict resolution
Te skills developed based on the principles learned will assist
participants in maintaining a highly efective, cohesive, and
productive team
1.50Category1CMECredits
D008 PUVA and Phototherapy Beyond Psoriasis
Room: 241
DIRECTOR WarwickL.Morison,M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 Discuss the therapeutic spectrum of PUVA and phototherapy
2 Select an appropriate form of phototherapy
3 Examine the approach to PUVA and phototherapy
DESCRIPTION
More than 30 dermatoses have now been reported to respond to
PUVA and phototherapy Atopic eczema, various other eczemas,
mycosis fungoides, vitiligo, photodermatoses, chronic graft-versus-
host disease, granuloma annulare, and morphea are among these
conditions Te practical details of how to manage these and other
dermatoses will be discussed
1.50Category1CMECredits
When you post a résumé/CV on
AADCareerCompass.org, you have access
to some of the most desirable positions
in dermatology!
JOB SEEKERS CAN:
• Upload multiple résumés/CVs
• Search hundreds of clinical and
academic/research positions,
including practices for sale
• Sign up for e-mail
alerts when positions
flling your criteria
become available
SEARCH.
APPLY.
WORK.
To start searching visit
www.aadcareercompass.org or
contact HealtheCareers Network
toll-free at (888) 884-8242.
FREE
FOR JOB
SEEKERS!
For description of session categories and fees see page 37
114
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
FOCUS SESSION
7:15 am to 8:45 am
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U038 Nanotechnology
Room: 274
DIRECTOR AdnanNasir,M.D.,Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Discuss the importance of nanotechnology
2 Identify the benefts of nanotechnology for consumers and for
dermatology
3 Distinguish and identify important pitfalls of nanotechnology
DESCRIPTION
Nanotechnology is a rapidly growing feld with enormous
implications for consumers, patients, and society Matter made at
the nano scale possesses unique properties allowing for the creation
of substances with advantages over macroscopic precursors Tese
advantages include specifcity, adaptability, and targeted active
ingredient delivery A substantial proportion of the patents issued
for nanotechnology-based discoveries are in the realm of cosmetics
and consumer skin care products Te interest in nanotechnology
and skin care is expected to burgeon Tis session introduces
dermatologists to the benefts and pitfalls of nanotechnology for
consumers, patients, and colleagues
1.50Category1CMECredits
U039 Good Closures Gone Bad:
A Story of Blood, Pus, and Tears
Room: 267/268
DIRECTOR EmilyJ.Fisher,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Identify the signs and symptoms of common surgical
complications, including bleeding, infection, dehiscence,
and necrosis
2 Develop strategies to minimize common surgical complications
3 Select appropriate management plans when surgical
complications arise
DESCRIPTION
Tis session will provide the attendee with an understanding of
the four common surgical complications: bleeding, infection,
dehiscence, and necrosis Te signs and symptoms of these
complications will be addressed, as will strategies to minimize
these complications based on current literature Te attendee
also will learn appropriate management plans for surgical
complications that may arise Te discussion will include
appropriate use of anticoagulants and perioperative antibiotics,
identifying sacred cows in dermatologic surgery as well as the
appropriate management of bleeding complications and both
common and rare postoperative infections Tis session will be
geared toward beginning practitioners and those interested in
incorporating more dermatologic surgery into their practice
1.50Category1CMECredits
U040 Military Unique Dermatology
Room: 285
DIRECTOR ChadHivnor,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Compare and diagnose unusual tropical dermatologic
conditions encountered while providing military humanitarian
mission support
2 Diagnose and treat dermatologic conditions from cases
submitted to the Army Medical Department (AMEDD)
teledermatology site (providing remote consultative services
to military treatment facilities lacking direct dermatology
support)
3 Summarize the deployed and stateside military dermatologists’
role in serving our nation in support of the ongoing confict in
Iraq
DESCRIPTION
Where are your tax dollars going? Tis session will review multiple
aspects of dermatology within the military We will discuss
unique approaches to new problems that we have not experienced
with previous conficts Fascinating cases seen on humanitarian
missions will be discussed We will examine the military
dermatologist’s role serving in the deployed wartime environment
As deployments leave fewer military dermatologists stateside,
teledermatology has been successfully utilized to fll this void, and
we will review unique cases encountered via our store-and-forward
teledermatology program Finally, we will explore the unique
training needs of a large military dermatology residency program
training a cadre of 21 Army/ Air Force residents
1.50Category1CMECredits
U041 Uncommon Cutaneous Infections:
Clinical and Histologic Features
Room: 235/236
DIRECTOR MelissaPiliang,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Assess and diagnose uncommon cutaneous infections
2 Identify key histologic features of rare cutaneous infections
DESCRIPTION
With increasing numbers of immunocompromised patients,
cutaneous infections are on the rise Tis will be a case-based
discussion demonstrating the clinical and histologic fndings of
rare cutaneous parasitic, fungal, and mycobacterial infections Te
focus will be on new and emerging pathogens, especially those
seen in immunocompromised patients Supportive diagnostic tests
and treatment options will be discussed
1.50Category1CMECredits
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
115
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
U044 Tumescent Liposuction, Lasers
and New Devices: A State-of-the-Art
Liposuction Practice
Room: 265/266
DIRECTOR KimberlyJ.Butterwick,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Determine how to initiate or enhance a tumescent liposuction
practice
2 Distinguish and evaluate new technologies for fat removal
3 Apply surgical pearls for optimal results and efcacy in a
liposuction practice
DESCRIPTION
Tumescent liposuction is one of the dermatologist’s safest and
most efective means of reshaping the body, yet its popularity is
waning New lasers, devices, and even noninvasive techniques
are emerging and will likely facilitate the removal of fat and
revitalize the public’s interest in these procedures Several new
laser and light devices for fat melting and skin tightening, utilized
in conjunction with liposuction, will be compared and contrasted
Clinical experience with the water-jet device will be reviewed
Early clinical studies of new ultrasonic devices and injectable
solutions are underway and available data will be presented
1.50Category1CMECredits
FOCUS SESSION
7:15 am to 8:45 am
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U042 The Vices of Devices in Dermatology
Room: 263
DIRECTOR StacyR.Smith,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Describe the various classes of medical devices and give
examples of their use in dermatology
2 Distinguish the diferent methods by which medical devices are
approved for sale by the FDA
3 Compare the quality and quantity of data provided in support
of a device approval against that provided for drugs or biologic
agents
DESCRIPTION
Attendees will receive an overview of the classifcation of medical
devices and an in-depth examination of the methods of approval
of medical devices in dermatology Te diferences in the quantity
and rigor of data used to approve devices, as opposed to drugs or
biologic agents, will be compared and contrasted with extensive
use of examples in dermatology At the conclusion of the session,
attendees will be better prepared to analyze and draw their own
conclusions about the evidence supporting the claims of devices
used in dermatology
1.50Category1CMECredits
U043 Dermatopathology Challenges
Encountered by the Mohs Surgeon
Room: 242
DIRECTOR ZeinaS.Tannous,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Diferentiate benign and malignant histology on frozen
sections
2 Determine when to seek permanent sections
3 Describe rare benign and malignant neoplasms for the Mohs
surgeon
DESCRIPTION
Tis session will focus on dermatopathology challenges
encountered by the Mohs surgeon Tis will be a clinically relevant
course It will diferentiate benign and malignant fndings on
frozen sections It will identify when the assistance of permanent
sections is indicated Finally, it will describe rare benign and
malignant tumors that may be encountered by the Mohs surgeon
1.50Category1CMECredits
For description of session categories and fees see page 37
116
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
FOCUS SESSION
7:15 am to 8:45 am
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U045 Non-cultured Epidermal Suspension in
Vitiligo: From Lab to Clinic
Room: 270
DIRECTOR DavinderParsad,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Use non-cultured epidermal suspension (NCES) in the surgical
management of vitiligo
2 Discuss various modifcations of NCES technique to achieve
optimum results
3 Apply selection criteria for considering patients for NCES
technique
DESCRIPTION
Te choice of surgical intervention should be individualized
according to the type of vitiligo, stability, localization of lesions,
and cost-efectiveness of the procedure Recently, non-cultured
epidermal suspension (NCES) is emerging as safe and highly
efective surgical modality for the treatment of vitiligo
Selection criteria and newer concepts in stability of vitiligo will
be discussed Basic principles of preparation of cell suspension
will be demonstrated Over the years, several modifcations have
been made to this procedure in order to make it faster, simpler,
and more efective Tese modifcations will be discussed with an
emphasis on how to achieve optimum results
1.50Category1CMECredits
U046 Social Media and Dermatology:
How Twitter and Facebook Will
Help You and Your Practice
Room: 264
DIRECTOR JefreyA.V.Benabio,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Defne social media and distinguish among platforms such as
Twitter, Facebook, and MySpace
2 Use social media to inform patients, disseminate information,
collaborate with peers, and promote your practice
3 Avoid risks of inappropriate communication with patients,
risks of liability, and potential HIPAA violations
DESCRIPTION
Social media is the use of electronic tools such as Facebook and
Twitter for connecting, sharing, and discussing information Tese
new tools have rapidly and widely been adopted by the public
I will show how proper use of social media can provide benefts
to health providers and to patients at an unparalleled scope I’ll
demonstrate how improper use of social media can waste time and
can make health providers liable for misconduct or malpractice
Connecting with patients appropriately can promote a practice
and connecting with peers can improve physicians’ diagnostic and
treatment skills
1.50Category1CMECredits
U047 Mini - MBA for the Dermatologist
Room: 298/299
DIRECTOR JefreyJ.Miller,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Identify critical steps for efective team performance
2 Develop key steps in the process of change management
3 Apply leadership priniciples to enhance your practice
DESCRIPTION
As dermatologists, we are called to “lead” and “manage” in the
setting of our work relationships Tis session introduces key
skills and concepts that will enhance your leadership brand In
addition, lessons learned during this session can be applied to your
practice setting, whether it’s university-or community-based Key
concepts will be illustrated through case discussions
1.50Category1CMECredits
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
117
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
SCIENTIFIC SESSIONS
F024 Evaluation and Management of
Hemangiomas
Room: 388/389/390
DIRECTOR JuliePowell,M.D.
SPEAkERS
Maria Cecilia Garzon, MD
Kimberly A Horii, MD
Amy J Nopper, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Recognize high-risk infantile hemangiomas, identify indications
for treatment, and select proper treatment modalities
2 Diferentiate which infantile hemangiomas require further
investigation and which tests to perform, specifcally the role
of imaging
3 Discuss the use of systemic therapies for problematic infantile
hemangiomas and their potential side efects
DESCRIPTION
Infantile hemangiomas (IH) are the most common benign tumors
of infancy Practicing dermatologists and residents should be
aware of potential complications that may require treatment to
prevent signifcant morbidity and/or mortality Tis forum will
focus on the identifcation, evaluation, and management of high-
risk IH, including an update on PHACE(S) syndrome Te role
of imaging will be presented as well as hemangioma mimickers
Te use of systemic treatments, including corticosteroids,
vincristine, interferon alfa, and beta-blockers, will be reviewed
Te management of ulcerated hemangiomas will also be discussed
Recent hemangioma literature and research will be highlighted
2.00Category1CMECredits
SCHEDULE
9:00 am High-Risk Hemangiomas / Dr.Horii
9:30 am Hemangioma Mimickers and the Role Of Imaging
/ Dr.Powell
10:00 am Topical Treatment of IH and Management of
Ulcerated Hemangiomas / Dr.Garzon
10:30 am Systemic Treatment of Infantile Hemangiomas
/ Dr.Nopper
FOCUS SESSION
7:15 am to 8:45 am
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U048 Challenging Cases in Pediatric
Dermatology
Room: 269
DIRECTOR LeahT.Belazarian,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Discuss the clinical features of several challenging pediatric
dermatology diagnoses
2 Identify an appropriate management strategy and treatment
plan for these diagnoses
DESCRIPTION
Tis focus session is designed for the general dermatologist and
dermatology resident who wants to gain more confdence with
difcult pediatric dermatology patients Several challenging cases
will be covered with regard to diferential diagnosis, laboratory
testing, dermatopathology, and management Examples
of diagnoses to be discussed include morphea and infantile
hemangiomas
1.50Category1CMECredits
FORUM
9:00 am to 11:00 am
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
For description of session categories and fees see page 37
118
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
FORUM
9:00 am to 11:00 am
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F025 Dramatic Oral Disease
Room: 255/256/257
DIRECTOR RoySteeleRogersIII,M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Recognize dramatic oral diseases
2 Describe the pathogenesis of these dramatic oral diseases
3 Evaluate and manage these dramatic oral diseases
DESCRIPTION
Tis forum will present a series of dramatic oral diseases
Conditions such as orofacial granulomatosis (Melkersson-
Rosenthal syndrome, Miescher’s cheilitis granulomatosa),
pyostomatitis vegetans, atypical gingivostomatitis, desquamative
gingivitis, mucosal variants of lichen planus, and simple and
complex aphthosis will be discussed Te learner will recognize,
understand, and be able to evaluate and manage these dramatic
oral diseases
2.00Category1CMECredits
F026 Chronic Urticaria and Angioedema:
What’s New in Pathogenesis and
Treatment
Room: 278/279/280
DIRECTOR DianeRomayneBaker,M.D.
SPEAkERS
James Baker, MD
Nicholas Arthur Soter, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Defne, recognize, and diferentiate patients with acute
urticaria, chronic idiopathic and chronic autoimmune urticaria
2 Diferentiate patients with urticaria with associated angioedema
from patients with C1 esterase defciency-related angioedema
3 Select appropriate treatments for acute urticaria patients and
for chronic urticaria patients not controlled by antihistamines
and for patients with hereditary angioedema
DESCRIPTION
Antihistamine-resistant chronic urticaria, with or without
angioedema, is a challenging condition for aficted patients to
live with and for physicians to treat In this session we will review
acute and chronic urticaria diagnosis and treatment, discuss the
diference between urticaria and angioedema, discuss autoimmune
urticaria as a subset of chronic idiopathic urticaria and provide
an update on diagnosis of and treatments for hereditary and
idiopathic angioedema A review of the recent literature on
treatments for severe cases of chronic urticaria as well as speakers’
personal experience will be presented
2.00Category1CMECredits
SCHEDULE
9:00 am Overview of Urticaria and Angioedema: Diagnosis
and Diferences, Pathogenesis and Treatment
/Dr.Baker
9:35 am Urticaria and Angioedema: Treatments Based on
Pathogenetic Mechanisms/Dr.Baker
10:10 am New and Novel Treatment Options for Severe Cases
of Chronic Urticaria/Dr.Soter
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
119
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
F028 What You Need to know About Coding
But Were Afraid to Ask
Room: 293/294
DIRECTOR JosephS.Eastern,M.D.
SPEAkERS
James A Zalla, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Complete the coding of insurance claims accurately and
efciently
2 Determine with improved accuracy the correct alternative
when multiple coding options are present
DESCRIPTION
Coding is a necessary evil in the modern practice of medicine It
is a skill all physicians and ofce administrators must master to
maximize speedy, fair, and equitable reimbursement for services
rendered In this forum, two members of the AAD Coding and
Reimbursement Task Force, each with many years of experience
in the process of coding and in dealing with coding issues afecting
private practitioners across the country, will discuss difcult coding
situations and dilemmas Tey also will update the audience on the
latest coding rules and controversies A substantial portion of the
allotted time will be reserved for questions from the audience
2.00Category1CMECredits
FORUM
9:00 am to 11:00 am
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F027 Practical Approaches to Patient
Problems
Room: 281/282
DIRECTOR MichaelP.Hefernan,M.D.
SPEAkERS
Grace D Bandow, MD Gary Goldenberg, MD
David Berk, MD Jefrey E Petersen, MD
Amit Garg, MD Matthew Zirwas, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Describe the best treatment options for difcult medical
dermatology problems
2 Outline the best approach to problematic surgical cases
3 Discuss treatment options for difcult pediatric dermatology
problems
DESCRIPTION
A panel of medical, surgical, and pediatric dermatologists
will discuss their practical approaches to difcult therapeutic
problems Trough the use of an audience-controlled electronic
input device, forum participants will be able to compare their
impressions anonymously with those of other attendees in real
time Additionally, audience participation during the discussion
will be encouraged
2.00Category1CMECredits
SCHEDULE
9:00 am Medical Dermatology/Dr.Zirwas
9:20 am Medical Dermatology/Dermpath/Dr.Bandow
9:40 am Surgical Dermatology/Dr.Petersen
10:00 am Pediatric Dermatology/Dr.Berk
10:20 am Medical Dermatology/Dermpath/Dr.Goldenberg
10:40 am Medical Dermatology/Dr.Garg
For description of session categories and fees see page 37
120
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
FORUM
9:00 am to 11:00 am
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F029 Acne and Rosacea Update
Room: 295/296
DIRECTOR JulieClaireHarper,M.D.
SPEAkERS
James Q Del Rosso, DO
Diane M Tiboutot, MD
Guy F Webster, MD, PhD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Evaluate the role of diet in the development of acne
2 Examine the role of benzoyl peroxide in the treatment of acne
and discuss controversies associated with isotretinoin
3 Identify the pathogenesis and treatment of rosacea
DESCRIPTION
Te session will focus on several important issues associated with
acne and rosacea First, the potential role of diet in acne will
be reviewed in detail Additionally, the importance of benzoyl
peroxide in the treatment of acne will be discussed Controversies
surrounding isotretinoin use will be covered including isotretinoin
and infammatory bowel disease Lastly, an update of rosacea
pathogenesis and treatment will be presented
2.00Category1CMECredits
SCHEDULE
9:00 am Diet and Acne/Dr.Tiboutot
9:20 am Questions and Answers/Dr.Tiboutot
9:25 am Isotretinoin Controversies/Dr.Harper
9:45 am Questions and Answers/Dr.Harper
9:50 am Benzoyl Peroxide/Dr.DelRosso
10:10 am Questions and Answers/Dr.DelRosso
10:15 am Rosacea Update/Dr.Webster
10:45 am Questions and Answers/Dr.Webster
F030 Managing Online Reputation
Room: 391
DIRECTOR ClifordWarrenLober,M.D.,J.D.
SPEAkERS
Brenda Jean Dintiman, MD
Steven R Feldman, MD, PhD
Kevin C Smith, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Manage his/her online reputation
2 Evaluate internet physician rating sites
3 Recognize efective means of responding to defamatory
comments on the internet
DESCRIPTION
It is critical that physicians be aware of comments made about
them on internet sites since disparaging comments can be
posted by disgruntled patients, former employees, competitors,
ex-spouses, etc Comments may appear on physician rating sites
as well as on more generic sites (yellowpagescom, angieslistcom,
etc) and persist for years Presenters will include a dermatologist
who has established and maintains a well-known physician
rating site We will examine the legal elements of libel as well
as the defenses raised by persons posting ofensive comments
We will then focus on if, when, and how to respond to negative
comments
2.00Category1CMECredits
SCHEDULE
9:00 am Introduction/Dr.Lober
9:05 am Slammed on the Internet!/Dr.Dintiman
9:15 am Survey of Internet Sites/Dr.Smith
9:35 am Is the Comment Legally Libel?/Dr.Lober
10:05 am Managing an Internet Rating Site/Dr.Feldman
10:30 am How to Respond to Libel/Dr.Lober
10:45 am Questions and Answers/Faculty
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
121
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
W004 MOC Self-Assessment: Procedural
Dermatology
M
O
C

Room: 288/289/290
DIRECTOR ChristieTraveluteAmmirati,M.D.
SPEAkERS
Elizabeth M Billingsley, MD Summer R Youker, MD
Christine Poblete-Lopez, MD
LEARNING OBjECTIVES
Following this workshop, the attendee will be able to:
1 Identify the strengths and weaknesses in one’s knowledge base
of dermatologic surgery and make improvements as needed
2 Demonstrate commitment to lifelong learning and
self-assessment via completion of a forum of 25 questions and
answers
DESCRIPTION
Tis session will present 25 questions that cover several subjects
in dermatologic surgery Te attendee will be able to assess his/her
level of understanding through the questions and explanations of
the correct answers
2.00Category1CMECredits
SCHEDULE
9:00 am Questions 1 through 5/Dr.Youker
9:25 am Questions 6 through 10/Dr.Billingsley
9:50 am Questions 11 through 15/Dr.Poblete-Lopez
10:15 am Questions 16 through 25/Dr.Ammirati
*Self-assessmentquestionsutilizedinthissessionarethe
sameasthoseusedforForumF086andWorkshop
W001MOC:Self-AssessmentoferedatAnnual
Meeting2009and2010.Physiciansshouldnot
claimCME/MOCcreditforattendingthissessionif
theyattendedForumF086andWorkshopW001at
AnnualMeeting2009and2010.
FORUM
9:00 am to 11:00 am
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F031 Food Allergy and Dermatology
Room: 252/253/254
DIRECTOR JonM.Hanifn,M.D.
SPEAkERS
James Bergman
Lawrence Eichenfeld, MD
Matthew Fenton, MD, PhD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Recognize the availability of the new NIAID food allergy
guidelines
2 Diferentiate between true food allergy and misapprehensions
3 Discuss the indications and limitations of allergy testing
DESCRIPTION
Te forum will review the development of the 2010 NIAID food
allergy guidelines and how they provide a structure for evidence-
based evaluation and care of possibly afected patients Emphasis
will focus especially on management of atopic dermatitis and on
counseling of patients and parents who seek diagnosis and testing
for food allergy
2.00Category1CMECredits
SCHEDULE
9:00 am NIAID Food Allergy Guidelines: Background and
Highlights/Dr.Fenton
10:00 am Controversies in Defnition, Assessment, and
Treatment/Dr.Hanifn
10:30 am Food Allergy Testing: Appropriate and Inappropriate
Use/Dr.Bergman
10:30 am Testing/Dr.Eichenfeld
WORkSHOP
9:00 am to 11:00 am
Tuition fee and ticket required for admission.
For description of session categories and fees see page 37
122
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
COURSE
9:00 am to 12:00 pm
Tuition fee and ticket required for admission.
C06E Basic Self-Assessment of
Dermatopathology Discussion
Room: 243/244/245
DIRECTOR ClayJ.Cockerell,M.D.
SPEAkERS
Antoanella Bardan, MD Pedram Gerami, MD
Brook L Brouha, MD Carrie L Kovarik, MD
Tomas L Davis, MD Scott D McClellan, MD
Rosalie Elenitsas, MD Carlos Ricotti Jr, MD
Steven R Feldman, MD, PhD Mary S Stone, MD
James E Fitzpatrick, MD Kien T Tran, MD, PhD
Kyle J Garton, MD
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1 Interpret and identify dermatologic histological diagnoses more
efectively and accurately
2 Classify and recognize common histopathologic skin conditions
and formulate diferential diagnoses
DESCRIPTION
Attendees will view 60 slides from skin biopsy specimens in a
format that will allow self-assessment Cases will span the full
spectrum of dermatopathology Each specimen will be discussed
by a faculty member with emphasis placed on establishing the
correct diagnosis and consideration of the diferential diagnosis
Tese sessions are directed to dermatology residents and practicing
dermatologists
2.00Category1CMECredits
SCHEDULE
9:00 am Cases 1-5/Dr.Fitzpatrick
9:15 am Cases 6-10/Dr.Stone
9:30 am Cases 11-15/Dr.Brouha
9:45 am Cases 16-20/Dr.Kovarik
10:00 am Cases 21-25/Dr.McClellan
10:15 am Cases 26-30/Dr.Elenitsas
10:30 am Cases 31-35/Dr.Gerami
10:45 am Cases 36-40/Dr.Ricotti
11:00 am Cases 41-45/Dr.Tran
11:15 am Cases 46-50/Dr.Davis
11:30 am Cases 51-55/Dr.Garton
11:45 am Cases 56-60/Dr.Feldman
12:00 pm Questions and Answers/Dr.Bardan
Pleasenote:Mustberegisteredforoneofthefollowingsessions
C06A,B,C,orDtoattendthissession.
C013 Advanced Botulinum Toxin: Live Patient
Demonstration
Room: Auditorium B
DIRECTOR SethL.Matarasso,M.D.
SPEAkERS
Fredric S Brandt, MD Ronald L Moy, MD
Joel Lee Cohen, MD Tomas E Rohrer, MD
Kyle Coleman, MD Nowell J Solish, MD
William P Coleman III, MD Patricia S Wexler, MD
Patricia Farris, MD Joshua M Wieder, MD
Mary P Lupo, MD
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1 Recognize the various etiologies of rhytids
2 Select and formulate the appropriate aesthetic treatment plan
with botulinum toxin and/or soft tissue augmentation for
patients who present for improvement in facial appearance
3 Identify and manage complications and adverse events of
procedures involving injectable materials
DESCRIPTION
Tere are many causes of facial wrinkles and a comparable
number of treatment options Tis course is designed to identify
the underlying cause of rhytids and distinguish the diferences
between photodamage, muscle hypertrophy, and subcutaneous
tissue loss Te indications and technique for the administration of
botulinum toxin in the upper third of the face will be addressed,
and the rationale and selection criteria for the use of fllers to
improve the lower face will be discussed Tis session uses a new
format that will attempt to incorporate audience participation and
interaction It is hoped that practical clinical questions regarding
toxin and fllers can be adequately addressed by the panel
3.00Category1CMECredits
SCHEDULE
9:00 am Welcome and Introduction /Dr.Matarasso
9:10 am Treating the Upper Tird of the Face with Botox
While Maximizing Brow Elevation /Dr.Wieder
9:25 am Complications with Botox in the Upper Tird
of the Face and How to Treat Tem /Dr.Moy
9:40 am Monotherapy with Botox in the Lower Tird
of the Face / Dr.Solish
9:55 am Complications with Botox in the Lower Tird
of the Face and How to Treat Tem /Dr.Cohen
10:10 am Dysport for Dummies: Everything You Wanted
to Know About Dysport But Were Afraid to Ask
/Dr.Rohrer
10:25 am Dysport, Te NYC Experience: Who, When and
Where Do I Treat / Dr.Wexler
10:50 am Neurotoxins on the Horizon and Teir Status
/Dr.Brandt
11:05 am Live Patient Demonstration with Neurotoxins
/ Dr.Coleman/Dr.Farris/Dr.Lupo
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
123
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
SCIENTIFIC SESSIONS
COURSE
9:00 am to 12:00 pm
Tuition fee and ticket required for admission.
C014 Coding, Documentation, and Practice
Management
Room: Auditorium A
DIRECTOR CharlesN.Ellis,M.D.
SPEAkERS
Clay J Cockerell, MD Wayne Sotile, PhD
Scott M Dinehart, MD Allan S Wirtzer, MD
Jesse M Kramer, MD Mark J Zalla, MD
Mary Sotile, PhD James A Zalla, MD
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1 Utilize CPT codes to describe provided professional services
accurately
2 Implement techniques leading to greater efciencies and
patient satisfaction
3 Use strategies to maximize personal accomplishment
DESCRIPTION
Tis popular session will continue its successful approach to
providing the latest updates on proper coding and documentation
of various types of professional services Practice management
topics will touch on patient and physician satisfaction, efciency
methods, and dealing with insurers Two nationally-recognized
speakers will demonstrate how physicians can maximize personal
resiliency and achievement We will endeavor to make each topic
practical and useful immediately upon return to work
3.00Category1CMECredits
REFERENCES
1 Derm Coding Consult Published quarterly by American
Academy of Dermatology
SCHEDULE
9:00 am Introduction to Course; Achieving the Pinnacle of
Patient Satisfaction/Dr.Ellis
9:20 am Improve Your Ofce Efciency/Dr.Kramer
9:40 am Negotiating with Insurance Carriers/Dr.Zalla
10:00 am Coding and Documentation: A Focused Approach
/Dr.Wirtzer
10:20 am Achieve More by Letting Go of What’s Holding
You Back/Mr.Sotile / Mrs.Sotile
10:50 am Surgical Coding/Dr.Zalla
11:10 am Dermatopathology Coding/Dr.Cockerell
11:30 am Updates from AAD Coding and Reimbursement
Task Force/Dr.Dinehart
11:45 am Questions and Answers/Faculty
Essential Manuals
for Every
Dermatology Practice
Teaches techniques that strengthen practice
operations and improve the patient experience.
Provides a framework for quickly hiring, training,
and managing offce staff.
Assists dermatologists and billing staff in
submitting accurate claims to improve the
reimbursement process.
Offce Policy and
Procedure Manual:
A Guide for
Dermatology Practices
Dermatology
Employment Manual:
A Guide to Personnel
Policies and Procedures
Order these manuals and
others from the PME Series
at the Academy Resource
Center Booth 3623 today!
AAD’s 2011 Coding
and Documentation
Manual: A Guide for
Dermatology Practices
N
E
W
!
For description of session categories and fees see page 37
124
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
SYMPOSIUM
9:00 am to 12:00 pm
Open admission, no tuition or ticket.
S014 Patient Safety and Quality
Room: 383/384/385
DIRECTOR JamesSelwynTaylor,M.D.
SPEAkERS
Jacques Michael Casparian, MD Tri H Nguyen, MD
Brett M Coldiron, MD Mark R Pittelkow, MD
C William Hanke, MD Robert Swerlick, MD
Hillary D Alice C Watson, MD
Johnson-Jahangir, MD, PhD
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Defne patient safety and quality and describe their major
tenets; and analyze the importance of patient safety and quality
metrics for delivering the best dermatological care
2 Describe the major patient safety issues in dermatology:
medication errors, misdiagnosis or delayed diagnosis, pathology
specimen processing, communication of laboratory or biopsy
results, wrong-site procedures, patient identifcation, and
supervision of ancillary staf
3 Summarize, evaluate and manage adverse events and errors
related to Mohs and ofce surgery, hygiene and preventive
strategies for infections and other patient safety measures
focused on practice improvement
DESCRIPTION
With the growing focus on patient safety and quality throughout
medicine, this year’s symposium will discuss both quality and
patient safety Speakers include national dermatology patient
safety experts who will review health care quality and its metrics;
the approach to quality at the VA, and quality issues related to
electronic medical records and patient medication sampling
We will also discuss patient safety issues in dermatology ofces
emphasizing laboratory errors, a focus on major safety issues in
Mohs and ofce surgery, ofce accreditation and patient safety
and the role of proper hand hygiene in preventing infections and
assessing safety and applying specifc patient safety principles
in the ofce Our goal is to provide you with a practical
understanding of ideas which are easy to implement in your
practice and which are in the best interests of your patients
3.00Category1CMECredits
REFERENCES
1 Elston D, Taylor JS, Coldiron B, et al Patient safety part 1:
Patient safety and the dermatologist JAmerAcadDermatol.
2009; 61:171-190
2 Elston D, Stratman E, Johnson H, et al Part 2: Opportunities
for improvement in patient safety JAm.AcadDermatol. 2009;
61:193-205
3 Cao L, Taylor JS, Vidimos AT Patient safety in dermtology,
A reveiw of the literature DermatolOnLineJ 2010; 16:3
SCHEDULE
9:00 am Introduction/Dr.Taylor
9:05 am Health Care Quality: What Is It and How Is It
Measured?/Dr.Johnson-Jahangir
9:25 am Health Care Quality at the Veterans Administration and
Its Relation to Dermatology Practice/Dr.Casparian
9:45 am Do Electronic Medical Records Improve Patient
Quality and Safety?/Dr.Pittelkow
10:05 am Sample Medication Dispensing and Quality Care
/Dr.Watson
10:20 am Patient Safety Issues in Dermatology and Avoiding
Laboratory Errors/Dr.Swerlick
10:40 am Real-Life Patient Safety Issues in Mohs and Ofce
Surgery/Dr.Nguyen
11:00 am Ofce Accreditation and Patient Safety/Dr.Coldiron
11:20 am Te Importance of Hand Hygiene in the Ofce
/Dr.Watson
11:40 am Is the Dermatology Ofce Safe?/Dr.Hanke
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
125
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
SCIENTIFIC SESSIONS
S016 Drug Actions
Room: 260/261/262
DIRECTOR BruceElliotStrober,M.D.,Ph.D.
SPEAkERS
Joel M Gelfand, MD, MSCE James G Krueger, MD, PhD
Kenneth B Gordon, MD Craig L Leonardi, MD
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Critically evaluate evidenced-based studies examining the use of
novel therapeutics for the treatment of cutaneous disease
2 Summarize the novel mechanisms of action that are related
to the pathophysiology of infammatory skin diseases such as
psoriasis and atopic dermatitis
3 Apply the knowledge of the mechanisms of action of
infammatory skin diseases to treatment during clinical
practice
DESCRIPTION
Based on the peer-reviewed literature and recently presented data
of the past year, this symposium will review the pathophysiologic
mechanisms of infammatory disease, with an emphasis on
psoriasis and atopic dermatitis Novel therapeutic options both in
early development and near FDA approval will be discussed with
regard to both safety and efcacy
3.00Category1CMECredits
SCHEDULE
9:00 am Drug Safety/Dr.Gelfand
9:30 am New Terapeutic Targets for Infammatory Skin
Disease/Dr.Krueger
10:00 am Update on IL-12/23 Inhibition for Psoriasis
/Dr.Leonardi
10:30 am Atopic Dermatitis: Update on Basic Science and
Terapeutics/Dr.Gordon
11:00 am Biologic Terapy: Controlling Immunogenicity and
Loss of Response/Dr.Strober
SYMPOSIUM
9:00 am to 12:00 pm
Open admission, no tuition or ticket.
S015 Advanced Pediatric Dermatology
Room: Auditorium C
DIRECTOR SheilaFallonFriedlander,M.D.
SPEAkERS
Anna Lee Bruckner, MD Denise W Metry, MD
Adelaide A Hebert, MD Amy S Paller, MD
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Apply recent fndings in the diagnosis and treatment of
mechanobullous disorders
2 Summarize the latest discoveries and therapies for infantile
vascular lesions
3 Review pharmacotherapeutic concepts relevant to pediatric
dermatology
DESCRIPTION
Tis advanced pediatric dermatology symposium will focus on
“state-of-the-art” issues in our specialty Recent advances and our
understanding of epigenetics and genetic disorders that impact
on pediatric practice will be reviewed Mechanobullous disorders
and pediatric vascular lesions will be discussed Te latest
pharmacotherapeutic fndings impacting on pediatric dermatology
will be ofered, and we will fnish with an overview of the state of
our specialty in 2011
3.00Category1CMECredits
REFERENCES
1 Textbook of Neonatal Dermatology - 2nd Edition
2 Hurwitz Clinical Pediatric Dermatology - 3rd Edition
3 Nelson Textbook of Pediatrics - 18th Edition
SCHEDULE
9:00 am Welcome/Dr.Friedlander
9:05 am Update on Mechanobullous Disorders in Children
/Dr.Bruckner
9:35 am Vascular Lesions in Children - What Have We
Learned?/Dr.Metry
10:05 am New Pharmacotherapeutic Concepts Impacting on
Pediatric Dermatology/Dr.Hebert
10:35 am Questions and Answers/Faculty
10:45 am Te “Genetic Landscape” in Pediatric Dermatology
/Dr.Paller
11:15 am Pediatric Dermatology: Te State of Our Specialty in
2011/Dr.Friedlander
11:45 am Questions and Answers/Faculty
For description of session categories and fees see page 37
126
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
SYMPOSIUM
9:00 am to 12:00 pm
Open admission, no tuition or ticket.
S017 Therapeutic Decision Making in
Cutaneous Oncology
Room: La Nouvelle Orleans Ballroom
DIRECTOR DesireeRatner,M.D.
SPEAkERS
Monica L Halem, MD Seaver Soon, MD
Hillary D Johnson- Bret Taback, MD
Jahangir, MD, PhD Timothy S Wang, MD
Elizabeth H Knobler, MD Fiona O’Reilly Zwald, MD
Deborah MacFarlane, MD, MPH
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Discuss current and evolving approaches to the evaluation and
management of patients with challenging skin cancers
2 Examine current controversies in the evaluation and
management of patients with melanoma, squamous cell
carcinoma, and angiosarcoma
DESCRIPTION
Current and evolving approaches to the evaluation and
management of challenging skin cancers will be the focus of this
session Controversial issues in cutaneous oncology will also be
addressed
2.75Category1CMECredits
SCHEDULE
9:00 am Introduction/Dr.Ratner
9:05 am How Do I Manage a Patient with Basal nevus
Syndrome Who Presents with Tens, if not Hundreds,
of Tumors?/Dr.Halem
9:20 am What Should I do When the Biopsy Says Tat My
Patient Has Angiosarcoma?/Dr.Wang
9:40 am How Do I Manage a Patient with Eruptive
Keratoacanthomas?/Dr.Soon
9:55 am Should I Even Consider Treating Lentigo Maligna
with Topical Imiquimod?/Dr.Zwald
10:10 am Questions and Answers/Faculty
10:20 am Break/Faculty
10:30 am When Should a Patient with a Melanoma Less Tan
1 mm in Depth Be Considered for a Sentinel Lymph
Node Biopsy?/Dr.Taback
10:45 am What Should I do When the Biopsy Report Shows a
Clonal T-cell Proliferation?/Dr.Knobler
11:05 am What Should I Do with a Patient Without a Personal
or Family History of Melanoma Who Presents with
More Tan 50 Large Asymmetric Nevi?
/Dr.Johnson-Jahangir
11:25 am Should I Perform Surgery When the Biopsy Suggests
Squamous Cell Carcinoma and I don’t Believe Tat
the Patient Has a Malignancy?/Dr.MacFarlane
11:45 am Questions and Answers/Faculty
S018 Late-Breaking Research
Room: 386/387
DIRECTOR RichardL.Gallo,M.D.,Ph.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Identify recent topics in skin research
2 Share information to increase progress in the diagnosis and
therapy of skin disease
3 Identify next steps for research in dermatology
DESCRIPTION
All members of the Academy are invited to submit abstract
presentations for review for Late-Breaking Research Te Late-
Breaking Research Session provides an opportunity for a 9-minute
presentation A maximum of 14 abstracts can be accepted for oral
presentation and 5-10 alternates Abstract descriptions are limited
to 150 words
3.00Category1CMECredits
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
127
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
SCIENTIFIC SESSIONS
C016 Advanced Self-Assessment of
Dermatopathology
Room: 275/276/277
DIRECTOR AnitaC.Gilliam,M.D.,Ph.D.
SPEAkERS
Lyn M Duncan, MD Rishi R Patel, MD
Tammie C Ferringer, MD Ronald P Rapini, MD
Whitney A High, MD John T Seykora, MD
Kord S Honda, MD Alun R Wang, MD
Jennifer Madison McNif, MD
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1 Recognize the pathology of 50 cases of challenging skin lesions
2 Identify the clinical and pathological features of the 50 cases
DESCRIPTION
Te self-assessment course in dermatopathology is designed to
allow participants to test their skills and knowledge Te faculty
is not able to give an all-inclusive review in this session, but they
will include the major areas of skin disease with emphasis on the
diagnosis and clinical correlations of some important skin diseases
6.00Category1CMECredits
COURSE
9:00 am to 5:00 pm
Tuition fee and ticket required for admission.
C015 Internal Medicine
Room: 238/239
DIRECTOR MartaJ.Petersen,M.D.
SPEAkERS
Timothy G Berger, MD Joseph C English III, MD
Jefrey D Bernhard, MD Warren R Heymann, MD
Jean L Bolognia, MD Whitney A High, MD
Kristina Patrice Callis-Dufn, MD Julie V Schafer, MD
Mark D P Davis, MD Robert Swerlick, MD
Dirk Michael Elston, MD John Joseph Zone, MD
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1 Diagnose skin conditions with systemic diseases more
efectively
2 Manage patients with skin disease associated with systemic
disease
3 Appropriately evaluate patients with skin disease and systemic
disease
DESCRIPTION
Tis course will provide an update on skin manifestations of
systemic disease as well as systemic diseases associated with skin
disease Skin fndings, evaluation and management of patients
with internal diseases including paraproteinemias, infammatory
bowel disease, thryoid disease, infections, rheumatoid arthritis,
and hypercoagulable states will be discussed Skin diseases with
associated systemic disease including bullous disease, psoriasis,
calciphylaxis, and pruritus will also be presented Tis course is
directed at practicing dermatologists and dermatology residents
6.00Category1CMECredits
SCHEDULE
9:00 am Introduction/Dr.Petersen
9:05 am Skin Signs of Systemic Disease/Dr.English
9:30 am Paraproteinemias and the Skin/Dr.Bolognia
10:00 am Calciphylaxis/Dr.Davis
10:30 am Te Skin and the Tyroid 2011/Dr.Heymann
11:00 am Pruritus: When Is It More Tan Skin Deep?
/Dr.Bernhard
11:30 am Cutaneous Vasculitis/Dr.Elston
2:00 pm Hypercoagulable States and the Skin/Dr.Swerlick
2:30 pm Cutaneous Manifestations of Infections/Dr.High
3:00 pm Psoriasis and its Co-Morbidities/Dr.Callis-Dufn
3:30 pm Systemic Disease Associated with Bullous Diseases
/Dr.Zone
4:00 pm Infammatory Bowel Disease and the Skin/Dr.Berger
4:30 pm Cutaneous Manifestations of Rheumatoid Arthritis
/Dr.Schafer
For description of session categories and fees see page 37
128
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
COURSE
9:00 am to 5:00 pm
Tuition fee and ticket required for admission.
C017 Advanced Dermoscopy
Room: 291/292
DIRECTOR RalphP.Braun,M.D.
SPEAkERS
Giuseppe Argenziano, MD Margaret C Oliviero, NP
Horacio Antonio Cabo, MD Giovanni Pellacani, MD
James M Grichnik, MD, PhD Susana Puig, MD
Rainer Hofmann-Wellenhof, MD Harold S Rabinovitz, MD
Robert H Johr, MD Alon Scope, MD
Harald Kittler, MD H Peter Soyer, MD
Joseph Malvehy, MD Wilhelm Stolz, MD
Ashfaq A Marghoob, MD Steven Q Wang, MD
Scott Menzies, MBBS, PhD Iris Zalaudek, MD
Nir Nathanson, MD, MHS
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1 Discuss new, more advanced dermoscopy topics
2 Diagnose and manage difcult situations with more
confdence
3 Utilize dermoscopy in practice with more confdence
DESCRIPTION
Tis course will cover selected new aspects of dermoscopy at an
advanced level such as new dermoscopy criteria and false-positive
or false-negative diagnosis Lesions in special locations (eg, scalp,
mucosa, face, acral, nails) will be covered We recommend that the
participants should be using dermoscopy already and be familiar
with the nomenclature Tis session will not cover all aspects of
dermoscopy nor the basic features
6.00Category1CMECredits
REFERENCES
1 Braun RP, Rabinovitz HS, Oliviero M, Kopf AW, and
Saurat JH Dermoscopy of pigmented skin lesions JAmAcad
Dermatol 2005; 52 (1):109-121,
2 Marghoob AA, Braun RP, and Kopf AW AnAtlasof
Dermoscopy, New York:Taylor Francis; 2005
3 Malvehy J, Puig S, Braun RP, Marghoob AA, Kopf AW
HandbookofDermoscopy. New York: Taylor Francis; 2006
SCHEDULE
9:00 am Subtypes of Melanoma / Dr.Stolz
9:20 am Dermoscopy in Te Gray Zone Between Nevus and
Melanoma / Dr.Grichnik
9:40 am Vascular Architecture / Dr.Rabinovitz
10:00 am Dermoscopy of Melanoma and Chrysalis-Like
Structures / Dr.Marghoob
10:20 am Unknowns for the Experts / Oliviero,NP
10:40 am Te Role of Dermatopathology in the Evaluation
of Equivocal Dermoscopic Lesions / Dr.Soyer
11:00 am Pattern Analysis: A New Concept / Dr.Kittler
11:20 am Digital Monitoring of Pigmented Lesions
/ Dr.Menzies
11:40 am Challenging Cases For Te Audience / Dr.Johr
2:00 pm Lesion Selection For Dermoscopy / Dr.Scope
2:15 pm Spitz Nevi / Atypical Spitz Nevi / Dr.Pellacani
2:30 pm Dermoscopy in General Dermatology / Dr.Puig
2:45 pm False-Positive and False-Negative Diagnosis
/ Dr.Argenziano
3:10 pm Dermoscopic Clues / Dr.Zalaudek
3:30 pm Unknowns for the experts / Dr.Argenziano
3:50 pm Nail Pigmentations / Dr.Braun
4:10 pm Difcult Acral Lesions / Dr.Hofmann-Wellenhof
4:25 pm Difcult Lesions of the Face / Dr.Malvehy
4:40 pm Unkowns for the Experts with Histopathological
Correlation /Dr.Malvehy
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
129
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
FORUM
12:00 pm to 2:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F032 Multidisciplinary Preventive Networking
in Occupational Contact Dermatitis
Room: 295/296
DIRECTOR SwenMJohn,M.D.
SPEAkERS
Stephan Brandenburg, JD Howard Ira Maibach, MD
D Linn Holness, MD Rosemary L Nixon, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Identify cases and describe systematic strategies for the
prevention of occupational skin disease (OSD)
2 Assess the socioeconomic burden of OSD and the active role of
dermatology for society
3 Distinguish the various pathogeneses of OSD and predict
outcome in individual cases
DESCRIPTION
Occupational skin diseases (OSD) are at the top of occupational
diseases in most industrialized countries and have a huge
socioeconomic impact due to prolonged sick leave and loss of
productivity In the past years, various concepts to improve OSD
prevention have been successfully put to practice; the focus is
on appropriate diagnostics and therapy and interdisciplinary
(dermatological/educational) skin protection training programs for
high-risk professions, involving clinics and practices Dermatologists
by their specifc knowledge and competence - in cooperation with
other disciplines - can save their patient’s health and jobs, and thus
also save expenses for taxpayers and insurance systems
2.00Category1CMECredits
SCHEDULE
12:05 pm Cases from the Coal Face/Dr.Nixon
12:35 pm Specialized Patch Testing in Occupational Allergic
Contact Dermatitis/Dr.Holness
1:00 pm Anti Irritants-Science and Reality-Hope?/Dr.Maibach
1:14 pm Evidence-Based Prevention From an Accident
Insurance’s Point of View/Mr.Brandenburg
1:28 pm Preventive Networking in Occupational Dermatology:
Future Options for Our Patients and Our Specialty
/Dr.John
Your website should
communicate your values,
educate your patients and create
your “brand identity” on the Internet.
AADDermsOnline.org, the official web
service provider of the American Academy
of Dermatology, has the tools to ensure you
have the best web presence possible!
33% off
set-up fees
for AAD
members!
YOUR WEBSITE
speaks for
YOUR PRACTICE…
What is your
website saying?




For more information on
AADDermsOnline.org,
visit the Academy Resource
Center Booth 3623!
For description of session categories and fees see page 37
130
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
FORUM
12:00 pm to 2:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F033 Introduction to Oral Dermatology
Room: 252/253
DIRECTOR GinatW.Mirowski,DMD,M.D.
SPEAkERS Bethanee Jean Schlosser, MD, PhD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Perform an oral examination and diagnose common oral
conditions efectively
2 Develop a therapeutic approach to challenging oral conditions
3 Select the proper oral biopsy technique
DESCRIPTION
Tis forum will review the oral examination and present common
oral lesions, a therapeutic approach to a number of challenging
oral conditions, and an introduction to performing oral biopsies
2.00Category1CMECredits
SCHEDULE
12:00 pm Introduction to the Oral Examination/Dr.Mirowski
12:30 pm Common and Challenging Oral Lesions/Dr.Schlosser
1:00 pm Challenging Oral Conditions/Dr.Mirowski
1:15 pm Te Oral Biopsy/Dr.Mirowski
F034 From the Dermatology Rheumatology
Clinics: Practical Tips and Advances in
Management
Room: 278/279/280
DIRECTOR AbrarA.Qureshi,M.D.,M.P.H.
SPEAkERS
Elizabeth A Buzney, MD Ruth Ann Vleugels, MD
Arturo P Saavedra- Laura S Winterfeld, MD
Lauzon, MD, PhD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Develop a combined clinic with physicians from multiple
specialties working together
2 Evaluate and work-up patients with cutaneous lupus,
dermatomyositis, fbrotic disorders, pyoderma gangrenosum,
and psoriasis/psoriatic arthritis in a multidisciplinary
environment
3 Treat patients with cutaneous lupus, dermatomyositis, fbrotic
disorders, pyoderma gangrenosum, and psoriasis/psoriatic
arthritis Case studies from multidisciplinary clinics will be
presented
DESCRIPTION
Tis session will include a brief discussion of multidisciplinary
clinic set-up Approach to the patient with cutaneous lupus,
dermatomyositis, psoriasis/psoriatic arthritis, fbrosing disorders, and
pyoderma gangrenosum, including taking a history and physical
examination, laboratory investigations and therapy, will be covered
As examples, case studies from our multidisciplinary clinics will be
presented as dermatologists work with other specialties to manage
and assess the patient together, dwelling on the management and
decision-making process Terapeutic approaches will focus on
case examples to illustrate choice of systemic therapies including
biologics We will spend time on of-label treatment options and
therapeutic pearls mainly, emphasizing the treatment of skin disease
in patients who also have multiorgan disease
2.00Category1CMECredits
SCHEDULE
12:00 pm What’s New in Cutaneous Lupus Erythematosus
/Dr.Buzney
12:20 pm Multidisciplinary Approach to Musculoskeletal Pain
in Psoriasis: Do’s and Don’t’s/Dr.Qureshi
12:40 pm Novel Diagnostic Tools and Terapeutic Advances in
Fibrotic Disorders of the Skin/Dr.Saavedra-Lauzon
1:00 pm Dermatomyositis: Dermatology’s Role in a
Multisystem Disease/Dr.Vleugels
1:20 pm Pyoderma Gangrenosum: Te Perils of Pathergy
/Dr.Winterfeld
1:40 pm Discussion/Faculty
For more information visit the
Academy Resource Center Booth 3623
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
131
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
SCIENTIFIC SESSIONS
F036 Careers in Academic Dermatology

Room: 255/256/257
DIRECTOR MichaelD.Tarp,M.D.
SPEAkERS
Daniel H Kaplan, MD
Mario E Lacouture, MD
Sheetal Mehta, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Recognize academic career opportunities
2 Diferentiate between academic careers and private practice
3 Identify individuals in dermatology departments/sections as
potential academic career advisors
DESCRIPTION
Te goal of this session is to provide dermatology residents and
fellows with an understanding of the opportunities available in
academic medicine Financial compensation and benefts as well
as lifestyle issues and job satisfaction will be discussed Ample time
will be allotted for questions for a panel of young members of
academic programs
2.00Category1CMECredits
SCHEDULE
12:00 pm Introduction to Choosing an Academic Career in
Dermatology/Dr.Tarp
12:10 pm A Career in Surgical Dermatology/Dr.Mehta
12:40 pm A Career in Clinical Dermatology/Dr.Lacouture
1:10 pm A Career in Investigative Dermatology/Dr.Kaplan
1:40 pm Panel Discussion/Faculty
FORUM
12:00 pm to 2:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F035 Practical Aspects of Biologic Therapy
Room: 281/282
DIRECTOR RichardG.B.Langley,M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Develop a practical approach to managing patients on biologic
therapies
2 Select appropriate patients with psoriasis for biologic therapies
DESCRIPTION
Tis session is a case-based, interactive, practical session involving
the use of biologic therapies in the treatment of psoriasis
Participants will be provided with a keypad to provide anonymous
responses to cases as part of an interactive audience response
system, to facilitate discussion, and for interest Cases will involve
the appropriate selection of patients, screening, and choosing the
appropriate biologic agent Practical aspects of managing patients
on biologic therapies will include cases involving vaccinations,
pregnancy, infections, and considerations for those undergoing
surgery Additional cases will be addressed depending on the
attendee’s interest or based on specifc requests
2.00Category1CMECredits
For description of session categories and fees see page 37
132
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
FORUM
12:00 am to 2:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F037 Pediatric Dermatology: Systemic
Evaluation of Cutaneous Findings in
Infants and Children: What’s New and
What’s True?
Room: 293/294
DIRECTOR BethAnnDrolet,M.D.
SPEAkERS
Ilona J Frieden, MD
Maria Cecilia Garzon, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Recognize the distribution and morphology of infantile
hemangiomas that are markers for developmental anomalies
and/or PHACE syndrome
2 Diferentiate benign facial capillary malformations from those
that may be at risk for Sturge-Weber syndrome, glaucoma, and
or other rare syndromes
3 Appropriately evaluate congenital midline anomalies of the skin
in infants and children
DESCRIPTION
Over the last several years there has been an abundance of new
information relating to the evaluation and management of
birthmarks in children How should dermatologists incorporate
this new information into their practices when caring for children
with common and uncommon diseases? Tis session will review
recent literature in pediatric dermatology focusing on appropriate
systemic and radiologic evaluation of cutaneous fndings Specifc
topics include: vascular tumors and malformations as markers
of systemic disease, congenital melanocytic nevi and risk for
neurocutaneous melanosis, and midline cutaneous abnormalities
and risk for developmental anomalies of the nervous system
2.00Category1CMECredits
F038 Itch
Room: 388/389/390
DIRECTOR GilYosipovitch,M.D.
SPEAkERS
Jefrey D Bernhard, MD Amy S Paller, MD
Peter A Lio, MD Tejesh Surenda Patel, MD
Toby A Maurer, MD Jacek C Szepietowski, MD
Scott A Norton, MD, MPH
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Recognize diferent types of itch
2 Describe the pathogenesis of these types of itch
3 Evaluate and manage these types of itch
DESCRIPTION
Tis forum is designed to highlight a variety of diferent types
of chronic itch Expert clinicians will share their experience in
diagnosis and management of neuropathic itch, pediatric itch, itch
in chronic kidney disease, itch in tropical diseases, HIV itch, and
pruritus in oncology patients as well as complementary therapies
for chronic itch Te learner will recognize, understand, and be
able to evaluate and manage these pruritic entities
2.00Category1CMECredits
SCHEDULE
12:00 pm Challenging cases of Neuropathic Itch/Dr.Bernhard
12:00 pm Alternative and Complementary Approaches to
Treatment of Chronic Itch/Dr.Lio
12:00 pm Challenging Cases of Itch: Tropical Infections
/Dr.Norton
12:00 pm HIV Itch and its Management/Dr.Maurer
12:00 pm Challenging Cases of Pediatric Itch/Dr.Paller
12:00 pm Itch in Oncology Patients/Dr.Patel
12:00 pm Challenging Cases of Uremic Itch and Teir
Management/Dr.Szepietowski
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
133
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
SCIENTIFIC SESSIONS
D009 Educate Your Patients and Improve
Outcomes
Room: 240
DIRECTOR KarenE.Edison,M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 Recognize the impact of limited health literacy on patients
2 Utilize existing resources designed to help improve
communication with patients
3 Apply techniques discussed when caring for patients
DESCRIPTION
Te average American reads at a 7th to 8th grade level; those
over age 65, at a 5th to 6th grade level Tis session will
present techniques and resources proven to enhance health
communication with patients Tese resources will assist the
attendee and the staf to communicate in a way that helps patients
process and understand information necessary to make good
health decisions and follow instructions for treatment
1.50Category1CMECredits
D010 Recent Advances in Skin Biology and
Skin Disease
Room: 241
DIRECTOR StephenI.Katz,M.D.,Ph.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 List innovative ways to manage patients with new or old
therapies
2 Identify methods to diagnose easier with new (or old)
information
3 Recognize and use available medications for of-label usage
DESCRIPTION
Attendees are requested to contribute ideas on diagnosis and/or
treatment, both new and old, but preferably innovative
1.50Category1CMECredits
WORkSHOP
12:00 pm to 2:00 pm
Tuition fee and ticket required for admission.
W005 MOC Self-Assessment:
Pediatric Dermatology
M
O
C
Room: 288/289/290
DIRECTOR MoiseL.Levy,M.D.
SPEAkERS
Bernard Cohen, MD
Teresa S Wright, MD
Katherine B Puttgen, MD
LEARNING OBjECTIVES
Following this workshop, the attendee will be able to:
1 Describe the classifcation of vascular birthmarks
2 Manage treatment options for vascular birthmarks
3 Examine the evaluation of selected genodermatoses
DESCRIPTION
Tis session will be of use to dermatologists interested in pediatric/
adolescent dermatology Clinical cases and questions relative to
the cases will be presented An understanding of key references in
pediatric/adolescent dermatology will be gained by attendees
2.00Category1CMECredits
*Self-assessmentquestionsutilizedinthissessionarethe
sameasthoseusedforWorkshopW002andW008
MOC:Self-AssessmentoferedatAnnualMeeting
2010,SummerMeeting2010.Physiciansshouldnot
claimCME/MOCcreditforattendingthissessionif
theyattendedWorkshopW002andW008atAnnual
Meeting2010andSummerMeeting2010.
DISCUSSION GROUP
12:15 pm to 1:45 pm
Tuition fee and ticket required for admission.
For description of session categories and fees see page 37
134
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
FOCUS SESSION
12:15 pm to 1:45 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U049 Avoiding Complications and Maximizing
Results in Cutaneous Laser Surgery
Room: 265/266
DIRECTOR EricF.Bernstein,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Recognize pitfalls in utilizing lasers and other devices on the
skin
2 Manage complications of laser surgery
3 Optimize parameters for safe and efective laser treatment
DESCRIPTION
Te complications workshop is a comprehensive review of
complications and how to avoid them in laser surgery With the
advent of so many new lasers, the ability to understand the key
points behind each technology, as well as pitfalls to avoid in using
these technologies, is becoming more and more difcult Common
pitfalls to avoid will be presented, as well as clues to optimal
treatment settings and tips for maximizing results Te science
behind these devices will be presented in a rudimentary fashion as
it pertains to safe usage of the devices
1.50Category1CMECredits
U050 Viral Exanthem Update
Room: 274
DIRECTOR CarloGelmetti,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Recognize viral exanthems more efectively
2 Diferentiate drug exanthems from microbic exanthems
DESCRIPTION
Exanthem is a word given to a widespread rash that is usually
accompanied by systemic symptoms such as fever or malaise It
is usually caused by an infectious condition such as a virus, and
represents either a reaction to a toxin produced by the organism
or an immune response Exanthems may also be due to a drug,
especially antibiotics Pathogenesis is quite clear only in a few
cases, as in herpes simplex in which the virus can be found in the
lesion In many other cases pathogenesis can only be suspected
and an antigen-antibody mechanism is supposed
1.50Category1CMECredits
U051 Therapy for Lipodermatosclerosis,
Venous Ulceration, and Atrophie Blanche
Room: 269
DIRECTOR JefreyE.Petersen,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Evaluate lower extremities for venous disease
2 Correctly manage lipodermatosclerosis, atrophie blanche, and
venous ulceration
3 Outline the surgical management necessary to improve diseases
of the lower extremities
DESCRIPTION
At the conclusion of the session, the participant should have an
understanding of venous anatomy of the lower extremity and the
associated disease processes One will have an understanding of
the surgical and medical therapy necessary for curative treatment
or control of the processes Te role of ultrasound in diagnosis will
also be reviewed
1.50Category1CMECredits
U052 Diseases of Male Genitalia
Room: 284
DIRECTOR AliMoiin,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Distinguish between the skin diseases afecting the penis
2 Discuss treatment of diferent conditions afecting the penis
DESCRIPTION
Tere will be over 60 diseases and conditions afecting the penis
discussed Tere will be a quiz given in this session, so please bring
a pen and a piece of paper Te treatments of these conditions will
be reviewed as well Please share with us if you have an interesting
case and bring pictures
1.50Category1CMECredits
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
135
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
SCIENTIFIC SESSIONS
U054 Building Beauty: Understanding Facial
Proportions, Phi, and the Use of
Volumizing Soft Tissue Fillers
Room: 285
DIRECTOR TimothyC.Flynn,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Analyze the face using principles of mathematical proportions
in order to make faces more attractive
2 Identify new methods of re-volumizing faces using soft tissue
fllers to restore a youthful appearance
3 Identify specifc deep areas of the face amenable to treatment
DESCRIPTION
Understanding facial proportions is key to working in the aesthetic
feld Key aspects of beauty that must be understood are balance,
symmetry, and harmony Te Greeks used the concept of the golden
proportion We now understand that proper relationships and curves
are essential to producing a more attractive appearance Youthful faces
have increased volume, making it diferent than the aging face Tis
talk will analyze facial proportions from a classic as well as medical
perspective Volume restoration techniques will be taught using soft
tissue fllers
1.50Category1CMECredits
U055 Practical Approaches to Cosmeceuticals
Room: 267/268
DIRECTOR EllenS.Marmur,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Describe the theoretical routes of penetration for topical
cosmeceuticals through the epidermis
2 Assess the available clinical trials that support cosmeceutical
efects
3 Formulate an informed approach to patient’s questions about
cosmeceuticals
DESCRIPTION
In this new age of cosmeceuticals, creative marketing seems
to promise amazing anti-aging efects Patients are hopeful
yet overwhelmed with choices and look for guidance from
the dermatologist Tis session will serve as an update on the
chemistry of cosmeceuticals and on the latest evidence-based
medicine that may support their use
1.50Category1CMECredits
FOCUS SESSION
12:15 pm to 1:45 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U053 Through the Looking Glass: The Use of
Dermoscopy in the Management of the
Pigmented Lesion Patient
Room: 264
DIRECTOR MaryC.Martini,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Identify melanocytic and nonmelanocytic patterns on
dermoscopy
2 Recognize and identify major dermoscopic fndings in
melanoma
3 Diferentiate between benign melanocytic nevi and melanoma
DESCRIPTION
Tis 90-minute session will present a wide array of dermoscopy
images of benign and malignant skin lesions Te clinician will be
instructed on a step-by-step approach to dermoscopy Emphasis
will be on pattern recognition and how to utilize dermoscopy in a
busy clinical practice Multiple cases that incorporate dermoscopic
images and the corresponding histopathologic diagnoses will be
presented Te attendee should become familiar with the various
benign melanocytic, nonmelanocytic, and melanoma patterns by
the close of the session and will be able to test his/her knowledge
with the fnal self-assessment slide presentation
1.50Category1CMECredits
For description of session categories and fees see page 37
136
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
FOCUS SESSION
12:15 pm to 1:45 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U056 Recommended Screening Practices in
Medical Dermatology
Room: 270
DIRECTOR NicoleFett,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Recognize the subsets of patients with autoimmune connective
tissue disease at risk for interstitial lung disease and implement
screening
2 Assess the risk of corticosteroid-induced osteoporosis in medical
dermatology patients and implement a prevention plan
3 Recognize the subsets of patients with autoimmune connective
disease who are at increased risk of malignancy
DESCRIPTION
Tis session is directed to general and medical dermatologists
and those in training for these positions Tis session will review
the literature pertaining to screening for systemic involvement in
patients with cutaneous manifestations of autoimmune disease
Based on the evidence in the literature, and standard practice
when the literature is lacking, recommendations for screening
tests and frequency of screening will be reviewed Te session will
specifcally focus on screening in patients with cutaneous lupus
erythematosus, dermatomyositis, morphea, and systemic sclerosis
1.50Category1CMECredits
U057 Procedural Safety in Dermatology
Room: 283
DIRECTOR JacobLevitt,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Identify areas of highest risk for injury in dermatological
practice
2 Identify ways to minimize risk for injury in dermatological
practice
3 Discuss personal experience with injuries and/or best safety
practices amongst the audience
DESCRIPTION
We will review the results of a survey to dermatology residents
regarding their experience with injury, emphasizing the situations
in which residents appear to be most injury prone We will
discuss best practices for safe technique, including demonstrations
of safe and unsafe technique We hope the audience will share
their experience with injury and ways they have discovered to
avoid them
1.50Category1CMECredit
U058 From Stem to Skin: Precursor Cells That
Have a Lot of Potential
Room: 235/236
DIRECTOR JenniferY.Lin,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Demonstrate understanding of basic defnition and biology of
keratinocyte/melanocyte stem cells
2 Identify the role of stem cells in cutaneous processes including
wound healing, hair regeneration, and cancer
3 Formulate ideas for the role of dermatology in future stem cell
therapeutics
DESCRIPTION
Stem cells are at the forefront of translational medicine as an
opportunity to regenerate organs and fx genetic diseases Te skin
is a rich source of stem cells and an understanding of their biology
will help clinical dermatologists understand common processes
such as wound healing, hair regeneration, and cancer Tis session
is directed towards clinicians and residents who seek to reach a
comfort level with the concept of stem cells and the numerous
clinical implications We will focus on precursor cells of the
epidermis and their role in skin disorders Emphasis will also be
placed on therapeutics on the horizon
1.50Category1CMECredits
U059 Potpourri of CPC
Room: 242
DIRECTOR JacquelineM.Junkins-Hopkins,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Recognize the limitations of histopathologic diagnosis
without clinical pathologic correlation in diagnosing certain
dermatologic disorders
2 Identify dermatologic conditions that may be associated with
systemic disease
3 List some conditions that require clinical-pathologic correlation
to make a diagnosis
DESCRIPTION
Te clinical and histopathologic diagnosis of dermatologic
conditions can be challenging, especially since several entities
have overlapping or nonspecifc features Clinical-pathologic
correlation is often critical in this situation In this session, there
will be several interesting cases presented in which either the
clinical or the histopathologic features contributed to making the
diagnosis Te director is a dermatologist and dermatopathologist,
so the discussion and content will focus on both clinical and
histopathologic aspects of the disorders Audience participation in
the discussion is encouraged
1.50Category1CMECredit
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
137
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
C018 Dermatologic Drug Safety and Effcacy
Room: 386/387
DIRECTOR JefreyPhillipCallen,M.D.
SPEAkERS
Boni E Elewski, MD Mark Lebwohl, MD
Dirk Michael Elston, MD Cindy Owen, MD
David Franklin Fiorentino, MD, PhD Neil H Shear, MD
Kenneth B Gordon, MD Kenneth Saag,
J Mark Jackson, MD MD, MSCE
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1 Identify safety issues for systemic therapies routinely used to
treat dermatologic disease
2 Describe the efcacy of systemic therapies for skin disease
3 Manage patients with dermatologic disease on systemic
therapies
DESCRIPTION
Systemic drugs are often used to treat patients with skin disease
Inherent with their use are potential toxicities Tis session will
familiarize the attendee with the indications for use, the selection
of the appropriate patient and the monitoring for toxicity that
should be carried out on treated patients
3.00Category1CMECredits
REFERENCES
1 Wolverton SE ComprehensiveDermatologicalDrugTerapy
2nd ed Philadelphia: Elsevier; 2007
2 Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I
TreatmentofSkinDisease 3rd ed Philadelphia: Elsevier; 2010
3 Callen JP, Jorizzo JL, Bolognia JL, Piette WW, Zone JJ
DermatologicalSignsofInternalDisease 4th ed Philadelphia:
Elsevier; 2009
SCHEDULE
2:00 pm Introduction/Dr.Callen
2:05 pm Tumor Necrosis Factor-Alpha Antagonists: Long-
Term Safety and Efcacy/Dr.Gordon
2:25 pm Methotrexate/Dr.Fiorentino
2:45 pm Azathioprine/Dr.Shear
3:05 pm Mycophenolate Mofetil/Dr.Jackson
3:20 pm Bisphosphonate Terapy: What the Dermatologist
Needs to Know/Dr.Saag
3:40 pm Isotretinoin/Dr.Owen
4:00 pm Systemic Antifungal Terapies/Dr.Elewski
4:20 pm Anti-IL 12/23/Dr.Lebwohl
4:40 pm Antibiotic Terapy/Dr.Elston
FOCUS SESSION
12:15 pm to 1:45 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U060 Stress, the Nervous System,
and Cutaneous Immunity
Room: 263
DIRECTOR RichardD.Granstein,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Summarize evidence that the nervous system can regulate
cutaneous immunity
2 Evaluate data that stress can afect immunity and infammation
in the skin
3 Discuss the possibility that stress and nervous system infuences
may impact infammatory skin disorders
DESCRIPTION
Tis session will review recent work demonstrating that
the nervous system and stress can infuence immunity and
infammation in the skin Te results of studies suggesting that
products of nerves can infuence immunity against chemical
haptens as well as malignant tumors will be presented Evidence
that chronic stress can modulate antitumor immunity will be
discussed Tere will be an emphasis on experimental results with
clinical implications Discussion with participation of all attendees
will be encouraged
1.50Category1CMECredits
COURSE
2:00 pm to 5:00 pm
Tuition fee and ticket required for admission.
For description of session categories and fees see page 37
138
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
COURSE
2:00 pm to 5:00 pm
Tuition fee and ticket required for admission.
C019 Hair and Nails
Room: 243/244/245
DIRECTOR AmyJ.McMichael,M.D.
SPEAkERS
Ulrike Blume-Peytavi, MD William Millard Parsley, MD
Robert S Haber, MD Leonard C Sperling, MD
Maria K Hordinsky, MD Curtis T Tompson, MD
Christopher James Miller, MD Antonella Tosti, MD
Nina Otberg, MD
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1 Diagnose hair, scalp, and nail diseases more efectively
with emphasis on new data for common disorders and
dermatopathologic-clinical correlation
2 Manage the patient with hair loss and nail disorders using
therapeutic ladders of medical and surgical treatment
3 Demonstrate optimal selection and processing of biopsy
specimens for the diagnosis of hair and scalp disorders
DESCRIPTION
Hair and nail unit disorders can be difcult to diagnose, both
clinically and pathologically Tis course will review the most
commonly encountered hair and nail disorders in both medical
and surgical dermatology Recent advances in nonscarring
and scarring alopecia research and treatment will be discussed
Diferences in treatment for patients of color will be presented
Advances in hair restoration/transplantation will be discussed
Dermatopathology of both infammatory and neoplastic disorders
of the nail unit and scalp will be discussed, with emphasis on
updates Tis course will be helpful for dermatopathologists and
dermatologists who manage hair and nail unit disorders
3.00Category1CMECredits
REFERENCES
1 McMichael AJ, Hordinsky M, eds HairandScalpDiseases:
Medical,Surgical,andCosmeticTreatments Informa
Healthcare, 2008
2 Scher RK, Daniel III CR, eds Nails:Diagnosis,Terapy,
Surgery. 3rd ed Philadelphia:WB Saunders; 2005
3 Sperling L AnAtlasofHairPathologywithClinical
Correlations Boca Raton, Fl: CRC Press, 2003
SCHEDULE
2:00 pm Introduction/Dr.McMichael
2:05 pm Diagnosis and Medical Treatment of Nail Disorders
/Dr.Tosti
2:25 pm Dermatopathologic Diagnosis of the Nail Unit
/Dr.Tompson
2:45 pm Surgical Management of the Nail Unit/Dr.Miller
3:05 pm Questions and Answers/Faculty
3:15 pm Female Pattern Hair Loss: Diagnostic Ofce Tools
and Terapeutic Updates/Dr.Blume-Peytavi
3:55 pm Alopecia Areata: Updates in Diagnosis and Terapy
/Dr.Hordinsky
4:15 pm Scarring Alopecia: Focus on African American Patients
/Dr.McMichael
4:30 pm Dermatopathologic Diagnosis of Alopecia/Dr.Sperling
4:35 pm Surgical Management of Alopecia/Dr.Parsley
4:50 pm Questions and Answers/Faculty
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
139
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
SCIENTIFIC SESSIONS
S019 Rheumatologic Dermatology
Room: 260/261/262
DIRECTOR JanP.Dutz,M.D.
SPEAkERS
Stefan Beissert, MD Heidi Tewich Jacobe, MD
M Kari Connolly, MD Julie V Schafer, MD
David Franklin Fiorentino, MD, PhD Victoria P Werth, MD
Christopher B Hansen, MD
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Recognize common and uncommon cutaneous manifestations
of rheumatic disease
2 Utilize standardized assessment tools to evaluate disease damage
and actvitiy
3 Develop treatment plans for these conditions based upon best
available evidence
DESCRIPTION
Cutaneous abnormalities can be early clues to signifcant systemic
disease Rheumatic diseases in particular can present with subtle
and not-so-subtle fndings on examination of the skin Patients do
not present to their physician with a diagnosis of connective tissue
disease, but rather an often localized lesion or complaint related
to the skin Early diagnosis may prevent signifcant morbidity In
this session, the speakers will discuss their approach to patients
with rheumatic skin disease Tey will share tips to help clinicians
recognize rheumatic skin disease promptly, and to assess disease
severity Tey will also present rationales for current and new
treatments of these challenging conditions
3.00Category1CMECredits
SCHEDULE
2:05 pm Morphea – How I Treat it/Dr.Jacobe
2:25 pm How I Approach Scleroderma/Dr.Connolly
2:50 pm How I Treat cutaneous Lupus/Dr.Dutz
3:10 pm How I Manage Dermatomyositis/Dr.Fiorentino
3:35 pm Measuring Disease Severity and Impact in
Rheumatologic Dermatology/Dr.Werth
3:55 pm How I Manage Vasculitis/Dr.Beissert
4:20 pm Cutaneous Features of Rheumatoid Arthritis
/Dr.Schafer
4:40 pm Drug-Induced Cutaneous Connective Tissue Disease
/Dr.Hansen
COURSE
2:00 pm to 5:00 pm
Tuition fee and ticket required for admission.
C020 Live Patient Demonstrations: Application
of Our Aesthetic Toolbox for the
Treatment of Medical and Dermatologic
Disorders
Room: Auditorium B
DIRECTOR SusanH.Weinkle,M.D.
SPEAkERS
Harold Joseph Brody, MD David J Goldberg, MD, JD
Jean DA Carruthers, MD Marina Landau, MD
William P Coleman III, MD Naomi Lawrence, MD
Lisa M Donofrio, MD Mary P Lupo, MD
Patricia Farris, MD Gary D Monheit, MD
Rebecca L Fitzgerald, MD Rhoda S Narins, MD
Timothy C Flynn, MD Robert J Weiss, MD
Dee Anna Glaser, MD
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1 Evaluate medical and dermatologic disorders and select the
most benefcial treatment
2 Develop techniques to maximize patient satisfaction
3 Develop methods to avoid surgical complications
DESCRIPTION
Tis three-hour live demonstration will include patient evaluation,
treatment options, and a discussion of possible complications
Tere will be interactive discussion between the treating physician
and the consulting physician Te experienced team of treating
physicians is multi-disciplinary, including two plastic surgeons
Audience participation and interaction will be welcomed
3.00Category1CMECredits
SCHEDULE
2:00 pm Introduction / Dr.Weinkle
2:15 pm Te Atrophic Face / Dr.Fitzgerald/Dr.Narins
2:25 pm Disorders of the Periorbital Region / Dr.Donofrio
/Dr.Carruthers
2:45 pm Acne Scarring / Dr.Flynn/Dr.Monheit
3:05 pm Angular Chelitis and the Lateral Lip Festoon
/Dr.Farris/Dr.Goldberg
3:25 pm Chemical Peels for Actinic Keratosis
/Dr.Lawrence/Dr.Brody
3:45 pm Efective Utilization of Sclerotherapy
/Dr.Lupo/Dr.Weiss
4:05 pm Te Atrophic Actinic Hand /Dr.Flynn/Dr.Landau
4:25 pm Innovative Applications for Treatment with
Botulinum Toxin / Dr.Coleman/Dr.Glaser
4:45 pm Gummy Smile / Dr.Weinkle
4:50 pm Questions and Answers / Faculty
SYMPOSIUM
2:00 pm to 5:00 pm
Open admission, no tuition or ticket.
For description of session categories and fees see page 37
140
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
SYMPOSIUM
2:00 pm to 5:00 pm
Open admission, no tuition or ticket.
S020 Birthmarks
Room: 383/384/385
DIRECTOR TorA.Shwayder,M.D.
SPEAkERS
Anita N Haggstrom, MD Crystal Pourciau, MD
Moise L Levy, MD Dakara A Rucker Wright, MD
Ashfaq A Marghoob, MD Sheryll L Vanderhooft, MD
Denise W Metry, MD Lisa Xu, MD
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Recognize diferent outcomes for growth-type hemangiomas
and vascular malformations
2 Distinguish benign from worrisome birthmarks and their
underlying systemic associations
3 Predict the correct percentage of patients with these
associations to better counsel the patient/parents
DESCRIPTION
Is that a worrisome birthmark? Do you know the ones that
progress, regress, or become malignant? Is it just a normal variant?
When should an MRI be performed? Is that child destined to be
developmentally delayed? Should a genetic counselor be called?
Come with me on a journey of most major and minor birthmarks,
and learn how to answer those questions
Topics to be covered:
aplasia cutis congenital;
café au lait macules;
congenital nevi;
epidermal nevi, nevus sebaceous and the epidermal nevus syndromes;
hemangiomas and segmental hemangiomas;
hypo-and hyperpigmented swirls and blotches and light spots;
port-wine stains
3.00Category1CMECredits
SCHEDULE
2:00 pm Hemangiomas/Dr.Haggstrom
2:30 pm Segmental Hemangiomas/Dr.Metry
2:55 pm Port-Wine Stains/Dr.RuckerWright
3:15 pm Aplasia Cutis Congenita/Dr.Pourciau
3:25 pm Cafe au Lait Macules/Dr.Xu
3:35 pm Hypo-and Hyperpigmented Swirls and Blotches
/Dr.Vanderhooft
3:45 pm Congenital Nevi/Dr.Marghoob
4:30 pm Ash-Leaf Spot and Nevus Depigmentosus
/Dr.Vanderhooft
4:40 pm Nevus Sebaceous, Epidermal Nevi, and Epidermal
Nevus Syndromes/Dr.Levy
Don’t Take Chances
When You Travel...
The AAD is pleased to offer you the MedjetAssist program, a leader in both domestic and international emergency
medical evacuations.
A MedjetAssist membership includes:
• Medical transportation to the hospital of your choice
at no cost when traveling more than 150 miles
(Domestic and International) from your primary
residence
• Emergency physician consultation (24 hours a day,
7 days a week)
Stop by the Academy Resource Center Booth 3623 for more information!
• Worldwide medical and legal referrals
• Monitoring of medical condition and emergency
message relay
• Translation assistance of foreign medical reports
• Travel intelligence and security information
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
141
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
SCHEDULE
2:00 pm Introduction / Dr.Gathers
2:05 pm Management of Common Disorders in Skin of Color
Patients /Dr.Alexis
2:25 pm Successfully Treating your Patients with
Hyperpigmentation / Dr.Pandya
2:40 pm Hair Loss and African American Women / Dr.Gathers
2:55 pm Vitiligo: Perspectives from the Cutting Edge
/ Dr.Hamzavi
3:10 pm Approaching Skin of Color: Te Asian and Hispanic
Perspective / Dr.Kundu
3:25 pm Questions and Answers / Faculty
3:40 pm Skin Cancer and Skin of Color /Dr.Gohara
3:55 pm Vitamin D and Skin of Color / Dr.Harvey
4:10 pm Peels, Botulinum Toxin and Fillers in Skin Of Color
/ Dr.Callender
4:25 pm Lasers in Skin of Color / Dr.Battle
4:45 pm Questions and Answers / Faculty
SYMPOSIUM
2:00 pm to 5:00 pm
Open admission, no tuition or ticket.
S021 Skin of Color
Room: Auditorium A
DIRECTOR RaecheleCochranGathers,M.D.
SPEAkERS
Andrew F Alexis, MD Iltefat H Hamzavi, MD
Eliot Franklin Battle, MD Valerie M Harvey, MD
Valerie D Callender, MD Roopal Vashi Kundu, MD
Mona Amira Gohara, MD Amit G Pandya, MD
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Recognize the most common skin and hair conditions
encountered among skin of color patients
2 Examine diverse cultural practices in skin of color patients and
develop culturally competent therapeutic and management
strategies
3 Identify cosmetic protocols and challenges in skin of color
patients
DESCRIPTION
Te prevalence of individuals with skin of color is rapidly
increasing in both the United States and around the globe In
addition to the unique dermatologic conditions encountered in
skin of color, the presentation and response to management of
common disorders may difer in individuals with darker skin hues
Tis symposium will discuss diverse cultural practices among skin
of color patients and review common disorders, including keloids,
acne, post-infammatory hyperpigmentation, pseudofolliculitis
barbae, alopecias, and vitiligo Skin cancer in skin of color will be
addressed, and common cosmetic protocols and pitfalls for skin of
color will be examined
3.00Category1CMECredits
REFERENCES
1 Kelly AP, Taylor SC DermatologyforSkinofColor New York,
McGraw-Hill; 2009
For description of session categories and fees see page 37
142
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
SYMPOSIUM
2:00 pm to 5:00 pm
Open admission, no tuition or ticket.
S022 Acne and Rosacea
Room: La Nouvelle Orleans Ballroom
DIRECTOR AndreaL.Zaenglein,M.D.
SPEAkERS
James Q Del Rosso, DO Lisa E Maier, MD
Emmy M Graber, MD Diane M Tiboutot, MD
Jonette Elizabeth Keri, MD, PhD Vicente Torres, MD
Jenny J Kim, MD, PhD Guy F Webster, MD, PhD
James Joseph Leyden, MD
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Discuss the pathogenesis of acne and rosacea and how it
infuences management of these conditions
2 Use acne and rosacea therapies, both old and new, safely and
efectively in patients
3 Identify difcult acne and rosacea cases and formulate an
appropriate treatment plan
DESCRIPTION
Tis year’s Acne and Rosacea Symposium will update attendees
on what is new in the diagnosis and management of these
disorders Expert panelists will highlight the latest advances in
the understanding of pathogenesis and how this relates to our
treament plan Problematic cases will be presented to aid the
attendee in troubleshooting difcult patients Additionally, a Latin
American perspective on acne and rosacea will be given Terapies
will be discussed in detail, covering the important issues of
antibiotic resistance, safe use of isotretinoin, the role of lasers, and
an update on what’s new in therapy
3.00Category1CMECredits
SCHEDULE
2:00 pm Introduction/Dr.Zaenglein
2:05 pm Te Latest From the Lab: An Update on the
Pathogenesis of Acne /Dr.Kim
2:20 pm Rosacea: Teories on Pathogenesis and Treatment
Implications/Dr.Maier
2:35 pm Difcult Rosacea Cases: What to Do?/Dr.Webster
2:50 pm Difcult Acne Cases and What I Learned From Tem
/Dr.Zaenglein
3:05 pm Treating Acne and Rosacea: A Latin Perspective
/Dr.Torres
3:20 pm Questions and Answers/Faculty
3:35 pm Facing Up to Acne and Rosacea: A Status Report
/Dr.DelRosso
3:50 pm Use of Isotretinoin in Acne and Rosacea/Dr.Tiboutot
4:05 pm Te Role of Lasers in Acne and Acne Scarring
/Dr.Graber
4:20 pm When and How to Use Hormonal Treatments in
Acne/Dr.Keri
4:35 pm Antibiotic Dosing in Acne and Rosacea: Factors Tat
Infuence Outcomes/Dr.Leyden
4:50 pm Questions and Answers/Faculty
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
143
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
SCIENTIFIC SESSIONS
SCHEDULE
2:00 pm Teledermatology as CME for Primary Care Providers
in Remote Areas/Dr.Colven
2:30 pm A Novel Approach to Outreach Using
Teledermatology/Dr.Kovarik
3:00 pm Evaluating Residents Trough Teir Teledermatology
Participation/Dr.Burdick/Dr.Pak
3:40 pm Use of Teledermatology as a Soft Power in Iraq and
Afghanistan/Dr.Henning
4:30 pm Teledermatology to Manage Ichthyosis (Partnership
with FIRST)/Dr.Dyer
4:00 pm Teledermatology: AAD Initiative to Expand
Volunteerism/Dr.James
SYMPOSIUM
2:00 pm to 5:00 pm
Open admission, no tuition or ticket.
S023 Teledermatology
Room: Auditorium C
DIRECTOR RoyMitchellColven,M.D.
SPEAkERS
Anne E Burdick, MD, MPH William D James, MD
Jonathan A Dyer, MD Carrie L Kovarik, MD
Jefrey Scott Henning, DO Hon S Pak, MD
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Examine how online, case-based education in dermatology for
non-dermatologists can improve skin disease care in remote
regions of the United States and abroad
2 Use teledermatology to help assess residents’ competence in
patient care, medical knowledge, communication, and systems-
based practice
3 Describe how teledermatology can be leveraged to serve
underserved populations in the United States and globally
DESCRIPTION
Te ability of dermatologists to reach patients and educate
providers in remote and underserved settings has expanded in
recent years with increasingly afordable technologies Trough
the discussion of cases from all over the world, we will show how
teledermatology has been successfully used as a tool to support
humanitarian missions abroad and to allow dermatologists in
underserved areas to reach more patients We will also illustrate
that teledermatology is a novel tool for evaluating trainees’
competence in communication skills, patient care, medical
knowledge specifc to dermatology, and systems-based practice for
dermatology residents and referring providers
3.00Category1CMECredits
REFERENCES
1 Krupinski E, Burdick A, Pak H, Bocachica J, Earles L, Edison
K, et al American Telemedicine Association’s practice
guidelines for teledermatology Telemed J E Health 2008
Apr;14:289-302
2 Burdick AE Teledermatology: extending specialty care beyond
borders ArchDermatol 2007 Dec;143:1581-1582
For description of session categories and fees see page 37
144
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
DISCUSSION GROUP
2:30 pm to 4:00 pm
Tuition fee and ticket required for admission.
FOCUS SESSION
2:30 pm to 4:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
D011 Women With Hair Loss
Room: 240
DIRECTOR LynnAnnetteDrake,M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 Determine the cause of the hair loss in some cases, often in a
short time
2 Diagnose and categorize hair loss in women more efectively
3 Treat hair loss appropriately
DESCRIPTION
Women with difuse hair thinning often can have a signifcant
underlying cause Te physician frequently must be a detective
Tis session will identify seven key areas that the physician can
explore to determine the possible underlying causes of hair
thinning, many of which may be serious diseases Methods to
do this in a timely manner (15-minute ofce workup) will be
discussed Finally, methods of treatment related to the underlying
etiology will be identifed
1.50Category1CMECredits
D012 Aging Skin: Mechanism-Based
Rejuvenation
Room: 241
DIRECTOR JohnJamesVoorhees,M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 Recognize premature aging on face and arms as especially
severe due to the simultaneous presence of both natural aging
and photoaging
2 Describe mechanisms whereby collagen defciency, collapsed
fbroblasts, and excess free radicals are key features of both
aging and photoaging
3 Explain how to prevent or rejuvenate aging skin based on
mechanisms identifed as key to the process of skin aging
DESCRIPTION
We now understand that loss of mechanical tension, leading to
collapsed fbroblasts, is at the heart of the aging process Te
collapse causes excess free radicals, which turn on collagen
breakdown and turn of new collagen formation How to use
this new information to prevent/rejuvenate aging skin will be
highlighted We have learned that loss of skin collagen during
aging surprisingly is not due to irreversible damage to fbroblasts,
as one might have expected Rather, when the aged fbroblasts are
removed from dermis, they make normal quantities of collagen
Tis raises the hope that one can fnd ways to cause fbroblasts to
make collagen in skin without removing them One example to
be presented is injectable fllers, which perform in this fashion,
causing collagen to accumulate
1.50Category1CMECredits
U061 Calciphylaxis
Room: 242
DIRECTOR JohnCharlesHall,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Examine and defne the syndrome of calciphylaxis and its
consequences
2 Distinguish who is a candidate to develop calciphylaxis
3 Identify the treatment of calciphylaxis
DESCRIPTION
Tis is a relatively new disease of skin and subcutaneous necrosis
that occurs mainly in patients with renal disease A few exceptions
will be discussed Te pitfalls in making the correct diagnosis
and the diferential diagnosis will be reviewed Te many reports
of therapeutic options will be discussed A safe and efective
therapeutic option fnally appears to be available
1.50Category1CMECredits
U062 Herpes Simplex and Varicella Zoster
Virus
Room: 270
DIRECTOR ArjenF.Nikkels,M.D.,Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Recognize the ever-growing spectrum of herpes simplex and
varicella zoster cutaneous manifestations
2 Choose the appropriate diagnostic methods
3 Select the most adequate treatment option for these viruses
DESCRIPTION
Herpes simplex viruses (HSV) are responsible for orolabial
and genital herpes, whereas varicella zoster virus (VZV) leads
to chickenpox and shingles Te recognition, diagnosis, and
treatment of the various HSV and VZV skin infections will be
discussed Te following new treatment options will be explored:
short-course antiviral treatments for orolabial and genital herpes,
providing increased patient compliance, reduced antiviral use, and
similar therapeutic outcomes; combination treatments, usin ganti-
infammatory and antiviral agents simultaneously for orolabial
herpes; hydrocolloid dressings for orolabial herpes; and shingles
vaccination, reducing the occurrence of shingles and postherpetic
neuralgia
1.50Category1CMECredits
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
145
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
U065 Dermoscopy: It’s Time for A Quiz
Room: 284
DIRECTOR JoelClaveau,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Recognize benign and malignant pigmented and non-
pigmented lesions
2 Review and utilize the main dermoscopic criteria and
algorithms
3 Assess own knowledge in dermoscopy
DESCRIPTION
Tis interactive session is directed to beginners and more advanced
dermoscopists A variety of instructive cases of pigmented and
non-pigmented lesions will be presented in a quiz format A brief
description of the main dermoscopic criteria for melanocytic and
non-melanocytic lesions will be presented Some cases to illustrate
new dermoscopic signs will also be discussed Participants will
be invited to vote during the session and are expected to increase
their interest and knowledge in this essential diagnostic tool
1.50Category1CMECredits
U066 Compliance in Pharmaceutical
Development: What You Need to know
Room: 264
DIRECTOR MaryC.Spellman,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Identify and defne the principles and requirements for
compliance in pharmaceutical development
2 Defne the basic roles and responsibilities of investigators as
related to the quality of clinical trials
3 Explain how good clinical practice impacts clinical research
progress
DESCRIPTION
Clinical development of pharmaceutical products requires diligent
compliance with current regulatory policies and mandates, or
signifcant consequences may result Tis session will provide
an overview of the principles and scope of applicable regulatory
compliance policies, and review the role of investigators and their
stafs in ensuring quality in clinical studies
1.50Category1CMECredits
FOCUS SESSION
2:30 pm to 4:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U063 Dermatoscopy
Room: 269
DIRECTOR HoracioAntonioCabo,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Recognize the diferent dermatoscopy structures and criteria for
melanocytic and non melanocytic lesions
2 Utilize the diferent methods of dermoscopy diagnosis
3 Diferentiate between melanocytic lesions and melanoma
DESCRIPTION
Dermoscopy is a two-step procedure: frst, diferentiating between
melanocytic lesions and non-melanocytic lesions, and second,
diferentiating between benign melanocytic lesions and melanoma
Recognizing which lesions are appropiate for dermatoscopy,
and understanding the dermatoscopy criteria, and knowing the
diferent methods of dermatocopy diagnosis will improve the
attendees’ clinical diagnostic ability
1.50Category1CMECredits
U064 Helping You Meet Component 4 of MOC
Room: 274
DIRECTOR RobertS.Kirsner,M.D.,Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Demonstrate an understanding of the MOC process
2 Develop a strategy for dealing with the MOC 4 component
3 Assess the various options provided by the AAD and other
organizations
DESCRIPTION
Tis session will focus on the Maintenance of Certifcation
(MOC) process, with a specifc emphasis on the relatively new
component of how to self-assess your own practice Discussion
will focus on the options that the AAD is working on to assist
members
1.50Category1CMECredits
For description of session categories and fees see page 37
146
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
FOCUS SESSION
2:30 pm to 4:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U067 Twists and Splits: How to Approach Hair
Shaft Disorders
Room: 265/266
DIRECTOR ParadiMirmirani,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Identify the basic structures of the hair follicle and hair shaft
2 Develop skills for evaluating the hair shaft in the ofce setting
3 Diagnose and diferentiate common hair shaft disorders
DESCRIPTION
Tis session will provide a basic overview of hair shaft disorders
and is geared toward residents and/or clinicians wanting to
improve their knowledge and skills Te attendee will be
presented with practical tips on evaluating the hair shaft in the
ofce setting “Unknowns” will then be presented to highlight
common clinical presentations and review pathogenetic
mechanisms of disease
1.50Category1CMECredits
U068 Electrosurgery Update
Room: 267/268
DIRECTOR ConnieM.Chung,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Recognize diferent modalities of electrosurgery and their
applications
2 Identify the risks and complications associated with
electrosurgery
3 Evaluate the current practice guidelines and develop
appropriate safety measures for patients with cardiac devices
DESCRIPTION
Electrosurgery is utilized daily in dermatology Te diferent
modalities and their applications will be reviewed With a
signifcant increase in patients with skin cancers and implantable
cardiac devices, safety measures become a concern Te current
practice guidelines are from the 1990s and were historically
derived from various surgical specialties Dermatology-specifc
complications and an update on cardiac devices will be presented
Te attendees then will have the opportunity to re-evaluate the
current safety guidelines to determine those that are applicable and
essential to dermatology
1.50Category1CMECredits
U069 Half-Truths, Lies, and Statistics:
Understanding Medical Statistics
for the Practitioner
Room: 263
DIRECTOR JoslynS.Kirby,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Discuss evidence-based medicine and critical appraisal of the
literature
2 Defne common statistical and epidemiologic terms
3 Apply these lessons during discussion of articles from the
dermatology literature
DESCRIPTION
Te literature guides the decisions we make for our patients and
practice, thus being a critical reader is essential An understanding
of statistics and epidemiology is invaluable when critically reading
the medical literature Tere are many statistical terms and methods
discussed in the literature and press Tis course will focus on
defning and applying common statistical and epidemiologic terms
and methods Articles from the dermatology literature will be used
as examples Te course is directed toward practicing dermatologists
1.50Category1CMECredits
U070 Getting Started with Interpolation Flaps
Room: 285
DIRECTOR JeremyS.Bordeaux,M.D.,M.P.H.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Perform an interpolation fap (paramedian forehead
fap, cheek-to-nose interpolation fap, and retroauricular
interpolation fap)
2 Develop a thoughtful approach to the indications, limitations,
design, and execution of straightforward interpolation faps
DESCRIPTION
Dermatologic surgeons encounter surgical defects best suited for
repair with interpolation faps (paramedian forehead fap, cheek-to-
nose interpolation fap, and retroauricular interpolation fap) Due
to lack of knowledge regarding these faps or lack of experience in
performing these faps, other surgical repairs that may be functionally
or aesthetically inferior are sometimes used Tis session is designed to
help dermatologic surgeons recognize surgical defects that may be best
suited for repair with interpolation faps Step-by-step instruction on
proper design and execution of these faps will be presented Videos
will be used and audience participation is encouraged
1.50Category1CMECredits
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
147
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
F039 Treating Severe Skin Disease in Children
Room: 255/256/257
DIRECTOR WynnisL.Tom,M.D.
SPEAkERS
Anna Lee Bruckner, MD
Kelly M Cordoro, MD
Katherine B Puttgen, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Recognize situations and conditions that warrant systemic
therapy in pediatric patients
2 Identify and choose appropriately among the available therapies
for conditions such as severe atopic dermatitis, psoriasis, and
high-risk hemangiomas
3 Develop an approach for the workup and management of
major genetic skin conditions
DESCRIPTION
Te dermatologist is at times faced with challenging, severe disease
in children and adolescents Tis session discusses the principles
and practice of using systemic therapy in the pediatric population,
particularly for severe atopic dermatitis and psoriasis and high-
risk infantile hemangiomas Te mechanisms of action, benefts,
and toxicities of recognized and novel therapies will be reviewed
In addition, children may present with fndings suspicious for a
genetic disorder, and approaches to their workup and management
will be presented
2.00Category1CMECredits
SCHEDULE
3:00 pm Systemic Terapy for Severe Psoriasis/Dr.Cordoro
3:25 pm Questions and Answers/Dr.Cordoro
3:30 pm Approaches to the Severe Atopic Child/Dr.Tom
3:55 pm Questions and Answers/Dr.Tom
4:00 pm Genodermatoses: What to Do/Dr.Bruckner
4:25 pm Questions and Answers/Dr.Bruckner
4:30 pm Te High-Risk Infantile Hemangioma: An Update
/Dr.Puttgen
4:55 pm Questions and Answers/Dr.Puttgen
FOCUS SESSION
2:30 pm to 4:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U071 Warts
Room: 235/236
DIRECTOR StephenK.Tyring,M.D.,Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Recognize clinical manifestations of human papillomaviruses
2 Recognize the oncogenic potential of certain human
papillomaviruses
3 Discuss the available therapies and preventions of human
papillomaviruses
DESCRIPTION
Tis session will cover the clinical manifestations of human
papillomaviruses (HPV) as well as laboratory tests that will
confrm the presence and type of HPV Te oncogenic potential of
certain HPV types will be discussed including co-factors that may
contribute to cancer development Te available therapies for HPV
will be covered and will include antiviral and immunomodulatory
treatments Prevention strategies will be discussed and will include
both quadrivalent and bivalent vaccines
1.50Category1CMECredits
U072 Pediatric Dermatologic Surgery in the
Outpatient Setting: Tricks of the Trade
Room: 283
DIRECTOR KennethE.Bloom,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Formulate an optimal approach to dermatology procedures
in the outpatient relative to: timing, obtaining parental
support, positioning, distraction techniques, topical anesthetic,
analgesia, and ofce nitrous oxide use
2 Perform and/or refer pediatric dermatology procedures for
basic conditions such as warts, molluscum, nevi, and vascular
lesions
DESCRIPTION
Tis session will focus on optimizing the pediatric dermatology
surgical experience in the awake ofce setting Topics will include
appropriate timing, parental support, patient positioning, and
distractive methods Additionally, other covered topics will include
the use of topical anesthetics, analgesia, and nitrous oxide use
Clinical cases will be used to discuss surgical approaches to basic
conditions such as warts, molluscum, nevi, and vascular lesions
1.50Category1CMECredits
FORUM
3:00 pm to 5:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
For description of session categories and fees see page 37
148
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
FORUM
3:00 pm to 5:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F040 Resident Transitions
Room: 252/253/254
DIRECTOR AngelaKyei,M.D.
SPEAkERS
Adam J Friedman, MD Elizabeth S Martin, MD
Antoinette E Hood, MD Amit G Pandya, MD
Jennifer Lucas, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Describe the structure, format, and process for the American
Board of Dermatology examination from the perspective of
ABD administrators as well as dermatologists who recently
took the examination
2 Recognize the challenges of launching a career in dermatology
and have the tools to get started in private practice and
academics
3 Identify opportunities to integrate volunteerism into one’s
dermatology residency and career
DESCRIPTION
After spending years training to be a dermatologist, residents fnd
themselves with major hurdles to pass before becoming successful
dermatologists, including taking the board examination and
deciding on a career path Tis session will provide information
on the structure, format, and process for the American Board
of Dermatology examination from the perspective of ABD
administrators and dermatologists who recently took the
examination Additionally, successful career dermatologists will
share some of the challenges they faced when launching a career
in academic and private practice, and the AAD Volunteerism
Committee Chair will discuss ways residents can make a diference
in their communities
2.00Category1CMECredits
SCHEDULE
3:00 pm Volunteerism Opportunities for Residents/Dr.Pandya
3:10 pm ABD Exam/Dr.Hood
3:25 pm Questions and Answers/Faculty
3:40 pm Transition from Resident to Fellow to Academic Staf
/Dr.Lucas
4:00 pm Transition to Private Practice/Dr.Martin
4:20 pm Questions and Answers/Faculty
4:30 pm Panel Discussion: Taking the ABD Exam/Faculty
F041 Finessing Facial Reconstruction
Room: 293/294
DIRECTOR TriH.Nguyen,M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Develop an advanced facial reconstructive strategy based on
optimal cosmesis and minimal morbidity
2 Identify appropriate measures to maximize patient safety,
comfort, and outcome
3 Examine key principles in rhinoplasty surgery as it relates to
nasal reconstruction
DESCRIPTION
Te reconstructive algorithm is vast for challenging facial repairs
Too often, before and after photos bypass the nuances of fap
design and closure Tis forum will focus on the fner details
of selected closures including appropriate patient preparation,
instrumentation, suturing techniques, structural support, and
closure Te sequencing of local anesthesia and anxiolysis, for
example, is essential to successful complex reconstruction in
the ofce Critical concepts in rhinoplasty surgery will also be
introduced as they apply to facial reconstruction
2.00Category1CMECredits
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
149
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
F043 Role of Dermatologist in Management of
Skin Disease in Solid Organ Transplant
Recipients
Room: 278/279/280
DIRECTOR MarcD.Brown,M.D.
SPEAkERS
Sarah T Arron, MD, PhD Harold S Rabinovitz, MD
Clay J Cockerell, MD Darrell S Rigel, MD
Oscar Colegio, MD, PhD Tomas Stasko, MD
Marcy Neuburg, MD Fiona O’Reilly Zwald, MD
Edit B Olasz, MD, PhD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Develop a skill set for long-term management of skin disease in
patients with solid organ transplants
2 Recognize the broad spectrum of skin disease afecting patients
with solid organ transplants, including both medical and
surgical problems
3 Detect, diagnose and manage common cutaneous sequelae
caused by chronic immunosuppression in solid organ
transplant recipients
DESCRIPTION
Tere are over 200,000 people in the United States with solid
organ transplants who have increasing life expectancy Tese
patients experience a broad variety of skin disease related to
long-term immunosuppression Tis includes high-risk skin
cancer development as well as medical problems including
infections Tis session will provide those attending with an
up-to-date comprehensive examination of issues that complicate
the management of these patients In addition, there will be new
insights into the specifc strategies that will improve the overall
care of organ transplant recipients
REFERENCE
Otley C, Stasko T Skin Disease in Organ Transplant Patients
2.00Category1CMECredits
SCHEDULE
3:00 pm Medical Problems in the Organ Transplant Recipient
/Dr.Colegio
3:20 pm Infections in the Organ Transplant Recipient
/Dr.Olasz
3:40 pm Skin Cancer in Organ Transplant Recipients,
Epidermiology and Risk Factors/Dr.Stasko
4:00 pm Field Disease and Field Terapy in Organ Transplant
Recipients/Dr.Arron
4:20 pm Recognition and Treatment of High-Risk Squamous
Cell Carcinomas in Organ Transplant Recipients
/Dr.Zwald
4:40 pm Te Role of Specialized Clinics in the Management of
Organ Transplant Recipients/Dr.Neuburg
FORUM
3:00 pm to 5:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F042 Hair and Nail Clinicopathologic
Correlations
Room: 388/389/390
DIRECTOR AdamRubin,M.D.
SPEAkERS
George Cotsarelis, MD Beth S Ruben, MD
Christopher James Miller, MD John T Seykora, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Diagnose hair and nail disorders more efectively
2 Perform clinicopathologic correlations for disorders of the hair
and nails more efectively
3 Determine optimal selection and submission of biopsy
specimens for the diagnosis of hair and nail disorders
DESCRIPTION
Hair and nail unit disorders can be difcult to diagnose both
clinically and histopathologically Te speakers in this forum will
present ways to optimally submit alopecia and nail unit biopsy
specimens Algorithms to evaluate scarring and non-scarring
alopecias will be discussed Clinical and histologic evaluation of
both infammatory and neoplastic disorders of the nail unit will
be reviewed Emphasis will be placed on correlating the histologic
fndings and clinical features in these anatomic areas Tis forum
will be helpful for dermatopathologists and dermatologists who
manage hair and nail unit disorders
2.00Category1CMECredits
SCHEDULE
3:00 pm Introduction/Dr.Rubin
3:05 pm Surgical Management of the Nail Unit/Dr.Miller
3:25 pm Melanonychia/Dr.Ruben
3:45 pm Infammatory Disorders of the Nail Unit/Dr.Rubin
4:05 pm Clinical Approach to the Alopecias/Dr.Cotsarelis
4:25 pm Histologic Approach to the Alopecias/Dr.Seykora
4:45 pm Questions and Answers /Faculty
For description of session categories and fees see page 37
150
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
FORUM
3:00 pm to 5:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F044 Dermatology Teaching and
Education Group
Room: 392
DIRECTOR PoncianoD.CruzJr.,M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Identify the best teaching outcomes from current and future
teachers of dermatology
2 Catalyze exchange of ideas and collaboration among
dermatologic educators
3 Apply lessons learned during this meeting to improve own
programs
DESCRIPTION
Tis forum highlights abstracts focusing on best outcomes in
dermatologic education presented by residency program directors
and current or future teachers of dermatology Te goal is to catalyze
exchange of ideas and collaboration among educators, and to challenge
and inspire teachers to improve their own programs by applying lessons
learned at this meeting
2.00Category1CMECredits
F045 Rosacea
Room: 295/296
DIRECTOR FrankC.Powell,M.D.
SPEAkER Jonathan Keith Wilkin, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Describe the spectrum of cutaneous presentations that come
under the diagnosis of rosacea
2 Recognize the diferent subsets of rosacea and how to select
therapy according to each subset
3 Interpret the diferential diagnosis of the rosacea subsets and
the investigations appropriate to alternative diagnoses
DESCRIPTION
Te interactive session will review the diferential diagnosis of
erythematous facial skin eruptions leading to the diagnosis of
rosacea Te reasons behind the classifcation of rosacea into subsets
will then be discussed together with the clinical relevance of these
subsets when choosing therapeutic interventions Te session will
conclude with discussion of possible etiologic factors in rosacea and
the potential future therapies for this chronic disorder
2.00Category1CMECredits
F046 Leading Your Team by Coaching and
Mentoring
Room: 391
DIRECTOR AmyS.Paller,M.D.
SPEAkER Paul Seymour, PhD, Center for Creative Leadership
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Describe the diferences between coaching and mentoring and
identify situations where each may be most appropriate
2 Demonstrate skills that are key to both coaching and
mentoring including active listening, communicating and
providing feedback, and guiding others to self-awareness
3 Determine how to initialize, maintain, and conclude a
mentoring or coaching relationship
DESCRIPTION
To get where you are today, you almost certainly had mentors
or coaches who set the example and helped to guide you Are
you ready to learn those key skills that make a good mentor or
coach so you can develop your team? Tis session will describe
the diference between coaching and mentoring, explain why
these are both important, and identify when each can be most
efective You’ll learn tools for successful communication, providing
efective feedback and guiding others to fnd the solution Tips
will be ofered on how to establish and maintain positive working
relationships Co-presented with a faculty member from the Center
for Creative Leadership, this interactive session will help you
develop necessary skills to be an efective coach or mentor, whether
you’re developing residents or faculty in an academic setting or
building an efective working team of staf in the private ofce
2.00Category1CMECredits
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
151
SCIENTIFIC SESSIONS
S
A
T
U
R
D
A
Y
,

F
E
B
R
U
A
R
Y

5
WORkSHOP
3:00 pm to 5:00 pm
Tuition fee and ticket required for admission.
W006 MOC Self-Assessment:
Contact Dermatology
M
O
C
Room: 288/289/290
DIRECTOR ChristenM.Mowad,M.D.
SPEAkERS
Bruce A Brod, MD Erin M Warshaw, MD
Susan T Nedorost, MD Kathryn A Zug, MD
LEARNING OBjECTIVES
Following this workshop, the attendee will be able to:
1 Identify the strengths and weaknesses in one’s dermatology
knowledge as it pertains to contact dermatitis and make
improvements as needed
2 Demonstrate commitment to lifelong learning and self-
assessment via completion of a forum of 25 questions and
answers
3 List allergens and patch-testing issues
DESCRIPTION
Tis session will be structured in a question-and-answer format
using an automated response system It will cover topics in
contact dermatology Te participant will have immediate
feedback for each section and will be able to identify any areas of
weakness that require further self-directed study
2.00Category1CMECredits
*Self-assessmentquestionsutilizedinthissessionarethe
sameasthoseusedforForumF035andWorkshop
W004MOC:Self-AssessmentoferedatAnnual
Meeting2009and2010.Physiciansshouldnot
claimCME/MOCcreditforattendingthissessionif
theyattendedForumF035andWorkshopW004at
AnnualMeeting2009and2010.
The American Academy of Dermatology designates MOCmd – Vol. 4 for a
maximum of 24 AMA PRA Category 1 Credits™. Physicians should only claim
credit commensurate with the extent of their participation in the activity. This CME
activity is recognized by the American Academy of Dermatology for 24 hours of
AAD Category 1 CME. Credit may be used toward the American Academy of
Dermatology’s Continuing Medical Education Award.
Looking for the Latest
Self-Assessment Tool?
MOCmd™ Vol. 4 offers:
•TheabilitytofulfillComponent2of
MaintenanceofCertification
•Self-assessmentquestionsfollowedby
imagesandsampleclinicalcasesavailable
inprint,CD-ROM,andonline
•Linkstoverifiedreferencesforfurther
self-study
•Upto24AMAPRACategory1Credits ™
Complete your self-assessment
library with MOCmd

Vol. 4
Visit the Academy
Resource Center
Booth 3623 to order!
N
E
W
!
For description of session categories and fees see page 37
152
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
SUNDAY, FEBRUARY 6
Discussion Groups — 7:00 a.m. to 8:00 a.m.
D013 Challenging Pediatric Dermatology Cases 154
D014 Advances in Pemphigus and Pemphigoid 154
Focus Sessions — 7:00 a.m. to 8:00 a.m.
U073 Amyloidosis: Changing Our
View in Dermatology 154
U074 Eczema Centers: World Experiences 154
U075 Drug Safety: Do No Harm 155
U076 Immunofuorescence in Dermatopathology 155
U077 Hair Disease and the African American Patient 155
U078 Case-Based Approach to Lentigo Maligna 156
U079 Dermatologic Disease in Asians 156
U080 Uncommon Neonatal Dermatosis 156
U081 Medical and Surgical Practice 156
U082 Practical and Realistic Ofce Mycology for the
Epidemiology, Diagnosis, and Treatment of
Hu man Myc o s e s 157
U083 Hair Highlights: Common and Challenging
Hair Loss Disorders 157
U084 Climate Change, Allergy and the Skin 157
U085 Emerging Laser and Aesthetic Technology 158
P151 Plenary Session — 8:00 a.m. to 12:00 p.m.
8:00 am Business and Bagels 159
8:45 am Welcome
LarryEichenfeld,M.D 159
8:50 am Clarence S Livingood, MD,
Award and Lectureship
NeilS.Prose,M.D. 159
9:15 am Introduction of President/President’s Address
WilliamD.James,M.D 160
9:45 am Marion B Sulzberger, MD, Memorial
Award and Lectureship Lectureship
TomasS.Kupper,M.D. 160
10:15 am President-Elect’s Address
RonaldL.Moy,M.D. 161
10:30 am Lila Gruber Memorial Cancer Research
Award and Lectureship
W.MarstonLinehan,M.D. 161
11:00 am Eugene J Van Scott Award for Innovative Terapy
of the Skin and Phillip Frost Leadership Lecture
AntonStuetz,Ph.D. 162
11:30 am Guest Speakers
MaryMatalinandJamesCarville 162
Symposium — 11:00 a.m. to 2:00 p.m.
S024 Residents and Fellows Symposium 163
Discussion Groups — 12:15 p.m. to 1:45 p.m.
D015 Urticaria and Angioedema 163
D016 Photodermatology 163
Poster Discussion Sessions — 12:15 p.m. to 1:45 p.m.
PD03 Acne 164
PD04 Psoriasis 164
Focus Sessions — 12:15 p.m. to 1:45 p.m.
U086 Melasma: Pathogenesis and Treatment 165
U087 Fulflling Great Expectations: Caring for
New Mothers and Mothers-to-Be 165
U088 Hereditary Diseases of the Epidermis 165
U089 Lasers 1 0 1 166
U090 Angiogenesis and Clinical Dermatology 166
U091 Challenging Cases in Dermatopathology 166
U092 Opening Your Own Practice:
Blunders and Breakthroughs 166
U093 Notes of a Terapeutic Iconoclast 167
U094 Dermatologic Manifestations of HIV and AIDS 167
U095 Biologic Drugs for Psoriasis:
Do We Us e Te mEn o u g h? 167
U096 Medical Terapies and How Tey Work 167
U097 Immunostimulatory Treatment of Skin Cancer 168
Symposia — 2:00 p.m. to 5:00 p.m.
S025 New Emerging Terapies 168
S026 Cutaneous Oncology 169
S027 Contact and Occupational Dermatitis 170
S028 Nails 171
S029 Lessons from Great Leaders 172
S030 Electronic Health Record (EHR) Physician
Demonstration Symposium 172
S031 Tro pical De rmato l o gy 173
OVERVIEW
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
Practice Management Session open to eligible
offce staff/registered nurses
Represents Patient Safety Session in program overviews
Patient Safety Session
Represents Audience Response System Session
Audience Response System Session
Represents activities that meet MOC-D

M
O
C
This activity has been approved by the ABD to satisfy
component 2 of MOC-D
Represents Leadership Institute in program overviews
Leadership Institute — addresses leadership
competencies specifc to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
153
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
OVERVIEW
Discussion Groups — 2:30 p.m. to 4:00 p.m.
D017 Churning Out the Learning 173
D018 Practice Tips and Surgical Gems 173
Focus Sessions — 2:30 p.m. to 4:00 p.m.
U098 HITEMRs and Documenting Clinical Care:
Pitfalls and Promises 174
U099 Lumps and Bumps in Children 174
U100 Current Management of Skin Cancer in
Transplant Patients 175
U101 Pediatric Drug Eruptions 175
U102 From Pigment to PUPP (or PEP): What to Expect
When Your Patient is Expecting 175
U103 Drug Reaction Update 2011 176
U104 Cosmeceuticals: Topical Terapies for Treating
the Aging Face 176
U105 Advances in Fat Transfer and Liposuction for
Correction of Lipodystrophy:
Te US C Expe rie n c e 176
U106 What’s Tat? Syndrome Update 176
U107 Dermatology in Cinema 177
U108 Safety of Biologic Terapies: What’s the
Real Story? 177
Forums — 3:00 p.m. to 5:00 p.m.
F047 Managing an Efcient Practice 177
F048 Psoriasis as a Systemic Disease 178
F049 Laser Pe arl s 178
F050 What’s New in Immunomodulation 179
F051 Controversies in Vitamin D 179
F052 Advanced Dermatopathology 180
F053 Autoimmune Disease Update 180
F054 Dermatologic Health of Women 181
Workshops — 3:00 p.m. to 5:00 p.m.
W007 Efective C o mmu n i c atio n 181
W008 Bas ic De rmo s c o p y 182
W009 MOC Se l f - As s e s s m e n tB 183
Visit the Resource Center
Booth 3623 to subscribe!
Save
$40
w
ith
online
version!
Members like you are using Dialogues in
Dermatology to stay informed each month on the
latest trends and important topics in dermatology.
With convenient formats, and quick 20-minute
segments, there isn’t an easier way to stay current!
NEW online version offers:
• MP3 download capability - great for iPods!
• Streaming audio
• Links to verifed references
• Printable transcripts
• Editor-in-Chief’s summary on each topic
This program is available for AMA PRA Category 1 Credits
TM
Don’t let another
month go by...
Without your
Dialogues subscription!
For description of session categories and fees see page 37
154
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
DISCUSSION GROUP
7:00 am to 8:00 am
Tuition fee and ticket required for admission.
FOCUS SESSION
7:00 am to 8:00 am
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
D013 Challenging Pediatric Dermatology Cases
Room: 240
DIRECTOR LawrenceA.Schachner,M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 Diagnose difcult and severe pediatric dermatosis
2 Demonstrate therapeutic acumen of difcult and severe
pediatric dermatosis
3 Summarize the most recent, cutting-edge literature on these
disorders
DESCRIPTION
Te session will focus on severe dermatosis in pediatric
dermatology; severe morphea, unremitting atopic dermatitis and
extensive alopecia areata will be reviewed in detail with emphasis
on best diagnostic techniques and most efcient therapy for these
challenging disorders
1.00Category1CMECredits
D014 Advances in Pemphigus and Pemphigoid
Room: 241
DIRECTOR LuisA.Diaz,M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 Diagnose pemphigus vulgaris, pemphigus foliaceus, and
bullous pemphigoid
2 Apply recognized and newer therapies in treatment of these
diseases
3 Diferentiate these autoimmune diseases based on the advances
in their pathogenesis
DESCRIPTION
Structural skin molecules are targeted by “pathogenic”
autoantibodies which are known to induce intra-epidermal and
subepidermal blisters in experimental animals In pemphigus
vulgaris and pemphigus foliaceus, desmosomal antigens, ie, Dsg3
and, Dsg1 respectively, are the targets In bullous pemphigoid
hemidesmosomal antigens, ie, BP230 and BP180, are bound
by these autoantibodies Tese pathogenic autoantibodies may
trigger blister formation by diferent mechanisms, eg, signal
transduction, apoptosis or infammation Terapies aimed at
eliminating pathogenic autoantibodies from these patients will
be discussed
1.00Category1CMECredits
U073 Amyloidosis: Changing Our View in
Dermatology
Room: 283
DIRECTOR OmarLupi,M.D.,Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Recognize clinical, genetic, and epidemiological aspects of the
amyloidosis
2 Discuss the new conception of the “conformational disorders”
3 Recognize new routes of transmission related to the
amyloidosis
DESCRIPTION
Amyloidosis is a group of metabolic diseases that lead to the
deposition of amyloid in diferent organs, including the skin;
amyloidosis is considered to be of unknown origin with few real
therapeutic opportunities Until recently, the analysis of the amyloid
structure was the same as described a century ago However, in
recent years a new body of evidence suggested that amyloidosis
is a group of misfolded protein disorders with a potential of
transmissibility that have been described by diferent routes It
is critical to develop a new approach for amyloidosis in order to
understand the new diagnostic and therapeutic possibilities
1.00Category1CMECredits
U074 Eczema Centers: World Experiences
Room: 235/236
DIRECTOR JeanFrancoisStalder,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Discuss the emerging concept of patient-oriented medicine
compared to the evidence-based paradigm
2 Identify experiences of eczema centers across the world and
global principles of patient education applied to chronic skin
disease
3 Develop a management plan for an education program
DESCRIPTION
It is an accepted fact today that chronic skin disease impacts a
patient’s quality of life and there is a general problem of weak
adherence to topical treatment Te attempt to tackle these
problems has led to the creation of ‘eczema centers’ or ‘atopic
schools’ Te objective of these centers is to enable the patient
to become an active partner in his/her treatment by increasing
knowledge and coping skills Tis session will provide an overview
on therapeutic education experiences worldwide and propose
recommendations and references for setting up education structure
1.00Category1CMECredits
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
155
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
U077 Hair Disease and the African American
Patient
Room: 263
DIRECTOR DianeM.Jackson-Richards,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Describe the unique structural and physiologic properties of
African textured hair
2 Recognize the prevalence of hair and scalp disorders among
African Americans and identify the most common of these
among African Americans
3 Develop culturally competent therapeutic protocols for
common hair and scalp disorders among African Americans
DESCRIPTION
Hair disease, an exceedingly common problem among African
American patients, can be associated with a number of medical,
psychosocial, and cosmetic issues Te unique structure and
physiology of African textured hair undoubtedly plays a role in
the pathogenesis of many disorders common among African
Americans Tis session will discuss the current state of the
knowledge regarding the anatomy and physiology of African
textured hair, and review the most common hair and scalp
disorders encountered among African American patients Te
importance of developing culturally competent management
techniques will be emphasized, and specifc recommendations
regarding therapeutic protocols and grooming practice instruction
will be made
1.00Category1CMECredits
FOCUS SESSION
7:00 am to 8:00 am
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U075 Drug Safety: Do No Harm
Room: 285
DIRECTOR BonnieT.Mackool,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Summarize the untoward side efects of routinely used topical
agents that have resulted in morbidity and/or even death
2 Outline important systemic drug interactions of systemic
agents used in dermatology practice
3 Recognize patient risk factors for iatrogenic efects from topical
and systemic agents and ultimately avoid morbidity and
mortality from their use
DESCRIPTION
Tis case-oriented approach will review what every dermatologist
should know about two important areas of iatrogenic illness in our
feld: frst, the potentially serious side efects of the entire range
of topical medications in our specialty, additionally the potential
drug interactions of systemic agents used in our feld Te use of
patient cases and audience participation will facilitate attendees’
formulation of individual patient risk in the use of topical or
systemic medication
1.00Category1CMECredits
U076 Immunofuorescence in
Dermatopathology
Room: 270
DIRECTOR RobertLaw,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Develop a comprehensive histopathologic difrential diagnosis
for the vesiculobullous diseases
2 Discuss the pathophysiology of the basement membrane zone
and major intercellular antigens
3 Choose the appropriate immunofuorescence modality when
faced with possible immunobullous or connective tissue
diseases
DESCRIPTION
Dermatologists and dermatopathologists rely heavily on the use of
adjunctive diagnostic tests in daily practice Immunofuorescence
techniques are vital in establishing many diagnoses, and require
specialized equipment and training to perform with profciency
Tis session reviews the basic pathophysiology of major
immunobullous diseases and discusses the methodology of both
direct and indirect immunofuorescence Attention is given to
common causes of clinicopathologic discrepancies, with discussion
of selected interesting cases
1.00Category1CMECredits
For description of session categories and fees see page 37
156
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
FOCUS SESSION
7:00 am to 8:00 am
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U078 Case-Based Approach to Lentigo Maligna
Room: 264
DIRECTOR DoriGoldberg,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Summarize the literature on treatment options for lentigo
maligna
2 Compare diferent surgical approaches to lentigo maligna
including excision and staged excision (slow Mohs) as well as
potential use of imiquimod as a topical agent
3 Develop a clinical approach to the management of lentigo
maligna
DESCRIPTION
Te management of lentigo maligna is often complicated by the
poorly defned tumor margins and location of lesions on the head
and neck Commonly used treatments currently include simple
excision and staged excision (slow Mohs), with Mohs surgery and
topical therapy with imiquimod less frequently employed options
In this session we will examine how to approach lentigo maligna
and develop a treatment strategy through the review of several
patient cases
1.00Category1CMECredits
U079 Dermatologic Disease in Asians
Room: 274
DIRECTOR RoopalVashiKundu,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Recognize common and uncommon cutaneous disorders in
Asian American skin
2 Demonstrate cultural competence when encountering
cutaneous disorders in patients with Asian ancestry
3 Manage Asian American patients with skin disorders using safe
and efective treatments
DESCRIPTION
Te Asian American population is comprised of persons with
ancestry from East Asia, Southeast Asia, and South Asia Te
US Census Bureau predicts the Asian American population will
total 40 million persons by 2050 Common and uncommon skin
disorders amongst these populations will be discussed emphasizing
acne, melasma, post-infammatory hyperpigmentation, erythema
dyschromicum perstans, and melanoma Dermatoses secondary
to Asian cultural practices such as coin rubbing, cupping,
moxibustion and henna tattoos will also be reviewed
1.00Category1CMECredits
U080 Uncommon Neonatal Dermatosis
Room: 269
DIRECTOR MargaritaM.Larralde,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Identify uncommon neonatal dermatoses
2 Discuss the diferential diagnoses
DESCRIPTION
Te session will provide practical information about diferent
and uncommon neonatal dermatoses Tere will be interactive
participation with attendees participating in quizzes Te session
will be targeted to general dermatologists, fellows, and residents
1.00Category1CMECredits
U081 Medical and Surgical Practice
Room: 265/266
DIRECTOR DuaneC.Whitaker,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Discuss elements of combining medical and surgical practice
2 Outline features of support staf performance
3 Explain elements of physician CME that are vital to a changing
and growing practice
DESCRIPTION
Patient care for cutaneous disease can be comprehensive, and
clinical practice more satisfying when we provide a wider range of
consultation and serivice to our patient population High-level
medical and surgical practice can be combined Optimal care in
this setting requires well-trained support staf and a practice ethic
and goal to manage surgical and medical patients in the same day
Well-selected CME, attentive and patient focused support staf
with excellent communication skill are essential to accomplish ths
goal Methods to do so and maintain high patient satisfaction are
presented
1.00Category1CMECredits
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
157
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
SCIENTIFIC SESSIONS
U084 Climate Change, Allergy, and the Skin
Room: 284
DIRECTOR JohannesRing,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Summarize exact data on facts regarding climate change from
the view of meteorology and atmospheric physics
2 Discuss the interaction among climate efects, anthropogenic
pollution, and allergen carriers such as pollen in the outdoor air
3 Examine the practical relevance of these climatic changes upon
skin health and allergy
DESCRIPTION
Tere is scientifc evidence that climate change is a reality and not
a myth Te increase in global earth surface temperature in the last
30 years is man-made and not due to solar irradiation Implications
of climate change for health will afect allergic and skin diseases
besides infectious diseases and cardiovascular problems due to heat
exposure Reasons for increases in allergy prevalence may be due to
prolonged allergen exposure (pollen fowering seasons have increased
in the Northern hemisphere by 10 to 14 days) Due to climate
change, neophytes and new allergens appear in many countries
Because of anthropogenic efects and atmospheric pollution,
increased allergen exposure can be predicted An example is the
new epidemic of ragweed (Ambrosiaartemisiifolia) sensitization
and allergy in Germany in the last 15 years Te same holds true
for contact dermatitis both allergic and irritant-toxic in origin
(eg, Taumatopoea or oak processionary caterpillar) in increasing
amounts in Northern countries
1.00Category1CMECredits
FOCUS SESSION
7:00 am to 8:00 am
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U082 Practical and Realistic Offce Mycology
for the Epidemiology, Diagnosis, and
Treatment of Human Mycoses
Room: 242
DIRECTOR DennisE.Babel,Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Diferentiate the cutaneous presentations of superfcial through
systemic mycoses more efectively
2 Utilize direct microscopy to determine the presence of
cutaneous fungal pathogens more efciently
3 Discuss the epidemiology of fungal diseases to better manage
recurrent mycoses
DESCRIPTION
Tis session will detail straightforward procedures that can be
utilized in the dermatology ofce to efciently diagnose superfcial
through systemic mycoses which demonstrate cutaneous lesions
Te role of efcient direct microscopy will be emphasized Te
most efective means of collecting patient specimen for diagnostic
confrmation will be outlined for each of these entities Te role
of epidemiology in pathogen transmission, disease recurrence,
and common fungal reservoirs will be discussed Numerous
case presentations will be used to demonstrate the variations in
mycoses presentation
1.00Category1CMECredits
U083 Hair Highlights: Common and
Challenging Hair Loss Disorders
Room: 267/268
DIRECTOR MaryH.Lien,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Select the most appropriate clinical tests to evaluate hair loss
2 Diagnose the diferent types of alopecia more efectively
3 Utilize the most appropriate treatments to manage the
common and challenging hair loss patients
DESCRIPTION
We all aim to maximize the efciency and to reduce the
frustration of the 15-minute alopecia visit Tis session will guide
providers in ordering the appropriate clinical tests to evaluate hair
loss patients Clinical presentations of non-scarring and scarring
alopecias will be reviewed Te correct tissue sampling techniques
for various alopecias and ethnicities, as well as tissue sectioning
preferences, will be discussed Tis session will be informative for
dermatologists who are interested in honing their diagnostic and
therapeutic skills in managing hair loss patients
1.00Category1CMECredits
For description of session categories and fees see page 37
158
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
FOCUS SESSION
7:00 am to 8:00 am
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U085 Emerging Laser and Aesthetic
Technology
Room: 298/299
DIRECTOR M.ChristineLee,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Compare new technologies with pre-existing older technology
2 Examine and evaluate the latest cutting-edge technologies
3 Recognize the latest research supporting the technology
DESCRIPTION
Tere has been a rapid proliferation of laser and aesthetic
technology over the last several years Examples include
innovations in lasers, light-based, radiofrequency, ultrasound,
and combination devices An overview of the evolution of laser
treatments for medical and cosmetic purposes, invasive and
noninvasive approaches, high-tech and low-tech techniques
will be presented New and emerging technologies will be
examined and evaluated for their potential roles in the physicians
armamentarium, and they will be compared to pre-existing older
technology Special emphasis will be placed on devices used in
common cosmetic dermatologic challenges One of the goals
of this session is to help the practitioner approach the decision-
making process of choosing and utilizing laser and aesthetic
technology with greater awareness and knowledge New and
emerging technologies will include skin tightening (comparing
monopolar with unipolar radiofrequency, infrared light sources,
ultrasound, needle delivery devices), all types of fractional
resurfacing, and comparisons of the newest fractional CO
2
lasers,
body contouring, and fat-melting devices
1.00Category1CMECredits For more information or
to nominate someone please visit
www.aad.org/namedlectureships
Everett C. Fox, M.D.,
Memorial Lectureship
The American Academy of Dermatology is pleased to
announce a Call for Nominations for the 2012 Everett C.
Fox, M.D., Memorial Lectureship. This distinguished
award is given to an expert clinical dermatologist
(including dermatopathologists and dermatologic surgeons).
The selected recipient will receive a cash award of
$10,000 and will present a lecture at the Plenary
Session of the AAD’s Summer Academy Meeting 2012.
Subm
ission
deadline is
June 8, 2011
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
159
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
P151 PLENARY SESSION
8:00 am to 12:00 pm
Room: La Nouvelle Orleans Ballroom
Open admission, no tuition or ticket.
Upto2.00Category1CMECredits
TeAmericanAcademyofDermatology’sAnnualBusiness
Meetingwillbe heldonFebruary6,2011intheLaNouvelle
OrleansBallroomat8a.m.Itwillfollowtheagendabelow:
8:00 am BUSINESS AND BAGELS
AMERICAN ACADEMY OF DERMATOLOGY
(AAD) BUSINESS MEETING
I. CallAssemblytoOrder
II. EstablishQuorum
III. IntroductionsandAcknowledgments
IV. President-ElectCandidates’Statements
V. RecognitionofIndustry
VI. AwardsAcknowledgments
VII. Secretary-Treasurer’sReport
VIII. UnfnishedBusiness
IX. NewBusiness
X. Announcements
XI. Adjournment
AMERICAN ACADEMY OF DERMATOLOGY
ASSOCIATION (AADA) BUSINESS MEETING
I. CallAssemblytoOrder
II. EstablishQuorum
III. Secretary-Treasurer’sReport
IV. UnfnishedBusiness
V. NewBusiness
VI. RecognitionofRetiringBoardOfcers
VII. Adjournment
INFORMAL DISCUSSION OF ISSUES OF
IMPORTANCE FROM THE FLOOR*
PursuanttotheAdministrativeRegulationsofthe
AmericanAcademyofDermatologyandAmerican
AcademyofDermatologyAssociation,duringany
debateatamembershipmeetingeachspeaker
mustintroducehimselforherselfbynameand
professionalposition.Heorshemustalsoidentify
anypotentialconfictsofinterest.
*NoCMECredit
8:45a.m. WELCOME
LarryEichenfeld,M.D.

*NoCMECredit
8:50a.m. CLARENCE S. LIVINGOOD, M.D., AWARD
AND LECTURESHIP
NeilS.Prose,M.D.

Cultivating Curiosity
Althoughcuriositykilledthecat,ithas
immeasurablevalueinthepracticeofdermatology.
When weapproachourpatientswithcuriosity,we
canbegintounderstandwhotheyreallyare.Asa
result,wecanprovidemoreempathicandmore
efectivecare.Howdowecultivatethisimportant
skillandincorporateitintoourpractice?
.50Category1CMECredits
For description of session categories and fees see page 37
160
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
9:45a.m. MARION B. SULZBERGER, M.D., MEMORIAL
AWARD AND LECTURESHIP
TomasS.Kupper,M.D.

Skin in the Game: New Perspectives on
T-Cells, Immunity, and Cancer
Advancesinourunderstandingof howTcells
protectskinischangingthewaywethinkabout
protectiveimmunity,vaccination,cancer,and
infammatoryskindiseases.Increasingly,these
insightsarebeingtranslatedintopatientcare.
NewapproachesbasedonT-celltrafckingto
treatingpatientswithcutaneousT-celllymphoma
willbediscussed.
.50Category1CMECredits
P151 PLENARY SESSION
8:00 am to 12:00 pm
Room: La Nouvelle Orleans Ballroom
Open admission, no tuition or ticket.
Upto2.00Category1CMECredits
9:15a.m. PRESIDENT’S ADDRESS
WilliamD.James,M.D.

Inhisplenaryaddress,Dr.Jameswillrefectonhis
yearaspresident,and,morebroadly,speak tothe
challengesandthemanyexcitingaccomplishments
thathaveshapedhisyearinofce.Hewilltalk
aboutlandmarkHealthSystemReformissuesthat
hasevolvedandbecomelegislationsincehehas
takenofce,anditsimpactondermatology.
Dr.Jameswillalsodiscusshowvolunteerism,
partnershipandcooperation havecoalescedto
strengthentheprofessionofdermatology;and
willbringattendeesthelatestinformationonthe
impactofseveralkeyissues,includingelectronic
healthrecords,thecomplexrequirementsforquality
reportingandclinicalperformanceassessment,
Medicare’sSustainableGrowthRateformula,
healthsystemreform,andtheAcademy’saggressive,
multi-frontwaragainstskincancer.
HismessagewilldemonstratehowtheAcademyhas
madeboldstridestoimprovepatientcare,educate
thepublic,andadvanceourspecialty.
* NoCMECredit
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
161
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
P151 PLENARY SESSION
8:00 am to 12:00 pm
Room: La Nouvelle Orleans Ballroom
Open admission, no tuition or ticket.
Upto2.00Category1CMECredit
10:15a.m. PRESIDENT-ELECT’S ADDRESS
RonaldL.Moy,M.D.

Aswelookaheadtodermatologyin2011and
beyond,RonaldMoy,M.D.,willpresenthis
forward-lookingvisionoftheAcademywhenhe
delivershisplenarymessageaspresident-elect.
Amonghisaspirationsforhisterm,Dr.Moyhas
expressedhisdesiretorevitalizetheAcademy,and
hewilloutlinehisplantogeneratemoreresources
toassistinrealizingtheAcademy’scontinuing
visionofexcellence.Dr.Moyhasadvocated
morecomprehensiveeducationofthepublicand
legislatorsbydermatologiststohelpachievethe
Academy’sgoals.
Hewilldiscussthevalueofpartnershipsand
teamwork,andwilloutlinehisplansforafuture
thatseekstobeprosperousfordermatologistsand
benefcialtopatients.
*NoCMECredits
10:30a.m.LILA GRUBER MEMORIAL CANCER RESEARCH
AWARD AND LECTURESHIP
W.MarstonLinehan,M.D.

Familial Kidney Cancer Syndromes with
Cutaneous Manifestations
MycolleaguesandIstudythegeneticbasisand
clinicalmanifestationsoffamilialhumankidney
cancersyndromes,twoofwhich,Birt-Hogg-Dubé
andhereditaryleiomyomatosisrenalcellcancer,
haveimportantcutaneousmanifestations.Our
clinicalandexperimentalanalysesareleadingto
improvedmanagementandtargetedtherapeutic
approachesforthesedisorders.
.50Category1CMECredits
For description of session categories and fees see page 37
162
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
11:30a.m.GUEST SPEAkERS
JamesCarvilleandMaryMatalin

All’s Fair: Love, War, and Politics
Inthishighlypopularjointpresentation,
Washington’sbest-lovedcouple,JamesCarvilleand
MaryMatalin,givesaudiencesanenlightening
andentertaininglookattoday’smostimportant
politicalissuesaswellasabehind-the-sceneslook
atWashingtonpolitics.Co-authorsofthenational
bestsellerAll’s Fair: Love, War, and Running
for President,bothMatalinandCarvilleare
keyplayersonthenationalpoliticalstage,having
betweenthemworkedforeverypresidentover
thelast25years.Inthispresentation,Carville
andMatalincombinetheiruniqueexperienceas
perennialpoliticalinsiderstoprovideaudienceswith
astimulating,candid,andprovocativeanalysisof
theday’sheadlinesandtoday’shot-buttonpolitical
issuesfrombothsidesofthepoliticalaisleforalively
andengagingexchangeofviews.
* NoCMECredit
PLN151 PLENARY SESSION
8:00 am to 12:00 pm
Room: La Nouvelle Orleans Ballroom
Open admission, no tuition or ticket.
Upto2.00Category1CMECredits
11:00a.m.EUGENE j. VAN SCOTT AWARD FOR
INNOVATIVE THERAPY OF THE SkIN AND
PHILLIP FROST LEADERSHIP LECTURE
AntonStuetz,Ph.D.

Lessons Learned During Research and
Development of New Medicines for Treatment
of Skin Diseases
Teallylamineantimycoticterbinafnehasbecome
theglobalstandardforthetreatmentoffungal
infectionsoftheskinandnails.Topicalcalcineurin
inhibitorshavebecomethefrstalternativeto
topicalcorticosteroidsinthetreatmentofatopic
dermatitis.Recentresearchindicatespotential
ofVEGFinhibitorsandtopicalSmoothened
inhibitorsfortreatmentofskindiseases.Lessons
learnedduringresearchanddevelopmentofthese
projectswillbediscussed,consideredtoberelevant
fortoday´sefortstocomeupwithnewdrugs.
.50Category1CMECredits
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
163
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
D015 Urticaria and Angioedema
Room: 240
DIRECTOR NicholasArthurSoter,M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 Develop an appropriate evaluation for patients with urticaria
and angioedema
2 Select the various classes of pharmacologic agents to treat
urticaria and angioedema
DESCRIPTION
Te evaluation of patients with urticaria and angioedema will
be presented based on pathogenesis Tese categories include:
immunologic IgE and IgE receptor-dependent processes,
abnormalities of plasma systems, agents that directly degranulate
the mast cell and alter arachidonic acid metabolism, and
idiopathic disease Antihistamines of the frst, second, and third
generations will be discussed as well as novel and anecdotal
therapeutic agents
1.50Category1CMECredits
D016 Photodermatology
Room: 241
DIRECTOR JohnLyndonMcLeodHawk,M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 Explain the mechanisms of normal and abnormal skin
responses to ultraviolet radiation exposure
2 Prevent or treat most of these responses efectively
3 Recognize many of the interactions of ultraviolet radiation
with skin
DESCRIPTION
Te nature of ultraviolet radiation damage to the skin and
of the common photodermatoses, particularly polymorphic
light eruption, the efective use of photoprotection and more
specifc treatments, and use and efcacy of phototherapy, will be
discussed In addition, matters of major general dermatological
interest such as vitamin D and sun exposure requirements,
sun beds, and sunscreens will be included Tis session is
directed at both general dermatologists and those with a specifc
photodermatological interest
1.50Category1CMECredits
SYMPOSIUM
11:00 am to 2:00 pm
Open admission, no tuition or ticket.
S024 Residents and Fellows Symposium
Room: 343
DIRECTOR DennisH.Oh,M.D.,Ph.D.
SPEAkERS
Michael E Ming, MD
Delphine J Lee, MD, PhD
Jefrey B Travers, MD, PhD
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Identify the latest laboratory-based and/or clinic-based research
fndings presented by dermatology residents and fellows
2 Recognize developing trends in research in cutaneous biology
and dermatologic disease
DESCRIPTION
New knowledge about the pathophysiology and treatment of
cutaneous diseases is cruical for the future of our specialty In
this session, talented young investigators who are actively working
in the laboratory and/or clinic will present their latest research
discoveries Te faculty, who will serve as judges, will select the
residents or fellows who present the most outstanding papers at
the symposium to receive the prestigious Everett C Fox Memorial
Lectureship
3.00Category1CMECredits
DISCUSSION GROUP
12:15 pm to 1:45 pm
Tuition fee and ticket required for admission.
For description of session categories and fees see page 37
164
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
POSTER DISCUSSION
12:15 pm to 1:45 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
PD03 Acne
Room: 283
NoCMECredits
MODERATOR
Jonette Elizabeth Keri, MD, PhD
P300
Clindamycin plus tretinoin gel: Treatment of acne patients with all
six Fitzpatrick skin types
P301
Tretinoin microsphere 01% gel for acne patients
P302
Faropenem is efective for infammatory acne
P303
High degree of safety, efcacy, tolerability, lower relapse rates, and
improved quality of life associated with high-dose isotretinoin
therapy
P304
Managing mild to moderate acne in adolescents: Cutaneous
tolerability benefts of tretinoin gel (005%) in a study
subpopulation of 983 subjects aged 10 to <18 years
P305
Exacerbation of facial acne vulgaris after consuming pure
chocolate
P306
Meta-analysis of randomized controlled trials using 5% benzoyl
peroxide and clindamycin versus 25% benzoyl peroxide and
clindamycin topical treatments in acne
PD04 Psoriasis
Room: 284
NoCMECredits
MODERATOR
Paolo Romanelli, MD
P400
Te efect of tumor necrosis factor-alpha inhibitors on the risk of
myocardial infarction in patients with psoriasis
P401
Determining the extent to which clinically efective treatment,
ustekinumab or etanercept, reverses the molecular disease profle
of psoriatic skin: Comparisons of lesional, non-lesional, and
normal skin
P402
Improvement in nail psoriasis is associated with improved efcacy
outcomes in hand and/or foot psoriasis in adalimumab-treated
patients: Subanalysis of REACH
P403
Ustekinumab demonstrates rapid onset of efcacy in the treatment
of moderate to severe psoriasis
P404
Cause-specifc mortality in patients with severe psoriasis: A
population-based cohort study
P405
Te safety of tumor necrosis factor antagonists in patients with
psoriatic disease: A systematic review and meta-analysis of
randomized controlled trials
P406
A pooled analysis of phase III, randomized, placebo-controlled
clinical trials of the anti-interleukin 12/23 monoclonal antibody,
ABT-874
P407
Gene expression profling in psoriatic scalp hair follicles:
Clobetasol propionate shampoo 005% normalizes psoriasis disease
markers
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
165
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
U088 Hereditary Diseases of the Epidermis
Room: 238/239
DIRECTOR TakashiHashimoto,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Diagnose hereditary diseases of the epidermis
2 Select the best methods for the diagnosis of hereditary diseases
of the epidermis
3 Identify the pathomechanism for the skin lesion in these
hereditary diseases
DESCRIPTION
Tis session will present the new fndings in various hereditary
diseases of the epidermis, including ichthyosis, palmoplantar
keratoderma and pachyonychia congenita, Darier disease,
Hailey-Hailey disease, and epidermolysis bullosa hereditaria
Te audience will learn to diagnose these diseases clinically
and histopathologically, and will be able to show patients the
genetic background of each disease Precise information about
the mutation of the responsible gene for each disease also will be
covered Furthermore, the lecturer will also explain about the
pathomechanism for the skin lesion in these hereditary diseases
of the epidermis Finally, gene therapy for these diseases will be
described
1.50Category1CMECredits
FOCUS SESSION
12:15 pm to 1:45 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U086 Melasma: Pathogenesis and Treatment
Room: 285
DIRECTOR AndreasD.Katsambas,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Recognize and identify melasma in patients
2 Develop and implement proper treatment for melasma
patients
DESCRIPTION
Melasma is a cosmetic problem that can sometimes cause great
emotional sufering Although no race is spared, melasma appears
to be more common in darker-skinned individuals of Hispanic,
Asian, and Indo-chinese origin Genetic predisposition, estrogens,
and solar radiation have been incriminated for the pathogenesis
of melasma Recent advances regarding the management of this
disease will be reviewed, including topical bleaching agents,
combination formulas, chemical peels, and lasers Finally, a
management plan for diferent skin types as well as diferent
categories of melasma (epidermal-mixed-dermal) will be presented
1.50Category1CMECredits
U087 Fulflling Great Expectations: Caring for
New Mothers and Mothers-to-Be
Room: 274
DIRECTOR JennyEileenMurase,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Discuss with pregnant and lactating patients safety data on
medications frequently used to treat common dermatologic
conditions
2 Diagnose and treat nipple dermatitis and thrush during
lactation, and make recommendations on prevention in
lactating mothers
DESCRIPTION
Dermatologists are often faced with difcult questions from new
mothers and mothers-to-be concerned about how the use of
medical therapy during pregnancy and lactation may afect their
children We will review, through an evidence-based medicine
approach, safety data in pregnancy and lactation We will discuss
medical malpractice surrounding use of dermatologic therapy in
pregnancy Finally, we will discuss the appropriate work-up of
nipple dermatitis, when to suspect thrush, medications and other
therapies that are safe to speed recovery, and the appropriate
management of the elusive entity chronic candidal mastitis
1.50Category1CMECredits
For description of session categories and fees see page 37
166
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
FOCUS SESSION
12:15 pm to 1:45 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U089 Lasers 101
Room: 265/266
DIRECTOR GeraldGoldberg,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Identify some of the basic principles and physics of laser-tissue
interaction, which are important in a variety of laser skin
treatments
2 Discuss and illustrate specifc attributes of multiple laser
modalities in the treatment of vascular entities, pigmented
lesions, wrinkles, scars, epidermal lesions, and unwanted hair
3 Develop an understanding of appropriate patient selection,
as well as proper preparation of patient expectation, by
appreciating the potential side efects, complications, and
limitations of skin laser treatments
DESCRIPTION
Tis session will ofer a brief review of the basic physics and
clinical applications of a wide variety of laser modalities Te use
of lasers for vascular lesions, pigment problems, hair removal,
and epidermal and dermal entities will be discussed Te session
will illustrate some of the primary uses of lasers with clinical cases
from 25 years of laser practice We will focus the discussion on
treatment of vascular lesions as well as the uses of some of the
new ablative, nonablative, and fractional resurfacing devices We
will also illustrate creative uses of lasers, alone and in combination
with other modalities We will discuss patient selection and
complications
1.50Category1CMECredits
U090 Angiogenesis and Clinical Dermatology
Room: 269
DIRECTOR JackL.Arbiser,M.D.,Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Determine how to use antiangiogenic therapy in clinical
practice
2 Determine which disorders have excessive or defcient
angiogenesis
DESCRIPTION
Malignant, infammatory, and infectious disease processes induce
angiogenesis in order to initiate and perpetuate themselves
Dermatologists already use antiangiogenic therapy for the
treatment of common skin conditions Tis session will discuss the
use of angiogenesis for skin cancer, infammatory skin conditions
(psoriasis/atopic dermatitis), and infectious processes such as warts
1.50Category1CMECredits
U091 Challenging Cases in Dermatopathology
Room: 264
DIRECTOR KlausSellheyer,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Identify difcult dermatopathological cases
2 Identify the most relevant diferential diagnoses
3 Perform the clinicopathological correlation
DESCRIPTION
We will cover about 30 difcult dermatopathological cases At
the end of the session the participant should be able to recognize
these cases which include infammatory, neoplastic, genetic, and
deposition disorders Te diferential diagnoses of these cases
will also be discussed Te session is meant to be interactive and
questions between audience and faculty are highly encouraged
1.50Category1CMECredits
U092 Opening Your Own Practice:
Blunders and Breakthroughs
Room: 267/268
DIRECTOR RobertL.Buka,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Determine whether private practice is the best next step
2 Develop a key understanding of foundations behind a
successful private practice
3 Demonstrate the leadership required to grow a business from
the ground up
DESCRIPTION
1 Decision Te discussion will begin with an overview of
whether this decision is the right one for participants, new
challenges in healthcare reimbursement, the pros/cons of more
autonomy, preparation required before opening a practice
2 Location Identifying the best location for a practice, a space
that will work for you for years to come Leasing, purchasing,
and lenders will all be reviewed
3 Setup What electronic features are worth it and which still
need further testing? Choosing ofce staf and associates
4 Recruitment Now the practice is open Where do you fnd
patients? A review of advertising and marketing for a new
practice
1.50Category1CMECredits
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
167
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
U095 Biologic Drugs for Psoriasis:
Do We Use Them Enough?
Room: 298/299
DIRECTOR RonaldB.Prussick,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Assess when to consider a biologic drug for a patient with
psoriasis
2 Choose which biologic to use
3 Evaluate and recognize how to monitor and manage patients
on biologic drugs
DESCRIPTION
Psoriasis is a systemic autoimmune disease Instead of a strict
stepwise approach, we will explore decisions based on patient
presentation, disease severity, presence of arthritis, and quality-
of-life measures We will detemine when it is appropriate to
consider treatment with a biologic drug and look at those available
to us, their advantages and disadvantages We will also discuss
monitoring guidelines Tis session is directed mainly to clinicians
in private practice
1.50Category1CMECredits
U096 Medical Therapies and How They Work
Room: 235/236
DIRECTOR KevinD.Cooper,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Choose medical therapies that are best suited for the
underlying disease mechanism
2 Explain to patients and family the rationale for drug choice in
relation to disease
3 Use drugs to treat infammatory disease mechanisms and
pathology patterns
DESCRIPTION
Medical therapies are increasingly targeted to specifc disease
mechanisms or are better understood as to which mechanisms
are afected Infammatory diseases as well as neoplastic disorders
in dermatology have such drugs available that help patients and
elucidate the underlying disease process Understanding drug-
targetable disease processes allows one to better treat patients whose
pathologic reaction pattern can be identifed but whose specifc
subtype might be poorly described in the literature Tis session
will discuss examples of medical therapies that target specifc basic
mechanisms, with an emphasis on infammatory disease
1.50Category1CMECredits
FOCUS SESSION
12:15 pm to 1:45 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U093 Notes of a Therapeutic Iconoclast
Room: 270
DIRECTOR NormanLevine,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Critically evaluate claims of therapeutic efcacy
2 Select optimal treatments for various dermatological
conditions
3 Manage patients using aggressive medical regimens
DESCRIPTION
Alternative views of medical and surgical therapies used in
dermatological practice will be discussed A review of the recent
literature as well as personal experiences and prejudices will form
the basis for conclusions about which treatments are efective and
which are not worth using Terapies such as the “pre-biologics,”
psychotropic medications, topical immune modulators, sentinel
node biopsies for melanoma, indications for Mohs micrographic
surgery will be presented Te evolving role of the pharmaceutical
industry in the lives of patients and health care providers will also
be discussed
1.50Category1CMECredits
U094 Dermatologic Manifestations of HIV
and AIDS
Room: 242
DIRECTOR AdamD.Lipworth,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Identify cutaneous manifestations of HIV and AIDS
2 Manage cutaneous manifestations of HIV and AIDS
DESCRIPTION
HIV and AIDS patients develop unique infectious and non-
infectious cutaneous diseases, many of which carry signifcant
morbidity and mortality Te rise of antiretroviral therapy has
decreased the prevalence of these complications in the United
States, decreasing familiarity with these diseases among US
dermatologists However, opportunistic infections, HIV-associated
malignancies, hypersensitivity reactions to HIV treatments, and
severe primary infammatory dermatoses persist in certain HIV-
infected populations in the developed world, and remain very
common in developing nations Tis case-based session will use
actual patient encounters from the United States, the United
Kingdom, and Africa to highlight diagnosis and management of
HIV-related skin diseases
1.50Category1CMECredits
For description of session categories and fees see page 37
168
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
FOCUS SESSION
12:15 pm to 1:45 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
SYMPOSIUM
2:00 pm to 5:00 pm
Open admission, no tuition or ticket.
U097 Immunostimulatory Treatment of Skin
Cancer
Room: 263
DIRECTOR StephenBrentTucker,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Explain immunologic mechanisms for eradicating cancer cells
2 Select which skin cancers are optimal for immunotherapy based
on histology, location, and patient
3 Treat skin cancers by immunostimulation and prevent future
skin cancers by patient education
DESCRIPTION
Te session will include results of immunostimulation for cancer
treatment in general, and applications for skin tumors specifcally
Basic science and histological aspects of immunotherapy in the
skin and the use of immunostimulation for prevention will be
covered Treatment guidelines to be presented include: selecting
appropriate tumors; discussion of this treatment option with
patients; prevention of side efects; cost of treatment; expected
short- and long-term outcomes, and advantages and disadvantages
of this treatment Specifc protocols using imiquimod, interferon
alfa, and combination treatment will be discussed for those
interested in alternatives to destructive methods
1.50Category1CMECredits
S025 New Emerging Therapies
Room: 243/244/245
DIRECTOR DavidEricCohen,M.D.
SPEAkERS
Macrene Alexiades- Bruce Elliot Strober, MD, PhD
Armenakas, MD, PhD Antonio Torelo, MD
Brian Berman, MD, PhD Ken Washenik, MD, PhD
Elizabeth K Hale, MD Guy F Webster, MD, PhD
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Identify new and emerging treatments for a wide variety of skin
diseases
2 Discuss the mechanisms of action of future therapies
3 Examine the efcacy and safety of new dermatologic therapies
DESCRIPTION
Tis symposium will review new and emerging therapies for
the treatment of a wide variety of dermatologic diseases Tis
conference will serve as a repository of information for the most
cutting edge treatments that have become available recently or that
may become part of our therapeutic armamentarium in the future
3.00Category1CMECredits
SCHEDULE
2:00 pm Introduction To New Emerging Terapies And
Discussion Of Te Allergen Of Te Year / Dr.Cohen
2:20 pm Psoriasis / Dr.Strober
2:40 pm Fillers And Injectable Cosmetic Devices / Dr.Hale
3:00 pm Acne And Rosacea / Dr.Webster
3:20 pm Alopecia, Hair And Scalp Disorders / Dr.Washenik
4:00 pm Actinic Keratosis And Skin Cancer / Dr.Berman
4:20 pm Laser Terapy / Dr.Alexiades-Armenakas
4:40 pm Questions and Answers / Dr.Cohen
4:40 pm Pediatric Dermatology / Dr.Torello
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
169
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
SCHEDULE
2:00 pm Introduction and Review of Today’s Session
/Dr.Rigel
2:05 pm Magnitude of the Problem: What Is the Real Number
of Non-melanoma Skin Cancers in the US?
/Dr.Coldiron
2:18 pm New Concepts in Merkel Cell Carcinoma
/Dr.Nghiem
2:31 pm Challenges in Photoprotection/Dr.Rigel
2:44 pm Topical Terapy for Skin Cancer: Old and New
Options /Dr.Rosen
2:57 pm Do Psoriasis Terapies Increase Skin Cancer Risk?
/Dr.Lebwohl
3:10 pm Managing the Melanoma Patient/Dr.Swetter
3:23 pm Questions and Answers/Dr.Faculty
3:31 pm Te Dilemma of the Dysplastic Nevus/Dr.Cockerell
3:44 pm Challenges in Skin Cancer Prevention: Can We Make
a Diference?/Dr.Robinson
3:57 pm When Our Patients Ask About Tanning and
Vitamin D/Dr.Spencer
4:10 pm Diagnosing Melanoma: New Options/Dr.Ceilley
4:23 pm Approaches to the Patient with Advanced Melanoma/
Dr.Friedman
4:36 pm Using Dermoscopy for the Face and Feet: Special
Considerations/Dr.Stein
4:47 pm Questions and Answers/Faculty
SYMPOSIUM
2:00 pm to 5:00 pm
Open admission, no tuition or ticket.
S026 Cutaneous Oncology
Room: Auditorium C
DIRECTOR DarrellS.Rigel,M.D.
SPEAkERS
Roger I Ceilley, MD June K Robinson, MD
Clay J Cockerell, MD Teodore Rosen, MD
Brett M Coldiron, MD James M Spencer, MD
Robert J Friedman, MD Jennifer A Stein, MD
Mark Lebwohl, MD Susan M Swetter, MD
Paul Nghiem, MD, PhD
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Develop better care for patients with skin cancer
2 Assess the risk factors and prognosis for skin cancer
3 Identify the typical questions that skin cancer patients raise
about their disease and therapies
DESCRIPTION
Te most important management issue that we face on a daily
basis in dermatology, from a life-and-death perspective, is skin
cancer In the past decade, dermatologists have evolved from
merely diagnosing skin cancer to being actively involved in all
phases of management It is therefore incumbent upon us to be
up to date on all aspects of cutaneous oncology Te goal of this
symposium is to provide the most up-to-date information on
melanoma to the practicing dermatologist so that patient care can
be optimized
3.00Category1CMECredits
REFERENCES
1 Rigel et al, eds Cancer of the Skin, 2nd ed Philadelphia:
Elsevier; February 2011
For description of session categories and fees see page 37
170
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
SYMPOSIUM
2:00 pm to 5:00 pm
Open admission, no tuition or ticket.
S027 Contact and Occupational Dermatitis
Room: La Nouvelle Orleans Ballroom
DIRECTOR SusanT.Nedorost,M.D.
SPEAkERS
Bryan Erik Anderson, MD Dianne Louise Silvestri, MD
Douglas L Powell, MD Erik Joseph Stratman, MD
Andrew J Scheman, MD
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Identify new occupational and personal care allergens
2 Demonstrate testing of patients with atopic dermatitis
3 Develop teaching about contact allergy for patients, colleagues,
and self
DESCRIPTION
Experts in contact dermatitis will provide updates on emerging
allergens and educational resources Testing in the atopic
dermatitis patient will be discussed in detail Learn how to teach
yourself, your patients, and colleagues about contact dermatitis
Tis session will be of interest to novice and experienced patch
testers
3.00Category1CMECredits
SCHEDULE
2:00 pm Emerging Allergens/Dr.Scheman
2:30 pm Patient Education in Contact Dermatitis/Dr.Silvestri
3:00 pm Skin Testing for Atopy and Urticaria/Dr.Powell
3:30 pm Occupational and Industrial Skin Disease: A Year in
Review/Dr.Anderson
4:00 pm Teaching and Learning Contact Dermatitis
/Dr.Stratman
4:30 pm Patch Testing in Atopic Dermatitis/Dr.Nedorost
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
171
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
SCHEDULE
2:00 pm Enlightening and Educational Nail Cases: CPC From
UCSF/Dr.Ruben
2:15 pm New Developments in the Diagnosis and
Management of Onychomycosis/Dr.Scher
2:35 pm Fungal Melanonychia: A Diagnostic and Terapeutic
Challenge/Dr.Hay
2:55 pm Update on the Evaluation and Management of Digital
Myxoid Cysts/Dr.Rigopoulos
3:10 pm Questions and Answers with the Experts
/ Dr.Rich/Dr.Daniel
3:20 pm Dermoscopy and imaging the Nail Unit/Dr.Tosti
3:40 pm New Developments and Techniques in Nail Surgery
/Dr.Richert
4:00 pm Update on the Management of Melanonychia and
Nail Melanoma/Dr.Haneke
4:20 pm Questions and Answers with the Experts
/ Dr.Rich/Dr.Daniel
4:30 pm Tertiary Care Nail Diseases: Te Bologna Experience
/Dr.Piraccini
4:45 pm Laboratory and Processing Pearls for Nail Pathology
/Dr.Rubin
SYMPOSIUM
2:00 pm to 5:00 pm
Open admission, no tuition or ticket.
S028 Nails
Room: Auditorium A
DIRECTOR NathanielJ.Jellinek,M.D.
SPEAkERS
C Ralph Daniel, MD Demetrios G Rigopoulos, MD
Eckart Haneke, MD Beth S Ruben, MD
Bianca Maria Piraccini, MD Adam Rubin, MD
Phoebe Rich, MD Richard K Scher, MD
Bertrand Richert, MD, PhD Antonella Tosti, MD
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Summarize the most important and relevant advances in
medical nail disease
2 Discuss innovations in nail surgery and recognize signifcant
nail neoplasms
3 Choose the best approach to nail diagnosis and treatment
DESCRIPTION
Tis is a symposium directed at clinicians, academicians, and
residents It will focus on the most signifcant and germaine
innovations and advances in the world of nail disease Updates
will be presented from an international group of physicians who
specialize in nail disease Topics include onychomycosis, common
infammatory nail disease, nail surgery, nail tumors (including nail
melanoma), and nail pathology
3.00Category1CMECredits
REFERENCES
1 Scher RK, Daniel CR III Nails:Diagnosis,Terapy,Surgery
Philadelphia: Elsevier Saunders; 2005
2 Baran R, Dawber RPR, de Berker DAR, Haneke E, Tosti
A BaranandDawber’sDiseasesoftheNailsandTeir
Management, 3rd ed Oxford, UK: Blackwell Science; 2001
3 Zaias N, TeNailinHealthandDisease Norfwalk, CT:
Appleton and Lange; 1990
For description of session categories and fees see page 37
172
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
SYMPOSIUM
2:00 pm to 5:00 pm
Open admission, no tuition or ticket.
S029 Lessons from Great Leaders
Room: 278/279/280
DIRECTOR C.WilliamHanke,M.D.
SPEAkERS
Jean L Bolognia, MD Victor J Marks, MD
Barbara Ann Gilchrest, MD David M Pariser, MD
Henry W Lim, MD Darrell S Rigel, MD
Mary E Maloney, MD Kim B Yancey, MD
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Recognize how past and present leaders have advanced the
specialty
2 Identify leadership competencies, accomplishments and styles
of past and present leaders in dermatology
3 Utilize the lessons of these leaders to advance own leadership
goals and the specialty in the future
DESCRIPTION
Each of the eight well-known speakers will each focus on one
past or present leader in dermatology, from across the specialty
Te accomplishments of each leader in a variety of leadership
settings will be highlighted through personal stories and refections
and used to illustrate one or more of the critical core leadership
competencies Te speakers will discuss how the seven core
leadership competencies for dermatologists have been successfully
utilized by these individuals
3.00Category1CMECredits
SCHEDULE
2:00 pm Overview/Dr.Hanke
2:05 pm Te AAD Leadership Institute/Dr.Maloney
2:20 pm Dr Marks on Rex A Amonette/Dr.Marks
2:40 pm Dr Rigel on Alfred W Kopf/Dr.Rigel
3:00 pm Dr Bolognia on Wilma F Bergfeld/Dr.Bolognia
3:20 pm Dr Hanke on Walter B Shelley/Dr.Hanke
3:40 pm Dr Yancey on Stephen I Katz/Dr.Yancey
4:00 pm Dr Gilchrest on Tomas B Fitzpatrick/Dr.Gilchrest
4:20 pm Dr Lim on Clarence S Livingood/Dr.Lim
4:40 pm Dr Pariser on Peyton E Weary/Dr.Pariser
S030 Electronic Health Record (EHR)
Physician Demonstration Symposium
Room: 260/261/262
DIRECTOR MarkD.Kaufmann,M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Assess how other dermatologists in various practice settings
successfully adopted electronic health record (EHR) systems
2 Implement an EHR utilizing best practices
3 Discuss how to enhance patient safety, strengthen care
coordination, and participate in quality improvements through
EHR systems
DESCRIPTION
Live interactive physician-only (no vendors) demonstration of
how EHR implementation was done and pearls on strategies that
worked best Tis session will provide members with an enhanced
understanding of the experiences of EHR dermatology champions
3.00Category1CMECredits
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
173
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
D017 Churning Out the Learning
Room: 240
DIRECTOR JohnA.Zic,M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 Develop strategies to engage audiences in the large group
setting
2 Design case presentations to enhance clinical reasoning skills in
the small group setting
3 Recognize teachable moments in the clinic setting and how to
give feedback
DESCRIPTION
Tis interactive session will enhance your teaching skills in a
number of diferent educational environments Dermatologists
who teach on any level will beneft from the shared experiences in
this discussion session Develop strategies to engage the audience
in the large group setting Te small group setting ofers diferent
challenges to the moderator and the learner How can you present
a case to enhance clinical reasoning skills? Finally, in the clinic
setting, how do you balance teaching and practicing dermatology?
How do you recognize teachable moments in the clinic? Bring
your tips and challenges as we share educational experiences
1.50Category1CMECredits
D018 Practice Tips and Surgical Gems
Room: 241
DIRECTOR RogerI.Ceilley,M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 Develop surgical skills and efciency
2 Develop practice skills, accuracy, and efciency
DESCRIPTION
Tis session will include an overview of practice tips and surgical
gems Tis will be an interactive session and registrants are
encouraged to comment, ofer surgical tips and practice pearls
1.50Category1CMECredits
SYMPOSIUM
2:00 pm to 5:00 pm
Open admission, no tuition or ticket.
S031 Tropical Dermatology
Room: Auditorium B
DIRECTOR AishaSethi,M.D.
SPEAkERS
Noah A Craft, MD, PhD Stephen K Tyring, MD, PhD
Scott A Norton, MD, MPH Justin Wasserman, MD
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 Recognize how travel, immigration, war, and adoption
geographically afect the practice of dermatology
2 Distinguish and diagnose imported dermatoses that
practitioners in developed countries will likely begin to
encounter
3 Outline appropriate diferential diagnoses and institute
appropriate therapy for these formerly exotic dermatoses
DESCRIPTION
Once-exotic tropical skin diseases are not so exotic anymore,
due to environmental changes, war, urbanization, refugee
movements, tourism, and the emergence of new diseases It is
increasingly important that dermatologists and dermatology
residents gain familiarity in this arena, as tropical dermatoses
become more prevalent in developed countries Tis session will
cover viral infections, leishmaniasis, and imported dermatoses that
dermatologists in academic and private practice should be on the
lookout for, given the increased ease of travel and globalization
3.00Category1CMECredits
REFERENCES
1 Monsel G, Caumes E Recent developments in dermatological
syndromes in returning travelers CurrOpinInfectDis 2008
Oct;21(5):495-499
2 Patel S, Sethi A Imported tropical diseases DermatolTer
2009 Nov-Dec;22(6):538-549
3 Lederman ER, Weld LH, Elyazar IR, von Sonnenburg F,
Loutan L, Schwartz E, Keystone JS; GeoSentinel Surveillance
Network Dermatologic conditions of the ill returned traveler:
an analysis from the GeoSentinel Surveillance NetworkIntJ
InfectDis 2008 Nov; 12:593-602
SCHEDULE
2:00 pm Viral Infections/Dr.Tyring
2:30 pm Leishmaniasis/Dr.Craft
3:00 pm Questions and Answers/Faculty
3:10 pm Exotic Skin Disease/Dr.Sethi
3:45 pm Tropical Dermatoses of Travelers and Expatriates
/Dr.Norton
4:20 pm Questions and Answers/Faculty
4:25 pm Tropical Pathology/Dr.Wasserman
4:55 pm Questions and Answers/Faculty
DISCUSSION GROUP
2:30 pm to 4:00 pm
Tuition fee and ticket required for admission.
For description of session categories and fees see page 37
174
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
U098 HIT EMRs and Documenting Clinical Care:
Pitfalls and Promises
Room: 264
DIRECTOR DavidJ.Altman,M.D.,Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Identify important issues in electronic medical record (EMR)
adoption including the impact of recent laws and certifcations
2 Recognize and assess your practice patterns and how they may
be afected by EMR adoption and utilization
3 Assess diferent types of EMR documentation with regard to these
practice patterns to determine which may be optimal for you
DESCRIPTION
Tis session will focus on aspects of EMRs dealing with the clinical
encounter and patient care, rather than practice management
We will look at implications of the HITECH Act and evolving
meaningful use criteria, and the evolving CCHIT certifcation
process, for clinical documentation in EMRs and the benefts and
limitations of these We will discuss examining practice patterns
and preferences for essential, preferred, unnecessary, wasteful,
and detrimental processes and habits that afect efciency and
efectiveness EMR methods for documenting the clinical encounter
and care delivered and their pitfalls and promises with regard to these
practice patterns will be discussed
1.50Category1CMECredits
U099 Lumps and Bumps in Children
Room: 269
DIRECTOR HanspaulMakkar,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Recognize common and less common birthmarks and
developmental anomalies in neonates and infants
2 Develop a systematic approach to the workup and management
of lumps and bumps in infants
3 Recognize and distinguish worrisome birthmarks from those
that are innocuous
DESCRIPTION
Birthmarks and nevi in children can be innocuous and most
are benign Developmental anomalies in neonates and children
occur as a result of errors during embryogenesis Tis session is
intended to describe some of these birthmarks and developmental
defects and to develop an algorithmic approach to workup of these
lesions, including when biopsy and additional workup might be
appropriate In addition, other lumps and bumps are discussed,
including malignancies that present in infancy
1.50Category1CMECredits
FOCUS SESSION
2:30 pm to 4:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
Switching from paper
to electronic
has never been easier!
Health Information Technology (HIT) has never
been more important. In order to keep up with its
growing demand, the AAD has created the HIT-kit.
This free online resource is here to assist members
as they transition their dermatology practices from
paper to electronic.
Within the HIT-kit:
• dEHRm – Provides all of the tools and
resources necessary in implementing
an EHR
• DermLex – Free online database
of dermatologic terminology
• E-prescribing – Learn how to
electronically prescribe and
apply for a Medicare Part B bonus
• HIT Dashboard – Become informed on federal
regulations within the feld of health
information technology
Visit the Academy Resource
Center Booth 3623
to demo today!
FREE Online Resource!
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
175
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
U101 Pediatric Drug Eruptions
Room: 274
DIRECTOR JohnC.Browning,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Identify the diferent types of pediatric drug eruptions
2 Discuss the pathophysiology of diferent drug eruptions
3 Assess the course of treatment when a drug eruption is present
DESCRIPTION
Te participant will learn about the wide range of pediatric drug
eruptions, including rare cases He or she will be able to recognize
these eruptions and know what treatment, if any, is appropriate
1.50Category1CMECredits
U102 From Pigment to PUPP (or PEP): What to
Expect When Your Patient is Expecting
Room: 270
DIRECTOR MiriamKeltzPomeranz,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Recognize physiologic changes in a pregnant patient
2 Diagnose dermatoses of pregnancy
3 Treat the pregnant patient with skin disease
DESCRIPTION
Pregnancy is a time of many changes in a woman’s body,
including her skin I will review the physiologic as well as the
pathophysiologic conditions that occur during gestation Te
discussion will include pigmentary alterations, vascular growths,
and other tumors Te specifc dermatoses of pregnancy will be
summarized Recent literature on treatment will be reviewed
Participants are encourage to bring cases for discussion
1.50Category1CMECredits
FOCUS SESSION
2:30 pm to 4:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U100 Current Management of Skin Cancer in
Transplant Patients
Room: 283
DIRECTOR AlexandraY.Zhang,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Recognize increased incidence, associated risk factors,
pathogenesis and the aggressive nature of certain cutaneous
malignancies in transplant patients
2 Explain the strategies for prevention and management of skin
cancers by utilizing both existing and novel emerging therapies
3 Recognize the importance of vigilant surveillance of skin cancer
in transplant patients
DESCRIPTION
Skin cancer is the most common malignancy in solid organ
transplant recipients that causes signifcant morbidity and
mortality Because of their immunocompromised status,
transplant patients are predisposed to develop certain types
of cutaneous malignancies such as squamous cell carcinoma,
basal cell carcinoma and Kaposi’s sarcoma Identifying high-
risk patients and individualizing prevention and treatment
strategies are critical in the management of transplant-associated
cutaneous malignancies because of their aggressive nature and
higher rate of metastasis Tis focus session reviews the clinical
use of existing and emerging therapies, such as surgical excisions,
topical chemotherapy, immunomodulators, photodynamic
therapy, and systemic chemoprevention with oral retinoids
Coordination of care by dermatologists and transplant physicians,
in order to optimize immunosuppressant regimens (reduction
of immunosuppression, and the use of proliferation signal
inhibitors), is paramount in the management of transplant-
associated cutaneous malignancies Interesting cases from the
transplant dermatology clinic will be presented as well
1.50Category1CMECredits
For description of session categories and fees see page 37
176
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
FOCUS SESSION
2:30 pm to 4:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U103 Drug Reaction Update 2011
Room: 242
DIRECTOR HeidiH.Kong,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Identify culprits causing newer drug reactions
2 Diferentiate the various skin toxicities associated with newer
targeted therapies
3 Manage these newer drug reactions
DESCRIPTION
Cutaneous drug reactions are one of the most common toxicities
associated with medications As new drugs are continually being
developed, dermatologists will be asked to know and manage
the skin toxicities related to these medications Tis session will
review the current literature on drug reactions, including targeted
therapies
1.50Category1CMECredits
U104 Cosmeceuticals: Topical Therapies for
Treating the Aging Face
Room: 265/266
DIRECTOR JenniferLungLinder,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Identify scientifcally proven topical ingredients that correct
current and prevent future dermal and epidermal damage
2 Develop well-rounded age control regimens tailored to the
individual patient
3 Measure product efcacy by evaluating ingredient mechanism
of action
DESCRIPTION
Developing a deeper understanding of how common
cosmeceutical ingredients interact with the skin will assist in
choosing the best topical products Topical therapies can help
the physician to correct superfcial imperfections and enhance
the results of more invasive procedures Identifying multi-
faceted ingredients that are supported by science will assist the
physician in determining the efcacy of skin care products Te
specifc mechanisms of action of anti-aging ingredients, including
retinoids, L-ascorbic acid, melanogenesis inhibitors, peptides
and antioxidants will be discussed Confdently recommending
products that contain ingredients that provide consistent results
can deepen the physician-patient relationship, and your practice’s
bottom line
1.50Category1CMECredits
U105 Advances in Fat Transfer and Liposuction
for Correction of Lipodystrophy:
The USC Experience
Room: 267/268
DIRECTOR IlyaReyter,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Diagnose lipodystrophy, particularly in the setting of HIV
disease
2 Select the best treatment for lipoatrophy and lipohypertrophy
3 Recognize the utility of autologous fat transfer for the
treatment of lipoatrophy
DESCRIPTION
Te session will focus on the use of liposuction and autologous
fat transfer for the treatment of lipodystrophy, particularly in
the setting of HIV disease Participants will learn to recognize
key features of lipodystrophy and to select the most appropriate
treatment for each patient Advanced techniques in autologous fat
transfer and liposuction will be emphasized, and current research
in fat grafting will be explored Cases from the USC Department
of Dermatology HIV Lipodystrophy Clinic will be presented and
discussed
1.50Category1CMECredits
U106 What’s That? Syndrome Update
Room: 235/236
DIRECTOR JamesG.Dinulos,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Develop a diagnostic approach to patients with epidermolysis
bullosa
2 Develop an approach to the management of patients with
common genetic syndromes
DESCRIPTION
Tis session will emphasize common syndromes involving
the epidermis such as ichthyosis, epidermolysis bullosa; and
syndromes involving the dermis and subcutis such as aplasia cutis
congenita, vascular malformations; and syndromes presenting
with malformations involving the skin appendages such as
the ectodermal dysplasias Clinical assessments and diagnostic
evaluations important to the practicing dermatologist will be
emphasized
1.50Category1CMECredits
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
177
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
F047 Managing an Effcient Practice

Room: 295/296
DIRECTOR BarryLeshin,M.D.
SPEAkERS
Frank Cohen, MPA
Glenn D Goldstein, MD
Victor J Marks, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Determine methods to improve ofce efciency
2 Describe how technology can be used to improve workfow
3 Recognize how process improvements can lead to greater
customer service
DESCRIPTION
Tis session will provide a comprehensive overview of how to
increase ofce efciencies including workfow, staf duties, and
general operations Best practices will be discussed including
how to optimize patient fow through process improvements
focused on front and back ofce operations as well as the positive
impact health information technology can have on your practice
Methods to increase patient satisfaction will also be discussed
2.00Category1CMECredits
SCHEDULE
3:00 pm Introduction/Dr.Leshin
3:10 pm Mastering Patient Flow and Process Improvements to
Improve Practice Efciencies/Mr.Cohen
3:40 pm Enhancing Customer Service and Patient Satisfaction
/Dr.Marks
4:10 pm Innovative Techniques in Ofce Efciency
/Dr.Goldstein
4:40 pm Enhancing Ofce Efciency Trough Use of
Electronic Health Records and Health Information
Technology /Dr.Leshin
FOCUS SESSION
2:30 pm to 4:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U107 Dermatology in Cinema
Room: 263
DIRECTOR VailC.Reese,M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Demonstrate to patients examples of skin conditions in movies
2 Identify categories of skin conditions seen in movies
3 Develop empathy for patients
DESCRIPTION
Spanning over 100 years of cinema, examples of skin conditions
depicted in movies will be presented, in both still images and video
Updated for 2011, these include adult acne, congenital lesions,
infectious disease, and neoplasms Te psychosocial implications
of the depiction of dermatoses will be explored Practical examples
that can be used for patient education will be emphasized
1.50Category1CMECredits
U108 Safety of Biologic Therapies:
What’s the Real Story?
Room: 284
DIRECTOR MarkR.Ling,M.D.,Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 Identify the ways in which short- and long-term safety of
biologic drugs can be properly assessed
2 Assess the specifc data regarding safety of the most widely used
biologics for psoriasis therapy
3 Analyze the relative risks and benefts of existing biologic drugs
as an aid to therapeutic decision making
DESCRIPTION
Biologic therapy for psoriasis has revolutionized our ability to treat
moderate to severe psoriasis Tese drugs, when compared to older
systemic agents, demonstrate a superior risk/beneft ratio, based
particularly on their apparently superb safety profles However,
much of what is held as gospel regarding biologic safety is based
on anecdote, misperception, and outright misrepresentation Te
aim of this session is to drill down to the actual available data
on safety Tis will allow us to understand these drugs in much
greater depth, allowing practitioners to make better therapeutic
decisions for their psoriasis patients
1.50Category1CMECredits
FORUM
3:00 pm to 5:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
For description of session categories and fees see page 37
178
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
FORUM
3:00 pm to 5:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F048 Psoriasis as a Systemic Disease
Room: 275/276/277
DIRECTOR JamesFrederickLibecco,M.D.
SPEAkERS
Kevin D Cooper, MD
Neil J Korman, MD, PhD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Recognize the systemic manifestations of psoriasis
2 Utilize current data and hypotheses to address the health
issues of patients with psoriasis, especially as related to vascular
disease
3 Formulate an approach to evaluate new and current
information on the treatment of psoriasis and related systemic
disease
DESCRIPTION
Tis session will review current data and hypotheses related to
the systemic manifestations of patients with psoriasis Tere may
be paradigm shifts in the evaluation and management of these
patients that are relevant to clinicians involved in both patient care
and research
2.00Category1CMECredits
F049 Laser Pearls
Room: 271/272/273
DIRECTOR KeyvanNouri,M.D.
SPEAkERS
Murad Alam, MD Jefrey S Dover, MD
Tina S Alster, MD Roy G Geronemus, MD
R Rox Anderson, MD David J Goldberg, MD, JD
Henry H L Chan, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Assess the laser treatment pearls of vascular lesions, pigmented
lesions, scars, hair removal, acne, psoriasis, hypopigmentation,
body tightening, and facial rejuvenation
2 Examine the nature of a vast array of laser/light devices in
various application settings in medical, surgical, and cosmetic
uses
3 Recognize pearls for prevention and/or management of
complications in the laser feld
DESCRIPTION
Tis forum will be devoted to gaining an insight into refnements
and pearls of the use of lasers/light devices in dermatology Pearls
on treatment of scars, hair removal, facial rejuvenation, acne,
psoriasis and hypopigmentation will be discussed It should cover
what devices, techniques, and settings are best suited for ethnic
skin Furthermore, the forum will deliver tips on body tightening
devices and pearls to enhance results Te emphasis will be on
practical tips and ways to avoid and manage complications
using lasers/light devices Finally, pearls on understanding the
use of lasers/light devices in diagnostics and therapeutics will be
discussed
2.00Category1CMECredits
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
179
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
F051 Controversies in Vitamin D
Room: 255/256/257
DIRECTOR KennethG.Linden,M.D.
SPEAkERS
Douglas W Johnson, MD
Henry W Lim, MD
James M Spencer, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Evaluate the controversies in the relationship of sunlight and
tanning beds to vitamin D synthesis and requirements
2 Discuss emerging information on the health efects of vitamin
D, including in cancer prevention
3 Manage and advise dermatology patients to optimize vitamin
D therapy to prevent and treat osteoporosis
DESCRIPTION
Te health efects of vitamin D are gaining prominence within
the medical community and with the public Vitamin D, as it
relates to dermatology, will be discussed in lively but friendly
presentations Speakers concerned about the levels of vitamin D
in the population and the efect that sun protection has on this, as
well as those who feel that the benefts of sun protection outweigh
any likely risks, will present Vitamin D and the prevention and
treatment of osteoporosis will be discussed, as will the emerging
science of the possible health efects of vitamin D, such as in
cancer prevention
2.00Category1CMECredits
SCHEDULE
3:00 pm Introduction to Vitamin D/Dr.Linden
3:30 pm Skin Types, Photoprotection and Vitamin D
/Dr.Lim
4:00 pm Vitamin D and Skin Cancer Prevention: What
Should Dermatologists Tell Teir Patients?
/Dr.Spencer
4:30 pm Diagnosis and Management of Osteoporosis and
Vitamin D in Dermatology/Dr.Johnson
FORUM
3:00 pm to 5:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F050 What’s New in Immunomodulation
Room: 291/292
DIRECTOR AnthonyA.Gaspari,M.D.
SPEAkERS
Andrew Blauvelt, MD Anna Di Nardo, MD, PhD
Jefrey Phillip Callen, MD Nanette Blythe Silverberg, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Discuss the mechanisms and clinical applications of IVIG
2 Examine the rationale and outcome of targeted therapies for
infammatory diseases such as psoriasis
3 Defne the biologic efects of antimicrobial peptides, topical
sensitizers and TLR agonists and the potential therapeutic
applications
DESCRIPTION
Dermatologists utilize a number of topical (locally acting) and
systemic medications to target the immune system as therapy
for a variety of skin conditions Based on recent advances in the
understanding of the pathophysiology of common skin diseases,
there are now targeted therapies such as biologics that can exhibit
dramatic clinical efcacy in psoriasis Other systemic treatments
to manipulate the immune system such as intravenous gamma
globulin (IVIG) will also be discussed Locally acting immune-
modulating therapies, such as topical sensitizers, antimicrobial
peptides, and toll like receptor antagonists, will also be discussed
Tis forum will address the existing and emerging clinical uses
of these immune-modulating agents, their mechanisms and their
risks and benefts
2.00Category1CMECredits
SCHEDULE
3:00 pm Welcome and Introduction/Dr.Gaspari
3:02 pm Immune Modulation with IVIG: Mechanisms and
Uses in Dermatology/Dr.Callen
3:26 pm New Developments in Blockade of the IL-23/IL-17
Pathway in Psoriasis/Dr.Blauvelt
3:50 pm Antimicrobial Peptides: Properties and Terapeutic
Potential/Dr.DiNardo
4:14 pm Use of Topical Sensitizers in the Treatment of Warts
in Children/Dr.Silverberg
4:38 pm What’s New in Toll Like Receptor Agonist Research
/Dr.Gaspari
5:00 pm Closing Comments/Dr.Gaspari
For description of session categories and fees see page 37
180
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
FORUM
3:00 pm to 5:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F052 Advanced Dermatopathology
Room: 252/253/254
DIRECTOR JenniferMadisonMcNif,M.D.
SPEAkERS
George W Elgart, MD Christine Ko, MD
Lynne J Goldberg, MD Beth S Ruben, MD
Jacqueline M Junkins-Hopkins, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Recognize the importance of clinicopathologic correlation in
dermatopathology
2 Identify fndings that are useful in avoiding pitfalls in
diagnosis
3 Recognize the value and limitations of special stains and new
techniques in evaluating tissue specimens
DESCRIPTION
Five experienced dermatopathologists with a background in
clinical dermatology have been asked to present one or more
challenging cases requiring close clinicopathologic correlation for
diagnosis Tere will be a detailed discussion of the diagnoses,
with emphasis on potential traps and pitfalls Tese presentations
will allow attendees to experience diagnostic challenges as they
presented originally, and to learn how the problems were solved
Tere will be an opportunity for questions and discussion
following each presentation
2.00Category1CMECredits
F053 Autoimmune Disease Update
Room: 238/239
DIRECTOR VictoriaP.Werth,M.D.
SPEAkERS
Jan P Dutz, MD Heidi Tewich Jacobe, MD
David Franklin Dedee F Murrell, MD
Fiorentino, MD, PhD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Discuss autoimmune skin diseases
2 Explain the recent developments in autoimmune skin diseases
3 Diagnose and treat autoimmune skin diseases
DESCRIPTION
Tis session is designed for clinical practitioners with an interest
in more complex autoimmune disease diagnosis, evaluation,
and treatment Tere will be an emphasis on the more difcult
diagnostic and management issues that arise in the care of these
patients Attendees are invited to bring cases/questions related to
these areas
2.00Category1CMECredits
SCHEDULE
3:00 pm Update on Dermatomyositis/Dr.Fiorentino
3:20 pm Update on Cutaneous Lupus/Dr.Dutz
3:40 pm Update on Morphea/Dr.Jacobe
4:00 pm Update on Autoimmune Blistering Diseases
/Dr.Murrell
4:20 pm Update on Quality of Life and Measurement of
Disease Severity in Autoimmune Skin Diseases
/Dr.Werth
4:40 pm Questions and Answers/Faculty
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
181
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
W007 Effective Communication
Room: 357
DIRECTOR PatriciaFarris,M.D.
LEARNING OBjECTIVES
Following this workshop, the attendee will be able to:
1 Prepare compelling and relatable key messages
2 Explain key messages clearly, concisely, and efectively
3 Develop strategies for staying focused on key messages in
challenging situations
DESCRIPTION
Te Academy has identifed efective communication as a
core competency for leadership in dermatology Learning
how to successfully craft and deliver key messages will help
you communicate efectively in any situation Attendees will
have the opportunity to practice what they’ve learned about
message development in mock media interviews designed to
challenge participants to stay focused while delivering their
message Te course director is a previous chair of the Council
on Communications She will be assisted by a communications
consultant
2.00Category1CMECredits
*Tis session is open to dermatologists and graduate members only
SCHEDULE
3:00 pm Efective Communications: Delivering Key Messages
/Dr.Farris
FORUM
3:00 pm to 5:00 pm
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F054 Dermatologic Health of Women
Room: 293/294
DIRECTOR MarianneN.O’Donoghue,M.D.
SPEAkERS
Jefrey Phillip Callen, MD June K Robinson, MD
Iltefat H Hamzavi, MD Diane M Tiboutot, MD
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 Diagnose and treat the special needs of women with acne and
acne rosacea
2 Recognize the socioeconomic barriers of health disease in
women
3 Manage the female patient with lupus erythematosus and with
hidradenitis suppuriativa
DESCRIPTION
Tis session will enable the physician to manage acne in women
It will also address the health care and socioeconomic barriers
for women It will give a comprehensive view of management of
lupus erythematosus in women Finally, it will address the latest
medical, surgical, and laser treatment for hidradenitis suppuriativa
2.00Category1CMECredits
SCHEDULE
3:00 pm Dermatology Health in Women/Dr.O’Donoghue
3:00 pm Management of Cutaneous Lupus Erythematosus-
Special Needs for Women/Faculty
WORkSHOP
3:00 pm to 5:00 pm
Tuition fee and ticket required for admission.
For description of session categories and fees see page 37
182
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
WORkSHOP
3:00 pm to 5:00 pm
Tuition fee and ticket required for admission.
W008 Basic Dermoscopy
Room: 281/282
DIRECTOR WilhelmStolz,M.D.
SPEAkERS
Giuseppe Argenziano, MD Ashfaq A Marghoob, MD
Ralph P Braun, MD Harold S Rabinovitz, MD
Joseph Malvehy, MD
LEARNING OBjECTIVES
Following this workshop, the attendee will be able to:
1 Analyze the basic criteria of dermatoscopy
2 Apply a logical dermatoscopic approach for the efcient
classifcation of both benign and malignant pigmented skin
lesions
3 Demonstrate the benefts from the application of dermatoscopy
in daily practice
DESCRIPTION
Te basic criteria of dermatoscopy will be introduced together
with an efcient stepwise algorithm for the detection of the
various benign and malignant pigmented skin lesions Experts
in dermatoscopy will present cases where the participants can
learn most Also, the dermoscopic criteria on the face, as well as
on palms and soles, will be described At the end of the session,
experts will work through some case diagnoses with the audience
2.00Category1CMECredits
SCHEDULE
3:00 pm Equipment; Diferentiation between Melanocytic and
Non-Melanocytic Skin Lesions/Dr.Marghoob
3:20 pm Principles of classifcation in dermatoscopy/Dr.Stolz
3:50 pm When Dermoscopy Changed My Mind
/Dr.Argenziano
4:10 pm Dermatoscopy in Special Locations/Dr.Stolz
4:20 pm Unknowns for the Experts and the Audience (I)
Experts Dr Malvehy and Dr Stolz/Dr.Braun
4:40 pm Unknowns for the Experts and the Audience (II)
Experts Dr Argenziano and Dr Marghoob
/Dr.Rabinovitz
•Viewover8,000slides
and400cases
•Identifyanddiagnose
lesionsoftheskin
•IncludestwoDVDs–
beginnerandadvanced
Dermoscopy:AGuidefor
thePhysicianhasbeen
approvedforAMA PRA
Category 1 Credits™.CMEonlyavailabletopurchasers.
Order your copy today
at the AAD Resource Center
Booth 3623!
Want more? Order
and continue perfecting the technique.
For description of session categories and fees see page 37
for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org
|
183
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
DESCRIPTION
Tis session is structured in a question-and-answer format
using an automated response system It will cover topics in
general dermatology, pediatric dermatology, dermatopathology,
dermatologic surgery, and cosmetic dermatology Te participant
will have immediate feedback for each session and will be
able to identify any areas of weakness that require further self-
directed study Due to the timed framework of this session, it is
imperative that participants arrive on time for this workshop
2.00Category1CMECredits
*Self-assessmentquestionsutilizedinthissessionare
thesameasthoseusedforWorkshopW006MOC:
Self-AssessmentoferedatAnnualMeeting2010.
PhysiciansshouldnotclaimCME/MOCcreditfor
attendingthissessioniftheyattendedWorkshopW006
atAnnualMeeting2010.
WORkSHOP
3:00 pm to 5:00 pm
Tuition fee and ticket required for admission.
W009 MOC Self-Assessment B

M
O
C
Room: 288/289/290
DIRECTOR StevenB.Deliduka,M.D.
LEARNING OBjECTIVES
Following this workshop, the attendee will be able to:
1 Identify the strengths and weaknesses in one’s dermatology
knowledge and make improvements as needed
2 Demonstrate commitment to lifelong learning and self-
assessment via completion of a forum of 25 questions and
answers
CLINICAL PERFORMANCE
ASSESSMENT TOOL
for dermatology
Report Quality Measures and improve patient care
with the Association you trust introducing...
AAD Measurement Tools!
AVAILABLE MODULES:
• 2011 PQRI Melanoma Reporting —
Eligible for 1% CMS bonus
• E-Prescribing
www.aad.org/QRS
Develop a clinical performance improvement plan,
specifically for your practice, while satisfying
Component 4 and earning CME!
AVAILABLE MODULES:
• Acne
• Melanoma
• Melanoma w/PQRI — Eligible for 1% CMS bonus
• Atopic Dermatitis
• Biopsy — coming soon!
www.aad.org/CPAT
Visit the AAD Resource Center Booth 3623 to demo both!
184
|
AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SCIENTIFIC SESSIONS
S
U
N
D
A
Y
,

F
E
B
R
U
A
R
Y

6
Do More than Value Your Leaders.
BECOME ONE.
Leadership is not only important to the specialty, but it provides dermatologists like you with the means to be
successful in your career and the communities you serve. You’re invited to partake in the AAD’s Leadership Institute
at the Annual Meeting, offering fresh new leadership educational sessions, popular events, and the places to
meet-and-greet with dermatology’s leaders of today and tomorrow.
www.aad.org/leadership
for more information about upcoming Leadership Institute events and ways you can participate.
Leaders Are as Good
as Gold!
Show your appreciation to the
mentor in your life by picking
up a gold star pin at the
Leadership Institute kiosk.
Share your thoughts and
participate in an “electronic
chat” about leadership
through the Academy’s
electronic messaging portal.
Check each day for a new
question and to hear what
your colleagues think about
leadership.
friDAY, fEBruArY 4
u012 Leading with your Strengths
7:15 a.m. – 8:45 a.m.
Room: 293/294
S005 Leading from Your Vision to Exceptional
Service
9:00 a.m. – Noon
Room: 293/294
S013 Leading Others for Peak Performance
2:00 p.m. – 5:00 p.m.
Room: 293/294
u024 Leading Confidently through Powerful
Communication
12:15 p.m. – 1:45 p.m.
Room: 293/294
SAturDAY, fEBruArY 5
D007 Leading from Conflict to resolution
7:15 a.m. – 8:45 a.m.
Room: 240
f046 Leading Your team by Coaching and
Mentoring
3:00 p.m. – 5:00 p.m.
Room: 391
SuNDAY, fEBruArY 6
S029 Lessons from Great Leaders
2:00 p.m. – 5:00 p.m.
Room: 278/279/280
MONDAY, fEBruArY 7
W011 Leading by Advocating for Dermatology
9:00 a.m. – 11:00 a.m.
Room: 393/394
tuESDAY, fEBruArY 8
f082 Managing Office Politics: Private Practice,
Academics, and Everything in Between
9:00 a.m. – 11:00 a.m.
Room: 392
Look for other Leadership Institute sessions at the Annual Meeting marked with the through the Program Book.
Don’t Miss these Highlighted Leadership institute Sessions:
AM11_Leardership Institute_revised.indd 1 9/15/2010 1:03:48 PM
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
185
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
MONDAY, FEBRUARY 7
Poster Discussion Sessions — 7:15 a.m. to 8:45 a.m.
PD05 Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .187
PD06 Internal Medicine . . . . . . . . . . . . . . . . . . . . . . . .187
Discussion Groups — 7:15 a.m. to 8:45 a.m.
D019 Enhancing Observational Skills. . . . . . . . . . . . . .188
D020 When Does Chronic Dermatitis Become Cutaneous
T-Cell Lymphoma? . . . . . . . . . . . . . . . . . . . . . .188
Focus Sessions — 7:15 a.m. to 8:45 a.m.
U109 Pediatric Connective Tissue . . . . . . . . . . . . . . . .189
U110 Review of Dermatological Adverse Reactions . . .189
U111 Reconstruction in Dermatologic Surgery:
An Introductory and Review Session . . . . . . . . .189
U112 Histopathology of Scarring Alopecia. . . . . . . . . .190
U113 Immunology for Dermatologists . . . . . . . . . . . . .190
U114 Stem Cells in Melanoma and Nevi . . . . . . . . . . .190
U115 Medication Use: Improving Adherence
and Compliance . . . . . . . . . . . . . . . . . . . . . . . . .191
U116 Utilize Web sites that Enhance Your Career . . . .191
U117 Diagnosis and Management of
Unusual Skin Tumors . . . . . . . . . . . . . . . . . . . . .192
U118 Holy Moly: Religion and the Skin . . . . . . . . . . .192
U119 New Botulinum Toxins Practice Integration . . . .192
Forums — 9:00 a.m. to 11:00 a.m.
F055 Vitiligo: Problems and Solutions. . . . . . . . . . . . .193
F056 Terapeutic Safety. . . . . . . . . . . . . . . . . . . . . . . .193
F057 Adolescent Dermatology. . . . . . . . . . . . . . . . . . .194
F058 Hair Loss in Women. . . . . . . . . . . . . . . . . . . . . .194
F059 Case-Based Discussion in Cutaneous
Lymphomas . . . . . . . . . . . . . . . . . . . . . . . . . . . .195
F060 Immunohistochemistry in Dermatology . . . . . . .195
F061 Medical Dermatology Challenge: Complex Cases
from the Collection of Dr. Samuel Moschella. . .196
F062 Ethical Dilemmas in Dermatology . . . . . . . . . . .196
Workshops — 9:00 a.m. to 11:00 a.m.
W010 MOC Self-Assessment: Cosmetic Dermatology .197
W011 Leading by Advocating for Dermatology. . . . . . .197
Courses — 9:00 a.m. to 12:00 p.m.
C021 Intermediate Cosmetic Surgery. . . . . . . . . . . . . .198
C022 Advanced Practice Management: Mini MBA . . .199
C023 Advanced Pediatric Dermatology . . . . . . . . . . . .200
Symposia — 9:00 a.m. to 12:00 p.m.
S032 Cutaneous Tumors Benign and Malignant . . . . .201
S033 Photodermatology. . . . . . . . . . . . . . . . . . . . . . . .202
S034 Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .203
S035 Controversies in Dermatologic Drug Terapy. . .204
S036 Blistering Disease . . . . . . . . . . . . . . . . . . . . . . . .205
S037 Key Surgical Principles We All Should Know . . .206
Courses — 9:00 a.m. to 5:00 p.m.
C024 Infectious Diseases . . . . . . . . . . . . . . . . . . . . . . .207
C025 Fundamentals of Dermoscopy . . . . . . . . . . . . . .208
Forums — 12:00 p.m. to 2:00 p.m.
F063 Young Physician Pearls and Pitfalls:
A Survival Guide for the First 10 Years . . . . . . . .209
F064 Te Approach to the Patient with Cutaneous
T-Cell Lymphoma. . . . . . . . . . . . . . . . . . . . . . . .209
F065 What’s New and Emerging:Terapeutics. . . . . . .210
F066 Merkel Cell Carcinoma: Diagnosis,
Management, and Controversies . . . . . . . . . . . . .210
OVERVIEW
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
Practice Management Session open to eligible
offce staff/registered nurses
Represents Patient Safety Session in program overviews
Patient Safety Session
Represents Audience Response System Session
Audience Response System Session
Represents activities that meet MOC-D

M
O
C
This activity has been approved by the ABD to satisfy
component 2 of MOC-D
Represents Leadership Institute in program overviews
Leadership Institute — addresses leadership
competencies specifc to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
For description of session categories and fees see page 37
186
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
F067 Managing Hair Loss Made Easy . . . . . . . . . . . . .211
F068 Use of Physician Extenders . . . . . . . . . . . . . . . . .211
F069 Cutaneous Oncology: Multidisciplinary
Management of Common and
Uncommon Skin Cancers . . . . . . . . . . . . . . . . . .212
F070 Fungal Infections . . . . . . . . . . . . . . . . . . . . . . . .212
Workshop — 12:00 p.m. to 2:00 p.m.
W012 Dealing with Difcult People and Looking
Forward to It . . . . . . . . . . . . . . . . . . . . . . . . . . . .213
Discussion Groups — 12:15 p.m. to 1:45 p.m.
D021 Dermatology, Diagnosis, and the Visual Arts . . .213
D022 Common Dermatologic Diseases with Myriad
Treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . .213
Focus Sessions — 12:15 p.m. to 1:45 p.m.
U120 Sexually Transmitted Infections:
Te Current Standard of Diagnosis and Care . . .214
U121 Update on Graft-Versus-Host Disease . . . . . . . .214
U122 High-Risk Squamous Cell Carcinomas:
A Clinical and Pathologic Case Review. . . . . . . .214
U123 Forensics in Dermatology . . . . . . . . . . . . . . . . . .215
U124 Graft-Versus-Host Disease. . . . . . . . . . . . . . . . . .215
U125 Penile Growths . . . . . . . . . . . . . . . . . . . . . . . . . .216
U126 Healing the Pyoderma Gangrenosum Ulcer:
Lessons for the PG Clinic . . . . . . . . . . . . . . . . . .216
U127 Interactive Clinical Pathologic Challenge . . . . . .217
U128 Leg Ulcer Quiz for the Astute Dermatologist! . .217
U129 Informed Shared Decision Making in
Psoriasis Management . . . . . . . . . . . . . . . . . . . . .217
U130 Sarcoidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . .217
U131 Neurofbromatosis. . . . . . . . . . . . . . . . . . . . . . . .218
U132 Te Year in Review in Pediatric Dermatology:
How Does It Change My Practice? . . . . . . . . . .218
Courses — 2:00 p.m. to 5:00 p.m.
C026 Basic Botulinum Toxin . . . . . . . . . . . . . . . . . . . .219
C027 Sclerotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . .220
C028 Soft Tissue Augumentation. . . . . . . . . . . . . . . . .220
Symposia — 2:00 p.m. to 5:00 p.m.
S038 Surgical Pearls . . . . . . . . . . . . . . . . . . . . . . . . . . .221
S039 Terapeutic and Diagnostic Pearls . . . . . . . . . . .221
S040 Fundamentals of Cutaneous Surgery. . . . . . . . . .222
S041 Clinical Issues in Medical Dermatology . . . . . . .223
S042 International Dermatology . . . . . . . . . . . . . . . . .224
S043 Melanoma Update . . . . . . . . . . . . . . . . . . . . . . .225
Discussion Groups — 2:30 p.m. to 4:00 p.m.
D023 Cutaneous T-Cell Lymphoma . . . . . . . . . . . . . . .226
D024 PAPA-Syndrome, SAPHO, and Acne:
Skin and Bones and Infammation . . . . . . . . . . .226
Focus Sessions — 2:30 p.m. to 4:00 p.m.
U133 Psychodermatology: Not Just a Delusion; ‘Bugs,’
Trichotillomania, and the Morgellons Debate. . .226
U134 Issue in Ofce Design. . . . . . . . . . . . . . . . . . . . .227
U135 What’s New in Dermatopathology and Why
It’s Important to You. . . . . . . . . . . . . . . . . . . . . .227
U136 Management of Challenging Pigmented Lesions. . . 227
U137 Developing a Unifed Approach to Investigating
Autoimmune Disease . . . . . . . . . . . . . . . . . . . . .227
U138 Digital Imaging and Medical Informatics: Decision
Support for Clinicians and Teachers . . . . . . . . . .228
U139 Inherited Cancer Syndromes:
Te Role of the Dermatologist . . . . . . . . . . . . . .228
U140 Past, Present, and Pearls of Treatment of
Autoimmune Bullous Disease . . . . . . . . . . . . . . .229
U141 Skin Signs of Systemic Disease . . . . . . . . . . . . . .229
U142 Cryosurgical Update . . . . . . . . . . . . . . . . . . . . . .229
Forums — 3:00 p.m. to 5:00 p.m.
F071 Advanced Treatment for Chronic Wounds . . . . .230
F072 Medium and Deep Chemical Peeling . . . . . . . . .230
F073 Techniques for Flap Success . . . . . . . . . . . . . . . .230
F074 Te Use of the Confocal Microscope in a
Private Clinical Practice . . . . . . . . . . . . . . . . . . .230
F075 Alopecia CPC. . . . . . . . . . . . . . . . . . . . . . . . . . .231
F076 Pediatric Dermatology . . . . . . . . . . . . . . . . . . . .232
F077 Aesthetic Dermatologic Complications . . . . . . . .232
F078 Epidermolysis Bullosa: Cases and Discussion . . .233
Workshop — 3:00 p.m. to 5:00 p.m.
W013 MOC Self-Assessment Ofce Based Safety . . . . .233
OVERVIEW
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
187
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
POSTER DISCUSSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
PD05 Cancer
Room: 283
No CME Credits
Moderator
Shasa Hu, M.D.
P500
High clinical response rate of Sézary syndrome with immune
modifying therapies: Prognostic markers of response
P501
Risk factors associated with the developement of a second
melanoma associated with nevus
P502
Signifcantly higher Breslow score of melanomas detected by
patients’ self-examination compared to melanomas detected during
annual dermatology check-up
P503
Application of a fltration and isolation by size technique for the
detection of circulating tumor cells in cutaneous melanoma
P504
Using standardized patients and moulage to assess students’ ability
to detect melanomas
P505
Characterizing regression in melanomas: a population-based study
P506
Prognosis and risk factors of local recurrence in cutaneous
melanoma
P507
Efectiveness of photodynamic therapy in Bowen disease: An
observational and descriptive study in 50 patients
PD06 Internal Medicine
Room: 284
No CME Credits
Moderator
Kenneth J. Tomecki, M.D.
P600
Tumour necrosis factor-alpha promoter -308G/A (TNFα -308G/
A) polymorphism in Mexican patients with alopecia areata
P601
Vulvo-cervico-vaginal manifestations and evaluation of
Papanicolaou smears in pemphigus vulgaris and pemphigus
foliaceus
P602
Analysis of the reactivity of indirect immunofuorescence in
patients with pemphigus foliaceus and pemphigus vulgaris using
rat bladder epithelium as a substrate
P603
A study of 383 patients of tungiasis in Haiti
P604
Antiphospholipid antibody syndrome by levamisole-tainted
cocaine: Case report and review of the literature
P605
Diagnostic guidelines for cellulitis: Recommendations based on
a retrospective analysis of cellulitis admissions to Massachusetts
General Hospital
P606
Expression of pro-infammatory protein s100a12 (EN-RAGE) in
Behçet’s disease and its association with disease activity
For description of session categories and fees see page 37
188
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
D019 Enhancing Observational Skills
Room: 240
DIRECTOR Irwin M. Braverman, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Discuss how visual training can improve observational skills.
2. Develop a better understanding of the obstacles impeding
accurate observation.
3. Examine how narrative paintings can serve as a surrogate for
patients in medical education.
DESCRIPTION
After introduction and review of principles of observational skills,
historical information and research studies will provide evidence
for efcacy of visual training. A hands-on experience using high
quality reproductions of narrative paintings from the Yale Center
for British Art will be provided to all attendees who will examine
these paintings and describe objectively what they see. Tis session
will be a replica of the workshop attended by Yale Medical School
students and dermatology residents as part of their curriculum.
Tis educational session also has been an integral part of the New
England Dermatology Society meetings for the past 10 years when
hosted by Yale Dermatology.
1.50 Category 1 CME Credits
D020 When Does Chronic Dermatitis Become
Cutaneous T-Cell Lymphoma?
Room: 241
DIRECTOR Sam T. Hwang, M.D., Ph.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Diferentiate clinical features of chronic dermatitis vs cutaneous
T-cell lymphoma (CTCL).
2. Order molecular tests that may diferentiate chronic dermatitis
from CTCL.
3. Identify unusual clinical stimulants of CTCL (such as allergic
contact dermatitis).
DESCRIPTION
Cutaneous T-cell lymphoma (CTCL) may share certain features
with common skin conditions such as atopic dermatitis, seborrheic
dermatitis, or allergic contact dermatitis. Tis session will be a case-
based discussion of specifc features and laboratory (molecular) tests
that will help clinicians distinguish chronic dermatitis from CTCL.
Te use of fow cytometry and PCR-based tests will be emphasized
as these technologies increase our ability to discern infammatory vs
neoplastic skin processes. A brief overview of the biology of skin-
derived T cells will be provided.
1.50 Category 1 CME Credits
DISCUSSION GROUP
7:15 a.m. to 8:45 a.m.
Tuition fee and ticket required for admission.
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
189
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
U110 Review of Dermatological Adverse
Reactions
Room: 298/299
DIRECTOR David R. Adams, M.D., Pharm.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Identify various drugs associated with adverse skin reactions.
2. Identify specifc treatment strategies, where appropriate, for
these reactions.
3. Recognize skin fndings as possible adverse drug reactions.
DESCRIPTION
Adverse drug reactions (ADRs) are in the diferential diagnosis for
most skin diseases. Tis session will review basic concepts on this
topic along with photo-driven cases and bullets for these ADRs.
Where indicated, specifc treatments will be presented.
1.50 Category 1 CME Credits
U111 Reconstruction in Dermatologic Surgery:
An Introductory and Review Session
Room: 265/266
DIRECTOR Juan-Carlos Martinez, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Describe a surgical defect accurately, including pertinent
characteristics and anatomic considerations.
2. Recognize the basic concepts of tissue movement and tension
vectors as they relate to primary, fap, and graft closures.
DESCRIPTION
Tis introductory session is ideal for residents and surgical fellows,
as well as those interested in reconstructive surgery. Te basics of
dermatologic reconstructive surgery will be covered, including the
concepts of tension vectors, tissue movement, and fap/graft
reconstruction. Multiple post-Mohs defects will be presented. Te
closures chosen by the surgeon, including immediate and long-
term photos will be shown along with discussion of why specifc
closures were chosen. Tere will be an emphasis on reconstructive
tips and tricks to optimize functional and aesthetic outcomes.
1.50 Category 1 CME Credits
FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U109 Pediatric Connective Tissue
Room: 242
DIRECTOR Eulalia Baselga, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize the most frequent clinical presentations and
cutaneous manifestations of connective tissue disease in
children.
2. Select the most adequate treatments for these conditions in
children.
3. Manage and monitor these diseases and the diferent treatments
proposed.
DESCRIPTION
Connective tissue diseases encompass a wide group of
infammatory disorders that includes among others lupus
erythematosus, scleroderma, dermatomyositis, and some overlap
syndromes such as mixed connective tissue disease. Many patients
present initially with similar clinical features, particularly during
the frst onset of symptoms, which frequently makes the diagnosis
of a specifc disease difcult. We will review the most frequent
clinical presentations of these diseases in children. We will also
discuss the workup that will be needed in these children, as well as
the diferent options of therapy. Finally monitoring treatment for
these patients will also be reviewed.
1.50 Category 1 CME Credits
For description of session categories and fees see page 37
190
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U112 Histopathology of Scarring Alopecia
Room: 235/236
DIRECTOR Catherine Margaret Stefanato, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to
1. Identify the ways in which short- and long-term safety of
biologic drugs can be properly assessed.
2. Assess the specifc data regarding safety of the most widely used
biologics for psoriasis therapy.
3. Analyze the relative risks and benefts of existing biologic drugs
as an aid to therapeutic decision-making.
DESCRIPTION
Biologic therapy for psoriasis has revolutionized our ability to treat
moderate to severe psoriasis. Tese drugs, when compared to older
systemic agents, demonstrate a superior risk/beneft ratio, based
particularly on their apparently superb safety profles. However,
much of what is held as gospel regarding biologic safety is based
on anecdote, misperception, and outright misrepresentation. Te
aim of this session is to drill down to the actual available data
on safety. Tis will allow us to understand these drugs in much
greater depth, allowing practitioners to make better therapeutic
decisions.
1.50 Category 1 CME Credits
U113 Immunology for Dermatologists
Room: 270
DIRECTOR Delphine J. Lee, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Summarize the well-established models for nevus and
melanoma progression.
2. Assess the current data on tissue and cancer stem cell biology.
3. Develop new insights into the biology of melanocytic
neoplasms and the potential ramifcations for diagnosis and
treatment.
DESCRIPTION
Te well-established model of melanoma dediferentiation
from a melanocyte passing through nevus stages and eventually
developing invasive and metastatic characteristics does not mesh
well with the clinical phenomenon. For example, it is difcult to
defne invasion as a malignant process since nevi clearly have the
same capacity, explain why the majority of melanomas develop
in normal skin, or explain phenomena such as eruptive nevi.
Tissue and cancer stem cell biology has now come to the research
forefront. Te presence of cells with stem cell-like characteristics in
melanomas has major implications for the etiology, diagnosis, and
treatment of melanocytic neoplasias.
1.50 Category 1 CME Credits
U114 Stem Cells in Melanoma and Nevi
Room: 267/268
DIRECTOR James M. Grichnik, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Distinguish the clinical features of diferent autoimmune
blistering diseases (AIBD).
2. Determine which tests to order for which autoimmune
blistering condition.
3. Identify current evidence for treatment of AIBD and a general
approach to management.
DESCRIPTION
Tis session will review the distinguishing clinical and pathological
features of the autoimmune blistering diseases and the tests needed
to diagnose them. Te evidence for treatment will be reviewed and
a general approach to treatment described based on this and the
guidelines by diferent dermatologic societies. Case examples will
be used in a lecture/discussion format.
1.50 Category 1 CME Credits
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
191
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
U116 Utilize Web Sites that Enhance
Your Career
Room: 274
DIRECTOR Helen Mary Torok, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Utilize clinical tools in the diagnosis of lentigo maligna
melanoma.
2. Recognize surgical and histologic pitfalls in the managment of
lentigo maligna melanoma.
DESCRIPTION
Te diagnosis and management of lentigo maligna melanoma
in the head and neck region presents multiple challenges due to
variable natural history and clinical presentation, location in a
cosmetically and functionally sensitive area, and unpredictable
subclinical extension beyond recommended excision margins.
Te goal of this session is to illustrate the multiple challenges and
present a comprehensive management approach including: 1)
clinical assessment tools; 2) excision techniques and corresponding
tissue grossing methods; 3) histological evaluation of surgical
margins and associated pitfalls.
1.50 Category 1 CME Credits
U115 Medication Use: Improving Adherence
and Compliance
Room: 285
DIRECTOR Steven R. Feldman, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Describe typical patterns of how patients use their medications.
2. List interventions to improve patients’ adherence behavior.
DESCRIPTION
Poor adherence to treatment is nearly ubiquitous. Poor treatment
outcomes and many other puzzling dermatologic phenomena are
mediated by poor use of medication. Tis session describes how
well people use their medication, relying on evidence obtained
using objective electronic monitors. Practical ways to improve
patients’ use of medication will be discussed. Tese measures can
help dramatically improve outcomes of treatment for patients with
many chronic skin diseases including acne, atopic dermatitis, and
psoriasis.
1.50 Category 1 CME Credits
FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
For description of session categories and fees see page 37
192
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U117 Diagnosis and Management of Unusual
Skin Tumors
Room: 264
DIRECTOR Erica Lee, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize less commonly encountered non-melanoma skin
cancers.
2. Discuss the key histopathologic tumor features.
3. Identify challenges and pitfalls in the management of these
unusual tumors.
DESCRIPTION
Tis session will review the clinicopathologic features of less
commonly encountered non-melanoma skin cancers including
microcystic adnexal carcinoma, dermatofbrosarcoma protuberans,
high-risk squamous cell carcinoma, and extramammary
Paget disease. Emphasis will be on the early recognition and
management of these tumors.
1.50 Category 1 CME Credits
U118 Holy Moly: Religion and the Skin
Room: 263
DIRECTOR Gary J. Brauner, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize dermatitides and traumatic reactive patterns caused
by application of garments or religious paraphernalia or
preparations.
2. Treat dermatoses with understanding of religious restrictions of
use of common dermatologic therapies.
3. Explain the reality of stigmata and religious stigmatization of
cutaneous diseases.
DESCRIPTION
Disparities in delivery of healthcare have made “cultural
competency” not merely a helpful but now a legally-required
remedy. Ethnicity and race are not the only relevant considerations.
Religious practices may cause or prevent cutaneous disease, heavily
weigh the social signifcance of certain diseases and impact on
delivery of proper dermatologic therapy. Tis focus session will
highlight such problems; please bring your own as well.
1.50 Category 1 CME Credits
U119 New Botulinum Toxins Practice
Integration
Room: 269
DIRECTOR Joel Schlessinger, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Discuss new options in botulinum toxins.
2. Contrast diferences in new botulinum toxins.
3. Discuss integration of new botulinum toxins into practice.
DESCRIPTION
Tere are several new botulinum toxin options either planned or
soon to be in use in dermatology practices. How do they compare
to onabotulinumtoxin A? How can practices integrate new
forms of botulinum toxin to their services and what methods are
considered best practices for these products? Tis course will allow
ample discussion among the participants of their usage patterns
and how they prepare, dilute, and market new and existing
products. Additionally, injection sites and diferences in responses
will be discussed.
1.50 Category 1 CME Credit
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
193
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
SCIENTIFIC SESSIONS
F056 Therapeutic Safety
Room: 391
DIRECTOR Joel M. Gelfand, M.D., MSCE
SPEAkERS
Macrene Alexiades-Armenakas, M.D., Ph.D.
Robert E. Kalb, M.D.
Susan J. Walker, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Discuss and analyze the methods used to evaluate the safety of
dermatologic therapeutics.
2. Rigorously assess the safety of dermatologic therapeutics.
DESCRIPTION
Tis session will focus on the critical appraisal of the safety of
dermatologic therapeutics. Te process of assessing safety of a
drug or device prior to and after FDA approval will be reviewed.
Strengths and limitations of our knowledge about risks associated
with therapeutics will be discussed. Recent data evaluating safety
issues associated with isotretinoin, methotrexatate, and dermal
fllers will be discussed as examples. Tis session is directed to all
physicians who prescribe drugs or use medical devices as well as
individuals who study the risks and benefts of therapeutics.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Safety assessment by FDA: What the Dermatologist
Needs to Know / Dr. Walker
9:30 a.m. Methotrexate Guidelines for Dermatologists:
To Biopsy or not to Biopsy / Dr. Kalb
10:00 a.m. Safety of Dermal Fillers / Dr. Alexiades-Armenakas
10:30 a.m. Current Controveries in Safety of Dermatologic
Terapeutics / Dr. Gelfand
FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F055 Vitiligo: Problems and Solutions
Room: 255/256/257
DIRECTOR Torello M. Lotti, M.D.
SPEAkERS
Rafael Falabella, M.D. Henry W. Lim, M.D.
Pearl E. Grimes, M.D. James J. Nordlund, M.D.
Iltefat H. Hamzavi, M.D. Mauro Picardo, M.D.
Jana Hercogova, M.D., Ph.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Discuss the mechanism of depigmentation.
2. Develop a strategy to diagnose vitiligo and related disorders.
3. Identify a winning approach to treatment, based on the choice
between well-established and new modalities.
DESCRIPTION
Tis symposium will review current knowledge on vitiligo.
Presenters will give you the headlines for an efcient
investigational approach to the problem and the critical
knowledge to make your practical choice between innovative and
conventional therapies. Newly available drugs will be discussed.
Tere will be a question and answer period at the end in which
practicing dermatologists and residents will be encouraged to
actively engage in the discussion.
2.00 Category 1 CME Credits
SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
194
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F057 Adolescent Dermatology
Room: 252/253/254
DIRECTOR Robert Silverman, M.D.
SPEAkERS
Kenneth E. Bloom, M.D. Robert L. Epps, M.D.
Bernard Cohen, M.D. Roselyn E. Epps, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Evaluate and manage selected dermatologic disorders in
adolescents.
2. Identify the basic rules that govern consent and confdentiality
for teens.
3. Outline interview techniques and hints for the ofce visit that
result in a successful patient encounter.
DESCRIPTION
Successful treatment of skin disease in the adolescent patient
can be a challenge. Teens will present with disorders that refect
their entry into adulthood and more often than not, they wish
to be treated as adults. However, in the eyes of the law, in the
United States, they are still children. Teir stage of psychosocial
development from early to late adolescence may signifcantly
impact a teen’s concerns and successful approach to solving their
problems.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Adolescent Development - Is It Normal?
/ Dr. Silverman
F058 Hair Loss in Women
Room: 388/389/390
DIRECTOR Mary Gail Mercurio, M.D.
SPEAkERS
Zoe Diana Draelos, M.D.
Nazanin Michelle Hanjani, M.D.
Leonard C. Sperling, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Evaluate and treat common forms of scarring and non-scarring
alopecias in women.
2. Identify when evaluation for hyperandrogenism is indicated in
a woman with androgenetic alopecia.
3. Determine which hair products may cause hair damage and
which are benefcial in women with alopecia.
DESCRIPTION
A variety of scarring and non-scarring forms of hair loss are
common in women. Tis symposium will focus on select
disorders emphasizing diagnostic clues, therapeutic challenges,
and treatment pearls. Tere will also be a discussion of hair care
products in the woman with alopecia.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Androgenetic Alopecia / Dr. Mercurio
9:30 a.m. Alopecia Areata / Dr. Hanjani
10:00 a.m. Cicatricial Alopecia / Dr. Sperling
10:30 a.m. Hair Care Products in Women with Alopecia
/ Dr. Draelos
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
195
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
SCIENTIFIC SESSIONS
F060 Immunohistochemistry in Dermatology
Room: 386/387
DIRECTOR Tammie C. Ferringer, M.D.
SPEAkERS
Whitney A. High, M.D.
Jacqueline M. Junkins-Hopkins, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Discuss the use of immunohistochemistry as it pertains to
melanocytic and lymphoid processes.
2. Describe how immunohistochemistry is used in other areas of
dermatopathology.
3. Explain the limitations of immunohistochemistry.
DESCRIPTION
Judicious use of immunohistochemistry can be an adjuvant
tool to traditional morphologic diagnosis. Te role in diagnosis
of melanocytic and lymphoid processes will be discussed with
emphasis on recent advances. Use in diagnostic dilemmas
involving other areas of dermatopathology will also be reviewed.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Immunohistochemistry in Melanocytic Lesions
/ Dr. Ferringer
9:30 a.m. Questions and Answers / Dr. Ferringer
9:40 a.m. Immunohistochemical Potpourri / Dr. High
10:10 a.m. Questions / Dr. High
10:20 a.m. Immunohistochemistry in Lymphoid Infltrates
/ Dr. Junkins-Hopkins
10:50 a.m. Questions / Dr. Junkins-Hopkins
FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F059 Case-Based Discussion in Cutaneous
Lymphomas
Room: 278/279/280
DIRECTOR Youn H. Kim, M.D.
SPEAkERS Uma Sundram, M.D., Ph.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Apply appropriate pathologic and clinical diagnostic tools in
cutaneous lymphomas.
2. Order the appropriate staging evaluation and discuss prognosis
and treatment alternatives with the patient.
3. Select and utilize the optimal therapy for the patient with
cutaneous lymphomas.
DESCRIPTION
Using a case-based format, this session will review the most
updated information essential for the proper diagnosis, staging,
and management of patients with cutaneous lymphoma for
the practicing clinicians. It includes an update of the advances
in our understanding of the pathogenetic mechanisms in
cutaneous lymphoma. Te session updates the clinical and
pathologic diagnostic methods including how to apply ancillary
tests in the optimal diagnosis. Te session concludes with
discussions of current management approaches integrating
expert recommendations, consensus practice guidelines, and
evidence-based options. Included in the treatment updates will
be innovative therapies that are currently under investigation and
available for patient participation.
2.00 Category 1 CME Credits
For description of session categories and fees see page 37
196
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
196
|
amerIcan academy oF dermatoLogy • 68th annuaL meetIng
FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F061 Medical Dermatology Challenge:
Complex Cases from the Collection of
Dr. Samuel Moschella
Room: 392
DIRECTOR Ruth Ann Vleugels, M.D.
SPEAkERS
Samuel Leonard Moschella, M.D. Jennifer Tan-Billet, M.D.
Arturo P. Saavedra- Charles R. Taylor, M.D.
Lauzon, M.D., Ph.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Visually identify and diagnose classic and atypical presentations
of cutaneous manifestations of systemic disease.
2. Select management options for complex medical dermatologic
disease based on the best available evidence from the literature.
3. Discuss the use of advanced systemic therapies for the
management of refractory dermatologic conditions.
DESCRIPTION
After following patients with complex medical dermatologic
disease for over ffty years, Dr. Samuel Moschella, along with
several colleagues, will share medical dermatology images and
discuss clinical clues for identifying complex skin conditions.
Tis session will ofer practical tips for diagnosis, appropriate
evaluation, and advanced therapeutic management of patients
with systemic diseases afecting the skin. Audience self-assessment
will be encouraged through Kodachrome review, and a case-
based approach will be utilized to highlight relevance for the
dermatology trainee or experienced clinician. Cases discussed
will include those focusing on granulomatous disease, renal
disease, lymphoproliferative disease, connective tissue disease, and
pediatric disease.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Image Session 1 / Dr. Taylor
9:25 a.m. Image Session 2 / Dr. Saavedra-Lauzon
9:45 a.m. Image Session 3 / Dr. Tan-Billet
10:05 a.m. Image Session 4 / Dr. Vleugels
10:25 a.m. Image Session 5 / Dr. Moschella
F062 Ethical Dilemmas in Dermatology
Room: 281/282
DIRECTOR Jack Selwyn Resneck Sr., M.D.
SPEAkERS
Brett M. Coldiron, M.D. Robert M. Portman, J.D.
Dirk Michael Elston, M.D. Teodore Rosen, M.D.
Steven R. Feldman, M.D., Ph.D. Stephen Burtis Webster, M.D.
Philip E. LeBoit, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Evaluate a practice setup in the context of own ethical
standards and outside ethical guidelines.
2. Develop standards for ethical conduct in everyday practice.
3. Explain how the AAD Ethics Committee functions.
DESCRIPTION
Several ethical dilemmas and problems encountered by
dermatologists in everyday practice will be presented by
provocative speakers representing each side of the issues. Is it
appropriate for dermatologists to discuss or promote their political
views with patients in the ofce? Is it ethical for your ofce to
bill patients and earn a proft for dermatopathology services done
elsewhere? Should dermatologic surgeons, in response to Medicare
payment reduction rules, only excise one lesion daily or send
Mohs closures elsewhere? Also covered will be the functioning of
the AAD Ethics Committee and how it afects you.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Introduction / Dr. Resneck
9:05 a.m. What Does the Ethics Committee Really Do?
/ Mr. Portman
9:15 a.m. Delaying a Repair or Multiple Procedures Is Not
Unethical / Dr. Coldiron
9:25 a.m. Insurance Payment Policies Should Not Impact the
Number of Surgeries Done in One Day / Dr. Elston
9:35 a.m. Discussion / Faculty
9:45 a.m. You Should Use Your Ofce to Educate Your Patients
About Your Political Views / Dr. Rosen
9:55 a.m. Te Ofce Is a Place of Healing, Not Politicking
/ Dr. Webster
10:05 a.m. Discussion / Faculty
10:15 a.m. Te Dermatologist Should be Allowed to Bill for Path
Done Elsewhere / Dr. Feldman
10:25 a.m. Slides Read by a Dermatopathologist Should be Billed
by that Person / Dr. LeBoit
10:35 a.m. Discussion / Faculty
10:45 a.m. Answers to Your Burning Ethical Questions / Faculty
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
197
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
SCIENTIFIC SESSIONS
W011 Leading by Advocating for Dermatology
Room: 393/394
DIRECTOR Bruce A. Brod, M.D
SPEAkERS
Jack S. Resneck Jr., M.D.
LEARNING OBjECTIVES
Following this workshop, the attendee will be able to:
1. Recognize both the complexities and the realities of taking
a policy proposal through the process, and efectively and
collaboratively work towards the adoption of such policies.
2. Demonstrate efective techniques for addressing opposition
and overcoming obstacles in face-to-face meetings with policy
makers and their staf.
DESCRIPTION
Ever wonder what goes on in Washington D.C. and where
the myriad policies afecting the practice of dermatology come
from? Are you interested in getting involved in the process so
that your voice can be heard during this time of many changes
in health care? Take a hands-on approach to understanding
policymaking in this new Leadership Institute Workshop where
attendees will develop key competencies such as “Managing
Politics and Infuencing Others” and “Building and Maintaining
Relationships.” Tese competencies are also useful in local politics,
managing a practice, working on a hospital staf, and in many
other settings.
Policy-making is a dynamic process, and dermatologists advocate
for the specialty in legislatures, regulatory agencies, and other
venues. Developing long-term relationships, building a reputation
by working constructively with others (even when you disagree),
thinking long-term and recognizing obstacles, forging alliances,
and knowing when to put aside personal politics are all critical
to success. Tis interactive workshop will demonstrate how
individual dermatologists, working together, can infuence the
policy-making process. Led by dermatologists with experience
advocating for dermatology and a national health policy strategist,
participants will both learn the basics of how the system works
and have a chance to develop valuable skills that will help them
further the cause of dermatology at a national or local level.
2.00 Category 1 CME Credits
WORkSHOP
9:00 a.m. to 11:00 a.m.
Tuition fee and ticket required for admission.
W010 MOC Self-Assessment:
Cosmetic Dermatology
M
O
C
Room: 288/289/290
DIRECTOR Emmy M. Graber, M.D.
LEARNING OBjECTIVES
Following this workshop, the attendee will be able to:
1. Identify the strengths and weaknesses in his/her cosmetic
dermatology knowledge and make improvements as needed.
2. Demonstrate commitment to lifelong learning and self-
assessment.
DESCRIPTION
Tis session will be structured in a question-and-answer format
using an automated response system. It will cover topics in
cosmetic dermatology.
2.00 Category 1 CME Credits
New Session for Annual Meeting 2011.
For description of session categories and fees see page 37
198
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
COURSE
9:00 a.m. to 12:00 p.m.
Tuition fee and ticket required for admission.
C021 Intermediate Cosmetic Surgery
Room: 291/292
DIRECTOR Naomi Lawrence, M.D.
SPEAkERS
Kimberly J. Butterwick, M.D. Mitchel Paul Goldman, M.D.
Sue Ellen Cox, M.D. Stephen Howard Mandy, M.D.
Lisa M. Donofrio, M.D. Seth L. Matarasso, M.D.
Richard Gordon Glogau, M.D. Susan H. Weinkle, M.D.
David J. Goldberg, M.D., J.D. Christopher B. Zachary, M.D.
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Utilize a comprehensive noninvasive cosmetic approach to
patients in various age groups.
2. Manage complications, dissatisfed patients, and practice
management issues.
3. Demonstrate improvement in scheduling for the cosmetic
practice.
DESCRIPTION
Tis course will emphasize a comprehensive but noninvasive
approach to cosmetic correction for patients in various age groups.
We will address the issue of handling diferent botulinum toxins
in the attendee’s clinical practice. As the fller market becomes
more complex, we will address an algorithm for use of multiple
diferent fllers. Te attendee will also learn a reasonable strategy
to evaluate new devices. Te lectures will incorporate practice
management issues in cosmetic surgery such as waiting room
dynamics and handling the dissatisfed cosmetic patient.
3.00 Category 1 CME Credits
REFERENCES
1. Carruthers ed. Soft Tissue Augmentation, Procedures in Cosmetic
Dermatology. 2nd ed. Philadelphia: Saunders; 2005.
2. Surgery of the Skin, Procedural Dermatology. Robinson et al
eds. 2nd ed. Philadelphia: Mosby; 2010.
SCHEDULE
9:00 a.m. Introduction / Dr. Lawrence
9:05 a.m. Te Waiting Room and Exam Room Experience
Before Seeing the Physician / Dr. Goldman
9:20 a.m. Te Science of Waiting in the Waiting Room
/ Dr. Lawrence
9:35 a.m. Questions and Answers / Faculty
9:45 a.m. Comprehensive Noninvasive Cosmetic Approach for
the 30-Year-Old Patient / Dr. Butterwick
10:00 a.m. Comprehensive Noninvasive Cosmetic Approach for
the 40 to 50-Year-Old Patient / Dr. Donofrio
10:15 a.m. Comprehensive Noninvasive Cosmetic Approach for
the 60+-Year-Old Patient / Dr. Weinkle
10:30 a.m. Questions and Answers / Faculty
10:40 a.m. Tips for Using Multiple Toxins / Dr. Matarasso
10:55 a.m. Filler Algorithm: How I Decide What to Use in
Who and Where / Dr. Cox
11:10 a.m. Don’t Buy Tat Device! Lasers: What You Really
Need and How to Accomplish It Cost Efectively
/ Dr. Zachary
11:25 a.m. Questions and Answers / Faculty
11:35 a.m. Managing Expectations in the Dissatisfed Cosmetic
Patient / Faculty
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
199
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
SCIENTIFIC SESSIONS
SCHEDULE
9:00 a.m. Introduction / Dr. Davey
9:05 a.m. Future Challenges for Dermatologists / Dr. Coldiron
9:25 a.m. Questions and Answers / Faculty
9:30 a.m. Acquiring Real Estate to Enhance Value and Quality
of Your Practice / Dr. Goldstein
9:50 a.m. Questions and Answers / Faculty
9:55 a.m. Tips for Hiring/Managing Personnel / Dr. Harmon
10:15 a.m. Questions and Answers / Faculty
10:20 a.m. Negotiating Contracts / Dr. Brown
10:40 a.m. Questions and Answers / Faculty
10:45 a.m. Enhancing Operations / Dr. Kent
11:05 a.m. Te Best Advice I Ever Got / Dr. Ceilley
11:25 a.m. Te Best Advice I Ever Got / Dr. Eastern
11:45 a.m. Final Questions and Answers / Faculty
COURSE
9:00 a.m. to 12:00 p.m.
Tuition fee and ticket required for admission.
C022 Advanced Practice Management:
Mini MBA
Room: 260/261/262
DIRECTOR William Patrick Davey, M.D.
SPEAkERS
Clarence W. Brown, Jr., M.D. Glenn D. Goldstein, M.D.
Roger I. Ceilley, M.D. Christopher B. Harmon, M.D.
Brett M. Coldiron, M.D. David E. Kent, M.D.
Joseph S. Eastern, M.D.
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Identify and practice successful management strategies.
2. Manage employees and inventory in a dermatology practice.
3. Develop negotiating skills.
DESCRIPTION
Successful dermatology practices excel at dermatologic diagnoses/
treatments and use excellent practice management. Many
dermatologists are excellent diagnosticians however receive
little training in ofce management. Tis session will highlight
some of the ofce management strategies utilized by successful
dermatology practices.
3.00 Category 1 CME Credits
The best dermatologic
literature review available!
Save time and stay up-to-
date with DermClips, the
Academy’s literature review
newsletter, featuring:
• Article review from some of the
most popular medical journals.
• Commentary based upon
application to everyday
practice setting
• References for further study
• AMA PRA Category 1 Credits
TM
Visit the Academy
Resource Center
Booth 3623 to subscribe!
For description of session categories and fees see page 37
200
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
COURSE
9:00 a.m. to 12:00 p.m.
Tuition fee and ticket required for admission.
C023 Advanced Pediatric Dermatology
Room: 293/294
DIRECTOR Albert C. Yan, M.D.
SPEAkERS
Magdalene A. Dohil, M.D. Ashfaq A. Marghoob, M.D.
Anita N. Haggstrom, M.D. Amy S. Paller, M.D.
Anne W. Lucky, M.D. Mary L. K. Williams, M.D.
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Recognize infectious complications of atopic dermatitis.
2. Diagnose pediatric skin lesions more efectively using clinical
clues and derm(at)oscopy.
3. Select the best treatments for children with pediatric skin
diseases such as hemangiomas, congenital ichthyoses, and
epidermolysis bullosa.
DESCRIPTION
Tis session will present updates as well as advanced perspectives
regarding a broad range of both common and rare pediatric
skin disorders. For those seeking a sophisticated examination of
pediatric dermatology issues, a combination of state-of-the-art
updates (on the infectious complications of atopic dermatitis,
infantile hemangiomas, derm(at)oscopy of pediatric skin lesions),
as well as clinical pearls (epidermolysis bullosa, disorders of
cornifcation, cutaneous lumps and bumps of childhood) will be
presented.
3.00 Category 1 CME Credits
REFERENCES
1. Beck LA, Boguniewicz M, Hata T, Schneider LC, Hanifn
J, Gallo R, Paller AS, et al. Phenotype of atopic dermatitis
subjects with a history of eczema herpeticum. J Allergy Clin
Immunol. 2009 Aug;124(2):260-269, 269.e1-7. Epub 2009
Jun 27.
2. Marghoob AA, Braun R. Proposal for a revised 2-step
algorithm for the classifcation of lesions of the skin using
dermoscopy. Arch Dermatol. 2010 Apr;146(4):426-428.
3. Metry D, Heyer G, Hess C, Garzon M, Haggstrom A, et
al. Consensus Statement on Diagnostic Criteria for PHACE
Syndrome. Pediatrics. 2009 Nov;124(5):1447-1456. Epub
2009 Oct 26.
SCHEDULE
9:00 a.m. Introductions / Dr. Yan
9:05 a.m. Atopic Dermatitis and Related Infections / Dr. Paller
9:35 a.m. Lumps and Bumps in Children / Dr. Dohil
10:05 a.m. Infantile Hemangiomas / Dr. Haggstrom
10:30 a.m. Questions and Answers / Faculty
10:40 a.m. Insights into Epidermolysis Bullosa / Dr. Lucky
11:00 a.m. Derm(at)oscopy of Pediatric Lesions / Dr. Marghoob
11:30 a.m. Insights into Ichthyosis / Dr. Williams
11:55 a.m. Questions and Answers / Faculty
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
201
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
SCHEDULE
9:00 a.m. Introduction / Dr. Russell
9:05 a.m. How I Approach Merkel Cell Carcinoma / Dr. Nghiem
9:25 a.m. How I Approach Dermatofbrosarcoma Protuberans
/ Dr. Ratner
9:45 a.m. How I Approach High-Risk Squamous Cell
Carcinoma / Dr. Zwald
10:05 a.m. How I Approach Lipomas / Dr. Clayton
10:25 a.m. How I Approach Lesions Associated with Syndromes:
Sebaceous Adenoma and Trichilemmoma
/ Dr. English
10:45 a.m. How I Approach Keloids / Dr. Baldwin
11:05 a.m. How I Approach Atypical Nevi / Dr. Swetter
11:25 a.m. How I Approach Giant Congenital Nevi / Dr. Padgett
11:45 a.m. How I Approach Lentigo Maligna / Dr. Goldberg
SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.
S032 Cutaneous Tumors Benign and Malignant
Room: 275/276/277
DIRECTOR Mark A. Russell, M.D.
SPEAkERS
Hilary E. Baldwin, M.D. Julia K. Padgett, M.D.
Anna S. Clayton, M.D. Desiree Ratner, M.D.
Joseph C. English III, M.D. Susan M. Swetter, M.D.
Dori Goldberg, M.D. Fiona O’Reilly Zwald, M.D.
Paul Nghiem, M.D., Ph.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Recognize various presentations for benign and malignant
cutaneous tumors.
2. Utilize the current literature to evaluate the potential clinical
course of such tumors.
3. Develop diagnostic and therapeutic plans for these conditions
based on the best available evidence.
DESCRIPTION
Frequently, dermatologists must recognize and treat a variety of
benign and malignant cutaneous lesions. Tese tumors may have
various presentations or associations which complicate diagnosis
and treatment. Te speakers will attempt to impart to the
audience how they approach patients with these conditions. Tey
will share tips to help clinicians recognize these tumors, discuss the
current understanding of the origin and biologic behavior of the
tumors, and present rationales for various proposed treatments.
Te speakers will relate examples from their own practices and
experiences to illustrate the difculties and dilemmas these
situations may present.
3.00 Category 1 CME Credits
Don’t Be the Last to Know About
Rx Recalls and Warnings!
• FDArequireddrugalertse-mailedto
youimmediately
• Nomoredelays,paper,and
mailboxclutter
• Endorsedbymajorliabilitycarriers
andmedicalsocieties
• Improvespatientsafetyandreduces
physicianliability
• RegistrationisFREEandtakesonlyminutes
tocomplete
Visit the Academy Resource Center Booth 3623
or register today at: www.aad.org/hcnn
F
R
E
E
M
em
ber
B
eneft!
For description of session categories and fees see page 37
202
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.
S033 Photodermatology
Room: Auditorium A
DIRECTOR Craig A. Elmets, M.D.
SPEAkERS
R. Rox Anderson, M.D. Jean T. Krutmann, M.D.
Sewon Kang, M.D. Marian Elizabeth Northington, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Develop a systematic approach to the assessment and
management of skin photoaging.
2. Summarize the management of actinic damage in organ
transplant recipients.
3. Discuss the role of ultraviolet radiation in rheumatic diseases.
DESCRIPTION
Tis symposium will review contemporary topics related to
photodermatology that are of particular interest to the practicing
dermatologist. Tis will include the newest developments in
photoaging of the skin. Tere will be a discussion of the role that
ultraviolet radiation plays in rheumatic diseases. Also, there will
be an update in the latest trends in lasers. New developments in
management of actinic damage in organ transplant recipients and
the chemoprevention of skin cancer will be reviewed.
3.00 Category 1 CME Credits
REFERENCES
1. Krutmann J, Honigsmann H, Elmets CA, eds. Dermatological
Phototherapy and Photodiagnostic Methods. New York: Springer.
2. Lim HW, Honigsmann H, Hawk JLM, eds. Photodermatology.
London: Informa Healthcare.
SCHEDULE
9:00 a.m. Introduction / Dr. Elmets
9:05 a.m. Ultraviolet Radiation and Rheumatic Disease
/ Dr. Callen
9:30 a.m. Photoaging: UVA and Beyond / Dr. Krutmann
9:55 a.m. Medical Management of Photoaging / Dr. Kang
10:20 a.m. Procedural Options for Photoaging / Dr. Northington
10:45 a.m. New Developments in Laser Terapy / Dr. Anderson
11:10 a.m. Management of Actinic Damage in the Organ
Transplant Recipient / Dr. Murphy
11:35 a.m. Non-melanoma Skin Cancer and Its
Chemoprevention / Dr. Elmets
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
203
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
SCIENTIFIC SESSIONS
REFERENCES
1. Gottlieb A, et al. Guidelines for the management of psoriasis
and psoriatic arthritis. Section 2: Psoriatic Arthritis: Overview
and guidelines of care. J Am Acad Dermatol. 2008; 58: 851-
864.
2. Gottlieb AB, et al. Phase II, randomised, double-blind placebo-
controlled study of ustekinumab, a human interleukin-12/23
monoclonal antibody, in psoriatic arthritis. Lancet. 2009;
373:633-640.
3. Strober B, et al. A series of cirtically challenging case scenarios
in moderate to severe psoriasis: A Delphi consensus approach.
J Am Acad Dermatol. 2009; 61(Supplement): S1-S42.
SCHEDULE
9:00 a.m. Welcome and Course Overview / Dr. Elewski
9:01 a.m. Diagnosing and Treating Patients with Psoriatic
Arthritis / Dr. Gottlieb
9:22 a.m. New and Emerging Terapies in Psoriasis / Dr. Lebwohl
9:45 a.m. Treatment of Children with Psoriasis / Dr. Teos
10:05 a.m. Recognizing and Managing Co-Morbidities in the
Psoriatic Patient / Dr. Callen
10:25 a.m. Panel Discussion / Faculty
10:40 a.m. Psoriasis Is Not the Only Problem: Managing
Treatments in the Presence of Hepatitis, HIV Disease,
Prior Malignancies, and EtOH Abuse
/ Dr. Van Voorhees
11:00 a.m. Management of Psoriasis in Pregnant Women
/ Dr. Kimball
11:15 a.m. Difcult Management Situations: Intertriginous and
Scalp Psoriasis and Management of Mild Psoriasis
/ Dr. Stein
11:30 a.m. Treatment of Nail Psoriasis / Dr. Tosti
11:45 a.m. Panel Discussion / Faculty
SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.
S034 Psoriasis
Room: La Nouvelle Orleans Ballroom
DIRECTOR Boni E. Elewski, M.D.
SPEAkERS
Jefrey Phillip Callen, M.D. Linda F. Stein, M.D.
Alice B. Gottlieb, M.D., Ph.D. Amy J. Teos, M.D.
Alexandra Boer Antonella Tosti, M.D.
Kimball, M.D., M.P.H. Abby S. Van Voorhees, M.D.
Mark Lebwohl, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Examine the current treatment of psoriasis and psoriatic
arthritis in adults and children, and to explore future options.
2. Identify psoriasis co-morbidities and learn if therapeutic
intervention might minimize or prevent certain risk factors.
3. Manage psoriatic patients in the setting of concurrent disorders
including alcohol abuse, hepatitis, infections, and cancer
history. Also, manage the pregnant women with psoriasis.
DESCRIPTION
Tis symposium reviews the newest therapies for psoriasis and
psoriatic arthritis, with emphasis on special populations including
nail psoriasis and psoriasis in children. Tere will also be a
discussion of managing psoriasis co-morbidities in the setting of
the biologic agents. Treating patients with concurrent disorders
including hepatitis, alcohol abuse, infections, and cancer will also
be highlighted.
3.00 Category 1 CME Credits
For description of session categories and fees see page 37
204
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.
S035 Controversies in Dermatologic Drug
Therapy
Room: Auditorium B
DIRECTOR Stephen E. Wolverton, M.D.
SPEAkERS
James Q. Del Rosso, D.O. Julie Claire Harper, M.D.
Joel M. Gelfand, M.D., MSCE Neil H. Shear, M.D.
Kenneth B. Gordon, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Develop awareness of both sides of the controversies
concerning various systemic and topical medications.
2. Identify several of the controversies that relate to physician
extenders and pharmaceutical representatives.
DESCRIPTION
Controversies abound in all aspects of dermatologic drug therapy.
Te speakers will address head on relevant issues in controversies
such as the cardiovascular risks of psoriasis, comparison of
various systemic drugs for psoriasis, discussion of the ever-present
controversies surrounding isotretinoin, and some controversial
black box warnings. Terapy-related controversies surrounding
physician extenders and pharmaceutical representatives are
likewise discussed. Attendees will gain a clear understanding of the
most current factors in these important controversies involving
dermatologic drug therapy.
3.00 Category 1 CME Credits
REFERENCES
1. Wolverton SE, ed, Comprehensive Dermatologic Drug Terapy.
Vol II, London: Elsevier, 2007.
SCHEDULE
9:00 a.m. What Are Several Controversies Pertaining to Use of
Physician Extenders in Dermatology? / Dr. Del Rosso
9:30 a.m. What is the Risk of Cardiovascular Disease in
Psoriasis and Terapeutic Implications of Tis Risk?
/ Dr. Gelfand
10:00 a.m. Are Biologics Really Any Better Tan Traditional
Systemics for Psoriasis? / Dr. Gordon
10:30 a.m. What are Several of the Recent Controversies in
Isotretinoin Terapy? / Dr. Harper
11:00 a.m. What Are the Pros and Cons of Meeting With
Pharmaceutical Reps? / Dr. Shear
11:30 a.m. Annoying and Controversial Black Box Warnings for
Dermatologic Drugs / Dr. Wolverton
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
205
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
REFERENCES
1. Murrell DF, Amagai M, Barnadas M, et al. Consensus
statement on defnitions of disease endpoints and therapeutic
response for pemphigus. J Am Acad Dermatol. 2008; 58 (June):
1043-1046.
2. Joly P, Mouquet H, Roujeau JC, et al: A single cycle of
rituximab for the treatment of severe pemphigus. N Engl J
Med. 2007 Aug 9;357(6):545-552.
3. Rosenbach M, Murrell DF, Bystryn J-C, et al. Comparison of
reliability and validity between two outcome instruments for
pemphigus. J Invest Dermatol. 2009; 109: 2404-2410.
SCHEDULE
9:00 a.m. Importance of Patient Support Groups for
Autoimmune Bullous Disease / Dr. Sirois
9:05 a.m. Practical Diagnosis of Pemphigus and Pemphigoid
/ Dr. Mascaro
9:25 a.m. Clinical Features and Diagnosis of Epidermolysis
Bullosa Acquisita / Dr. Caux
9:35 a.m. Questions and Answers on Diagnosis / Dr. Murrell
9:45 a.m. Lab Testing for Diagnosis of AIBD / Dr. Farvolden
9:55 a.m. Genetic Predisposition Towards Pemphigus and
Pemphigoid / Dr. Sprecher
10:10 a.m. Environmental Triggers to Pemphigus and
Pemphigoid / Dr. Aoki
10:25 a.m. Questions and Answers on Testing and Causes
/ Dr. Murrell
10:35 a.m. Evidence-Based Management of Pemphigus / Dr. Joly
11:05 a.m. Measuring Extent and Activity of Disease in
Pemphigus / Dr. Werth
11:15 a.m. Evidence-Based Management of Bullous Pemphigoid
/ Dr. Borradori
11:35 a.m. Prognosis and Avoiding Complications of Treatment
/ Dr. Pandya
11:50 a.m. Questions and Answers on Treatment / Dr. Murrell
SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.
S036 Blistering Disease
Room: 295/296
DIRECTOR Dedee F. Murrell, M.D.
SPEAkERS
Valeria Aoki, M.D. Jose-Manuel Mascaro Jr., M.D.
Luca Borradori, M.D. Amit G. Pandya, M.D.
Fredric Caux, M.D. David A. Sirois, DMD, Ph.D.
Davis G. Farvolden, M.D. Eli Sprecher, M.D., Ph.D.
Pascal Joly, M.D., Ph.D. Victoria P. Werth, M.D.
LEARNING OBjECTIVES
1. Summarize the criteria for diagnosis of pemphigus, pemphigoid
and epidermolysis bullosa acquisita.
2. Evaluate the evidence for therapies for pemphigus and
pemphigoid.
3. Outline the genetic and environmental factors that predispose
to development of pemphigus and pemphigoid.
DESCRIPTION
Tis session will highlight advances in the diagnosis,
characterization, and therapeutic options related to pemphigus,
pemphigoid and epidermolysis bullosa acquisita. Attendees will
learn about the genetic and environmental factors that predispose
patients to develop pemphigus and pemphigoid. Experienced
international bullous experts will give a critical review of the
evidence for traditional and novel therapies. Te key role played
by the patient support group, IPPF, to advance the diagnosis and
management of these orphan diseases will be explained.
3.00 Category 1 CME Credits
For description of session categories and fees see page 37
206
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.
S037 key Surgical Principles We All
Should know
Room: Auditorium C
DIRECTOR Christopher James Miller, M.D.
SPEAkERS
Jeremy S. Bordeaux, M.D., M.P.H. Nathaniel J. Jellinek, M.D.
Teris M. Chen, M.D. Joseph Sobanko, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Operate safely and confdently on any area of the body,
including high-risk areas, such as the temple, the mandible,
and the posterior triangle of the neck.
2. Apply principles of efective surgical design and technique to
achieve reproducibly excellent surgical results with routine
scalpel-based surgeries.
3. Illustrate enhancements in patient perceptions of outcomes
with efcient management of common dermatologic
procedures.
DESCRIPTION
Tis practical session will emphasize surgical fundamentals to
help dermatologists who want to perform routine scalpel-based
procedures with greater confdence and efciency. Comprised of
academic dermatologic surgeons who teach residents, our panel
of speakers will use clinical cases, photos, and videos from their
own practices to illustrate key principles necessary to succeed at
every step of common procedures in any dermatology practice.
Topics have been chosen carefully to allow in-depth coverage of
practical information that will enhance the surgical practice of any
dermatologist. Sufcient time is allotted for panelists to address
audience questions.
3.00 Category 1 CME Credits
REFERENCES
1. Boyer JD. Zitelli JA, Brodland DG. Undermining in
cutaneous surgery. Dermatol Surg. 2001; 27(1): 75-78.
2. Dzubow LM. Te dynamics of dog-ear formation and
correction. J Dermatol Surg Oncol. 1985; 11(7): 722-728.
3. Salasche SJ, Bernstein G, Senkarik M. Surgical Anatomy of the
Skin. Norwalk, Connecticut/San Mateo, California: Appleton
and Lange.
SCHEDULE
9:00 a.m. Improving Surgical Outcomes for Scalpel-Based
Surgeries: Striving for Reproducibly Excellent
Results / Dr. Miller
9:05 a.m. Critical Anatomy Made Simple: A Framework to
Operate with Confdence and Efciency, Even in
“Danger” Zones / Dr. Jellinek
9:30 a.m. Questions and Answers / Faculty
9:35 a.m. Aesthetic Design of Surgical Reconstruction and
Variations of the Ellipse: Key Principles to Make
Scars Less Perceptible / Dr. Bordeaux
10:00 a.m. Taming the Dog Ear: Why Tey Occur and How to
Deal with Tem / Dr. Chen
10:25 a.m. Questions and Answers / Faculty
10:30 a.m. Cysts, Lipomas, and More: Reliable Strategies for
Common Procedures / Dr. Sobanko
10:55 a.m. Questions and Answers / Faculty
11:00 a.m. Excising and Undermining with Confdence:
Why How We Cut Is Just as Important as How
We Stitch / Dr. Miller
11:20 a.m. Overcoming Common Challenges to Placing Deep
and Top Sutures: Keys to Success / Dr. Miller
11:45 a.m. Putting It All Together: Video Presentation and
Questions and Answers / Dr. Miller
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
207
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
REFERENCES
1. McConeghy KW, Mikolich DJ, LaPlante KL. Agents for the
decolonization of methicillin-resistant Staphylococcus aureus.
Pharmacotherapy. 2009 Mar;29(3):263-80.
2. Hochedez P, Caumes E. Common skin infections in travelers.
J Travel Med. 2008 Jul-Aug;15(4):252-62.
3. Crum-Cianfone N, Weekes J, Bavaro M. Recurrent
Community-Associated Methicillin-Resistant Staphylococcus
aureus Infections among HIV-Infected Persons: Incidence and Risk
Factors. AIDS Patient Care STDS. 2009 Jun 16.
SCHEDULE
9:00 a.m. Unusual Arthropod Assaults from the South
/ Dr. Rapini
9:25 a.m. Tuberculosis / Dr. Bravo
9:50 a.m. Vaccines to Prevent Infectious Diseases with
Cutaneous / Dr. Tyring
10:15 a.m. Update on HIV-Related Infectious Skin Disease
/ Dr. Kovarik
10:40 a.m. Fungal Infections / Dr. Elgart
11:05 a.m. Bacterial Infections Other than MRSA
/ Dr. Goldenberg
11:30 a.m. How to Handle a MRSA Outbreak / Dr. Elston
2:00 p.m. STDs Other Tan Syphilis / Dr. High
2:25 p.m. Dermatologic Treats from Exotic Pets / Dr. Rosen
2:50 p.m. Spirochetes / Dr. Brinster
3:15 p.m. Parasites / Dr. Elston
3:40 p.m. Barnyard Zoonoses / Dr. Ferringer
4:05 p.m. Infections in Patients on Biologic Terapy
/ Dr. Warschaw
4:30 p.m. Leishmaniasis / Dr. Tomecki
COURSE
9:00 a.m. to 5:00 p.m.
Tuition fee and ticket required for admission.
C024 Infectious Diseases
Room: 238/239
DIRECTOR Dirk Michael Elston, M.D.
SPEAkERS
Francisco G. Bravo, M.D. Carrie L. Kovarik, M.D.
Nooshin Ketabchi Ronald P. Rapini, M.D.
Brinster, M.D. Teodore Rosen, M.D.
George W. Elgart, M.D. Kenneth J. Tomecki, M.D.
Tammie C. Ferringer, M.D. Stephen K. Tyring, M.D., Ph.D.
Gary Goldenberg, M.D. Karen Warschaw, M.D.
Whitney A. High, M.D.
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Distinguish and diagnose and treat bacterial skin infections.
2. Interpret and diagnose and treat viral skin infections.
3. Demonstrate and diagnose and treat fungal skin infections.
DESCRIPTION
Te course focuses on important infectious pathogens as well as
new developments in the diagnosis and treatment of infectious
diseases of the skin.
6.00 Category 1 CME Credits
For description of session categories and fees see page 37
208
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
COURSE
9:00 a.m. to 5:00 p.m.
Tuition fee and ticket required for admission.
C025 Fundamentals of Dermoscopy
Room: 271/272/273
DIRECTOR Robert H. Johr, M.D.
SPEAkERS
Ralph P. Braun, M.D. Ashfaq A. Marghoob, M.D.
Rainer Hofmann-Wellenhof Scott Menzies, MBBS, Ph.D.
Harald Kittler, M.D. Wilhelm Stolz, M.D.
Emma Lanuti, M.D. David L. Swanson, M.D.
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Use the two-step algorithm when evaluating skin lesions.
2. Recognize all of the important dermoscopic criteria and
patterns.
3. Use pattern analysis to evaluate skin lesions.
DESCRIPTION
Te incidence of melanoma is increasing at an alarming rate.
Clinicians evaluating patients with pigmented skin lesions should
be very skilled even cutting edge at diagnosis. Dermoscopy is
the standard of care in many countries around the world. It
signifcantly increases the accuracy of the clinical diagnosis of
melanocytic, non-melanocytic benign and malignant skin lesions.
Te ultimate goal is not to miss or misdiagnose important benign
and malignant skin lesions and dermoscopy has been proven to
help reach this goal.
6.00 Category 1 CME Credits
REFERENCES
1. Johr RH, Stolz, W. Dermoscopy: An Illustrated Self-Assessment
Guide. New York: McGraw Hill; 2010.
2. Marghoob AA, Braun RP, Kopt AW. Atlas of Dermoscopy.
Taylor and Francis Group; 2005.
3. Menzies SW, Crotty KA, Inguar C, McCarthy, WH. An Atlas
of Surface Microscopy of Pigmented Skin Lesions: Dermoscopy.
New York: McGraw Hill; 2003.
SCHEDULE
9:00 a.m. Melanocytic vs. Non-Melanocytic: Te Two Step
Algorithm / Dr. Braun
9:30 a.m. Local Criteria: Trunk and Extremities Melanocytic
Lesions / Dr. Marghoob
10:00 a.m. Melanoma-Specifc Criteria: Trunk and Extremities
/ Dr. Marghoob
10:30 a.m. Pattern Analysis: Case Presentations / Dr. Johr
11:00 a.m. Face, Mucosa, Palms, Soles, Nails, Genitalia
/ Dr. Stolz
11:30 a.m. Important Vascular Structures / Dr. Kittler
11:45 a.m. Questions and Answers / Faculty
2:00 p.m. Melanocytic Nevi (Congenital, Acquired, Dysplastic,
Blue, Combined) / Mr. Hofmann-Wellenhof
2:15 p.m. Spitzoid Patterns / Dr. Kittler
2:30 p.m. Te Many Faces of Melanoma / Dr. Menzies
3:00 p.m. Seborrheic Keratosis, Hemangiomas,
Dermatofbromas / Dr. Swanson
3:15 p.m. Basal Cell and Squamous Cell Carcinoma, Sebaceous
Gland Hyperplasia / Dr. Braun
3:30 p.m. Solar Lentigo, Actinic Keratosis, Lichen Planus
Keratosis, Ink Spot Lentigo / Dr. Stolz
3:45 p.m. University of Miami Resident Case Presentation
/ Dr. Lanuti
4:00 p.m. Case Presentations: Self Assessment / Dr. Johr
4:45 p.m. Questions and Answers / Faculty
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
209
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
F064 The Approach to the Patient with
Cutaneous T-Cell Lymphoma
Room: 252/253/254
DIRECTOR Peter W. Heald, M.D.
SPEAkERS
Ginette Hinds, M.D.
Jo-Ann Latkowski, M.D.
Antonio Subtil, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Diagnose mycosis fungoides and recognize the conditions that
can mimic it clinically and histologically.
2. Classify patient’s cutaneous T-cell lymphoma (CTCL) utilizing
the most modern classifcation scheme along with clincial and
histological components.
3. Evaluate and stage a patient with CTCL in order to develop
a prognosis and a set of parameters that will be used to guide
therapy.
DESCRIPTION
In this session there will be speakers with expertise in the clinical
and histologic fndings that are useful in the recognition and
classifcation of cutaneous T-Cell lymphomas (CTCLs). Patients
will be presented with demonstrative examples of all variants of
that disease and its mimickers.
2.00 Category 1 CME Credits
SCHEDULE
12:00 p.m. Diagnosing Mycosis Fungoides (MF) / Dr. Heald
12:15 p.m. Recognizing MF in Skin of Color / Dr. Hinds
12:35 p.m. Diagnosis of MF by Biopsy / Dr. Subtil
1:05 p.m. Distinct Variants of MF/CTCL / Dr. Latkowski
1:25 p.m. Non-MF CTCL / Dr. Subtil
1:45 p.m. Staging, Testing, and the Toolbox for MF/CTCL
/ Dr. Heald
FORUM
12:00 p.m. to 2:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F063 Young Physician Pearls and Pitfalls:
A Survival Guide for the First 10 Years

Room: 392
DIRECTOR Brian R. Sperber, M.D., Ph.D.
SPEAkERS
Brian Leach, M.D. Eric Stratman, M.D.
Maithily Nandedkar, M.D. Nathan Trookman, M.D.
Brian Sperber, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Efectively manage ofce staf, minimize clinical and
administrative errors and use technology in practice.
2. Prepare for Maintenance of Certifcation.
3. Demonstrate how to build and maintain a successful
relationship with the community.
DESCRIPTION
Te frst 10 years in practice are both demanding and exhilarating!
Tis session will address some of the most common challenges
faced by the young dermatologist in both private practice and
academia, including Maintenance of Certifcation. We will discuss
strategies for managing a successful ofce staf, minimizing clinical
and administrative errors, and building and maintaining a positive
relationship with community. In addition, we will outline ways
to maximize the potential of information technology in your
practice. Te session will close with a panel discussion of practice
pearls and advice for maintaining a healthy work-life balance.
2.00 Category 1 CME Credits
SCHEDULE
12:00 p.m. Introduction / Dr. Sperber
12:05 p.m. Maintenance of Certifcation / Dr. Stratman
12:20 p.m. Te Reality Show of Ofce Staf / Dr. Leach
12:35 p.m. Technology in the Ofce / Dr. Nandedkar
12:50 p.m. Building your Reputation in the Community
/ Dr. Trookman
1:05 p.m. All the Stupid things I’ve Done / Dr. Sperber
1:20 p.m. Practice Pearls and Work-Life Balance
/ Panel Discussion
1:45 p.m. Questions and Answers
For description of session categories and fees see page 37
210
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
FORUM
12:00 p.m. to 2:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F065 What’s New and Emerging: Therapeutics
Room: 278/279/280
DIRECTOR William Howard Eaglstein, M.D.
SPEAkERS
Leslie Baumann, M.D. Craig A. Elmets, M.D.
Jefrey Phillip Callen, M.D. Kenneth A. Katz, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Describe current medical methods by sunscreen to prevent
skin cancer.
2. Evaluate and choose agents for cosmetic dermatologic
purposes.
DESCRIPTION
Tis session is aimed at new and emerging therapies especially
in the areas of medical dermatology, cosmetic dermatology, skin
cancer preventions, and evaluation of therapies.
2.00 Category 1 CME Credits
SCHEDULE
12:00 p.m. Introduction / Dr. Eaglstein
12:05 p.m. Cosmetic Dermatology / Dr. Baumann
12:30 p.m. Skin Cancer Prevention: Beyond Sunscreens
/ Dr. Elmets
12:55 p.m. Evaluating New Terapeutics / Dr. Katz
1:20 p.m. Medical Dermatology / Dr. Callen
F066 Merkel Cell Carcinoma: Diagnosis,
Management, and Controversies
Room: 281/282
DIRECTOR Paul Nghiem, M.D., Ph.D.
SPEAkERS
Linda Chung-Chin Wang, M.D., J.D.
Siegrid S. Yu, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Discuss areas of controversy and consensus regarding the
risk factors, incidence, clinical, pathologic, and prognostic
characteristics of Merkel cell carcinoma.
2. Analyze data linking the Merkel cell polyomavirus and immune
evasion by this cancer to outcomes and emerging therapies.
3. Utilize this information to guide the multi-disciplinary
management of representative cases.
DESCRIPTION
Merkel cell carcinoma (MCC) is a polyomavirus-associated skin
cancer with a higher disease-associated mortality (~46%) than
melanoma (~15%) and an increasing incidence of ~1600 cases/
year in the US. Management is challenging because therapy is
diferent in nature than for other skin malignancies and is
controversial within the literature. Multi-disciplinary care
involving surgery, radiation and medical oncology is often
indicated. Tis session will highlight areas of consensus and
controversy in the viral etiology, clinical presentation, staging,
pathology, and management of MCC. Representative and
challenging cases will be presented to highlight treatment options
and relevant data.
2.00 Category 1 CME Credits
SCHEDULE
12:00 p.m. Introduction, Clinical and Prognostic Features
/ Dr. Nghiem
12:30 p.m. Role of Imaging and Radiation Terapy in MCC
Management / Dr. Wang
12:50 p.m. Interactive Management Discussion of Representative
Cases / Dr. Yu
1:30 p.m. New Directions in Prognosis and Terapy of MCC
/ Dr. Nghiem
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
211
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
F068 Use of Physician Extenders
Room: 386/387
DIRECTOR David M. Pariser, M.D.
SPEAkERS
Paul R. Bergstresser, M.D. Suzanne Olbricht, M.D.
Robert David Greenberg, M.D. Abel Torres, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Identify and discuss issues related to the use of non-physician
clinicians in the practice of dermatology.
2. Recognize the education and dermatologic training aforded
physician extenders specializing in dermatology.
3. Summarize the legal and ethical aspects related to the
supervision and training of physician extenders in dermatology.
DESCRIPTION
Te increasing demand for dermatologic services and undersupply
of dermatologists nationwide contribute to the use of physician
extenders in many dermatology practices. Speakers will relate how
physician extenders are educated, trained, and used in dermatology
practices. Speakers will provide information about hiring, training,
and supervising these professionals. Both a dermatology NP and
PA will discuss their respective professional training and clinical
experience in dermatology. Details will be provided on how
physician extenders are used successfully, what pitfalls to avoid,
how to bill for their services, and what the ethical and legal
implications are in having physician extenders in your practice.
2.00 Category 1 CME Credits
SCHEDULE
12:00 p.m. Te AAD’s Policy Statement on the use of Non-
Physician Clinicians / Dr. Olbricht
12:25 p.m. Training of Non-Physician Clinicians in Dermatology
/ Dr. Bergstresser
12:35 p.m. Legal and Liability Concerns / Dr. Torres
12:45 p.m. Supervision of Physician Extenders:
Practical Considerations / Dr. Greenberg
1:25 p.m. Role of Unlicensed Medical Assistants in
a Dermatologic Practice / Dr. Pariser
FORUM
12:00 p.m. to 2:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F067 Managing Hair Loss Made Easy
Room: 388/389/390
DIRECTOR Vera H. Price, M.D.
SPEAkERS Paradi Mirmirani, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Recognize salient details of the history.
2. Assess signs that identify and diferentiate the alopecias.
3. Select appropriate therapy, and track response parameters
systematically.
DESCRIPTION
Tis session will address the critical shortage of dermatologists
who are willing to see patients with hair loss. Te aim of the
session is to make the management of alopecia areata, cicatricial
alopecia, and androgenetic alopecia easy with a fresh, systematic
approach. New advances in these three important conditions will
be discussed. Te session is directed to clinicians, academicians,
and residents.
2.00 Category 1 CME Credits
For description of session categories and fees see page 37
212
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
FORUM
12:00 p.m. to 2:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F069 Cutaneous Oncology: Multidisciplinary
Management of Common and Uncommon
Skin Cancers
Room: 391
DIRECTOR Tomas Kupper, M.D.
SPEAkERS
Keri S. Chaney, M.D. Chrysalyne Delling Schmults, M.D.
Arturo P. Saavedra- Linda Chung-Chin Wang, M.D., J.D.
Lauzon, M.D., Ph.D. Andrew Werchniak, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Discuss the medical and surgical management of melanoma,
squamous cell carcinoma, cutaneous T-cell lymphoma, Merkel
cell carcinoma, and graft-versus-host disease.
2. Identify the variables associated with the risk of recurrence,
metastasis, and mortality in these patients.
3. Formulate an efective treatment plan for these common and
uncommon skin cancers.
DESCRIPTION
Modern medicine requires the dermatologist to have a greater
familiarity with the multidisciplinary management of common
and uncommon cutaneous skin cancers and associated disorders,
including melanoma, squamous cell carcinoma, cutaneous T-cell
lymphoma, Merkel cell carcinoma, and graft-versus-host disease.
New concepts of pathogenesis, epidemiology, and the spectrum
of clinical presentations will be discussed. Te complexities of
staging by clinical-pathological correlation as well as new and
evolving imaging techniques will be reviewed. Practical tips for
optimal management and innovative therapeutic strategies will
be presented using challenging cases seen at the Dana-Farber/
Brigham and Women’s Cancer Center.
2.00 Category 1 CME Credits
F070 Fungal Infections
Room: 255/256/257
DIRECTOR Aditya K. Gupta, M.D., Ph.D.
SPEAkERS
Lawrence F. Eichenfeld, M.D. Nathaniel J. Jellinek, M.D.
Boni E. Elewski, M.D. Antonella Tosti, M.D.
Sheila Fallon Friedlander, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Evaluate treatments for dermatophyte and non-dermatophyte
mold onychomycosis.
2. Assess current treatments for tinea capitis.
3. Discuss the non-medical management of onychomycosis
including the role of debridement and surgery.
DESCRIPTION
Tis session reviews the management of onychomycosis in
children and adults. Dermatophyte and non-dermatophyte
infections will be included, as well as the surgical management of
onychomycosis. Te current treatment options for tinea capitis
will be presented.
2.00 Category 1 CME Credits
SCHEDULE
12:00 p.m. Pediatric Onychomycosis and Nail Disorders
/ Dr. Eichenfeld
12:20 p.m. Tinea Capitis / Dr. Friedlander
12:40 p.m. Update on Onychomycosis Treatment / Dr. Gupta
1:00 p.m. Topical Terapies for Onychomycosis / Dr. Elewski
1:20 p.m. Non-Dermatophyte Molds / Dr. Tosti
1:40 p.m. Surgical Management of Onychomycosis / Dr. Jellinek
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
213
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
D021 Dermatology, Diagnosis, and the
Visual Arts
Room: 240
DIRECTOR John E. Wolf Jr., M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Assess the depiction of skin disorders in a variety of art forms.
2. Discuss the use of art interpretation in historical research and
clinical diagnosis.
3. Recognize the impact of skin diseases on famous artists.
DESCRIPTION
Just as the skin often reveals the body’s interior disharmony, art is
a window into the human soul. Te visual arts ofer many intimate
glimpses of skin diseases and of powerful emotional responses
to those disorders of the fesh. We shall consider artistic works
as diverse as pre-Columbian sculptures, Old Masters, medieval
miniatures, and anonymous tribal art. Tis lecture will stress the
fact that art interpretation can be a useful tool to refne clinical
diagnostic skills. Finally, for those who may have attended before,
signifcant new material has been added to the presentation.
1.50 Category 1 CME Credits
D022 Common Dermatologic Diseases with
Myriad Treatments
Room: 241
DIRECTOR Richard B. Odom, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Identify the many therapeutics involved in the management of
more complex or complicated dermatological diseases.
2. Utilize the standard approaches to treatment of extensive or
unusual skin conditions.
3. Demonstrate newer and innovative ideas about treating skin
conditions that are recalcitrant to standard management
schemes.
DESCRIPTION
Tis discussion group will present newer and innovative ideas and
approaches involved in the management of more extensive and
complex skin diseases. Some treatment modalities are evidence-
based and other schemes are anecdotal but supported with case
reports. Active audience participation will be encouraged and
appreciated.
1.50 Category 1 CME Credits
WORkSHOP
12:00 p.m. to 2:00 p.m.
Tuition fee and ticket required for admission.
W012 Dealing with Diffcult People and Looking
Forward to It
Room: 288/289/290
DIRECTOR Steven Kenneth Shama, M.D., M.P.H.
LEARNING OBjECTIVES
Following this workshop, the attendee will be able to:
1. Discuss the many reasons why we become upset at various
people or situations.
2. Demonstrate tools and techniques for dealing with these
challenging people/patients.
DESCRIPTION
Difcult people/patients elicit emotions you may prefer not to
have. We’ll fnd creative ways of dealing with these people, so
you make peace, not war! It takes two people to make situations
“difcult.” What part do you play in this? What can you learn
about yourself and them? Participants will be asked to suggest
difcult scenarios and we’ll generate many diferent approaches
to solving these frustrating situations. Handouts will be provided
giving “answers” to life’s most frustrating interactions. Te session
will be touching, flled with laughter, and incidentally excellent
for risk management. Guaranteed to be memorable, practical, and
life/spirit enriching!
2.00 Category 1 CME Credits
DISCUSSION GROUP
12:15 p.m. to 1:45 p.m.
Tuition fee and ticket required for admission.
For description of session categories and fees see page 37
214
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U120 Sexually Transmitted Infections: The
Current Standard of Diagnosis and Care
Room: 235/236
DIRECTOR Whitney A. High, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Summarize the latest diagnostic techniques for sexually
transmitted disease.
2. Identify the latest therapeutic options for treating sexually
transmitted disease.
3. Compare and contrast signs and symptoms of sexually
transmitted diseases as compared to other skin disease that may
afect the genitalia.
DESCRIPTION
Tis course will seek to review the signs and symptoms of sexually
transmitted disease (STD), and compare and contrast these
conditions to other dermatological illness that may involve the
genitalia. Te latest diagnostic techniques will be discussed and
the current therapeutic guidelines for STDs will be reviewed.
1.50 Category 1 CME Credits
U121 Update on Graft-Versus-Host Disease
Room: 283
DIRECTOR Jonathan Cotliar, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize indications for and methods of hematopoietic stem
cell transplantation.
2. Recognize the clinical presentation of graft-versus-host disease.
3. Learn about new diagnostic tools and therapeutic options for
graft-versus-host disease.
DESCRIPTION
Tis session is intended for dermatologists and residents with an
interest in the treatment of graft-versus-host disease. Attendees
will learn about the unique cutaneous complications associated
with hematopoietic stem cell transplantation. Tis session will
explore indications for and methods of hematopoietic stem
cell transplantation, with an emphasis on new insights into the
pathophysiology of graft-versus-host disease, along with emerging
diagnostic tools and therapeutic modalities.
1.50 Category 1 CME Credits
U122 High-Risk Squamous Cell Carcinomas:
A Clinical and Pathologic Case Review
Room: 265/266
DIRECTOR David E. Geist, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Identify squamous cell carcinomas (SCC) with high risk
features.
2. Explain the limitations of standard surgical excision for these
tumors.
3. Develop an aggressive management plan for high-risk SCC
including margin-controlled surgery, close monitoring, and
possibly adjuvant therapy.
DESCRIPTION
While some squamous cell carcinomas are amenable to simple
excision, other squamous cell carcinomas carry a heightened
risk of recurrence and metastasis and are said to be high risk.
Prognostic factors such as depth, histologic grade, perineural
invasion, location, and immune status have been identifed.
Mismanagement of these tumors may result in signifcant
morbidity and mortality. Cases of complicated tumors with good
and poor outcomes will be presented with clinical photos and
pathology. Strategies for early recognition and multidisciplinary
management will be discussed.
1.50 Category 1 CME Credits
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
215
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
U124 Graft-Versus-Host Disease
Room: 267/268
DIRECTOR Edward W. Cowen, M.D
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize the risk factors associated with graft-versus-host
disease (GVHD).
2. Diferentiate between the diagnostic and non-diagnostic
cutaneous features of chronic GVHD.
3. Formulate a treatment plan for the management of cutaneous
GVHD.
DESCRIPTION
Graft-versus-host disease (GVHD) is the major cause of
non-relapse-related morbidity following allogeneic stem cell
transplantation. Although multi-organ involvement is common,
cutaneous GVHD is one of the most frequent presenting features
of both acute and chronic disease. Tis session will discuss the
features of both acute and chronic GVHD, with an emphasis on
classifcation of chronic GVHD based on recent NIH consensus
criteria. Treatment recommendations tailored to the type of
skin involvement will be discussed, as well as the importance
of dermatologic input in a multi-disciplinary approach to
management.
1.50 Category 1 CME Credits
FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U123 Forensics in Dermatology
Room: 298/299
DIRECTOR Eve Judith Lowenstein, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Ofer an understanding of the areas of forensic science, defne
forensic terminology, and describe the forensic exam.
2. Recognize the scope of forensics in dermatology, including
understanding types of wounds and patterns of injury to skin,
hair, and nails.
3. Determine the role of the dermatologist in forensic recognition
of the signs suggestive of murder, torture, abuse, assault,
neglect, self-inficted injuries, poisonings, and bioterrorism.
DESCRIPTION
Examination of the skin is a critical part of the forensic
examination.Te skin may reveal clues to the identity, time of
death or injury, and signs of internal disease or external trauma.
Dermatologists may be called upon to provide their opinions
in forensics cases. It is important for physicians to learn to use
forensic terminology appropriately to describe and document
dermatologic fndings, as well as to be able to distinguish between
normal postmortem changes in the skin and signs of disease or
trauma. In this review, we ofer an overview of dermatologic
fndings in forensic pathology and highlight their signifcance.
1.50 Category 1 CME Credits
For description of session categories and fees see page 37
216
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U125 Penile Growths
Room: 270
DIRECTOR Giuseppe A. Micali, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Utilize dermatoscopy in clinical practice beyond the usual
indication for cutaneous pigmented lesions.
2. Recognize those skin conditions in which dermatoscopy may
be more useful.
3. Choose the most appropriate technical devices and
magnifcations for each condition.
DESCRIPTION
Dermatoscopy is a noninvasive technique which allows a rapid
and magnifed (X10-X1000) in vivo observation of the skin
with the visualization of morphologic features invisible to the
naked eye. Apart from its most common use for the diagnosis
of pigmented skin lesions, it has been demonstrated that
dermatoscopy has further applications in dermatology, including
infammatory diseases, parasitoses, hair and nails abnormalities,
and a large variety of other skin conditions. Depending on the
disorder, dermatoscopy may be useful for diferential diagnosis,
prognostic evaluation, and monitoring response to treatment.
Te aim of this forum is to advance knowledge of dermatoscopy
beyond the traditional indication of pigmented lesions, focusing
on those conditions in which this technique may be useful. Te
session is directed to encourage dermatologists to alternative use of
dermatoscopy in clinical practice based on the presenter’s personal
experience, and on literature review.
1.50 Category 1 CME Credits
U126 Healing the Pyoderma Gangrenosum
Ulcer: Lessons for the PG Clinic
Room: 264
DIRECTOR Laura S. Winterfeld, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize classic and unusual presentations of pyoderma
gangrenosum.
2. Apply an algorithm for the diagnosis and treatment of patients
with pyoderma gangrenosum.
DESCRIPTION
Pyoderma gangrenosum (PG) is an infammatory ulcerative
condition that causes signifcant morbidity and can be extremely
challenging to treat. In this session, we will discuss clinical
settings of PG, and the state-of-the-art topical and systemic agents
to suppress infammation and promote wound healing. Our
experience in using novel anti-infammatory and biologic agents
and tissue-engineered therapies for PG will be discussed.
1.50 Category 1 CME Credits
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
217
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
U129 Informed Shared Decision Making in
Psoriasis Management
Room: 263
DIRECTOR Jerry Kim Leng Tan, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Defne informed shared treatment decision making.
2. Identify the roles of physician and patient in treatment
decisions.
3. Describe means to engage patients in values clarifcation.
DESCRIPTION
Tis session is directed at practicing dermatologists and trainees.
Informed shared decision making involves patient-physician
interaction combining patient autonomy and self-determination
with the expert knowledge and guidance of the clinician to fulfll
the mandate of informed choice. However, the myriad options for
moderate to severe psoriasis with difering attributes (risk, beneft,
and cost) requires recognition of patient perspectives, preferences,
and values. Inadequate training in informed counseling and a lack
of time and resources is unlikely to facilitate informed choice.
Potential solutions include the development of educational
resources and decision aids to inform and engage patients in the
decision-making process.
1.50 Category 1 CME Credits
U130 Sarcoidosis
Room: 274
DIRECTOR Misha Rosenbach, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Diagnose cutaneous sarcoidosis more efectively.
2. Evaluate patients with cutaneous sarcoidosis for systemic
involvement.
3. Manage patients with cutaneous sarcoidosis with a step wise,
multi-agent approach.
DESCRIPTION
Sarcoidosis is a multisystem granulomatous disease of unknown
cause that frequently afects skin. Tis session will review the
current understanding of cutaneous sarcoidosis, including new
theories about the etiopathogenesis of this poorly understood
entity. During the session we will review how to diagnose
cutaneous sarcoidosis; the broad clinical spectrum and multiple
morphologies of this protean disease will be discussed. We will
then review how to evaluate patients for systemic involvement
once a diagnosis is made. Finally, we will review the treatment
options and present a step wise, practical approach to the
management of these challenging patients.
1.50 Category 1 CME Credits
FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U127 Interactive Clinical Pathologic Challenge
Room: 285
DIRECTOR Soon Bahrami, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Apply clinical-pathologic correlation more efectively in the
diagnosis of skin diseases.
2. Recognize pitfalls of clinical and microscopic evaluation that
can lead to diagnostic errors.
3. Select appropriate ancillary methods to enhance diagnostic
accuracy.
DESCRIPTION
Tis session will utilize an interactive approach in the presentation
of a series of unique and challenging cases from an academic
dermatopathology practice. Emphasis will be placed on
correlating clinical and microscopic features to achieve accurate
patient diagnoses. Ancillary testing and potential pitfalls will be
discussed. Neoplastic and infammatory dermatologic diseases
will be presented in a stepwise “build the case” approach. Tis
session is directed towards dermatologists with an interest in
dermatopathology, dermatopathologists, and residents and fellows.
1.50 Category 1 CME Credits
U128 Leg Ulcer Quiz for the Astute Dermatologist!
Room: 269
DIRECTOR Alain Brassard, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Identify venous, arterial, diabetic, pyoderma gangrenosum and
unusual leg ulcers.
2. Demonstrate leg ulcer knowledge in an interactive format.
DESCRIPTION
Retention of knowledge is far superior when one participates in
the discussion. Tis is an interactive session based on the American
TV show, Jeopardy. It is delivered to a group of 60 individuals
maximum, divided in 6 to 10 teams. Te game is divided into
fve categories: arterial ulcers, venous ulcers, diabetic foot ulcers,
pyoderma gangrenosum and, Unusual ulcers. Each category has
questions and sub-questions. Te audience will participate in the
discussion of diferent leg ulcer case scenarios in a fun and relaxed
atmosphere. Te winning team will be congratulated by applause.
1.50 Category 1 CME Credits
For description of session categories and fees see page 37
218
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U131 Neurofbromatosis
Room: 242
DIRECTOR Amy J. Teos, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Diagnose patients with neurofbromatosis (NF) type 1 and
NF1-like syndrome.
2. Discuss the diferential diagnosis and approach to patients with
multiple cafe au lait spots.
3. Discuss the role of genetic testing in the workup of patients
with NF1 and its variants.
DESCRIPTION
Neurofbromatosis type 1 (NF1) and its variants are disorders
likely to be seen by dermatologists. Tis session will review the
important clinical features and discuss the management of NF1
from a dermatological perspective. Te clinical features of a newly
described NF1-like syndrome (Legius syndrome) will be reviewed.
Te role of genetic testing, which has recently become available,
will be discussed. An update on management and clinical
treatment trials will be provided. Tis session is geared to any
dermatologist interested in an update on NF1.
1.50 Category 1 CME Credits
U132 The Year in Review in Pediatric
Dermatology: How Does It Change My
Practice?
Room: 284
DIRECTOR Robert Sidbury, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Demonstrate practical applications of the latest developments
in pediatric dermatology.
2. Review the evolving story of beta-blockade for infantile
hemangiomas.
DESCRIPTION
Tis session will review the most recent advances in
pathophysiology, diagnosis, and management of common
pediatric skin conditions. Emphasis will be placed on practical
application of these fndings to daily clinical experience. Topics
covered will include beta-blockade for infantile hemangiomas,
genetics of alopecia areata and vitiligo, vitamin D and skin disease,
infections and atopic dermatitis as well as issues related to the use
of common medications such as isotretinoin and cantharidin.
1.50 Category 1 CME Credits
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
219
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
SCHEDULE
2:00 p.m. Introduction / Dr. Ozog
2:05 p.m. Relevant Anatomy for the Botulinum Toxin User
/ Dr. Wieder
2:15 p.m. Questions and Answers / Dr. Wieder
2:19 p.m. Preparing, Dosing, and Injecting Botulinum Toxins
/ Dr. Scherschun
2:29 p.m. Questions and Answers / Dr. Scherschun
2:33 p.m. Botulinum Toxins for Glabella with Video
/ Dr. Harmon
2:43 p.m. Questions and Answers / Dr. Harmon
2:47 p.m. Botulinum Toxins for Forehead with Video
/ Dr. Rubin
2:57 p.m. Questions and Answers / Dr. Rubin
3:01 p.m. Botulinum Toxins for Peri-orbital Area with Video
/ Dr. Jones
3:11 p.m. Questions and Answers / Dr. Jones
3:15 p.m. Botulinum Toxins for Lower Face and Neck with
Video / Dr. Matarasso
3:25 p.m. Questions and Answers / Dr. Matarasso
3:29 p.m. Botulinum Toxins for Hyperhidrosis / Dr. Glaser
3:39 p.m. Questions and Answers / Dr. Glaser
3:43 p.m. “A Tale of Two Toxins” and Clinical Pearls
/ Dr. Carruthers
3:53 p.m. Questions and Answers / Dr. Carruthers
3:57 p.m. Building a Botulinum Toxin Practice and Clinical
Pearls / Dr. Obagi
4:07 p.m. Questions and Answers / Dr. Obagi
4:11 p.m. Preventing and Managing “Complications”:
Touchups and Other Clinical Pearls / Dr. Cohen
4:21 p.m. Questions and Answers / Dr. Cohen
4:25 p.m. “To Arch or Not to Arch - Tat is the Question”:
Eyebrow Position and Other Clinical Pearls
/ Dr. Carruthers
4:35 p.m. Questions and Answers / Dr. Carruthers
4:39 p.m. Seven Tips for the Novice Injector: How I Do It
/ Dr. Sengelmann
4:48 p.m. Questions and Answers / Dr. Sengelmann
4:52 p.m. Review of Literature and Of-Label Dermatology Uses
/ Dr. Kouba
COURSE
2:00 p.m. to 5:00 p.m.
Tuition fee and ticket required for admission.
C026 Basic Botulinum Toxin
Room: 260/261/262
DIRECTOR David M. Ozog, M.D.
SPEAkERS
Alastair Carruthers, M.D. Seth L. Matarasso, M.D.
Jean D.A. Carruthers, M.D. Suzan Obagi, M.D.
Joel Lee Cohen, M.D. Mark G. Rubin, M.D.
Dee Anna Glaser, M.D. Lubomira Scherschun, M.D.
Christopher B. Harmon, M.D. Roberta D. Sengelmann, M.D.
Derek H. Jones, M.D. Joshua M. Wieder, M.D.
David Kouba, M.D., Ph.D.
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Utilize FDA-approved reconstituted botulinum toxins safely
and with optimal dosing.
2. Treat wrinkle lines of the glabella, forehead, crow’s feet, lower
face, and neck.
3. Discuss botulinum toxin treatments comfortably and
confdently with patients.
DESCRIPTION
Tis session should teach the attendee how to prepare, how to
inject, how to prevent complications, and how to keep patients
satisfed when using botulinum toxins. Luminaries in the feld
of cosmetic dermatology will teach the audience tricks and
pearls they have learned over the years in treating botulinum
toxin patients. Both FDA-approved botulinum toxins will be
thoroughly discussed.
3.00 Category 1 CME Credits
For description of session categories and fees see page 37
220
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
COURSE
2:00 p.m. to 5:00 p.m.
Tuition fee and ticket required for admission.
C027 Sclerotherapy
Room: 293/294
DIRECTOR Margaret A. Weiss, M.D.
SPEAkERS
David Michael Dufy, M.D.
Mitchel Paul Goldman, M.D.
Robert A. Weiss, M.D.
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Recognize the anatomy and pathophysiology of superfcial
venous disease of the leg.
2. Utilize this information to better perform sclerotherapy of
unwanted veins.
3. Minimize and treat complications from sclerotherapy.
DESCRIPTION
Venous disease of the legs afects millions; many seek symptomatic
and/or cosmetic relief. Tis session will cover the treatment of
varicose and telangiectic leg and non-leg veins. Anatomy and the
recognition of common patterns will be supplemented by video
demonstration, including brief Doppler/Duplex examination, a
critical step for dermatologists seeking to expand their treatment
from telangiectasia to larger varicosities. Te important advance of
foamed sclerotherapy will be discussed and shown. Complications
will be discussed. Tis session is intended to beneft the
beginner but will include more advanced techniques to help the
experienced.
3.00 Category 1 CME Credits
SCHEDULE
2:00 p.m. Te Old Gray’s Anatomy Ain’t What it Used to Be,
But Tere’s Still Some Tings You Should Know
/ Dr. Weiss
2:15 p.m. Nothing Compares to Watching Video of How to
Perform Sclerotherapy / Dr. Weiss
2:45 p.m. Sclerosing Solutions: Why Polidocanol Will Replace
Hypertonic Saline / Dr. Weiss
3:00 p.m. Navigating Trough Turbulence: Avoiding
Complications of Foam and Non-Foam Sclerotherapy
/ Dr. Goldman
3:45 p.m. Questions and Answers / Faculty
4:00 p.m. Only Detergent Solutions Can Foam: How Tis
Technique is Changing Vein Treatments / Dr. Weiss
4:15 p.m. What About Tose Ugly Chest and Hand Veins:
Non-Leg Sclerotherapy / Dr. Weiss
4:35 p.m. Practice Pearls / Dr. Weiss
4:45 p.m. Questions and Answers / Faculty
C028 Soft Tissue Augumentation
Room: 291/292
DIRECTOR Heidi A. Waldorf, M.D.
SPEAkERS
Vivian Wasserteil Bucay, M.D. Derek H. Jones, M.D.
Cheryl M. Burgess, M.D. Rhoda S. Narins, M.D.
Rebecca L. Fitzgerald, M.D. Hema A. Sundaram, M.D.
Brooke A. Jackson, M.D. Susan H. Weinkle, M.D.
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Identify the clinical characteristics and flling properties of
available flling agents.
2. Design a realistic plan for soft tissue augmentation during a
cosmetic consultation.
3. Demonstrate minimizing risk and manage complications when
they occur.
DESCRIPTION
Tis session will provide a detailed examination of soft tissue
augmentation. Patient evaluation and aspects of a thorough
consultation will be outlined. Te scientifc basis and best
practices for use will be reviewed for each product category.
Special considerations for patient subgroups as well as avoiding
and managing complications will be stressed. Both beginner and
experienced injectors should leave with pearls to improve their
practice.
3.00 Category 1 CME Credits
SCHEDULE
2:00 p.m. A Modern Approach to Soft Tissue Augmentation
/ Dr. Waldorf
2:20 p.m. Update on Hyaluronic Acid Filling Agents / Dr. Jones
2:40 p.m. Questions and Answers / Dr. Jones
2:45 p.m. Calcium Hydroxylapatite: A Scientifc Approach
/ Dr. Sundaram
3:05 p.m. Questions and Answers / Dr. Sundaram
3:10 p.m. Best Practices for Poly-L-Lactic Acid / Dr. Fitzgerald
3:30 p.m. Questions and Answers / Dr. Fitzgerald
3:35 p.m. Permanent Fillers: How and When / Dr. Burgess
3:50 p.m. Questions and Answers / Dr. Burgess
3:55 p.m. Soft Tissue Augmentation of the Face / Dr. Weinkle
4:10 p.m. Questions and Answers / Dr. Weinkle
4:15 p.m. Augmenting Skin of Color: Special Considerations
/ Dr. Jackson
4:30 p.m. Questions and Answers / Dr. Jackson
4:35 p.m. Managing Filler Complications / Dr. Bucay
4:55 p.m. Questions and Answers / Dr. Bucay
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
221
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
S039 Therapeutic and Diagnostic Pearls
Room: La Nouvelle Orleans Ballroom
DIRECTOR Stephen P. Stone, M.D.
SPEAkERS
Joseph B. Bikowski, M.D. Ronald C. Hansen, M.D.
Stuart M. Brown, M.D. Mark Lebwohl, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Use innovative therapies for patients with complicated
conditions or common maladies unresponsive to commonly
efective approaches.
2. Safely and efectively utilize established medications for of-
label uses.
3. Develop some unusual arrows for the therapeutic and
diagnostic quiver.
DESCRIPTION
Faculty will present innovative approaches to some treatment-
resistant dermatologic problems, some using newer drugs and
treatments, others reaching back to therapies that worked in the
past but may have been forgotten. Of-label and ABM (anecdote-
based management) will predominate, with a few evidence-based
pearls as well. Target audience is the ofce-based dermatologist.
Participants are urged to e-mail challenging cases to drspstone@
gmail.com in advance of the meeting for discussion by the faculty.
3.00 Category 1 CME Credits
REFERENCES
1. Stone SP. Unusual, innovative, and long-forgotten remedies. In
Dermatological Clinics, Teirs, BH: ed. 18:2. 323-338, April
2000
2. Ely H. Dermatologic therapies you’ve probably never heard of.
Dermatological Clinics 1989 Jan;7(1):19-35.
3. Lebwohl, M. et al. Treatment of Skin Disease. Philadelphia:
Mosby. in press
SCHEDULE
2:00 p.m. Introduction / Dr. Stone
2:05 p.m. Of Label But Not Of the Wall / Dr. Stone
2:35 p.m. More Ofce Tips / Dr. Lebwohl
3:05 p.m. A Potpourri of Pearls… / Dr. Brown
3:35 p.m. Not in the Textbooks... / Dr. Bikowski
4:05 p.m. Pediatric Dermatological Pearls / Dr. Hansen
4:35 p.m. Questions, Challenges, and Answers from the Faculty
/ Faculty
SYMPOSIUM
2:00 p.m. to 5:00 p.m.
Open admission, no tuition or ticket.
S038 Surgical Pearls
Room: 275/276/277
DIRECTOR Summer R. Youker, M.D.
SPEAkERS
Christie Travelute Ammirati, M.D. Kenny J. Omlin, M.D..
Jeremy S. Bordeaux, M.D., M.P.H. Jefrey E. Petersen, M.D.
Christine Elizabeth Cabell, M.D. Bertrand Richert, M.D., Ph.D.
Christopher James Miller, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Recognize the difculties of surgery in special sites and develop
strategies to overcome them.
2. Identify practical techniques for fnessing closures.
3. Identify useful surgical pearls to take back to your practice.
DESCRIPTION
Tis session is directed toward general dermatologists and
dermatologists-in-training who wish to improve their surgical
skills. Key subjects to be covered include tips for surgery on the
nails, the scalp, and the lower leg; tips for scar refnement; and tips
for achieving the best surgical result possible. Tis session is not
intended for accomplished dermatologic surgeons.
3.00 Category 1 CME Credits
SCHEDULE
2:00 p.m. Surgery on the Scalp / Dr. Ammirati
2:20 p.m. Surgery on the Lower Leg / Dr. Petersen
2:40 p.m. Questions and Answers / Faculty
2:45 p.m. Optimizing Suture Technique / Dr. Bordeaux
3:05 p.m. Finessing the Standing Cone / Dr. Youker
3:25 p.m. Questions and Answers / Faculty
3:30 p.m. Painless Anesthesia and Scar Revision / Dr. Cabell
4:10 p.m. Questions and Answers / Faculty
4:15 p.m. Cosmetic Pearls / Dr. Omlin
4:35 p.m. Easy Flaps and How to Use Tem / Dr. Miller
4:50 p.m. Basic Nail Surgery / Dr. Richert
4:55 p.m. Questions and Answers / Faculty
For description of session categories and fees see page 37
222
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
SYMPOSIUM
2:00 p.m. to 5:00 p.m.
Open admission, no tuition or ticket.
S040 Fundamentals of Cutaneous Surgery
Room: Auditorium B
DIRECTOR Elizabeth M. Billingsley, M.D.
SPEAkERS
Sumaira Zareen Aasi, M.D. Joslyn S. Kirby, M.D.
Christie Travelute Ammirati, M.D. Mollie A. MacCormack, M.D.
Christine Elizabeth Cabell, M.D. Fiona O’Reilly Zwald, M.D.
M. Amanda Jacobs, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Evaluate patients preoperatively and efectively plan basic
dermatology surgical procedures.
2. Perform skin and nail biopsies, simple excisions, and layered
closures.
3. Manage common surgical complications.
DESCRIPTION
Tis symposium is designed for the dermatologist with little or no
experience in cutaneous surgery, as well as the more experienced
dermatologist wishing to improve surgical judgment, skills, and
outcomes. Preoperative patient evaluation, basic biopsy and
excision techniques, and suturing essentials will be discussed.
Information on suture types, surgical instruments, anesthesia,
and surgical dressings and wound care will be presented. Time
will also be spent discussing the recognition and management of
surgical complications.
3.00 Category 1 CME Credits
SCHEDULE
2:00 p.m. Preoperative Considerations / Dr. Aasi
2:20 p.m. Surgical Instruments and Sutures / Dr. Zwald
2:35 p.m. Anesthesia for Cutaneous Surgery / Dr. Kirby
2:55 p.m. Questions and Answers / Faculty
3:00 p.m. Biopsy and Excision: Techniques and Tips
/ Dr. Jacobs
3:20 p.m. Suturing Techniques and Finessing the Closure
/ Dr. Ammirati
3:45 p.m. Surgical Dressings and Wound Care
/ Dr. MacCormack
4:00 p.m. Questions and Answers / Faculty
4:05 p.m. Basics of Nail Biopsies and Nail Surgery
/ Dr. Billingsley
4:25 p.m. Recognition and Management of Surgical
Complications / Dr. Cabell
4:50 p.m. Questions and Answers / Faculty
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
223
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
SCHEDULE
2:00 p.m. Introductory Remarks / Dr. Bolognia
2:05 p.m. Pyoderma Gangrenosum: Rx and Dx / Dr. Davis
2:35 p.m. Questions and Answers / Dr. Davis
2:40 p.m. Controversies in Contact Dermatitis: From Systemic
Contact Dermatitis to Implanted Medical Devices
/ Dr. Cohen
3:10 p.m. Questions and Answers / Dr. Cohen
3:15 p.m. Recently Described Disorders: Clinicopathologic
Correlations / Dr. Ko
3:45 p.m. Questions and Answers / Dr. Ko
3:50 p.m. What’s New in Skin Diseases in
Immunocompromised Hosts / Dr. Cowen
4:20 p.m. Questions and Answers / Dr. Cowen
4:25 p.m. Severe Cutaneous Drug Reactions: SJS/TEN, AGEP
and DRESS / Dr. Schafer
4:55 p.m. Questions and Answers / Dr. Schafer
SYMPOSIUM
2:00 p.m. to 5:00 p.m.
Open admission, no tuition or ticket.
S041 Clinical Issues in Medical Dermatology
Room: Auditorium A
DIRECTOR Jean L. Bolognia, M.D.
SPEAkERS
David Eric Cohen, M.D. Christine Ko, M.D.
Edward W. Cowen, M.D. Julie V. Schafer, M.D.
Mark D. P. Davis, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Recognize the clinical spectrum of severe cutaneous drug
reactions.
2. Develop a clinical approach to the diagnosis and treatment of
pyoderma gangrenosum.
3. Recognize newly described dermatologic disorders.
DESCRIPTION
Te interface between internal medicine and dermatology
continues to play an important role in both the outpatient and
inpatient settings. Tis session will update the dermatologist
with regard to newly described dermatologic disorders, severe
cutaneous drug reactions, and the clinical approach to pyoderma
gangrenosum. Controversies in contact dermatitis will be discussed
as well as cutaneous disorders in immunocompromised hosts.
3.00 Category 1 CME Credits
REFERENCES
1. Callen JP, et al. Dermatological Signs of Internal Disease. 4th ed.
Elsevier:London, 2009.
2. Weenig RH, Davis MDP, et al. Skin ulcers misdiagnosed as
pyoderma gangrenosum. N Engl J Med. 2002; 347:1412-1418.
3. Wolf R, et al. Life-threatening acute adverse cutaneous drug
reactions. Clin Dermatol. 2005;23:171-181.
For description of session categories and fees see page 37
224
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
SYMPOSIUM
2:00 p.m. to 5:00 p.m.
Open admission, no tuition or ticket.
S042 International Dermatology
Room: 295/296
DIRECTOR Sidney N. Klaus, M.D.
SPEAkERS
Noah A. Craft, M.D., Ph.D. James J. Nordlund, M.D.
Roderick J. Hay, M.D. Scott A. Norton, M.D., M.P.H.
Peter Hotez, M.D. Wingfeld Ellis Rehmus, M.D.
Carrie L. Kovarik, M.D. Aisha Sethi, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Recognize the range and depth of dermatology problems
worldwide.
2. Assess approaches currently in use to alleviate these problems.
DESCRIPTION
Tis symposium will focus on issues that impact on skin disorders
and the dermatologic community worldwide, including emerging
and reemerging skin infections, the HIV/AIDS epidemic, societal
disruptions caused by confict and drought, and global climate
change. It will also examine eforts currently underway by the
international dermatologic community to alleviate these problems
through training programs to enhance the delivery of skin care
at the local level and discuss the possibilities of control or even
elimination of tropical skin infections.
3.00 Category 1 CME Credits
SCHEDULE
2:00 p.m. Introduction / Dr. Klaus
2:05 p.m. Emerging Skin Diseases / Dr. Norton
2:25 p.m. Impact of Global Climate Change on Distribution of
Skin Diseases / Dr. Rehmus
2:45 p.m. Practice Of Dermatology In Developing Countries
/ Dr. Kovarik
3:05 p.m. Efects of Societal Disruption on Epidemiology of
Skin Disorders / Dr. Sethi
3:25 p.m. Enhancing Skin Care in Africa Trough Training
Programs / Dr. Nordlund
3:45 p.m. How Close Are We to the Control of Tropical Skin
Infections? / Dr. Hotez
4:05 p.m. Role of International Dermatology Organizations
/ Dr. Hay
4:25 p.m. Te Role of Dermatology in the Control of HIV/
AIDS / Dr. Craft
4:45 p.m. Questions and Answers / Faculty
M A K E A W O R L D O F D I F F E R E N C E
Find volunteer
opportunities
in dermatology
that best fit your lifestyle
Make a difference by
volunteering in your
community or abroad
Join the Leadership
Circle for Volunteerism
Visit the
Academy Resource Center
Booth 3623
today to learn more!
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
225
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
SCHEDULE
2:00 p.m. Introduction / Dr. Friedman
2:05 p.m. Difcult Melanocytic Lesions of Childhood and Teir
Management / Dr. Schafer
2:20 p.m. Adjunctive Tools in the Diagnosis of Melanoma
/ Dr. Rabinovitz
2:35 p.m. Saving Lives in Melanoma / Dr. Friedman
2:50 p.m. Epidemiology of Melanoma: Can We Make a
Diference? / Dr. Rigel
3:05 p.m. Causes Of Melanoma: UVR —Yes Or No?
/ Dr.Wang
3:20 p.m. A Successful Plan to Prevent Melanoma and its
/ Dr. Swetter
3:35 p.m. Questions and Answers / Faculty
3:45 p.m. Clinical Diagnosis of Melanoma / Dr. Stein
4:00 p.m. Te Broad Spectrum of Atypical Nevi and their Risk
for Developing Melanoma: Clinical Dermatoscopy
Imaging Technology / Dr.Chen
4:15 p.m. Te Toughest Melanocytic Lesions I’ve Diagnosed
/ Dr. Cockerell
4:30 p.m. Te Clinical Management of the Melanoma Patient
from Curable In Situ to Tick High-Risk Disease
/ Dr. Rogers
4:45 p.m. Questions and Answers / Faculty
SYMPOSIUM
2:00 p.m. to 5:00 p.m.
Open admission, no tuition or ticket.
S043 Melanoma Update
Room: Auditorium C
DIRECTOR Robert J. Friedman, M.D.
SPEAkERS
Suephy C. Chen, M.D. Julie V. Schafer, M.D.
Clay J. Cockerell, M.D. Jennifer A. Stein, M.D.
Harold S. Rabinovitz, M.D. Susan M. Swetter, M.D.
Darrell S. Rigel, M.D. Steven Q. Wang, M.D.
Gary S. Rogers, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Outline the diagnostic and therapeutic management of patients
with melanoma; outline the issues surrounding the epidemic of
melanoma; discuss the diagnostic conundrum associated with
melanoma.
2. Examine the role of UV and the use of sun protective behaviors
in preventing cancers of the skin; gain a better understanding
of the role of genetic testing for melanoma risk.
3. Evaluate new concepts in the diagnosis of melanoma, including
dermoscopy, confocal laser microscopy, and computer vision;
gain a better understanding of the newest treatments for
advanced melanoma.
DESCRIPTION
Te incidence of skin cancer/melanoma continues to rise
throughout the world. Dermatologists are faced each day with
the need to diagnose difcult pigmented lesions and to assess risk
for melanoma in such patients. As the incidence of melanoma
increases, we are challenged by the need to make accurate
diagnoses and treat this relatively common and potentially deadly
malignancy. Tose attending this symposium will be exposed
to the teaching of a world-renowned faculty who will present
the most up-to-date and cutting-edge diagnostic and treatment
techniques for melanoma and other atypical pigmented lesions.
Te goal is to be able to utilize the information presented and
apply it to everyday patient care.
3.00 Category 1 CME Credits
REFERENCES
1. Rigel, DS, et al, eds. Cancer of the Skin. Philadelphia: Elsevier;
2011.
For description of session categories and fees see page 37
226
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
DISCUSSION GROUP
2:30 p.m. to 4:00 p.m.
Tuition fee and ticket required for admission.
FOCUS SESSION
2:30 p.m. to 4:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
D023 Cutaneous T-Cell Lymphoma
Room: 240
DIRECTOR Gary S. Wood, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Identify the key clinicopathologic features of cutaneous T-cell
lymphoma (CTCL).
2. Recognize recent advances in the tumor biology of CTCL.
3. Apply these advances to improve the management of CTCL
patients.
DESCRIPTION
Important advances have been made in our understanding of
utaneous T-cell lymphoma (CTCL) tumor biology that can be
used to improve clinical management. Tese include our ability to
identify and track the tumor clone, the implications of diferent
tumor clone homing behaviors, recognition that CTCL tumors
(T3 lesions) sort into biologically and clinically distinct subsets, the
importance of a robust host response and how to best maintain it
during therapy, and the role of dysregulated apoptosis in CTCL
pathogenesis and therapy. Tese topics will be addressed following a
brief review of the clinicopathological features of CTCL.
1.50 Category 1 CME Credits
D024 PAPA Syndrome, SAPHO, and Acne: Skin
and Bones and Infammation
Room: 241
DIRECTOR Gerd Plewig, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Explain how interleukin-1 receptor antagonists immediately
improve pyoderma gangrenosum.
2. Discuss these conditions and their treatment options.
DESCRIPTION
Hereditary and acquired infammatory signs and symptoms
afecting skin, bones, and gut may be seen in PAPA syndrome
(pyogenic arthritis, pyoderma gangrenosum, and acne),
SAPHO syndrome (synovitis, acne, pustulosis [palmoplantaris],
hyperostosis, and osteitis), cryopyrinopathies, and Muckle-
Wells syndrome. Tis session focuses on important knowledge
of proteins interacting with pyrin. Furthermore acne inversa is
associated with Crohn disease and ulcerative colitis.
1.50 Category 1 CME Credits
U133 Psychodermatology: Not just a Delusion;
‘Bugs,’ Trichotillomania, and the
Morgellons Debate
Room: 235/236
DIRECTOR Gary Goldenberg, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Perform the appropriate evaluation and testing on a patient
that “sees bugs.“
2. Manage a patient who says “I have Morgellons disease.”
3. Appropriately evaluate and treat a patient that pulls at hair or
picks at skin.
DESCRIPTION
Tis session will discuss the approach to a patient who presents with
‘bugs on the skin.’ We will “pick apart” the diferential diagnoses,
including true infections, delusions (from organic and psychiatric
causes), somatoform disorders, hypochondriasis, and delirium.
We will review appropriate history taking, physical examination,
and laboratory testing for these patients. Clinical examples will
be used, and a basic treatment algorithm will be presented. Tis
session will feature an open discussion regarding the controversial
term “Morgellons disease.” We will also discuss a basic approach to
trichotillomania, skin picking, and body dysmorphic disorder. Tis
session is intended for all dermatologists.
1.50 Category 1 CME Credits
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
227
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
U136 Management of Challenging Pigmented
Lesions
Room: 270
DIRECTOR Caroline C. Kim, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Characterize clinical and pathologic features of challenging
pigmented lesions.
2. Identify the most appropriate management strategies for
challenging pigmented lesions.
3. Recognize current diagnostic limitations for certain cases and
formulate practical treatment plans.
DESCRIPTION
Dermatologists are presented with the difcult task of evaluating
and managing patients with challenging pigmented lesions. Trough
case examples, this session will review a variety of complex cases and
discuss practical management strategies, including surgical margins,
the role of sentinel lymph node biopsy, and appropriate follow-
up. Topics to be covered include atypical mole syndrome, atypical
spitz nevi, melanocytic tumors of uncertain malignant potential
(MELTUMP), and childhood melanoma. Current limitations of
histopathological diagnosis in certain pigmented lesions will be
discussed, as well as practical management strategies for such lesions.
Tis session will be directed towards all general dermatologists.
1.50 Category 1 CME Credits
U137 Developing a Unifed Approach to
Investigating Autoimmune Disease
Room: 264
DIRECTOR John Harris, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Categorize autoimmune diseases of the skin with those of other
organ systems.
2. Predict pathogenic mechanisms for autoimmune diseases based
on distribution, symptoms, and evolution of disease.
3. Develop novel treatment strategies based on disease categories
of pathogenesis.
DESCRIPTION
Autoimmune diseases of the skin are numerous and complex. Recent
discoveries in basic and clinical sciences have challenged established
categories of autoimmune disease but provide new insights into
how these diseases manifest in our patients. New discoveries in basic
science will be discussed, as well as clinical characteristics that allow
us to compare and contrast individual autoimmune diseases afecting
the skin or other organ systems. Developing a strategy to categorize
autoimmune diseases provides an opportunity to understand how
these diseases are interrelated, to predict which novel treatments
might beneft our patients, and to better focus clinical and basic
research questions.
1.50 Category 1 CME Credits
FOCUS SESSION
2:30 p.m. to 4:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U134 Issue in Offce Design
Room: 283
DIRECTOR James A. Zalla, M.D.
LEARNING OBjECTIVES
1. Recognize the numerous important issues in design of a
dermatology ofce.
2. Design functional and efcient front ofce and clinical space
and patient fow.
3. Apply new ideas and tips to existing ofce facilities.
DESCRIPTION
Tis session refects 35 years of practice experience as applied to
the design of a 10,000 square foot group practice dermatology
ofce. Te space includes general, surgical, and pediatric
dermatology, Mohs surgery, dermatopathology lab, and cosmetic
consultation room. Tips on ofce design, room sizes and layout,
seating, wall and foor covering, other furnishings, equipment,
lighting, signage, phone, audio, nurse call systems, fre sprinkling
system, soundproofng, and storage recommendations will all be
shared. Time will also be available for questions.
1.50 Category 1 CME Credits
U135 What’s New in Dermatopathology and
Why It’s Important to You
Room: 263
DIRECTOR Gary Goldenberg, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Identify and describe recent clinically relevant studies in
dermatopathology.
2. Evaluate and recognize clinically relevant use of
immunohistochemical stains in dermatopathology.
DESCRIPTION
Tis focus session is intended to update clinical dermatologists
on a wide spectrum of recent developments in dermatopathology.
Te conference will spotlight clinically relevant research. Attention
will be given to infammatory and neoplastic diseases. Use of
immunohistochemical stains, and their clinical application, will
also be discussed.
1.50 Category 1 CME Credits
For description of session categories and fees see page 37
228
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
FOCUS SESSION
2:30 p.m. to 4:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U138 Digital Imaging and Medical Informatics:
Decision Support for Clinicians and
Teachers
Room: 274
DIRECTOR Arthur Papier, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Discuss digital trends in dermatology and medical information.
2. Summarize advances in health information technology and
imaging, as it relates to teaching and dermatologic care.
3. Defne clinical decision support.
DESCRIPTION
Recent healthcare reform legislation includes signifcant
physician reimbursement for using electronic health records that
meaningfully incorporate decision support. What is decision
support and how can it eventually improve the care dermatologists
deliver? Dermatology as a visual specialty has unique information
needs when considering the patient visit. During this session
clinical and academic dermatologists will learn of new information
technologies for handheld and desktop computing, and how
technology innovations can aide diagnosis and visual record
keeping. Te integration of decision support with teledermatology
and the creation of an educational “feedback loop” for the
referring physician will be described.
1.50 Category 1 CME Credits
U139 Inherited Cancer Syndromes:
The Role of the Dermatologist
Room: 265/266
DIRECTOR Richard Eric White, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize individuals at risk for inherited cancer syndromes.
2. Apply screening protocols for individuals at risk for inherited
cancer syndromes.
3. Develop referral practices for individuals at risk for inherited
cancer syndromes.
DESCRIPTION
Inherited cancer syndromes account for 5-10% of all malignancies.
Dermatologists routinely manage individuals who are at risk for these
syndromes. Tis session presents four inherited cancer syndromes:
familial melanoma, muir-torre, hereditary breast and ovarian cancer
and, hereditary leiomyoma renal cell cancer. Te ability to recognize
the dermatologic manifestations of these syndromes empowers the
attendee to identify at-risk individuals. Te dermatologist has an
essential role in screening, management and referral. Te session
participant will learn to obtain a focused pedigree, apply diagnostic
criteria, order screening studies, and provide referrals. Te session
will conclude with an overview of genetic counseling.
1.50 Category 1 CME Credits
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
229
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
U141 Skin Signs of Systemic Disease
Room: 242
DIRECTOR Joseph C. English III, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Discuss new skin disease associations with systemic disease.
2. Describe new systemic disease associations with classical skin
signs of internal disease.
3. Examine the need for the interaction of all specialities with
dermatology to enhance patient care.
DESCRIPTION
Tis session is dedicated to updating practicing dermatologist with
the most current evidence-based dermatology fndings concerning
the evaluation and management of skin signs of systemic disease.
Part I is organ system based disease followed by new skin fndings.
Part II is classic skin signs followed by a review of new and old
associated systemic diseases.
1.50 Category 1 CME Credits
U142 Cryosurgical Update
Room: 267/268
DIRECTOR Gloria F. Graham, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Choose the appropriate treatment for benign, premalignant
and malignant skin lesions.
2. Select the best method for specifc patients.
3. Identify side efects and their prevention.
DESCRIPTION
Te session will present a variety of skin tumors and conditions
amenable to cryosurgery with the goal of achieving improved
cure rate and cosmetic result. Pretreatment of the skin in some
conditions can improve the overall cure rate and cosmetic result.
Selection of technique includes cotton swab, probe, or spray
with or without use of cone or thermocouple needle. Some
newer technology and techniques will be discussed including
cryoimmunology, fractional cryosurgery, and confocal microscopy
as aid in determining tumor depth prior to cryosurgery. A
new device to measure temperature control may prove useful.
Clinicians and residents may fnd this useful in their practices.
1.50 Category 1 CME Credits
FOCUS SESSION
2:30 p.m. to 4:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U140 Past, Present, and Pearls of Treatment of
Autoimmune Bullous Disease
Room: 269
DIRECTOR Naveed Sami, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Discuss local and systemic therapeutic options available,
including the latest treatments.
2. Formulate a general treatment algorithm and discuss specifc
questions the audience may have regarding specifc patients.
3. Discuss possible treatment pearls which may help in the
treatment of autoimmune mucocutaneous blistering disease
patients.
DESCRIPTION
Autoimmune mucocutaneous blistering diseases can vary in their
presentation and treatment response. Tere are very few case
controlled studies on the usage of certain systemic agents. Most
of treatment knowledge has been derived from the experience of
dermatologists over the several decades. Tis session will attempt to
present the various treatment agents available today. A treatment
algorithm of what could be used in a realistic scenario will be
discussed. Specifc treatment pearls will be shared by the presenter
which may help clinicians in the management of their patients.
Specifc questions will be addressed in a discussion format.
1.50 Category 1 CME Credits
For description of session categories and fees see page 37
230
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
FORUM
3:00 p.m. to 5:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F071 Advanced Treatment for Chronic Wounds
Room: 252/253/254
DIRECTOR Marco Romanelli, M.D.
SPEAkERS
Francisco Kerdel, M.D. Maria Miteva, M.D.
Severin R. Laeuchli, M.D. Paolo Romanelli, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Identify patients who are candidates for advanced treatment in
chronic wound management.
2. Formulate approaches to therapy for difcult-to-heal wounds.
3. Compare the safety and efcacy profles of various advanced
treatments.
DESCRIPTION
Tis session will give an overview of advanced treatment available
for the management of common and atypical chronic wounds.
Clinical usefulness, appropriateness, and cost-efectiveness of
the most recent advances will be covered, including topical
antimicrobials, active dressings, systemic drugs, medical devices,
and tissue engineering.
2.00 Category 1 CME Credits
F072 Medium and Deep Chemical Peeling
Room: 278/279/280
DIRECTOR Harold Joseph Brody, M.D.
SPEAkER Seaver Soon, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Choose and compare photoaging, wrinkles and scarring
indications for medium and deep combination chemical peeling.
2. Utilize exact techniques for medium trichloroacetic acid
chemical peeling and deep regional phenol chemical peeling
in combination on the face.
DESCRIPTION
Dermatologic surgeons can treat photoaging in the form of
hyperpigmentation, moderate to severe wrinkles, actinic keratoses,
and pitted scarring in a cost-efective manner using combinations
of chemical resurfacing techniques. Tis session will teach exact
techniques for medium depth trichloroacetic acid (TCA) chemical
peeling and regional deep phenol peeling (i.e., around the mouth)
on the photoaged face. Didactic instruction and extensive video
will be used. Superfcial peeling will not be emphasized, and
complications will be covered briefy only with respect to medium
and deep peeling. Familiarity with chemical peeling agents in
advance is very helpful.
2.00 Category 1 CME Credits
F073 Techniques for Flap Success
Room: 255/256/257
DIRECTOR Ken K. Lee, M.D.
SPEAkERSs
Sumaira Zareen Aasi, M.D.
Andrew J. Kaufman, M.D.
Steven M. Rotter, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Examine diferent types of faps.
2. Apply diferent fap designs to various defects.
3. Recognize the advantages and limitations of various faps.
DESCRIPTION
Tis session will provide an in-depth examination of diferent
fap types: advancement, transposition, rotation, pedicle, and
interpolated faps. Te speakers will discuss the advantages
and limitations of each of these faps, as well as ofer pearls for
the proper execution of these faps. Many examples of various
defects closed with diferent faps will be shown. Additionally,
management of complications will be reviewed.
2.00 Category 1 CME Credits
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
231
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
FORUM
3:00 p.m. to 5:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F075 Alopecia CPC
Room: 388/389/390
DIRECTOR Lynne J. Goldberg, M.D.
SPEAkERS
Michael D. Iofreda, M.D.
Leonard C. Sperling, M.D.
Catherine Margaret Stefanato, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Develop an appreciation for information that can be obtained
from a scalp biopsy.
2. Compare scalp biopsy results with the patients clinical picture,
maximizing diagnostic accuracy.
DESCRIPTION
Tis forum features four dermatologists/dermatopathologists with
a special interest in alopecia. Each will present patients whose
biopsies were especially instructive. Histologic clues and pitfalls
will be discussed, and pointers as to how to correlate the biopsy
report with the patients clinical fndings given. Along the way
expect tips on approach to the alopecia patient, clinical fndings
of various alopecias, where to obtain the biopsy, narrowing down
what information you are seeking from the biopsy, and how to
dissect this information from the biopsy report. Presentations will
be informal, and questions and discussion encouraged. Suitable for
both dermatopathologists and dermatologists.
2.00 Category 1 CME Credits
F074 The Use of the Confocal Microscope in a
Private Clinical Practice
Room: 391
DIRECTOR Harold S. Rabinovitz, M.D.
SPEAkERS
Verena Ahlgrimm-Siess, M.D. Giovanni Pellacani, M.D.
Sara Bassoli, M.D. Susana Puig, M.D.
Joseph Malvehy, M.D. Alon Scope, M.D.
Scott Menzies, MBBS, Ph.D. Iris Zalaudek, M.D.
Margaret C. Oliviero, NP
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Describe the confocal features of normal skin.
2. Diferentiate benign and malignant neoplasms of the skin.
3. Identify the confocal features of specifc neoplasms.
DESCRIPTION
Te refectance confocal microscope is a new imaging device that
can be used as an aid in the evaluation of diseases of the skin.
Tis course will focus on introducing this device, its terminology,
and basic mechanics. Te attention will be on both benign and
malignant melanocytic and non-melanocytic neoplasms of the skin.
2.00 Category 1 CME Credits
SCHEDULE
3:00 p.m. Principles and Terminology of Refectance Confocal
Microscopy (RCM) / Dr. Scope
3:20 p.m. Benign Melanocytic Neoplasms / Dr. Bassoli
3:40 p.m. Melanoma Diagnosis / Dr. Pellacani
4:00 p.m. Refectance Confocal Microscopy of Non-Melanocytic
Neoplasms / Dr. Ahlgrimm-Siess
4:20 p.m. How the Confocal Microscope is Used Daily in a
Clinical Setting / Ms. Oliviero
4:40 p.m. Unknowns for the Experts / Dr. Malvehy
/ Dr. Puig / Dr. Rabinovitz / Dr. Zalaudek
For description of session categories and fees see page 37
232
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
FORUM
3:00 p.m. to 5:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F076 Pediatric Dermatology
Room: 386/387
DIRECTOR Mary Wu Chang, M.D.
SPEAkERS
Richard J. Antaya, M.D.
Hanspaul Makkar, M.D.
Karen Wiss, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Recognize the diagnostic methods necessary to distinguish
blistering diseases in infancy and early childhood.
2. Identify birthmarks that require specifc surgical or medical
management.
3. Discuss examples of unique pediatric dermatoses.
DESCRIPTION
Get out your pencils, its time for a quiz! Four pediatric
dermatologists return to bring interesting and informative cases to
share with the audience for a stimulating and practical session. Te
cases will be presented in a pre-test format at the beginning of the
session, followed by discussion. Tere will be a mix of classic as
well as rare entities. Audience participation is encouraged.
New cases and updates are included this year.
2.00 Category 1 CME Credits
SCHEDULE
3:00 p.m. Introduction / Dr. Chang
3:03 p.m. Photo Quiz / Faculty
3:20 p.m. Discussion of Cases / Faculty
4:45 p.m. Questions and Answers / Faculty
F077 Aesthetic Dermatologic Complications
Room: 392
DIRECTOR Ranella J. Hirsch, M.D.
SPEAkERS
Jean D.A. Carruthers, M.D.
Jefrey S. Dover, M.D.
Roberta D. Sengelmann, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Prevent, evaluate, and manage aesthetic dermatologic
complications.
2. Develop best practices for optimizing complication outcomes.
DESCRIPTION
Tis interactive session will orient the attendee to best practices
for the prevention, evaluation, and management of aesthetic
dermatologic complications. Te audience is invited to present
difcult cases they have encountered for discussion with the panel.
2.00 Category 1 CME Credits
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
233
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
,

F
E
B
R
U
A
R
Y

7
SCIENTIFIC SESSIONS
W013 MOC Self-Assessment: Offce-Based
Safety
M
O
C
Room: 288/289/290
DIRECTOR Hillary Johnson-Jahangir, M.D., Ph.D.
LEARNING OBjECTIVES
Following this workshop, the attendee will be able to:
1. Identify strengths and weaknesses in one’s knowledge of
issues in patient safety that are relevant to the practice of
dermatology.
2. Integrate and apply concepts in patient safety to improve
dermatologic care.
DESCRIPTION
Tis session will be structured as a question-and-answer format
using an automated response system. Concepts in patient safety
that are relevant for dermatologists will be highlighted. Safety
issues important in procedural and medical dermatologic practice
will be addressed in order to better care for our patients.
2.00 Category 1 CME Credits
* Self-assessment questions utilized in this session are
the same as those used for Workshop W004 MOC:
Self-Assessment ofered at Summer Meeting 2010.
Physicians should not claim CME/MOC credit for
attending this session if they attended Workshop W004
at Summer Meeting 2010.
FORUM
3:00 p.m. to 5:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
F078 Epidermolysis Bullosa: Cases and
Discussion
Room: 281/282
DIRECTOR Anne W. Lucky, M.D.
SPEAkERS
Anna Lee Bruckner, M.D.
Elena Pope, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Recognize some of the important issues in the care of patients
with epidermolysis bullosa.
2. Utilize new strategies for caring for patients with epidermolysis
bullosa.
DESCRIPTION
Tis focus session will provide an opportunity to present cases of
epidermolysis bullosa that illustrate unique features or problems
with diagnosis and/or treatment. Tere will be some didactic
discussion of the new classifcation of epidermolysis bullosa and
updates of research in progress in this feld. Participants are
encouraged to submit their cases before the meeting.
2.00 Category 1 CME Credits
WORkSHOP
3:00 p.m. to 5:00 p.m.
Tuition fee and ticket required for admission.
For description of session categories and fees see page 37
234
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
/
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

7
/
8
COURSE
9:00 a.m. to 5:00 p.m.
Tuition fee and ticket required for admission.
C029 Dermatology Review
Room: 243/244/245
DIRECTOR Phoebe Rich, M.D.
SPEAkERS
David R. Adams, M.D., Pharm.D George J. Murakawa, M.D.
Pamela S. Allen, M.D. David Michael Pariser, M.D.
Andrew Blauvelt, M.D. Darrell S. Rigel, M.D.
Jefrey Phillip Callen, M.D. Janet Louise Roberts, M.D.
Clay J. Cockerell, M.D. Teodore Rosen, M.D.
David Eric Cohen, M.D. Eric Lawrence Simpson, M.D.
Raymond L. Cornelison Jr., M.D. Stephen K. Tyring, M.D., Ph.D.
Benjamin David Ehst, M.D., Ph.D. Guy F. Webster, M.D., Ph.D.
Alfons Krol, M.D. Victoria P. Werth, M.D.
Henry W. Lim, M.D. Kim B. Yancey, M.D.
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Demonstrate an understanding of cutaneous disease by
reviewing new information concepts, and discoveries from the
current literature.
2. Integrate and apply cutting edge research and knowledge
to improve patient care and to prepare for certifcation
examinations.
DESCRIPTION
Tis course will provide encapsulated new information in
a soup- to-nuts coverage of dermatology. World-renowned
dermatologists will summarize their areas of expertise in an
informative and engaging fashion. Tis will provide current
information in dermatology that will improve clinical practice and
provide concise information helpful in reviewing for certifcation
examinations.
12.00 Category 1 CME Credits
SCHEDULE
Monday, February 7, 2011
9:00 a.m. Introduction / Dr. Rich
9:05 a.m. Advances in Cutaneous T-Cell Lymphoma / Dr. Duvic
9:35 a.m. Bacterial Skin Infection Update: MRSA and More
/ Dr. Murakawa
10:05 a.m. Immunodermatology / Dr. Blauvelt
10:35 a.m. Questions and Answers / Faculty
10:45 a.m. Infectious Skin Disease: Viral and More: What’s New!
/ Dr. Tyring
11:15 a.m. Atopic Dermatitis Update / Dr. Simpson
11:45 a.m. Questions and Answers / Faculty
2:00 p.m. Blistering Diseases / Dr. Yancey
2:30 p.m. Rheumatic Skin Disease / Dr. Werth
3:00 p.m. Hair Disorders: What’s New! / Dr. Roberts
3:30 p.m. Dermatologic Emergencies / Dr. Rosen
4:00 p.m. Drug Reactions / Dr. Adams
4:35 p.m. Questions And Answers / Faculty
Tuesday, February 8, 2011
9:00 a.m. Pediatric Dermatology Update / Dr. Krol
9:30 a.m. Contact Dermatitis Update / Dr. Cohen
10:00 a.m. Dermatolopathology Update / Dr. Cockerell
10:30 a.m. Questions and Answers / Faculty
10:35 a.m. Melanoma Update / Dr. Rigel
11:05 a.m. Skin Signs of Systemic Disease / Dr. Callen
11:30 a.m. Photodermatology Update / Dr. Lim
2:00 p.m. Skin Manifestations of HIV Disease / Dr. Ehst
2:30 p.m. Laser Update / Dr. Allen
3:00 p.m. Botulinum Toxin for Hyperhidrosis Update
/ Dr. Pariser
3:30 p.m. Questions and Answers / Faculty
3:45 p.m. Nails Update! / Dr. Rich
4:15 p.m. Psoriasis-Biologics Update / Dr. Cornelison
4:45 p.m. Questions and Answers / Faculty
MONDAY/TUESDAY, FEBRUARY 7, 8
Courses — 9:00 p.m. to 5:00 p.m.
C029 Dermatology Review. . . . . . . . . . . . . . . . . . . . . .234 C030 Basic Dermatology . . . . . . . . . . . . . . . . . . . . . . .235
OVERVIEW
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
Practice Management Session open to eligible
offce staff/registered nurses
Represents Patient Safety Session in program overviews
Patient Safety Session
Represents Audience Response System Session
Audience Response System Session
Represents activities that meet MOC-D

M
O
C
This activity has been approved by the ABD to satisfy
component 2 of MOC-D
Represents Leadership Institute in program overviews
Leadership Institute — addresses leadership
competencies specifc to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
For description of session categories and fees see page 37
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
235
SCIENTIFIC SESSIONS
M
O
N
D
A
Y
/
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

7
/
8
C030 Basic Dermatopathology
Room: 383/384/385
DIRECTOR Rosalie Elenitsas, M.D.
SPEAkERS
Raymond L. Barnhill, M.D. Rossitza Z. Lazova, M.D.
Nooshin Ketabchi Brinster, M.D. Jason Bok Lee, M.D.
Clay J. Cockerell, M.D. Carlos H. Nousari, M.D.
Carrie Ann R. Cusack, M.D. Ronald P. Rapini, M.D.
George W. Elgart, M.D. Leslie Robinson-Bostom, M.D.
Tammie C. Ferringer, M.D. Adam Rubin, M.D.
James E. Fitzpatrick, M.D. Andras Schafer, M.D.
Maxwell A. Fung, M.D. Mary S. Stone, M.D.
Jane Margaret Grant-Kels, M.D. Michael Tetzlaf, M.D.
Antoinette Foote Hood, M.D. Karen Warschaw, M.D.
Michael D. Iofreda, M.D. Clifton Robert White Jr., M.D.
Hideko Kamino, M.D. Caroline S. Wilkel, M.D.
Christine Ko, M.D.
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Recognize the histologic features of common infammatory
dermatoses.
2. Diferentiate the histologic feaures of the common cutaneous
neoplasms.
3. Demonstrate a solid foundation in basic dermatopathology.
DESCRIPTION
Tis session is designed to ofer an overview of the histologic
features of a wide spectrum of cutaneous infammatory dermatoses
and neoplasms. Criteria used to establish diagnoses and to
diferentiate among lesions with similar histopathologic features
will be reviewed. Pattern analysis will be emphasized. Lectures
will be illustrated with clinical and histopathologic photographs.
Syllabus material will be provided.
11.00 Category 1 CME Credits
REFERENCES
1. Elder DE, Elenitsas R, Johnson BL, Murphy GF, Xu X.
Lever’s Histopathology of the Skin. 10th ed. Philadelphia, PA:
Lippincott Williams and Wilkins; 2009
2. Weedon D. Weedon’s Skin Pathology. 3rd ed. Churchill
Livingstone; 2010
3. Ackerman AB, Boer A, Bennin B, Gottlieb GG. Histologic
Diagnosis of Infammatory Skin Diseases. 3rd ed. New York, NY:
Ardor Scribendi; 2005
SCHEDULE
Monday, February 7, 2011
9:00 a.m. Introductory Comments / Elenitsas
9:05 a.m. A Method for Histopathologic Diagnosis of
Infammatory Skin Diseases / Dr. Fitzpatrick
9:25 a.m. Vacuolar and Lichenoid Dermatitis / Dr. Lee
9:45 a.m. Intraepidermal Vesicular Dermatitis / Dr. Hood
10:10 a.m. Psoriasiform and Spongiotic Dermatitis / Dr. Wilkel
10:25 a.m. Intermission / Faculty
10:40 a.m. Subepidermal Vesicular Dermatitis / Dr. Nousari
11:05 a.m. Nodular and Difuse Dermatitis (Sweet syndrome and
Granuloma Faciale) / Dr. Grant-Kels
11:35 a.m. Vasculitis / Dr. Stone
11:55 a.m. Questions and Answers / Faculty
12:00 p.m. Lunch / Faculty
2:00 p.m. Fibrohistiocytic Neoplams / Dr. Kamino
2:30 p.m. Fat and Osseous Neoplasms / Dr. Cockerell
2:50 p.m. Metastatic Neoplasms / Dr. Elgart
3:10 p.m. Intermission / Faculty
3:25 p.m. Benign Melanocytic Neoplasms / Dr. Barnhill
3:55 p.m. Malignant Melanocytic Neoplasms / Dr. Fung
4:25 p.m. Pre-malignant and Malignant Epithelial Neoplasms
/ Dr. Cusack
4:55 p.m. Questions and Answers / Faculty
Tuesday, February 8, 2011
9:00 a.m. Panniculitis / Dr. Robinson-Bostom
9:25 a.m. Alopecia / Dr. Iofreda
9:50 a.m. Nail Histology, Common Infammatory Skin Disease
and Neoplasms / Dr. Rubin
10:10 a.m. Depositions and Dermal Disorders / Dr. Tetzlaf
10:25 a.m. Intermission / Faculty
10:40 a.m. Practical Immunoperoxidase Staining / Dr. Ferringer
11:10 a.m. Follicular Neoplasms / Dr. Rapini
11:30 a.m. Neural Neoplasms / Dr. White
11:50 a.m. Questions and Answers / Faculty
12:00 p.m. Lunch / Faculty
2:00 p.m. Lymphoma and Pseudolymphoma / Dr. Schafer
2:30 p.m. Muscle Neoplasms / Dr. Ko
2:50 p.m. Sebaceous Neoplasms / Dr. Lazova
3:15 p.m. Intermission / Faculty
3:30 p.m. Apocrine and Eccrine Neoplasms / Dr. Warschaw
4:00 p.m. Vascular Neoplasms / Dr. Brinster
4:25 p.m. Benign Epithelial Neoplasms and Cysts / Dr. Elenitsas
4:55 p.m. Questions and Answers / Faculty
COURSE
9:00 a.m. to 5:00 p.m.
Tuition fee and ticket required for admission.
236
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

8
For description of session categories and fees see page 37
OVERVIEW
TUESDAY, FEBRUARY 8
Discussion Groups — 7:15 a.m. to 8:45 a.m.
D025 Integration of Photodynamic Terapy into
Your Practice. . . . . . . . . . . . . . . . . . . . . . . . . . . .238
D026 A Practical Approach to Photosensitivity. . . . . . .238
Focus Sessions — 7:15 a.m. to 8:45 a.m.
U143 Pediatric Surgery. . . . . . . . . . . . . . . . . . . . . . . . .238
U144 Serial Screening for Melanoma: Measures Tat have
Consistently Achieved Early Detection and Cure 238
U145 Advances in Psoriasis. . . . . . . . . . . . . . . . . . . . . .239
U146 Management of Cutaneous Toxicity in the Era
of Targeted Chemotherapy . . . . . . . . . . . . . . . . .239
U147 Dermatological Signs of Child Abuse . . . . . . . . .239
U148 Lessons Learned from Challenging Pediatric Cases:
Targeted Novel Molecular Terapies . . . . . . . . .239
U149 Overgrowth Syndromes . . . . . . . . . . . . . . . . . . .240
U150 Skin Cancer Viruses: Bench to Bedside. . . . . . . .240
U151 Approach to Non-Scarring Hair Loss in Women . .240
U152 Cutaneous Mucinosis . . . . . . . . . . . . . . . . . . . . .241
U153 Facing Facial Dermatoses . . . . . . . . . . . . . . . . . .241
Forums — 9:00 a.m. to 11:00 a.m.
F079 Update on Alopecia Areata . . . . . . . . . . . . . . . . .241
F080 Fractional Laser and Light-Based Technologies . .242
F081 Geriatric Dermatology . . . . . . . . . . . . . . . . . . . .242
F082 Managing Ofce Politics: Private Practice,
Academics, and Everything in Between. . . . . . . .243
F083 Psoriasis Terapy in the Age of Biologics . . . . . .243
F084 Medical Applications of Topical
Photodynamic Terapy. . . . . . . . . . . . . . . . . . . .243
F085 Autoimmune Blistering Disorders. . . . . . . . . . . .244
Workshop — 9:00 a.m. to 11:00 a.m.
W014 Dermoscopy Cases . . . . . . . . . . . . . . . . . . . . . . .244
Courses — 9:00 a.m. to 12:00 p.m.
C031 Advanced Cosmetic Surgery and Aesthetics . . . .245
C032 Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .246
Symposia — 9:00 a.m. to 12:00 p.m.
S044 Terapeutic Hotline . . . . . . . . . . . . . . . . . . . . . .247
S045 Disorders of Mucous Membranes . . . . . . . . . . . .247
S046 Pediatric Dermatology . . . . . . . . . . . . . . . . . . . .248
S047 Managing Melanoma in the Modern
Millennium. . . . . . . . . . . . . . . . . . . . . . . . . . . . .249
S048 Cutaneous Lymphomas. . . . . . . . . . . . . . . . . . . .249
S049 Cosmetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .250
S050 Organizational Approaches to AIDS/STDs
From a Global Perspective. . . . . . . . . . . . . . . . . .250
Forums — 12:00 p.m. to 2:00 p.m.
F086 BCC Update and Options of Treatment . . . . . . .251
F087 Nail Disorders in Children . . . . . . . . . . . . . . . . .251
F088 Clinical Trials . . . . . . . . . . . . . . . . . . . . . . . . . . .252
F089 Advances in Photomedicine . . . . . . . . . . . . . . . .252
F090 Autoimmune Mucocutaneous Blistering
Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .253
F091 Supportive Onco-Dermatology:
Dermatologic Reactions in Oncology . . . . . . . . .253
F092 Diagnosing and Monitoring Hair
and Scalp Disease . . . . . . . . . . . . . . . . . . . . . . . .254
Discussion Group — 12:15 p.m. to 1:45 p.m.
D027 Diferential Diagnosis of Leprosy in
a Non-Endemic Country . . . . . . . . . . . . . . . . . .254
Focus Sessions — 12:15 p.m. to 1:45 p.m.
U154 Caring for the Hospitalized Patient: Interesting
Cases from the Inpatient Consultative Service . .255
U155 What’s New in Skin Cancer Prevention . . . . . . .255
U156 Finding the Needle in the Haystack:
A Guide to More Efective Patch Testing . . . . . .255
U157 Rosacea Update. . . . . . . . . . . . . . . . . . . . . . . . . .255
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
Practice Management Session open to eligible
offce staff/registered nurses
Represents Patient Safety Session in program overviews
Patient Safety Session
Represents Audience Response System Session
Audience Response System Session
Represents activities that meet MOC-D

M
O
C
This activity has been approved by the ABD to satisfy
component 2 of MOC-D
Represents Leadership Institute in program overviews
Leadership Institute — addresses leadership
competencies specifc to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
237
SCIENTIFIC SESSIONS
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

8
For description of session categories and fees see page 37
U158 Acne: Etiopathogenesis and Treatment 2011. . . .256
U159 An Approach to Cultural
Diversity in Dermatology . . . . . . . . . . . . . . . . . .256
U160 Pigmented Lesions in Pediatric Dermatology . . .257
U161 Actinic Keratoses Update . . . . . . . . . . . . . . . . . .257
U162 Full Facial Approach with Botulinum Toxin
and Hyaluronic Acid: Cases From a
European Practice . . . . . . . . . . . . . . . . . . . . . . . .257
U163 Garden Variety Derm: Identifying and Managing
Exposures to Hazardous Plants and Arthropods in
the Garden . . . . . . . . . . . . . . . . . . . . . . . . . . . . .258
U164 Hypercoagulability, Purpura, and the Skin . . . . .258
U165 Te Management of TEN/SJS:
Te US Army Burn Unit Experience . . . . . . . . .258
Courses— 2:00 p.m. to 5:00 p.m.
C033 Advanced Surgery . . . . . . . . . . . . . . . . . . . . . . . .259
C034 Skin Resurfacing and Rejuvenation. . . . . . . . . . .259
Symposia — 2:00 p.m. to 5:00 p.m.
S051 Evidence-Based Medicine . . . . . . . . . . . . . . . . . .260
S052 Surgical Complications . . . . . . . . . . . . . . . . . . . .260
Focus Sessions — 2:30 p.m. to 4:00 p.m.
U166 Great Cases in Teledermatology . . . . . . . . . . . . .261
U167 Establishing a Mohs’ Practice:
Pearls for New Surgeons . . . . . . . . . . . . . . . . . . .261
U168 Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .261
U169 Cryosurgery Present and Future . . . . . . . . . . . . .261
U170 Pitfalls in Dermatopathology: When Tings Are
Not What Tey Seem to Be . . . . . . . . . . . . . . . .262
U171 Frontiers of Dermatopathology: Utility,
Methodology, and Interpretation of Current
(and Future) Molecular Testing. . . . . . . . . . . . . .262
U172 Transplant Research in Dermatology . . . . . . . . .262
Forums — 3:00 p.m. to 5:00 p.m.
F093 Psychocutaneous Medicine . . . . . . . . . . . . . . . . .263
F094 Melasma: Advances in the Treatment of a
Terapeutically Challenging Disease . . . . . . . . . .263
F095 Challenges in the Diagnosis and Management of
Lentigo Maligna Melanoma . . . . . . . . . . . . . . . .264
F096 Phototherapy . . . . . . . . . . . . . . . . . . . . . . . . . . .264
OVERVIEW
238
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

8
For description of session categories and fees see page 37
U143 Pediatric Surgery
Room: 270
DIRECTOR Annette M. Wagner, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Identify practical tips to improve surgical and laser outcomes in
pediatric patients in their practice.
2. Distinguish and manage common birthmarks that require
surgery using appropriate anesthetic agents and optimal timing.
3. Utilize vascular lasers appropriately in the pediatric population.
DESCRIPTION
Te use of lasers and surgical procedures is becoming common
in pediatric dermatology practice. Tis session will provide
participants with updated information applicable to performing
procedures in children. Practical surgical and laser pearls
to improve outcomes in this population will be discussed.
Controversies and more advanced surgical techniques for the
pediatric dermatologic surgeon will be presented.
1.50 Category 1 CME Credits
U144 Serial Screening for Melanoma:
Measures that have Consistently
Achieved Early Detection and Cure
Room: 265/266
DIRECTOR Ronald Nevin Shore, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Select patients at increased risk of skin cancers for whom serial
screening would be appropriate.
2. Select lesions for which biopsy or monitoring would be
appropriate.
3. Develop an efective serial screening program.
DESCRIPTION
Tis session is intended to assist practitioners in establishing
or improving ofce-based, serial screening programs with the
objective being to achieve very high rates of cure for skin cancer,
particularly melanoma, through consistent early detection. Te
scientifc basis of various measures in our screening program will
be reviewed, including how these relate to the developmental
biology and chronology of melanoma. Tose measures that have
been particularly helpful in our program’s achieving 100% survival
from all skin cancers in over 18 years will be discussed, and several
fascinating, new observations on the nature of melanoma will be
described.
1.50 Category 1 CME Credits
FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
D025 Integration of Photodynamic Therapy into
Your Practice
Room: 240
DIRECTOR Nellie Konnikov, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Discuss and teach leprosy.
2. Diferentiate leprosy from the endemic dermatologic entities in
practice.
3. Evaluate and appreciate leprosy as a model for other
dermatologic diseases which have systemic overtones.
DESCRIPTION
Since leprosy is not endemic in the U.S., one might feel comfortable
not including it in diferential diagnoses. Te potential source of disease
in practice is immigrants from highly endemic areas such as Brazil and
India. How can one best be sensitized to this disease and diagnosis?
Why not describe what diseases it can look like in your practice and
then tell you why it is not leprosy? Tis approach will not only tell
you how to make a diagnosis of leprosy, but will make you realize that
leprosy in many ways can be a model for other dermatologic entities.
1.50 Category 1 CME Credits
D026 A Practical Approach to Photosensitivity
Room: 241
DIRECTOR Robert P. Sarkany, M.D., MBBS
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Clinically assess and create a clinical diferential diagnosis for
patients presenting with photosensitivty.
2. Demonstrate which tests to do on which patients and to
understand the principles and diagnostic role of specialist tests
such as photopatch and phototesting.
3. Manage patients with photosensitivity.
DESCRIPTION
Te audience will receive the tools to manage photosensitive patients
in their own practices. Speakers will interactively discuss how
photosensitive patients present in the general dermatology clinic; how to
clinically assess (history and examination) photosensitive patients to gain
a diferential diagnosis in the clinic; which investigations to do in which
clinical scenarios, and particularly in which situations the specialist tests
(phototests, photopatch tests, porphyrin tests etc.) are useful and where
they are needed; create a simple practical framework so dermatologists
can manage photosensitive patients. After the session you should have
the rudiments to manage patients presenting with photosensitive
dermatoses.
1.50 Category 1 CME Credits
DISCUSSION GROUP
7:15 a.m. to 8:45 a.m.
Tuition fee and ticket required for admission.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
239
SCIENTIFIC SESSIONS
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

8
For description of session categories and fees see page 37
U147 Dermatological Signs of Child Abuse
Room: 269
DIRECTOR Arnold Pieter Oranje, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize the clinical spectrum of dermatologic signs of child
abuse and formulate a comprehensive diferential diagnosis for
the case.
2. Demonstrate the proper diagnosis by choosing an adequate
workup, including an independent double-interdisciplinary
evaluation, to come to the most correct conclusions.
3. Recognize the necessity for cooperation between the forensic
pediatrician and the pediatric dermatologist.
DESCRIPTION
Tis interactive session will concentrate on the difcult and
unusual cases that one may encounter in consultations when child
abuse is suspected. Te problems will be illustrated by several
cases and discussed in a comprehensive manner with input from
everyone present. A multidisciplinary approach is demanded in
cases of suspected child abuse. In the Netherlands, a working
group for forensic pediatrics is active and recommended as the
best approach (Robert AC Bilo, Arnold P Oranje).
1.50 Category 1 CME Credits
U148 Lessons Learned from Challenging
Pediatric Cases: Targeted Novel
Molecular Therapies
Room: 284
DIRECTOR Joyce Teng, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Describe the relevant clinical and management challenges of a
variety of interesting pediatric dermatologic cases.
2. Discuss targeted molecular diagnostic and therapeutic
approaches for several challenging dermatologic conditions.
3. Outline other potential molecular therapies and novel
application of light based treatments.
DESCRIPTION
In this session, several challenging pediatric vascular, neoplastic,
and genetic dermatoses will be presented. Te session will review
some of the difculties in both diagnosis and management
from the dermatologic perspectives. It intends to educate the
attendee about developing novel therapeutic concepts to manage
challenging dermatologic conditions based on recent developments
in molecular biology.
1.50 Category 1 CME Credits
U145 Advances in Psoriasis
Room: 267/268
DIRECTOR Jefrey M. Weinberg, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Assess the latest clinical data for tumor necrosis factor-
inhibitors.
2. Determine the latest clinical data for T-cell targeted therapies
and antibodies to IL-12/23.
3. Review the latest clinical data for novel oral and biologic
therapies in development for psoriasis.
DESCRIPTION
Tere are a growing number of new and investigational therapies
for psoriasis. Te latest efcacy and safety data for available and
investigational biological agents will be reviewed. In addition,
an update on oral therapies in development will be presented.
Recommendations for appropriate monitoring of patients on these
agents will be discussed.
1.50 Category 1 CME Credits
U146 Management of Cutaneous Toxicity in the
Era of Targeted Chemotherapy
Room: 264
DIRECTOR Milan J. Anadkat, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize the common manifestations of chemotherapy skin
toxicity.
2. Diferentiate the varying mechanisms of chemotherapy-induced
cutaneous reactions.
3. Manage patients with cutaneous toxicity due to systemic
chemotherapy.
DESCRIPTION
Systemic chemotherapy has always resulted in varying forms
of cutaneous toxicity. With the advance in molecular targeted
chemotherapy, cutaneous adverse reactions have become a leading
cause of morbidity and dose limitation for aficted patients. In
this session, dermatologists will learn to recognize the varying
forms of cutaneous toxicity resulting from targeted chemotherapy,
the mechanisms underlying these reactions, and how to manage
these perplexing scenarios.
1.50 Category 1 CME Credits
FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
240
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

8
For description of session categories and fees see page 37
U151 Approach to Non-Scarring Hair Loss
in Women
Room: 235/236
DIRECTOR Jefrey Donovan, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Identify important features from a patient’s history and clinical
examination that help diferentiate causes of non-scarring hair
loss in women.
2. Complete appropriate investigations to further assess the cause
of hair loss.
3. Select appropriate treatments based on the type of hair loss.
DESCRIPTION
Concerns about hair loss are common among women. Although
the diagnosis can sometimes be immediately evident, at other
times making the correct diagnosis can be aided by a systematic
approach. Tis session is designed to assist participants to perform
a focused history and clinical examination. Te participant will
know when and which blood tests to order as part of a workup
and when to consider a scalp biopsy. Appropriate treatments will
be reviewed along with discussion of their efcacy and potential
side efects.
1.50 Category 1 CME Credits
U149 Overgrowth Syndromes
Room: 283
DIRECTOR Kristen P. Hook, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Identify distinguishing characteristics of overgrowth syndromes
to aid in diagnosis.
2. Determine appropriate workup and clinical monitoring.
3. Discuss appropriate treatment and referral options.
DESCRIPTION
Overgrowth syndromes can be defned by the type of soft
tissue hypertrophy and the presence of vascular malformations.
Distinguishing characteristics of syndromes and diagnostic features
will be identifed. Appropriate workup and clinical monitoring
recommendations will be discussed, as well as recent knowledge
regarding potential complications. Referral and treatment options
will be mentioned in brief.
1.50 Category 1 CME Credits
U150 Skin Cancer Viruses: Bench to Bedside
Room: 274
DIRECTOR Sarah T. Arron, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Defne viruses associated with skin cancer.
2. Describe molecular mechanisms for viral carcinogenesis.
DESCRIPTION
Over 15% of human cancers are caused by viruses. When a new
virus is discovered in cancer, researchers must demonstrate an
epidemiologic association as well as a molecular mechanism for
carcinogenesis. We will review the evidence for three viruses
associated with skin cancer: HHV-8 and Kaposi’s sarcoma,
HPV and squamous cell carcinoma, and MCPyV and Merkel
cell carcinoma. Tis session will introduce dermatologists to
techniques for viral discovery, viral mechanisms for carcinogenesis,
and potential antiviral therapies for cancer.
1.50 Category 1 CME Credits
FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
241
SCIENTIFIC SESSIONS
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

8
For description of session categories and fees see page 37
F079 Update on Alopecia Areata
Room: 238/239
DIRECTOR Elise Olsen, M.D.
SPEAkERS Jerry Shapiro, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Discuss the most recent information on the etiology of alopecia
areata.
2. Use microscopic evaluation of hair bulbs obtained by hair pull,
dermoscopic evaluation of the scalp and scalp biopsy to help
make the diagnosis.
3. Summarize the many efective treatments available for the
various subtypes of alopecia areata.
DESCRIPTION
Tis forum is one of an annual series covering an update on
various hair loss conditions. Tis year we will focus on alopecia
areata. We will cover new information on the etiology as well
as educate the attendee on how to use the microscopic hair
examination, dermoscopic examination of the scalp and scalp
biopsy to help make the diagnosis of alopecia areata. We will also
present a practical and thorough review of therapeutic options and
camoufage techniques for alopecia areata.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Diagnosis of Alopecia Areata / Dr. Olsen
9:20 a.m. Etiological Factors in Alopecia Areata / Dr. Shapiro
9:40 a.m. Skin Directed Terapy, Part I (Steroids, Minoxidil)
/ Dr. Dr. Olsen
10:00 a.m. Skin Directed Terapy, Part II (Anthralin, Sensitizers,
Newer Agents, Camoufage Methods) / Dr. Shapiro
10:20 a.m. Systemic Agents / Dr. Olsen
10:40 a.m. Case Presentations and Discussion / Faculty
FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
U152 Cutaneous Mucinosis
Room: 242
DIRECTOR Raymond L. Cornelison Jr., M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Demonstrate how to defuse the potential frustration that both
the physician and the patient may bring to the ofce.
2. Utilize words, gestures and tonality to encourage memorable
and meaningful interactions.
DESCRIPTION
Tis session will bring together both physician practitioners and a
patient with a chronic skin disease to present both the physicians
and the patients perspective. Medical training has taught physicians
to fx the human body but not necessarily how to heal patients. Te
objective of this session is to make physicians aware of their intense
impact on the life of the patient and to explore the many ways that
the physician can facilitate the moments of joy, inspiration, and
deep personal satisfaction that can take place during an ofce visit.
Tis session will be unforgettable, guaranteed!
1.50 Category 1 CME Credits
U153 Facing Facial Dermatoses
Room: 263
DIRECTOR Joseph B. Bikowski, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Perform a complete diferential diagnosis of facial dermatoses.
2. Diagnose and treat the common and not so common facial
dermatoses.
DESCRIPTION
Tis session emphasizes evaluation of facial dermatoses including
diferential diagnosis and medical management. Tis will include
presentation and discussion of: an innovative new acne grading
system, isotretinoin treatment pearls, unusual presentations of
rosacea, Demodex dermatitis, Pityrosporum folliculitis, and
unusual contact dermtitis.
1.50 Category 1 CME Credits
FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
242
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

8
For description of session categories and fees see page 37
F081 Geriatric Dermatology
Room: 388/389/390
DIRECTOR Wendy E. Roberts, M.D.
SPEAkERS Robert A. Norman, D.O.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Recognize the need for an experience in geriatric dermatology.
2. Identify dermatologic issues in the geriatric patient.
3. Categorize and summarize new treatments in geriatric
dermatology.
DESCRIPTION
Te total geriatric population stands at 12.4%. By the year 2050
1 in 5 people in the US will be age 65 and older. It becomes
increasingly important for the dermatologist to have experience in
managing dermatologic issues in this age group. We will discuss
emerging trends in geriatric dermatology as well as the recognition
and management of disorders of older patients.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Geriatric Dermatology Update / Dr. Roberts
10:00 a.m. Issues in Geriatric Dermatology / Dr. Norman
F080 Fractional Laser and Light-Based
Technologies
Room: 252/253/254
DIRECTOR Jill S. Waibel, M.D.
SPEAkERS
R. Rox Anderson, M.D. Roy Geronemus, M.D.
Henry H. L. Chan, M.D. E. Victor Ross Jr., M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Evaluate the current indications, limitations, and potential for
fractional laser and light-based devices.
2. Gain insight into advanced techniques for optimal patient
results in both medical and aesthetic arenas.
3. Discuss new fractional technologies and update on the latest
research in fractional lasers and light-based technology.
DESCRIPTION
Tis session is directed at both potential and experienced users
of fractional laser and light technologies. Using evidence-based
approaches our dynamic panel will examine current applications,
and the strengths and weaknesses of fractional light. A review of
the practical aspects of fractional lasers will help clinicians in daily
practice on aspects such as physics, parameters, complications and
patient selection. We will also explore the use fractional light
around the world in patients with skin of color. Te session will
end with a global view of the future of fractional light.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Highlights from Fractional Laser Literature
and Experience: Indications, Parameters and
Complications / Dr. Waibel
9:20 a.m. Physics, Strengths and Weakness of Fractional Lasers
and Light-Based Technology / Dr. Ross
9:40 a.m. Maximizing Aesthetic and Medical Results with
Fractional Lasers / Dr. Geronemus
10:00 a.m. Fractional Laser Light-Based Technologies in Skin of
Color: A View from Around the World / Dr. Chan
10:20 a.m. Emerging Fractional Research and Technologies:
Te Future of Light / Dr. Anderson
10:40 a.m. Questions and Panel Discussion / Faculty
FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
243
SCIENTIFIC SESSIONS
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

8
For description of session categories and fees see page 37
F084 Medical Applications of Topical
Photodynamic Therapy
Room: 386/387
DIRECTOR Rolf-Markus Szeimies, M.D.
SPEAkERS
Robert Bissonnette, M.D. Colin A. Morton, M.D.
Percy M. Lehmann, M.D. Luis A. Torezan, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Evaluate the use, limitations and potential of topical
photodynamic therapy for premalignant, malignant, and
infammatory skin conditions.
2. Recognize practical aspects of the therapy and select
appropriate patients.
3. Select treatment conditions for particular situations and handle
specifc therapy-related side efects and complications.
DESCRIPTION
Tis session is directed at both potential and experienced users of
photodynamic therapy (PDT). Using evidence-based approaches,
current applications of topical PDT for non-melanoma skin
cancer and infammatory skin conditions will be examined. Te
speakers will present treatment details and expected outcomes, and
discuss side efects and complications and how to cope with them.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Update on Photosensitizers and Light Sources
/ Dr. Szeimies
9:20 a.m. Topical PDT for Actinic Keratosis / Dr. Torezan
9:40 a.m. Topical PDT for Bowen’s Disease and Basal Cell
Carcinoma / Dr. Morton
10:00 a.m. Questions and Answers / Faculty
10:10 a.m. Topical PDT for Infammatory Skin Conditions
/ Dr. Bissonnette
10:30 a.m. Side Efects of Topical PDT and How to Manage
Tem / Dr. Lehmann
10:50 a.m. Audience Questions for all Panelists / Faculty
F082 Managing Offce Politics:
Private Practice, Academics, and
Everything in Between
Room: 393/394
DIRECTOR Margaret E. Parsons, M.D.
SPEAkERS
Philip L. Bailin, M.D.
Susan H. Weinkle, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Identify the skill sets for understanding and navigating small to
large organizations.
2. Summarize the political realities of medical practice.
DESCRIPTION
Success in any leadership role requires a skill set of understanding
and navigating an organization. Te skill set we all need will be
reviewed and refected in diferent environments: ofce, clinic,
academic, and organized medicine. Our speakers bring experience
that will demonstrate political skills and how the fnesse of
utilizing those skills has helped them succeed as leaders in their
practice settings.
2.00 Category 1 CME Credits
F083 Psoriasis Therapy in the Age of Biologics
Room: 281/282
DIRECTOR Robert E. Kalb, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Diferentiate among the available treatments for moderate to
severe psoriasis.
2. Illustrate optimal therapy with conventional systemic agents
and phototherapy.
3. Recognize situations where individual biologic therapies may
have advantages.
DESCRIPTION
Te goal of this session is to update and review the treatment
of moderate to severe psoriasis. Topics to be covered include
phototherapy, conventional systemic therapy, and biologic
therapy. Guidelines and practical tips for each treatment option
will be covered. Tere is special emphasis on literature published
in the past 12 months. Cost, insurance regulations, prior
authorization requirements, and physician administered therapy
will all be discussed. Te session is designed to facilitate the
treatment of moderate to severe psoriasis in the typical private
practice dermatology ofce.
2.00 Category 1 CME Credits
FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
244
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

8
For description of session categories and fees see page 37
W014 Dermoscopy Cases
Room: 343
DIRECTOR Giuseppe Argenziano, M.D.
SPEAkERS Iris Zalaudek, M.D.
LEARNING OBjECTIVES
Following this workshop, the attendee will be able to:
1. Utilize dermoscopy with confdence under routine conditions.
2. Identify and interpret the most important dermoscopy criteria.
3. Develop a practical approach for the diagnosis of pigmented
lesions and melanoma.
DESCRIPTION
Dermoscopy is an in vivo method that has been reported to be
useful for the early recognition of melanoma. It uses an immersion
technique and optical magnifcation. Taken together, these optical
means allow the visualization of structures up to the dermis. Tis
session will provide a review of the most important dermoscopic
criteria for diagnosing melanoma, as well as clinical scenarios
and case examples where the use of dermoscopy and specifc
management rules will help clinicians improving skin cancer
screening in the routine patient.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Dermoscopy to Examine Patients NOT Lesions!
/ Dr. Argenziano
10:00 a.m. Relevant Clinical Scenarios Using Dermoscopy
/ Dr. Zalaudek
10:30 a.m. Dermoscopy Quiz for the Audience / Dr. Argenziano
WORkSHOP
9:00 a.m. to 11:00 a.m.
Tuition fee and ticket required for admission.
F085 Autoimmune Blistering Disorders
Room: 391
DIRECTOR Neil J. Korman, M.D., Ph.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. To describe the clinical features that aid in diagnosis of
pemphigus, bullous and mucous membrane pemphigoid.
2. To learn about the limited evidence based medicine available
to treat these conditions.
3. To understand and appreciate the practical therapeutic
approaches that are utilized to treat the autoimmune blistering
diseases.
DESCRIPTION
Tis session will present the latest information on the diagnosis
and treatment of patients with pemphigus, bullous pemphigoid
and mucous membrane pemphigoid. Attendees will learn about
the relatively limited but latest evidence available supporting
the use of diferent therapeutic approaches. After discussing
the evidence, we will then discuss a practical approach to the
treatment of patients with autoimmune blistering diseases
including appropriate screening and follow up laboratory studies.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Test / Dr. Korman
FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the ofcial start time.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
245
SCIENTIFIC SESSIONS
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

8
For description of session categories and fees see page 37
REFERENCES
1. Carruthers J, Carruthers A. Botulinum toxin A in the mid and
lower face and neck. Dermatol Clin. 2004;22:151-158.
2. Fincher EF, Moy RL. Cosmetic blepharoplasty. Dermatol Clin.
2005;23:431-442.
3. Klein AW. Techniques for soft tissue augmentation: an “A to
Z.” Am J Clin Dermatol. 2006;7:107-120.
SCHEDULE
9:00 a.m. My Approach to the Cosmetic Patient / Dr. Fincher
9:15 a.m. Te Latest Techniques for Cellulite Treatment
/ Dr. Goldman
9:30 a.m. Advanced Botulinum Toxin Injection Techniques
/ Dr. Cohen
9:45 a.m. Advanced Facial Augmentation Techniques
/ Dr. Tung
10:00 a.m. Panel Discussion / Faculty
10:10 a.m. Advanced Ablative Fractional Resurfacing Techniques
/ Dr. Zachary
10:25 a.m. Advances in Radiofrequency Rejuvenation
/ Dr. Hantash
10:40 a.m. Advances in Ultrasound Tightening and Less Invasive
Contouring / Dr. Alam
10:55 a.m. Panel Discussion / Faculty
11:05 a.m. Advanced Techniques in Leg Vein Terapy
/ Dr. Weiss
11:20 a.m. Advanced Techniques In Liposuction / Dr. Fincher
11:35 a.m. Blepharoplasty Pearls / Dr. Moy
11:47 a.m. Face-lift Highlights / Dr. Gladstone
C031 Advanced Cosmetic Surgery and
Aesthetics
Room: 255/256/257
DIRECTOR Hayes B. Gladstone, M.D.
SPEAkERS
Murad Alam, M.D. Basil Hantash, M.D., Ph.D.
Joel Lee Cohen, M.D. Ronald L. Moy, M.D.
Edgar Fincher, M.D., Ph.D. Rebecca Clare Tung, M.D.
Helen Horn Fincher, M.D. Robert A. Weiss, M.D.
Mitchel Paul Goldman, M.D. Christopher B. Zachary, M.D.
LEARNING OBjECTIVES
1. Defne the specifc technical aspects of these advanced cosmetic
procedures.
2. Determine which advanced cosmetic procedures are
appropriate for specifc cosmetic conditions.
3. Evaluate cosmetic conditions more efectively.
DESCRIPTION
As the population ages it has become more sophisticated about
rejuvenation options. Dermatologists must be familiar with, and
be able to perform, more advanced cosmetic procedures to meet
the public’s expectations. Dermatologic surgeons have been leaders
in minimally invasive aesthetic procedures. Tis session will focus
onkey points of advanced techniques of common rejuvenation
procedures, such as botulinum toxin, fllers, and lasers, as well as
highlight advanced cosmetic procedures, including blepharoplasty,
face-lifts, and liposuction. In addition to other learning objectives,
key steps of these procedures will be reviewed and practice pearls
from the individual speakers will be shared.
3.00 Category 1 CME Credits
COURSE
9:00 a.m. to 12:00 p.m.
Tuition fee and ticket required for admission.
246
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

8
For description of session categories and fees see page 37
REFERENCES
1. Kauvar ANB, ed. Principles and Practices of Cutaneous Laser
Surgery. New York: Taylor and Francis; 2005.
SCHEDULE
9:00 a.m. Introduction / Dr. Kauvar
9:05 a.m. Laser Treatment of Pigmented Lesions and Tattoos
/ Dr. Uebelhoer
9:20 a.m. Laser Treatment of Vascular Lesions / Dr. Dierickx
9:40 a.m. Laser and Light Treatment of Acne / Dr. Ross
9:55 a.m. Laser Hair Removal / Dr. Grossman
10:20 a.m. Non-ablative Fractional Resurfacing / Dr. Tanzi
10:40 a.m. Ablative Fractional Resurfacing / Dr. Alster
11:00 a.m. Skin Tightening / Dr. Zachary
11:15 a.m. Non-invasive Fat Reduction and Body Contouring
/ Dr. Avram
11:30 a.m. What’s on the Horizon in Deviced-based Treatments?
/ Dr. Anderson
C032 Lasers
Room: 275/276/277
DIRECTOR Arielle N. B. Kauvar, M.D.
SPEAkERS
Tina S. Alster, M.D. E. Victor Ross Jr., M.D.
R. Rox Anderson, M.D. Elizabeth Tanzi, M.D.
Mathew M. Avram, M.D. Nathan S. Uebelhoer, D.O.
Christine C. Dierickx, M.D. Christopher B. Zachary, M.D.
Melanie C. Grossman, M.D.
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Apply advanced laser techniques for the treatment of
pigmented lesions, vascular lesions, unwanted hair, and acne.
2. Recognize and diferentiate the advantages and disadvantages
of skin resurfacing with non-ablative and ablative fractional
devices.
3. Describe the current devices for body contouring and fat
reduction and recognize future directions in cutaneous laser
surgery.
DESCRIPTION
Tis intermediate-level course is designed for dermatologists with
a basic understanding of cutaneous laser surgery. Attendees will
learn the most advanced techniques for the treatment of facial
photodamage, scars, vascular and pigmented lesions, acne and
unwanted hair. An in-depth review of ablative and non-ablative
fractional skin resurfacing, skin tightening devices, and non-
invasive fat reduction and body contouring treatments will provide
the audience with the most recent information to enhance clinical
outcomes. A presentation on the future of cutaneous laser surgery
will provide a glimpse into the direction of evolving technology.
3.00 Category 1 CME Credits
COURSE
9:00 a.m. to 12:00 p.m.
Tuition fee and ticket required for admission.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
247
SCIENTIFIC SESSIONS
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

8
For description of session categories and fees see page 37
S045 Disorders of Mucous Membranes
Room: 291/292
DIRECTOR Rochelle R. Torgerson, M.D., Ph.D.
SPEAkERS
Alison June Bruce, MBChB Lynette J. Margesson, M.D.
Libby Edwards, M.D. Ginat W. Mirowski, DMD, M.D.
Nasim Fazel, M.D. Bethanee Jean Schlosser, M.D., Ph.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Develop an approach to the evaluation of patients with oral
and vulvovaginal complaints.
2. Diagnose and manage some of the more common oral and
vulvovaginal diseases.
3. Identify the diagnostic and treatment dilemmas encountered in
challenging cases of oral and vulvovaginal diseases.
DESCRIPTION
Te diagnosis and management of mucous membrane diseases
is the realm of the dermatologist. Tis session will simplify the
evaluation of such patients by presenting a logical and thorough
approach to the oral and vulvar examinations. A case-based
format will be used to explore the diagnosis and management
of frequently encountered mucous membrane diseases as well as
rarer, more challenging mucous membrane disorders. Ultimately
a well-learned approach to patients with mucous membrane
complaints can make management of both common and rare
diseases rewarding.
3.00 Category 1 CME Credits
REFERENCES
1. Eisen D, Lynch DP, eds. Te Mouth: Diagnosis and Treatment.
Philadelphia: Mosby.
2. Lynch PJ, Edwards L. Genital Dermatology. Churchill-
Livingstone.
SCHEDULE
9:00 a.m. Oral Examination and Common Findings
/ Dr. Torgerson
9:15 a.m. Gingival Lumps and Bumps / Dr. Mirowski
9:35 a.m. Ulcerative Oral Lesions / Dr. Fazel
9:55 a.m. Challenging Oral Cases / Dr. Bruce
10:20 a.m. Questions and Answers: Oral Cases / Faculty
10:30 a.m. Vulvar Examination and Common Findings
/ Dr. Torgerson
10:45 a.m. Te “Lichens” / Dr. Margesson
11:05 a.m. Vulvar Manifestations of Systemic Disease
/ Dr. Schlosser
11:25 a.m. Challenging Vulvar Cases / Dr. Edwards
11:50 a.m. Questions and Answers: Vulvar Cases / Faculty
S044 Therapeutic Hotline
Room: 271/272/273
DIRECTOR Teodore Rosen, M.D.
SPEAkERS
Glynis R. Ablon, M.D. Darrell S. Rigel, M.D.
Erin E. Boh, M.D., Ph.D. Noah S. Scheinfeld, M.D., J.D.
Scott W. Fosko, M.D. Kenneth J. Tomecki, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Utilize latest topical therapeutic agents.
2. Apply new cosmetic innovations.
3. Identify therapeutics for skin cancer, infections, and psoriatic
arthritis.
DESCRIPTION
Tis session is designed to expand therapeutic horizons
by highlighting new, relevant information and innovative
interventions. Subject matter will be diverse, including: skin
cancer, cosmetic dermatology, cutaneous infections, psoriatic
arthritis, cutaneous surgery, and topical therapeutics. Tis session
will be clinically germane and almost immediately applicable to
daily patient care.
3.00 Category 1 CME Credits
REFERENCES
1. Atanaskova A, Tomecki KJ. Innovative management of
recurrent furunculosis. Dermatol Clin. 2010;28:479-487.
2. Swanson N, et al. Imiquimod 2.5% and 3.75% for the
treatment of actinic keratoses. J Am Acad Dermatol.
2010;62:582-590.
3. Rigel DS. Trends in dermatology: Melanoma incidence. Arch
Dermatol. 2010;146:318.
SCHEDULE
9:00 a.m. What’s New in Melanoma Terapy? / Dr. Rigel
9:30 a.m. What’s New in Cosmetic Dermatology? / Dr. Ablon
10:00 a.m. What’s New in Cutaneous Infection Terapeutics?
/ Dr. Tomecki
10:30 a.m. Modern Management of Psoriatic Arthritis / Dr. Boh
11:00 a.m. Antibiotics and Cutaneous Surgery: 2010 / Dr. Fosko
11:30 a.m. What’s New in Topical Terapeutics? / Dr. Scheinfeld
SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.
248
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

8
For description of session categories and fees see page 37
REFERENCES
1. Haggstrom AN, Drolet BA, Baselga E, Chamlin SL,
Garzon MC, Horii KA, et al. Prospective study of infantile
hemangiomas: clinical characteristics predicting complications
and treatment. Pediatrics. 2006;118:882-887.
2. Fine JD, Eady RA, Bauer EA, Bauer JW, et al. Te
classifcation of inherited epidermolysis bullosa (EB): Report
of the 3rd International Consensus Meeting on Diagnosis and
Classifcation of Epidermolysis Bullosa. J Am Acad Dermatol.
2008;58:931-950.
3. Paller AS, Mancini AJ. Hurwitz Clinical Pediatric Dermatology.
3rd ed. London: Elsevier; 2006.
SCHEDULE
9:00 a.m. Introduction / Dr. Mancini
9:05 a.m. Infantile Hemangiomas: Emerging Observations
/ Dr. Haggstrom
9:30 a.m. Te Child with Recalcitrant Dermatitis: When to
Worry / Dr. Levy
9:50 a.m. Exanthems in Children: An Update / Dr. Dyer
10:15 a.m. Diaper Dermatitis: More than Meets the Eye?
/ Dr. Kwong
10:35 a.m. Questions and Answers / Faculty
10:45 a.m. Pediatric Bacterial Infections / Dr. Sidbury
11:10 a.m. Epidermolysis Bullosa: An Update for the
Dermatologist / Dr. Pope
11:35 a.m. Pediatric Procedural Pearls / Dr. Burch
11:55 a.m. Questions and Answers / Faculty
S046 Pediatric Dermatology
Room: 260/261/262
DIRECTOR Anthony J. Mancini, M.D.
SPEAkERS
Joanna M. Burch, M.D. Pearl C. Kwong, M.D.
Elizabeth Alvarez Connelly, M.D. Moise L. Levy, M.D.
Jonathan A. Dyer, M.D. Elena Pope, M.D.
Anita N. Haggstrom, M.D. Robert Sidbury, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Recognize and treat common and atypical exanthems and
bacterial skin infections in the pediatric patient.
2. Determine when to evaluate the child with recalcitrant
dermatitis for other potential disorders.
3. Utilize a variety of clinical pearls to perform surgical procedures
and laser therapy in non-sedated children.
DESCRIPTION
We will review evolving observations about pathogenesis,
associations, and treatments for infantile hemangiomas, as well
as several common and atypical exanthems in children, focusing
on clinical presentation and diagnosis. We will be updated on
methicillin-resistant Staphylococcus aureus infections in children and
review the contemporary classifcation of epidermolysis bullosa.
Additionally, we will learn about features which should point to
possible underlying nutritional defciency, immunodefciency, or
syndrome in the child with recalcitrant dermatitis. Conditions
which may present with an eruption in the diaper area will be
reviewed, and we’ll learn some procedural pearls for performing
surgery and laser therapy in non-sedated children.
3.00 Category 1 CME Credits
SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org
|
249
SCIENTIFIC SESSIONS
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

8
For description of session categories and fees see page 37
S048 Cutaneous Lymphomas
Room: 295/296
DIRECTOR Madeleine Duvic, M.D.
SPEAkERS
Joan Guitart, M.D. Alain H. Rook, M.D.
Youn H. Kim, M.D. Gary S. Wood, M.D.
Ellen J. Kim, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Describe and understand the pathogenesis and current
categorization of cutaneous lymphomas.
2. Order appropriate studies for staging cutaneous lymphomas.
3. Select appropriate stage-specifc treatments for cutaneous
lymphomas.
DESCRIPTION
Tis is an overview of the most commonly encountered
cutaneouslymphomas. Speakers will review the current status of
cutaneous B-cell lymphoma (CBCLs), CD30+ lymphoproliferative
disorders, CD8+ and NK/NKT cell lymphomas, mycosis
fungoides, and Sézary syndrome. Te speakers will review
diagnosis based on specifc serologic and molecular markers,
current staging systems, and stage-specifc treatments.
3.00 Category 1 CME Credits
REFERENCES
1. Kim EJ, et al. Immunopathogenesis and therapy of cutaneous
T cell lymphoma. J Clin Invest. , 2005;115(4): 7.
2. Senf NJ, Noordijk EM, Yim YH. et al. EORTC and ISCL
consensus recommendations for the management of cutaneous
B-cell lymphomas. Blood. Jun 20, 2008.
3. Horwitz SM, Olsen EA, Duvic M. et al. Review: treatment
of mycosis fungoides and Sézary syndrome: a stage-based
approach. J Natl Compr Canc Netw. 2008 Apr;6(4):436-442.
SCHEDULE
9:00 a.m. Introduction / Dr. Duvic
9:05 a.m. Everything You Need to Make the Diagnosis of
Cutaneous Lymphomas / Dr. Wood
9:30 a.m. Cutaneous B-Cell Lymphomas: Classifcations,
Staging, and Treatment / Dr. Kim
10:00 a.m. Sorting Out CD30+ Lymphoproliferative Disorders
/ Dr. Duvic
10:30 a.m. Cytotoxic and Assorted Uncommon Peripheral T-Cell
Lymphomas / Dr. Guitart
11:00 a.m. Diagnosis, Staging, and Treatment of Mycosis
Fungoides / Dr. Kim
11:30 a.m. Combined Immunotherapy for Sézary Syndrome and
What to Do Next / Dr. Rook
S047 Managing Melanoma in the Modern
Millennium
Room: 293/294
DIRECTOR Hensin Tsao, M.D., Ph.D.
SPEAkERS
Keith Flaherty Kenneth Yee Tsai, M.D.
Allan C. Halpern, M.D. Jennifer Wargo, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Recognize high-risk individuals and high-risk lesions through
modern technologies.
2. Defne the molecular targets that defne subclasses of
melanoma and their treatments.
3. Describe current advances in melanoma immunotherapy.
DESCRIPTION
Current melanoma practice relies heavily on visual description:
skin type, lesion morphology, and histopathology. In this
symposium, we will explore recent advances in molecular genetics,
cancer genomics, imaging modalities, and immunobiology and
how these gains can be leveraged to identify (1) individuals most
susceptible to melanoma; (2) high-risk pigmented lesions; (3)
molecular subclasses within melanocytic tumors; (4) novel targeted
treatments; and (5) new immunoltherapeutic approaches. For
decades, melanoma has remained impenetrable on many fronts.
Now, with the current molecular revolution, this disease may
fnally become comprehensible and conquerable.
3.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Personal Risk Profling in Melanoma / Dr. Tsao
9:35 a.m. Update on Imaging Modalities for Pigmented Lesions
/ Dr. Halpern
10:10 a.m. Molecular Pathology for Melanoma Classifcation
/ Dr. Tsai
10:45 a.m. Update on Targeted Terapies for Melanoma
/ Mr. Flaherty
11:20 a.m. Modern Melanoma Immunotherapy / Dr. Wargo
11:50 a.m. Questions and Answers / Faculty
SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.
250
|
amerIcan academy oF dermatoLogy • 69th annuaL meetIng
SCIENTIFIC SESSIONS
T
U
E
S
D
A
Y
,

F
E
B
R
U
A
R
Y

8
For description of session categories and fees see page 37
S050 Organizational Approaches to AIDS/STDs
From a Global Perspective
Room: 278/279/280
DIRECTOR Toby A. Maurer, M.D.
SPEAkERS
Erin H. Amerson, M.D. Scott A. Norton, M.D., M.P.H.
Jennifer Cafardi, M.D. Marcio Soares Serra, M.D.
Carrie L. Kovarik, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Summarize the new guidelines to treatment of HIV and its
impact on dermatology.
2. Recognize the new dermatologic issues of HIV/AIDS.
3. Discuss the impact of dermatology in the global fght against
HIV/AIDS.
DESCRIPTION
HIV/AIDS continues to be an important and ever-expanding area
of dermatology with national and international implications.
Te role of dermatologists in HIV/AIDS continues and evolves.
We will address how these roles are important and changing.
We will also be hearing about the new treatment guidelines in
HIV/AIDS and examine how this may change dermatologic
practice and manifestations. Early detection in Kaposi’s sarcoma
remains an issue globally. New thoughts on Kaposi’s sarcoma as
they emerge in the US and globally will also be addressed.
3.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. AIDS/STDs- Hot Topics, New Issues / Dr. Maurer
SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.
S049 Cosmetics
Room: Auditorium A
DIRECTOR Mary P. Lupo, M.D.
SPEAkERS
Diane S. Berson, M.D. Rashmi Sarkar, M.D.
Vic A. Narurkar, M.D. Susan H. Weinkle, M.D.
Wendy E. Roberts, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Apply cosmetic procedures into a medical dermatology
practice.
2. Demonstrate that dermatology is a broa